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I. INTRODUCTION 
Diabetes mellitus has emerged into a steadily increasing health problem of global 
extent and a considerable cause of early death nowadays (Roglic and Unwin, 
2010; Scully, 2012; Shaw et al., 2010). The predicted future dimension of the 
global diabetic epidemic is alarming. A tremendous increase in the prevalence of 
diabetes mellitus from currently 346 million to over 400 million affected people 
worldwide by the year 2030 was extrapolated (Scully, 2012; Shaw et al., 2010). In 
consideration of the growing burden of diabetes mellitus, research efforts are 
imperative to provide a basis for the development of preventive and therapeutic 
strategies (Wild et al., 2004; Zimmet et al., 2001). Diabetic rodent models have 
traditionally been used in this field and contributed decisively to the clarification 
of important disease mechanisms and pathomorphological consequences (Aigner 
et al., 2008). However, the pig is becoming firmly established as biomedical 
model for translational diabetes research due to its enhanced comparability to 
human conditions (Aigner et al., 2010; Bahr and Wolf, 2012; Douglas, 1972; 
Lunney, 2007). To date insulin-deficient diabetes mellitus in the pig has been 
experimentally induced by either total pancreatectomy or by cytotoxic "-cell 
destruction through diabetogenic agents such as streptozotocin. Both methods 
have substantial drawbacks (Dufrane et al., 2006; Stump et al., 1988; Wilson et 
al., 1986). Therefore the establishment of genetically engineered diabetic pig 
models represents an opportunity to overcome disadvantages of existing methods 
to induce diabetes. 
The aim of the present study was the generation as well as the genotypic and 
phenotypic characterization of the first genetically engineered porcine animal 
model of permanent neonatal diabetes mellitus, corresponding to the human 
INSC96Y mutation and the Ins2 mutation of the Akita mouse model. Hemizygous 
INSC94Y transgenic pigs develop a severe diabetic phenotype based upon 
expression of a mutated INS gene (INSC94Y), leading to a clinically relevant 
disturbance of pancreatic "-cells. In this thesis, the underlying disease 
mechanisms, clinical features and pathomorphological properties of hemizygous 
INSC94Y transgenic pigs were investigated. 
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II. REVIEW OF THE LITERATURE 
1.  Diabetes mellitus 
1.1. Definition and description of diabetes mellitus 
The term diabetes mellitus encompasses a heterogeneous group of metabolic 
disorders characterized by steadily increasing blood glucose levels, polydipsia, 
polyuria, weight loss as well as diabetic ketoacidosis (DKA) and nonketotic 
hyperosmolar syndrome in life-threatening consequence of metabolic 
decompensation (Expert Committee on the Diagnosis and Classification of 
Diabetes Mellitus,2003; ADA, 2013; Kuzuya et al., 2002; Yared and Chiasson, 
2003). These characteristic symptoms and a variety of severe long-term 
complications of sustained diabetes mellitus such as cardiovascular diseases, 
diabetic retinopathy, diabetic nephropathy and diabetic neuropathy leading to 
substantial organ failure and supposed to be a major cause of death with diabetes, 
predispose diabetes mellitus towards a general health problem nowadays (ADA, 
2013; Wild et al., 2004). The pathogenesis of hyperglycemia in diabetes is due to 
insulin deficiency resulting from inadequate insulin secretion or insufficient tissue 
response to insulin (ADA, 2013). A large range of pathogenic processes 
diversifies the etiology of this disease, which is therefore not completely 
elucidated.  
1.2. Classification criteria of diabetes mellitus 
The first organization, who went about establishing a systematic classification for 
diabetes mellitus, was the National Diabetes Data Group of the USA (NDDG) and 
the second World Health Organization Expert Committee on Diabetes Mellitus in 
1979 and in 1985 respectively (Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, 2003). Since the introduction of this first 
classification scheme in 1980, the classification for diabetes mellitus was 
constantly revised and current knowledge was included (Alberti and Zimmet, 
1998; Harris, 1988). These days, the generally accepted classification criteria 
based on etiologic and pathogenic aspects were first established by an Expert 
Committee of the American Diabetes Association (ADA) in 1997 and is annually 
published after revision by the ADA (Gavin, 1998). According to the definitions 
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of the ADA, diabetes mellitus in humans is subdivided into four etiopathogenic 
groups. The majority of diabetic patients are assigned to type 1 and type 2 
diabetes mellitus, which accounts for 5 to 10% and 90 to 95% respectively of 
those with diabetes and mainly contributes to diabetes mellitus emerging as 
epidemic (ADA, 2013). The third group is outlined as other specific types of 
diabetes and summarizes a group of monogenetic disorders accompanied by 
mutations in genes encoding for several transcription factors (HNF1A, HNF4A, 
HNF1B, IPF1/PDX1, NEUROD1) and for the glucokinase (GCK) (Froguel et al., 
1992; Horikawa et al., 1997; Stoffers et al., 1997a; Yamagata et al., 1996a; 
Yamagata et al., 1996b). These genetic defects result in a disturbed !-cell function 
and are referred to as maturity-onset diabetes of the young 1-6 (MODY1-6) 
according to the respective gene involved (ADA, 2013; Vaxillaire and Froguel, 
2006). Recently, the clinical variants transient neonatal diabetes mellitus (e.g. 
ZAC/HYAMI imprinting defect on chromosome 6q24) and permanent neonatal 
diabetes mellitus (e.g. KCNJ11) were included in this category (ADA, 2013; 
Aguilar-Bryan and Bryan, 2008; Hutchison et al., 1962; Polak and Cave, 2007; 
Shield, 2000). Additionally the third group combines abnormalities of insulin 
action resulting from genetic disturbance of the insulin receptor function in 
consequence of mutations in the insulin receptor gene (INSR) and mainly presents 
within a pediatric syndrome (ADA, 2013). Furthermore affections of the exocrine 
pancreas including recurrent pancreatitis, traumata and neoplasia as well as 
hormone-related diabetogenic metabolic status of certain endocrinopathies and 
several infectious diseases can be causative for diabetes mellitus and are likewise 
categorized in the third group (ADA, 2013). As approximately 7% of pregnant 
women are diagnosed with diabetes mellitus or diminished glucose tolerance with 
first onset during pregnancy and associated with adverse effects on fetuses, a 
fourth systematic group was defined, called gestational diabetes mellitus (Metzger 
et al., 2007).  
1.2.1. Diabetes mellitus – a major public health problem 
Diabetes mellitus has evolved into a steadily increasing socioeconomic health 
problem of global extent and a considerable cause of early death nowadays 
(Roglic and Unwin, 2010; Shaw et al., 2010). According to extrapolations, the 
demographic change, urbanization attended by changing lifestyles and the overall 
growing world population will provoke an explosive increase of the prevalence of 
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diabetes mellitus worldwide by the year 2030 (Ramachandran et al., 1999; Wild et 
al., 2004). A tremendous increase from currently 346 million to 439 million 
affected people suffering from diabetes mellitus worldwide is expected by the 
year 2030 (Scully, 2012; Shaw et al., 2010). This represents an increase of 20% in 
the Western civilization and an increase of 68% in developing and newly 
industrialized countries, with the main focus on India, China, Indonesia, 
Bangladesh and Brazil for instances. The greatest absolute increase is extrapolated 
for India and China (Shaw et al., 2010; Wild et al., 2004). In addition these 
calculations are based on the assumption that the effects of other risk factors 
including general public adiposity will remain constant and that a large number of 
people are undiagnosed with diabetes mellitus (Flores-Le Roux et al., 2011; Gray 
et al., 2004; Ishihara et al., 2006). Therefore, the estimates of the extent of the 
global diabetic epidemic are anticipated to be even exceeded by the year 2030 
(Wild et al., 2004). An enormous economic burden for the healthcare systems is 
unavoidable. Due to the chronic character of the disease and the severe 
complications a doubling of the costs is expected by the year 2034 (Huang et al., 
2009). Moreover, expenses caused by economic exposure through premature 
morbidity and disability should not be neglected. The total expenditures just spent 
for medical care of diabetes patients and financial losses sustained by reduced 
national economic productivity in the USA will increase from $ 174 billion 
determined in 2007 to $ 336 billion due to the increased population of diabetics by 
the year 2034 (ADA, 2008; Huang et al., 2009; Tao et al., 2010). In consideration 
of the serious global and societal implications of the growing burden of diabetes 
mellitus, internationally concerted research efforts are imperative to clarify the 
etiology and pathogenesis of the various forms of diabetes mellitus in order to 
create the basis for comprehensive new prevention strategies and the development 
of new diagnostic and treatment methods (Wild et al., 2004; Zimmet et al., 2001). 
1.2.1.1. Type 2 diabetes mellitus – a heterogeneous disease 
Indeed, the epidemic of diabetes mellitus is chiefly represented through type 2 
diabetics (Zimmet et al., 2001). Strong genetic predisposition for glucose 
intolerance and obesity caused by an unhealthy hypercaloric diet and physical 
inactivity are risk factors for the dysregulation of glycemic control and at last 
clinically overt diabetes mellitus (ADA, 2013; Leahy, 2005). In the early latency 
phase, a dynamic interaction between insulin secretion and insulin resistance is 
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crucial to maintain normal glucose tolerance. Therefore the prediabetic phase 
remains unnoticed for years (ADA, 2013; DeFronzo, 2004). Nevertheless the 
increased risk of developing severe diabetes-associated long-term vascular 
complications persists (ADA, 2013). The insulin resistant organism reacts to 
chronically elevated blood glucose levels with increased insulin secretion and 
insulin synthesis as positive adaptive response (DeFronzo, 2004; Kahn, 2003). 
The increased insulin supply leads to a reduction of the density of peripheral 
insulin receptors present on the cell surface of all insulin target tissues. Thus the 
peripheral insulin resistance of the target cells results in a relative insulin 
deficiency vice versa (ADA, 2013; DeFronzo, 2004; Leahy, 2005). Certainly, 
obesity itself or an increased proportion of abdominal fat tissue contributes to 
insulin resistance even in non-diabetic subjects on a large scale (Bogardus et al., 
1985; Ludvik et al., 1995). The exhaustion of these compensatory mechanisms 
consequently results in an increased apoptosis rate of pancreatic !-cells with a 
progressive reduction of pancreatic !-cell mass through exposure to high blood 
glucose levels. Consecutive hypoinsulinemia leads to clinical manifestation of 
diabetes mellitus, reaching reduction of functional !-cell mass by 60% (Butler et 
al., 2003). Moreover pancreatic islet amyloidosis triggering !-cell apoptosis are 
supposed to contribute to the development of insulin resistance and impaired 
insulin secretion in type 2 diabetes patients (Butler et al., 2003; DeFronzo, 2004).  
1.2.1.2. Type 1 diabetes mellitus – glycemic dysregulation through 
autoimmunity  
Type 1 A diabetes mellitus is a chronic autoimmune disease (Imagawa et al., 
2000). Cellular autoimmune-mediated inflammatory processes in the endocrine 
pancreas and the consecutive destruction of pancreatic islet mass by CD4+ and 
CD8+ cytotoxic T cells and macrophages lead to an insufficient endogenous 
insulin secretion and thereby to an absolute insulin deficiency (ADA, 2013; 
Gillespie, 2006). At diagnosis of pathognomonic symptoms, 70 to 80% of 
functional !-cell mass has been destroyed (Cnop et al., 2005). Autoantibodies, 
consistently present in type 1 diabetics, show specific binding affinity to islet cells 
(ICA), to insulin (IAA), to glutamic acid decarboxylase (GAD 65), to zinc 
transporter 8 (ZnT8) and to protein tyrosine phosphatases IA-2 and IA-2!, both 
transmembrane proteins expressed in human pancreatic islets. The detection of 
any of these autoantibodies in otherwise healthy individuals is highly predictive in 
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even diagnosing those with increased risk (Gillespie, 2006; Kukreja and 
Maclaren, 1999; Lan et al., 1996; Lu et al., 1996; Merger et al., 2012; Notkins et 
al., 1996). Moreover the progression to insulin dependency is also related to 
genetic predisposition associated with 20 chromosomal regions including 
contribution of the major histocompatibility complex region (MHC) on 
chromosome 6p21, namely the human leukocyte antigen (HLA) risk alleles (DQ, 
DR) (ADA, 2013; Cudworth and Woodrow, 1975; Kukreja and Maclaren, 1999; 
Merger et al., 2012; Pociot and McDermott, 2002). Unfortunately an additional 
susceptibility to other autoimmune endocrine diseases including Hashimoto´s 
thyroiditis, Addison disease, vitiligo and myasthenia gravis for instances can be 
diagnosed as a corollary of diabetes mellitus in these patients (ADA, 2013; 
Merger et al., 2012). Gestational infections, hemolytic diseases of the newborn 
(erythroplastosis fetalis), viral infections (e.g. Coxsackie B virus, human 
rotavirus, cytomegalovirus, measles virus) and some dietary proteins of milk and 
wheat are supposed to contribute to !-cell autoimmunity by generation of 
monoclonal autoantibodies through molecular mimicry to cell components of the 
host (Bach, 1994; Kukreja and Maclaren, 1999; Larsson et al., 2004). Evidence 
for autoimmunity and risk HLA haplotypes are not mandatory for 10% of the 
patients newly diagnosed with type 1 diabetes mellitus and the etiology remains 
idiopathic (type 1 B) (ADA, 2013; Imagawa et al., 2000). Type 1 diabetes 
mellitus is likely to be diagnosed between childhood and puberty with a second 
peak in the fifth decade of life due to preservation of sufficient residual !-cell 
function for years and therefore fairly resembling characteristics of type 2 
diabetes mellitus (ADA, 2013; Karjalainen et al., 1989; Merger et al., 2012). In 
early childhood diabetic ketoacidosis (DKA) is commonly the first clinical 
manifestation of previously undiagnosed diabetes mellitus and young patients are 
hospitalized with distinctive symptoms in an altered state of consciousness 
(Expert Comittee on the Diagnosis and Classification of Diabetes mellitus,  2003; 
ADA, 2013; Merger et al., 2012).  
1.2.2. Diabetes mellitus – a rare monogenetic disorder 
In rare cases of juvenile-onset diabetes mellitus classic autoimmunity related to 
type 1 diabetes is not the underlying pathogenesis, but rather monogenetic 
diseases (Edghill et al., 2008; Shield et al., 1997). In general, monogenetic 
diabetes is subdivided into maturity-onset diabetes of the young (MODY) and 
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neonatal diabetes (Edghill et al., 2008; Malecki and Mlynarski, 2008; Molven et 
al., 2008). MODY subjects are normally diagnosed under the age of 25 years 
revealing progressive !-cell dysfunction with primarily disturbed glucose-
stimulated insulin secretion and autosomal dominant inheritance of the genetic 
defects intimately connected with multigenerational pedigree (ADA, 2013; 
Edghill et al., 2008; Fajans et al., 2001; Vaxillaire and Froguel, 2006; Velho and 
Froguel, 1998; Yamagata et al., 1996a). Severe !-cell dysfunction accompanied 
by insulin deficiency causing severe hyperglycemia requiring supplementary 
insulin and ketoacidosis within six months of age, highly-associated with heredity, 
are pathognomonic characteristics of neonatal diabetes mellitus and a monogenic 
origin of the disease should be implicitly evidenced (Edghill et al., 2006; Polak 
and Cave, 2007; Shield et al., 1997; von Muhlendahl and Herkenhoff, 1995). 
Although monogenicity is very rare with diabetes mellitus, precise elucidation of 
the genetic defect is essential for accurate prognosis and an optimized treatment 
regimen for previously unspecified diabetics possibly through gene-based 
therapies in the future (Hattersley, 2005; Malecki and Mlynarski, 2008; Pearson et 
al., 2003; Slingerland, 2006; Stoy et al., 2007). Furthermore the well-known 
pattern of inheritance offers the possibility to identify further carriers of specific 
mutations in MODY-associated genes in pedigrees at risk through genetic 
screening for augmented prediabetic therapeutic intervention (Fajans et al., 2001). 
1.2.2.1. Maturity-onset diabetes of the young (MODY) 
Mutations in six susceptibility alleles on different chromosomes have been 
unveiled so far as a cause of maturity-onset diabetes of the young (MODY) 
(ADA, 2013; Froguel and Velho, 1999; Hansen et al., 2002; Vaxillaire and 
Froguel, 2006). Comprising 2% to 5% of rarely obese patients previously 
diagnosed with type 2 diabetes, MODY is the most common form of monogenetic 
diabetes mellitus, especially by reason of the very prevalence of 15% to 20% of 
MODY subjects with abnormalities in unknown genes and the high feasibility of 
further monogenetic forms of type 2 diabetes to be identified soon (Edghill et al., 
2008; Frayling et al., 2003; Hansen et al., 2002; Vaxillaire and Froguel, 2006). 
Since the discovery of heterozygous monogenetic mutations in the glucokinase 
locus (GCK) on chromosome 7p as a cause of deficient glucose-stimulated insulin 
release of pancreatic !-cells as well as imbalance of hepatic glycogen storage and 
gluconeogenesis through defective glycolytic enzyme glucokinase in 1992, more 
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than 130 distinct monogenetic mutations have been identified in the GCK related 
to MODY 2 (Fajans et al., 2001; Froguel et al., 1992; Glaser et al., 1998; 
Matschinsky et al., 1998; Velho et al., 1996). Clinical MODY criteria are also 
linked to monogenetic defects of transcription factors predominantly expressed in 
pancreatic !-cells (Fajans et al., 2001). Hepatocyte nuclear factor 1" (HNF1A, 
MODY 3), HNF 4 " (HNF4A, MODY 1), insulin promoter factor 1 (IPF1/PDX1, 
MODY 4), HNF 1! (HNF1B, MODY 5) and neurogenic differentiation factor 1 
(NEUROD1, MODY 6) are nuclear proteins mediating glucose metabolism and 
prenatal pancreas development through specific transcriptional modulation of 
genes encoding insulin (INS), somatostatin (SST), glucokinase (GCK), islet 
amyloid polypeptide (IAPP) as well as the glucose transporter 2 (GLUT-2) but 
also collaborating in the regulation of hepatic gene expression (Fajans et al., 2001; 
Froguel and Velho, 1999; Horikawa et al., 1997; Jonsson et al., 1994; Ladias et 
al., 1992; Malecki et al., 1999; Stoffel and Duncan, 1997; Stoffers et al., 1997a; 
Yamagata et al., 1996a; Yamagata et al., 1996b). MODY 2 and MODY 3, 
diagnosed in one third of MODY patients and therefore estimated to be the most 
common subtypes of monogenetic diabetes among adults and the other very rare 
MODY-associated mutations are linked to clinical heterogeneity of the severity of 
hyperglycemia and time point of the onset of conspicuous symptoms (ADA, 2013; 
Edghill et al., 2008; Fajans et al., 2001; Froguel and Velho, 1999; Vaxillaire and 
Froguel, 2006).  
1.2.2.2. Neonatal diabetes mellitus (NDM) 
Neonatal diabetes, also referred to as congenital diabetes mellitus is divided into 
two clinical variants - transient neonatal diabetes mellitus (TNDM) and permanent 
neonatal diabetes mellitus (PNDM) - according to whether insulin dependency 
goes into complete remission or remains throughout life (Aguilar-Bryan and 
Bryan, 2008; Hutchison et al., 1962; Polak and Cave, 2007; Shield, 2000). With 
an estimated incidence rate of 1:300000 to 1: 500000 live newborns, diabetes 
mellitus is diagnosed on very rare occasions within the neonatal period (Aguilar-
Bryan and Bryan, 2008; Polak and Cave, 2007; Shield et al., 1997). Clinical 
features such as intrauterine growth retardation (IUGR) attributed to the absence 
of insulin in utero as fetal growth factor, life-threatening hyperglycemia with 
ketoacidosis and emaciation are hardly implementable for accurate discrimination 
between TNDM and PNDM. Diagnosis at the molecular level becomes obligatory 
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(Cave et al., 2000; Hutchison et al., 1962; Polak and Cave, 2007; Shield et al., 
1997; von Muhlendahl and Herkenhoff, 1995). In general infants born with 
TNDM recover completely from their severe symptoms and become independent 
of insulin medication most likely within one year but are susceptible to relapse 
into a non-autoimmune related diabetic state requiring permanent medical care 
usually around adolescence. Thus preventive checkups at close intervals are 
advised (Fosel, 1995; Gentz and Cornblath, 1969; Gottschalk et al., 1992; Polak 
and Cave, 2007; Shield et al., 1997; Vanelli et al., 1994). Disturbed glucose 
tolerance and type 2 diabetes mellitus after 20 years of complete remission occur 
to some extent but also permanent remission throughout life was observed 
(Temple et al., 1996; von Muhlendahl and Herkenhoff, 1995). Both TNDM and 
PNDM are each related to numerous specific genetic mutations, which can be 
identified in almost 60 to 90% of the cases (Aguilar-Bryan and Bryan, 2008; 
Edghill et al., 2010; Hamilton-Shield, 2007; Shield, 2000). The genetic basis of 
insulin secretory failure present in PNDM is based upon a more heterogeneous 
genetic background and diabetes mellitus either arises as solitary disease or 
constitutes as an epiphenomenon of a multisystem pediatric syndrome including 
neonatal diabetes mellitus (Edghill et al., 2004; Polak et al., 2008; Stoy et al., 
2007). Predominantly heterozygous activating mutations in the KCNJ11 gene 
encoding the pore-forming inwardly rectifying protein subunit (Kir6.2) and less 
frequent in the ABCC8 gene responsible for sulfonylurea receptor (SUR1) 
expression of the ATP-sensitive potassium channel (KATP) localized within the 
membranes of pancreatic !-cells lead to PNDM due to disturbance of 
transmembrane depolarization and failure of insulin exocytosis through absent 
fusion of the insulin secretory granules with the membrane (Babenko et al., 2006; 
Edghill et al., 2004; Gloyn et al., 2004; Polak and Cave, 2007). Accounting for 
80% of subjects diagnosed with KCNJ11 mutations, the mutation arose 
spontaneously (Gloyn et al., 2004; Stoy et al., 2007). Furthermore offspring of 
parents carrying a heterozygous mutant GCK both, are prone to homozygosity and 
permanent neonatal diabetes mellitus resulting from lack of glycolytic activity 
(Fajans et al., 2001; Njolstad et al., 2001; Stoy et al., 2007). Moreover 
homozygous patients with an autosomal recessive point mutation in the human 
insulin promoter factor 1 gene (IPF1/PDX1) within codon 63 display severe 
diabetic symptoms with additional impairment of the exocrine function of the 
pancreas resulting from pancreas aplasia (Polak and Cave, 2007; Stoffers et al., 
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1997b). Mutations in the forkhead box P3 gene (FOXP3) transcriptionally 
regulating immune homeostasis through regulatory T cells was found as leading 
cause of the autosomal recessive human immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), which combines 
permanent diabetes mellitus and failure of many organ systems resulting from 
inflammatory infiltration with autoreactive immune cells (Bennett et al., 2001; 
Wildin et al., 2002; Zhang and Zhao, 2007). The Wolcott-Rallison syndrome is 
another severe autosomal recessive pediatric syndrome linked to mutations of the 
gene encoding the eukaryotic translation initiation factor 2 " kinase 3 (EIF2AK3) 
mapped to chromosome 2p12 (Delepine et al., 2000). In addition to progressive 
diabetes mellitus, disturbed regulation of protein synthesis with consecutive 
increased stress on the endoplasmic reticulum leads to a variety of fatal 
concomitant symptoms including spondylo-epiphyseal dysplasia, hepatomegaly, 
renal failure and mental retardation (Polak and Cave, 2007; Wolcott and Rallison, 
1972). Another rare congenital syndromic disorder characterized by pancreas and 
cerebellar hypoplasia is caused by mutant pancreas specific transcription factor 1" 
(PTF1A) being expressed in pancreatic !-cells as well as in the cerebellum 
(Sellick et al., 2004). Mutations in the GLIS family zinc finger 3 transcription 
factor gene (GLIS3) have recently been identified as a cause of permanent 
neonatal diabetes mellitus accompanied by hypothyroidism and deformity of the 
face amongst others (Hamilton-Shield, 2007; Senee et al., 2006). Paternally 
inherited anomalies of an imprinted region on chromosome 6q24 including 
paternal uniparental disomy (UPD 6), paternal partial duplication as well as 
incomplete or absent methylation, which each result in overexpression of critical 
paternally expressed alleles due to imprinting malfunction, are frequently leading 
cause of the diabetic phenotype in transient diabetic neonates (Cave et al., 2000; 
Gardner et al., 2000; Polak et al., 2008; Shield, 2000; von Muhlendahl and 
Herkenhoff, 1995). Genes encoding zinc finger protein pleiomorphic adenoma-
like protein 1 (PLAGL1), antiproliverative transcription factor of the cell cycle, 
pituitary adenylate cyclase polypeptide (PACAP1) involved in insulin secretion, 
and the imprinted HYMAI gene (hydatidiform mole associated and imprinted 
gene) are supposed as suitable candidate genes due to their location on 
chromosome 6 (Arima et al., 2001; Arima et al., 2000; Spengler et al., 1997). 
Mutations in the KCNJ11 and the ABCC8 genes, encoding the critical protein 
subunits Kir6.2 and SUR1 of the KATP-channels of pancreatic !-cells have also 
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been demonstrated as a rare cause of TNDM (Babenko et al., 2006; Flanagan et 
al., 2007; Gloyn et al., 2005; Polak et al., 2008). 
1.2.2.3. Insulin gene mutations 
Recently screening studies with linkage analyzes of families with PNDM 
substantiated reasonable suspicion that the insulin gene (INS) on chromosome 
11p15 might be a candidate gene involved in the pathogenesis of subjects 
diagnosed with permanent neonatal diabetes of unknown genetic background but 
unrelated to autoimmunity (Edghill et al., 2008; Stoy et al., 2007; Stoy et al., 
2010). To date, 20 heterozygous missense mutations in the human INS gene have 
been identified as common cause of insulin-deficient, permanent diabetes mellitus 
diagnosed predominantly in the neonatal period but definitely within one year of 
life and therefore referred to as mutant INS gene-induced diabetes of youth 
(MIDY) (Colombo et al., 2008; Edghill et al., 2008; Liu et al., 2010; Stoy et al., 
2007). Classified by a nomenclature according to their position in the polypeptide 
chain of the mature insulin molecule and under specification of the amino acid 
residues being affected, identified dominant-acting heterozygous INS mutations 
were located at following codons: A24D at the signal peptide, H29D, L30P/V, 
G32S/R, L35P, L39_Y40delinsH, C43G, G47V and F48C located at the B-chain, 
R89C at the enzymatic cleavage site between C-peptide and the A-chain, as well 
as G90C, C95Y, C96Y/S, S101C, Y103C and Y108C/X situated in the A-chain of 
the preproinsulin molecule could be identified and are highly preserved 
throughout species (Colombo et al., 2008; Edghill et al., 2008; Stoy et al., 2010). 
Accounting for 56% of all INS mutations detected in permanent diabetic probands 
so far, A24D, G32S/R, F48C, R89C and C96Y/S were supposed to be the most 
common (Stoy et al., 2010). Diagnosed at the median age of nine to eleven weeks, 
neonatal patients suffer from severe hyperglycemia with menacing plasma 
glucose levels of 681 mg/dl accompanied by ketoacidosis, mostly undetectable C-
peptide levels reflecting complete insulin deficiency and barely residual !-cell 
function. Drastically reduced birth weights showing tendency towards cachexia 
are regularly observed (Edghill et al., 2008; Stoy et al., 2007; Stoy et al., 2010). 
Glycemia in all investigated subjects was controlled with exogenous insulin 
medication in usually full replacement dosage of 0.5 units per kg per day 
leastwise (Edghill et al., 2008). Thus, symptoms of PNDM due to heterozygous 
mutations in the INS gene are hardly capable of being differentiated from those of 
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KCNJ11 and ABCC8 mutations previously described (Stoy et al., 2007). 
Moreover in the vast majority of subjects carrying mutant INS heterozygosity so 
far, the mutation arose de novo, except for around 20% of probands born to 
affected parents showing autosomal dominant inheritance in origin (Colombo et 
al., 2008; Edghill et al., 2008; Stoy et al., 2010). By the way of an exception, 
mutations at codon A23S/T, R6C/H, G32S, L30M, R46Q and R55C at the 
enzymatic cleavage site between B-chain and C-peptide as well as R89C were 
identified to be also rare cause of idiopathic childhood-onset type 1 B diabetes 
mellitus, maturity-onset diabetes of the young (MODY) and unusually early 
type 2 diabetes mellitus associated with generally mild diabetic phenotypes, even 
though the estimated incidence was less than 2% (Bonfanti et al., 2009; Edghill et 
al., 2008; Molven et al., 2008; Polak et al., 2008; Rubio-Cabezas et al., 2009; Stoy 
et al., 2010). Beyond severe permanent diabetes mellitus due to dominantly acting 
INS mutations, recessive INS mutations in the homozygous state affecting 
essential regulatory nucleotide sequences for proinsulin biosynthesis are potent 
enough to result in permanent neonatal diabetes mellitus, non-autoimmune type 1 
B diabetes mellitus and by the way of an exception in transient neonatal diabetes 
mellitus (Stoy et al., 2010). Due to the recessive inheritance pattern, neonates born 
to asymptomatic heterozygous carriers and especially subjects of consanguineous 
pedigrees are at increased risk of homozygosity and clinical manifestation of 
diabetic symptoms (Garin et al., 2010). Pathogenicity is based on recessively 
acting mutations occurring to transcription factor binding sites of the INS gene 
promoter region (c.366_-343del, c.-218A>C, c.331C>G/A, c.332C>G), to the 
translation initiation site c.3G>A/T, to the polyadenylation signal of the 
3´untranslated region (3´UTR) (c.*59A>G) as well as resulting in a nonsense 
mutation c.184C>T (p.Q62X) and a complete multiexon deletion (M1_Q62del) 
affecting translation initiation site M1I (Garin et al., 2010; Hay and Docherty, 
2006; Matsuoka et al., 2003; Naya et al., 1995; Wicksteed et al., 2007). Another 
subgroup of autosomal dominant inherited mutations in the INS gene was detected 
earlier to contribute on rare occasions to familial syndromes of 
hyperproinsulinemia as well as hyperinsulinemia by point mutations followed by 
amino acid substitution and have already been known for years as classical 
insulinopathies (Liu et al., 2010; Steiner et al., 1990; Stoy et al., 2010). The earlier 
described missense INS mutations V93L at position 3 of the A-chain, F48S and 
F49L at position 24 and 25 of the B-chain respectively are located at critical 
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recognition regions for insulin receptor binding and thereby influence the 
biological activity of the mutant insulin molecules (Haneda et al., 1983; Kwok et 
al., 1983; Nanjo et al., 1986; Tager et al., 1979). Hyperinsulinemia in these 
patients results from reduced receptor-mediated endocytosis through diminished 
receptor binding affinity of structurally abnormal insulin molecules (Steiner et al., 
1990; Stoy et al., 2010). Additionally point mutations at codon H34D at position 
10 of the B-chain as well as R89H/L/P at the endoproteolytic cleavage site 
between C-peptide and A-chain of the proinsulin polypeptide chain impair 
physiological processing to mature insulin and promote marked 
hyperproinsulinemia by releasing unprocessed or partially cleaved proinsulin 
intermediates into the circulation (Carroll et al., 1988; Chan et al., 1987; Collinet 
et al., 1998; Warren-Perry et al., 1997; Yano et al., 1992). In contrast to the 
disease pattern of the recently reported heterozygous and homozygous INS 
mutations, patients displaying familial hyperinsulinemia or hyperproinsulinemia 
mainly remain asymptomatic or reveal a certain degree of glucose intolerance and 
mild diabetic symptoms driven by insulin resistance with increasing age but 
barely overt diabetes mellitus (Oohashi et al., 1993; Steiner et al., 1990; Stoy et 
al., 2007). Hence, INS mutations were disregarded as potent pathogenic factors 
contributing to severe !-cell failure a long time (Stoy et al., 2010). 
2. Pathophysiological consequences of insulin gene 
mutations 
2.1. Insulin biosynthesis and posttranslational modification in the 
endoplasmic reticulum in the context of insulin gene mutations 
Throughout vertebrate species the amino acid sequence of insulin is fairly well 
preserved and was first completely enlightened by Frederick Sanger in 1951 with 
bovine insulin followed by Nicol and colleagues in 1960 sequencing the human 
insulin (Mayer et al., 2007; Nicol and Smith, 1960; Sanger, 1959; Stoy et al., 
2010). The insulin gene (INS) located at chromosome 11p15 is the encoding 
region for a cytosolic single-chain precursor molecule preproinsulin comprising 
the signal peptide of 24 amino acid residues, the B-chain consistent of 30 amino 
acid residues, the C-peptide flanked on both sides by dibasic cleavage sites and 
the A-chain of 21 amino acid residues in length (Liu et al., 2010; Stoy et al., 2010; 
Weiss, 2009). Efficiency of initiation and elongation of insulin mRNA towards 
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the nascent preproinsulin polypeptide is predominantly adjusted consistent with 
blood glucose levels (Welsh et al., 1986). Signal recognition particle-mediated 
transfer (SRP) through the cytosol of pancreatic !-cells and co-translational 
delivery into the lumen of the endoplasmic reticulum (ER) are enabled by the 
sequence of the signal peptide mediating required interactions (Liu et al., 2010). 
Following translocation into the ER and cleavage of the signal peptide, folding 
and posttranslational modification including formation of highly conserved 
disulfide bonds connecting B7-A7, B19-A20 and A6-A11 cysteine residues of the 
resulting proinsulin monomer is achieved successively with the objective of 
achieving biological activity linked to the three-dimensional structure of the 
mature insulin molecule (Mayer et al., 2007; Stoy et al., 2010). Subsequent 
processing of the prohormone including sorting into immature secretory granules, 
hexamer formation and endoproteolytic cleavage of the C-peptide via a des-31, 32 
split proinsulin intermediate is completed transitioning through the Golgi 
compartment (Halban, 1994; Liu et al., 2010). Finally, the mature hormone is 
densely packed as Zn2+-hexameric assembly through hydrogen-bonding in mature 
secretory granules of pancreatic !-cells until being secreted as monomers into the 
portal circulation (Huang and Arvan, 1994). X-ray crystallography has shown that 
the mature insulin molecule is a globular protein constituted of three "-helical 
domains facilitating disulfide bonding by approximating appropriate amino acid 
residues (Baker et al., 1988; Liu et al., 2010). The A-chain forms two "-helices 
including amino acid residues A3 to A8 as well as A 13 to A19 adjoining 
antiparallel to each other and enabling C95(A6) - C100(A7) and C31(B7) – 
C96(A7) alignment (Baker et al., 1988; Derewenda et al., 1989; Hua et al., 2002; 
Liu et al., 2010). The B-chain is composed of a N-terminal chain, a central "-helix 
by the amino acid residues 9 to 19 contributing to the acquisition of the C43(B19) 
- C109(A20) linking as well as two !-turns spanning residues B7 to B10 and B20 
to B23 respectively (Baker et al., 1988; Hu et al., 1993; Nakagawa et al., 2006). 
The steric arrangement of the U-shaped double helix of the A-chain and the 
helical segment of the B-chain surrounds a hydrophobic core keeping non-polar 
amino residues inwardly (Baker et al., 1988; Mayer et al., 2007). Indeed, the 
highly preserved structural topology of the mature insulin, which consists 
ultimately of two polypeptide chains connected through disulfide bonds, hydrogen 
bonds as well as several hydrophobic and numerous non-covalent interactions 
showing strict homology in their localization within the molecule throughout 
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species, is most likely of particular importance for physiological competence of 
the hormone such as receptor binding affinity and structural stability (Hua et al., 
2006a; Mayer et al., 2007; Zoete and Meuwly, 2006). Therefore, heterozygous 
mutations of the INS gene causing steric rearrangement of the insulin molecule 
give rise to a profound failure of hormone biosynthesis and action (Liu et al., 
2010; Mayer et al., 2007).   
2.2. Structural and functional consequences of insulin gene mutations 
Heterozygous missense mutations in the INS gene disturbing insulin biosynthesis 
by shifting the amino acid sequence of the insulin precursor molecule have 
recently been reported as a new monogenetic cause of permanent neonatal 
diabetes mellitus through activation of the unfolded protein response and 
ultimately endoplasmic reticulum stress-induced !-cell apoptosis (Colombo et al., 
2008; Edghill et al., 2008; Garin et al., 2010; Stoy et al., 2007). The majority of 
the dominant-acting mutations either directly affect integrity of the three highly 
conserved disulfide bonds (C31(B7)–C96(A7), C43(B19)-C109(A20), C95(A6)-
C100(A11)) occurring in coding regions for cysteine residues involved in 
proinsulin disulfide pairing (C43G, C95Y, C96Y/S) or indirectly, occurring in 
critical regions for thermodynamic stability in the vicinity of such disulfide bonds 
(H29D, L30P/V, G32S/R, G47V, Y108X) (Colombo et al., 2008; Edghill et al., 
2008; Liu et al., 2010; Mayer et al., 2007; Stoy et al., 2007). The side chain of the 
histidine imidazole ring at B5 is indispensably entangled in A7–B7 alignment 
during biosynthesis and therefore substitution of the histidine residue at B5 for 
aspartic acid (H29D) hampers the kinetic folding process in the ER (Hua et al., 
2006a; Liu et al., 2010). Additionally H29 substitution directly affects steric 
configuration of the mature insulin protein and prevents aggregation towards a 
compact dimer by destabilizing the A7–B7 disulfide bridge, which is completely 
exposed on the surface of the molecule predominantly stabilized by the histidine 
residue at position B5 and thereby influences the conformation of neighboring 
structures (Baker et al., 1988; Hua et al., 2006a). The mutation L30P/V leads to 
augmented hydrophobicity and to altered orientation of the N-terminal domain of 
the B-chain provoking negative steric impact on A7 – B7 disulfide conjunction 
and on receptor recognition domains of the A-chain. Reduced receptor binding 
potency and folding capability were found to arise as a consequence (Blundell et 
al., 1972; Mayer et al., 2007; Nakagawa and Tager, 1991). A characteristic feature 
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of hexameric insulin is the capability of transitioning between the T and the R 
confirmation mainly directed by the glycine residue at position 8 of the B-chain 
exhibiting a positive dihedral angle or an anhedral angle. The stereospecific 
conformational change facilitates stability through disulfide pairing and folding of 
the immature molecule adopting the T-state confirmation but enhancing biological 
activity and receptor binding potency in the R-state (Nakagawa et al., 2005). The 
mutation G32S/R substituting the glycine residue at position B8 for L-serine or L-
arginine necessitates an axially symmetric rotation of the N-terminal domain of 
the B-chain, imitating R-like confirmation, which in consequence impairs folding 
by impeding A7–B7 disulfide linking (Hua et al., 2006c; Stoy et al., 2007). The 
G47V mutation at position B23 results in L-amino acid substitution and thereby 
affects A20–B19 disulfide bond and additional folding steps by perturbation of 
the specific A20–B19-related folding nucleus (Hua et al., 2006b; Nakagawa et al., 
2006; Stoy et al., 2007). Replacing the tyrosine residue at position A19 with a 
variable amino acid residue (Y108X) introduces a premature stop codon within 
the insulin mRNA neighboring the C43(B19)-C109(A20) disulfide bond. 
Therefore Y108X mutation directly inhibits translation of cysteine (C109) at 
position A20 as well as asparagine at position A21 of the N-terminal domain of 
the A-chain and the resultant preproinsulin cDNA completely lacks the utmost 
important disulfide bond C43(B19)-C109(A20) (Colombo et al., 2008). 
Furthermore several mutations in the INS gene introduce additional unpaired 
cysteine residues (F48C, R89C, G90C, S101C, Y103C, Y108C) increasing the 
risk of mispairing in critical regions of proteolytic cleavage sites at the A-chain-C-
peptide junction and especially in the contiguity to the C43(B19)-C109(A20) 
disulfide bond (Stoy et al., 2007). Additionally critical mutations were found at 
the N-terminal site of the signal peptide (R6C/H) or at the C-terminal cleavage 
site of the signal peptide (A24D), which are assumed to have adverse effects 
either on translocation of nascent preproinsulin into the lumen of the ER mainly 
through alterations of electrical properties or on cleavage of the signal peptide 
affecting the subsequent protein folding pathway in the ER (Park et al., 2010; 
Stoy et al., 2007; von Heijne, 1988). As previously described, the mutual steric 
alignment of the A-chain and the B-chain is predominantly perpetuated by 
hydrophobic interactions of several non-polar amino acids (L102(A13), 
L105(A16), L30(B6), L35(B11), L39(B15), V42(B18), Y108(A19)) constituting a 
hydrophobic core (Mayer et al., 2007; Zoete and Meuwly, 2006). Presumably, 
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mutations around these critical residues, such as L35P (B11) and the in-frame 
substitution L39_Y40delinsH (B15, B16) are highly conducive to serious 
conformational changes of the entire proinsulin monomer especially through 
hydrophobic interaction with neighboring water molecules and therefore to 
impairment of thermodynamic stability, imperative for the subsequent protein 
folding process (Colombo et al., 2008; Schroder and Kaufman, 2005; Zoete and 
Meuwly, 2006). Moreover insulin receptor recognition-site of the mature insulin 
molecule is equably composed of the invariant amino acid residues G90(A1), 
Q94(A5), Y108(A19), N110(A21), V36(B12),Y40(B16), G47(B23), F48(B24) as 
well as F49(B25) conveying high affinity binding energy to the receptor. Besides 
steric impact on secondary structure of the immature protein, mutant alleles 
encoding these amino acids consequently abate biological activity of the resultant 
insulin hormone defined by efficient receptor binding acquirement (Mayer et al., 
2007; Mirmira et al., 1991; Mirmira and Tager, 1989). By way of derogation, 
rarely observed mutations at codon A23S/T, L68M, and G84R are supposed to be 
barely pathogenic, as they are either capable to escape entrapment within the ER 
and effectively reach the Golgi compartment or as they are located at CpG 
hotspots for mutations in mammalians and thus are not conserved throughout 
species (Edghill et al., 2008; Park et al., 2010; Stoy et al., 2010). Furthermore 
mutant proinsulin variants are assumed to additionally affect biosynthesis and 
secretion of the synchronously expressed wild-type proinsulin in a dominant-
negative pattern by constituting covalent intermolecular protein complexes 
recruiting wild-type proinsulin molecules through highly reactive cysteine 
residues and hydrophobic interactions (Hodish et al., 2010; Liu et al., 2007; Park 
et al., 2010; Weiss, 2009). Hence, additionally retained wild-type insulin 
contributes to already insufficient insulin supply and acuminates ER-stress 
culminating in !-cell death (Hodish et al., 2010). Indeed, the diabetic phenotype in 
subjects genotyped with heterozygous INS mutations are based upon perturbation 
of proinsulin biosynthesis and assembly (Stoy et al., 2007; Weiss, 2009). In 
general mutant proinsulin shows an increased propensity to incorrect folding and 
steric rearrangement definitely failing the quality inspection in the endoplasmic 
reticulum (ER) and is therefore trapped within the ER (Ellgaard and Helenius, 
2003; Park et al., 2010; Rajan et al., 2010; Stoy et al., 2007). Altered side chain 
properties of the substituted amino acid residues, incorrect disulfide pairing with 
resultant reactive unpaired cysteine residues and accumulation of unfolded 
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immature proteins presumably through defective communication of the mutant 
proinsulin polypeptide with the folding machinery of the ER, initiate an unfolded 
protein response pathway (UPR) ultimately triggering  !-cell apoptosis 
accompanied by absolute insulin deficiency (Colombo et al., 2008; Liu et al., 
2007; Noiva, 1999; Stoy et al., 2010; Wedemeyer et al., 2000; Weiss, 2009).     
2.3. The endoplasmic reticulum stress – critical role in the pathogenesis 
of diabetes mellitus  
2.3.1. Physiology of the endoplasmic reticulum – complex interaction of 
concomitant cellular factors  
The endoplasmic reticulum is a highly specialized and prolific organelle of 
eukaryotic cells featuring a suitable oxidative environment for the 
posttranslational modification of newly synthesized proteins and is therefore 
pivotal for the cells to survive (Araki et al., 2003; Ma and Hendershot, 2002; 
Scheuner and Kaufman, 2008; Sundar Rajan et al., 2007). Almost all secretory 
proteins are initially delivered to the endoplasmic reticulum for further 
modification followed by the release to target sites (Eizirik et al., 2008; 
Ghaemmaghami et al., 2003; Schroder and Kaufman, 2005). Nascent polypeptides 
are recruited into ribosome-nascent-chain-signal-recognition-particle complexes 
mediating translocation into the luminal space of the endoplasmic reticulum 
through the Sec61p protein channel (Adesnik et al., 1976; Connolly and Gilmore, 
1989; Neuhof et al., 1998; Walter and Johnson, 1994; Wilkinson et al., 1997). The 
ER harbors complex folding machinery composed of a diversity of molecular 
chaperones, several protein foldases as well as lectins imperative to accomplish 
numerous posttranslational modifications to the immature proteins. N-linked 
glycosylation and formation of disulfide bonds were identified to be the most 
common biosynthetic functions of the ER (Freedman, 1989; Gething and 
Sambrook, 1992; Schroder and Kaufman, 2005; Sundar Rajan et al., 2007; Walsh 
and Jefferis, 2006). The protein disulfide isomerase (PDI), catalyzing dithiol 
oxidation of protein substrates through a high intrinsic reduction potential of 
cysteine pairs in their active site, is the essential contributor of disulfide formation 
(Freedman, 1989; Gething and Sambrook, 1992; Kemmink et al., 1997; Sundar 
Rajan et al., 2007). Furthermore the oxidative redox state of the luminal 
compartment of the endoplasmic reticulum is mainly perpetuated by the electron 
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acceptor glutathione (GSH$GSSG) buffering thiol-disulfide exchange reactions 
(Hwang et al., 1992). In either case, proteins, undergone ER-associated 
posttranslational modification and assumed to be folded properly, are not  targeted 
to subsequent compartments a priori but have to pass through an quality control 
program (Ellgaard et al., 1999; Sayeed and Ng, 2005; Schroder and Kaufman, 
2005). A variety of molecular mechanisms function as effective monitoring 
system for correct folding of immature polypeptides by stabilizing misfolded 
protein intermediates, preventing aggregation, and retaining them in the ER 
(Ellgaard et al., 1999; Marquardt and Helenius, 1992). Unfolded polypeptides are 
characterized by completely or fractionally exposed hydrophobic regions or 
unpaired cysteine residues, normally kept safe within the core of a mature protein 
and are therefore certainly identified (Parodi, 2000; Schroder and Kaufman, 
2005). The adenosine triphosphate (ATP)-dependent chaperone BiP, highly 
expressed in pancreatic !-cells, binds folding intermediates energized by ATP 
hydrolysis through a N-terminal ATPase (Araki et al., 2003; Flynn et al., 1989). 
The calnexin-calreticulin cycle, also referred to as glucose trimming, is a dynamic 
process of glycosylation linked to increased substrate binding affinity of calnexin-
calreticulin and deglycosylation adherent with substrate release from the lectin 
anchor. This process is alternately regulated by the uridine 5’-diphosphate (UDP)-
glucose:glycoprotein glucosyl transferase (UGGT) and the "(1,3) glucosidase II 
(Ellgaard et al., 1999; Sousa et al., 1992). Improperly processed glycoproteins are 
efficiently retrieved via their hydrophobic properties and withdrawn by UGGT 
through another round of reglycosylation. Thus, the inchoate protein is retained 
within the endoplasmic reticulum and subjected to further folding cycles exerting 
for complete folding and steric conformation (Ellgaard et al., 1999; Parodi, 2000; 
Sousa and Parodi, 1995; Sousa et al., 1992). Furthermore, the protein disulfide 
isomerase (PDI) features an additional substrate-binding domain functioning as a 
molecular chaperone (Kemmink et al., 1997; Noiva, 1999; Ren et al., 1998; 
Wang, 1998). Following a stringent quality control, properly folded proteins are 
targeted for final modifications and sorting to the Golgi apparatus mediated by a 
vesicular transport system, known as ER-Golgi intermediate compartment or 
vesicular-tubular clusters (VTC) (Lee et al., 2004). De facto transport is mediated 
through COPII- and COPI-coated vesicles (Gorelick and Shugrue, 2001). 
Pancreatic !-cells are exceedingly addicted to a highly developed and undisturbed 
ER function due to their highly effective insulin biosynthesis (Araki et al., 2003; 
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Van Lommel et al., 2006). Vice versa, perturbations of the complex operational 
sequences of protein biosynthesis within the ER of pancreatic !-cells are often 
devastating (Eizirik et al., 2008; Liu et al., 2007; Sundar Rajan et al., 2007). 
Hence, mutations such as heterozygous mutations in the INS gene, affecting their 
own physiological protein folding process and provoking aggregation of unfolded 
polypeptides, have the ability to exert chronic stress on the ER and at last 
apoptotic cell death (Eizirik et al., 2008; Harding and Ron, 2002). 
2.3.2. The unfolded protein response (UPR) of the endoplasmic reticulum 
– distinct pathway in answer to ER stress 
Endoplasmic reticulum stress describes per definition a cellular state, which 
occurs when the functional demand on the ER overburdens the folding capacity of 
the ER resulting in the accumulation of incorrectly folded or unfolded proteins in 
the luminal space of the endoplasmic reticulum (Harding and Ron, 2002; Sundar 
Rajan et al., 2007; Yamamoto et al., 2004). The unfolded protein response (UPR) 
is a positive adaptive signaling pathway of the endoplasmic reticulum adapting 
the folding capacity and efficiency to variable requirements in order to overcome 
a certain level of ER stress (Bernales et al., 2006; Eizirik et al., 2008; Rutkowski 
and Kaufman, 2004). Thus the accumulation of unfolded proteins prompts a 
complex signaling pathway largely resulting in the transcriptional enhancement of 
molecular chaperones and folding enzymes to prevent aggregation, adjustment of 
new protein synthesis on the transcriptional level to prevent advancing 
accumulation of client polypeptides and augmented ER-associated degradation 
(ERAD) by the ubiquitin-proteasome pathway following retro-translocation to the 
cytosol to discard irreversibly unfolded proteins (Araki et al., 2003; Eizirik et al., 
2008; Patil and Walter, 2001; Sundar Rajan et al., 2007). 
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Figure 1: The unfolded protein response (UPR) pathway 
The UPR initializes broadly based strategies to overcome ER stress and to 
preserve cellular integrity (Araki et al., 2003); with kind permission from the 
Society of Experimental Biology and Medicine. 
 
2.3.2.1. Signal transduction of the unfolded protein response – ambitious 
interdisciplinary efforts to preserve cellular integrity 
The inositol requiring ER-to nucleus signal kinase 1 " (IRE1"), RNA-dependent 
protein kinase-like endoplasmic reticulum eIF2" kinase (PERK) and activating 
transcription factor 6 " and ! (ATF6"/!) are stress-regulated transcription factors 
triggering signal transduction from the ER to the nucleus as proximal components 
of the UPR in eukaryotic cells (Bertolotti et al., 2000; Harding et al., 1999; Haze 
et al., 2001; Rutkowski and Kaufman, 2004; Scheuner and Kaufman, 2008; Shi et 
al., 1998; Tirasophon et al., 1998; Wu et al., 2007; Yoshida et al., 1998). IRE1", 
PERK and ATF6 are maintained in the inactive state through complex formation 
with the molecular chaperone BiP bound to their luminal domains (Bertolotti et 
al., 2000; Ron, 2002; Shen et al., 2002). PERK is a type I transmembrane protein 
kinase, which possesses an oligomerized and trans-autophosphorylated luminal 
domain in its active state increasing protein-kinase activity of the cytoplasmic 
domain (Bertolotti et al., 2000; Harding et al., 1999; Liu et al., 2000; Taylor et al., 
1996). Activated PERK phosphorylates the highly conserved serine residue 51 
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located in the "-subunit of the guanine nucleotide binding protein (G-protein) 
eukaryotic initiation factor-2" (eIF2"), diminishing protein synthesis through 
disturbed translation initiation (Harding et al., 1999; Samuel, 1993; Shi et al., 
1998; Vachon et al., 1990). Phosphorylated eIF2" (PeIF2") is unable to 
interconnect with the translation initiator methionyl tRNA (Met-RNA), imperative 
for guanine triphosphate (GTP)-dependent binding to the 40S ribosomal subunit 
and translation initiation of most client mRNAs (de Haro et al., 1996; Harding et 
al., 2000; Pain, 1996; Samuel, 1993). PeIF2" reveals augmented affinity for 
guanine diphosphate (GDP) and is therefore sequestered in the inactive 
conformation (Clemens, 1994; de Haro et al., 1996; Pain, 1996). Beyond the 
attenuation of mRNA translation, PERK is additionally involved in the 
transcriptional regulation of the UPR through translational up-regulation of the 
activating transcription factor 4 (ATF4) by PeIF2" mediating selective translation 
of two upstream open reading frames (uORF) in the 5’untranslated region of 
ATF4 mRNA (Harding et al., 2000; Hinnebusch, 1997; Lu et al., 2004; Pain, 
1996; Sundar Rajan et al., 2007; Vattem and Wek, 2004). Moreover ATF4 is an 
important activator of the proapoptotic transcription factor C/EBP homologous 
protein (CHOP) mRNA expression and therefore involved in apoptosis initiation 
(2.3.2.2) (Harding et al., 2000; Liu and Kaufman, 2003; Oyadomari and Mori, 
2004). The highly preserved type I transmembrane protein kinase IRE1" is also 
activated by oligomerization and autophosphorylation in almost the same manner 
as stated for PERK activation displaying vast homology in their stress-sensing 
luminal domains (Bertolotti et al., 2000; Liu et al., 2000; Liu et al., 2002; 
Tirasophon et al., 2000). Activated IRE1" elicits distinct endoribonuclease 
activity in the cytoplasmic carboxy-terminal domain and participates in 
downstream signaling by splicing an intron of 26 nucleotides in length from the 
basic domain/leucin zipper (bZIP) protein X-box binding protein 1 (XBP1) 
mRNA (Calfon et al., 2002; Tirasophon et al., 1998; Yoshida et al., 2001a). 
Spliced XBP1 (XBP1s) is characterized by a translational frame shift through 
selective translation of overlapping open reading frames (ORFs) resulting in the 
exchange of the C-terminal domain for a bZIP containing domain enhancing 
transcriptional activity (Lee et al., 2003; Yoshida et al., 2001a). Microarray 
analysis identified XBP1s to most likely target ERAD components after 
translocation to the nucleus (Lee et al., 2003). Moreover IRE1" is supposed to 
directly enable mRNA degradation by hampering translocation through alterations 
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in the target message of client mRNAs by endonucleolytic cleavage (Hollien et 
al., 2009; Hollien and Weissman, 2006; Lipson et al., 2008). In addition, IRE1" is 
instrumental upon others in initiating stress-induced apoptosis through activation 
of the mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase (JNK) 
and nuclear factor #B (NF-#B) (2.3.2.2.) (Davis, 1999; Hu et al., 2006; Urano et 
al., 2000). The bZIP transcription factors ATF6" and ATF6! are type II 
transmembrane glycoproteins and function as the third stress sensing institution of 
the UPR in mammalian cells (Eizirik et al., 2008; Haze et al., 1999; Nadanaka et 
al., 2007). The only difference between ATF6" and ATF6! appears to be, that 
they are encoded by different genes, the ATF6 gene on chromosome 1 and the 
G13 (cAMP response element-binding protein-related protein) gene (ATF6B) 
localized on chromosome 6 (Haze et al., 2001; Yoshida et al., 2001b). ATF6 ("/!) 
is compound of a cytosolic N-terminal bZIP-portion, a luminal domain containing 
three highly conserved N-linked glycosylation sites modulating interaction with 
the calnexin-calreticulin cycle as well as two Golgi localization sequences (GLS1, 
GLS2) mediating stable attachment to the molecular chaperone BiP and 
trafficking of the activated cytosolic domain of ATF6 to the Golgi compartment 
(Haze et al., 1999; Hong et al., 2004; Schroder and Kaufman, 2005; Shen et al., 
2002; Shen et al., 2005). ER stress entails ATF6 activation through regulated 
intramembrane proteolysis (Rip) (Brown et al., 2000; Ye et al., 2000). Following 
divestiture of the BiP-ATF6 complex in response to ER stress, monomeric ATF6 
is released towards the Golgi compartment through vesicular transport and 
targeted by exposed GLS2 (Chen et al., 2002; Nadanaka et al., 2007; Nadanaka et 
al., 2004; Shen et al., 2002). Golgi-resident site-1 (S1P) and site-2 (S2P) proteases 
cleave ATF6 and an activated transcription factor composed of the cytosolic bZIP 
portion achieves the competence to enter the nucleus and exert influence on the 
expression of UPR-related target genes in order to optimize the folding capacity 
of the ER (Haze et al., 1999; Melville et al., 1999; Okada et al., 2002; Wu et al., 
2007; Yamamoto et al., 2007; Ye et al., 2000; Yoshida et al., 1998). Furthermore 
activated ATF6 interferes with the IRE1-XPB1 pathway through 
heterodimerization with XPB1 and is thereby synergistically conducive to the 
transcriptional regulation of ERAD mediators (Lee et al., 2003; Yamamoto et al., 
2007; Yoshida et al., 2003). In addition, the ATF6 pathway and the previously 
described ATF4 pathway converge in the transcriptional activation of the CHOP 
promoter resulting in enhanced expression of the CHOP gene commencing 
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growth arrest and apoptosis (Ma et al., 2002; Yoshida et al., 2000; Zinszner et al., 
1998). UPR-related transcription factors deploy their transcriptional activity 
through direct DNA binding sites in the promoter regions of their target genes 
(Haze et al., 1999; Kokame et al., 2001; Roy and Lee, 1999; Yoshida et al., 1998). 
In mammals, a cis-acting tripartite consensus sequence 5’CCAAT-9 nucleotides-
CCACG’3, which is in part reiterated as structural identic CCAAT motif 
throughout the whole promoter sequence, has been identified as crucial for stress-
induced transcriptional up-regulation of genes coping with endoplasmic reticulum 
stress and was therefore referred to as ER stress response element (ERSE) (Roy 
and Lee, 1999; Yoshida et al., 1998). Another cis-acting ER stress response 
element sequence (ERSE-II) ATTGG-N-CCACG was solely found in the 
promoter region of the homocysteine-induced endoplasmic reticulum protein 
(Herp), an ER-stress induced integral membrane protein of unknown function to 
date (Kokame et al., 2000; Kokame et al., 2001; Yamamoto et al., 2004). 
Enhancer activity for ERSE II was stated for ATF6 just as for XBP1 binding to 
the CCACG motif (Kokame et al., 2001; Yamamoto et al., 2004). The third 
regulatory cis-acting element involved in ER stress-associated induction of UPR-
related genes is the mammalian unfolded protein response element (UPRE) 
characterized by the palindromic sequence TGACGTGG/A mediating induction 
of ERAD components through prevailing XBP1 binding (Wang et al., 2000; 
Yamamoto et al., 2007; Yamamoto et al., 2004; Yoshida et al., 2001a). ATF6 
attain binding affinity to UPRE merely by heterodimerization with XBP1 
displaying even higher binding affinity than XBP1 homodimer reclusively 
(Yamamoto et al., 2007; Yoshida et al., 2001a). 
2.3.2.2. Stress-induced apoptosis triggers tissue dysfunction - !-cell 
apoptosis causes insulin deficiency in permanent neonatal diabetes  
Under conditions of sustained and insuperable endoplasmic reticulum stress to all 
appearances, programmed apoptotic cell death is instituted predominantly through 
inducible proapoptotic activity of UPR-associated regulators PERK, ATF6 and 
IRE1" mediating downstream signaling aimed at preservation of the integrity of 
the organism (Eizirik et al., 2008; Harding and Ron, 2002; Rao et al., 2004; 
Sundar Rajan et al., 2007; Szegezdi et al., 2006; van der Kallen et al., 2009). 
Unfortunately progressive cell demise undermines physiological tissue function 
and ultimately contributes to various diseases (Kaufman, 2002; Kim et al., 2008; 
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van der Kallen et al., 2009). Although the complex cross linking of ER stress-
induced apoptotic signaling is barely elucidated, three apoptotic pathways are 
defined: The upregulation of the proapoptotic transcription factor CHOP, the 
activation of the mitogen-activated protein kinases (MAPK) JNK and apoptosis 
signal-regulating kinase 1 (ASK1) as well as the bipartite activation of caspase 12 
(CASP12) (Fornace et al., 1988; Nakagawa and Yuan, 2000; Nishitoh et al., 1998; 
Urano et al., 2000; Yoneda et al., 2001; Zinszner et al., 1998).  
The activating phosphorylation of the mitogen-activated protein kinase (MAPK) 
c-Jun N-terminal kinase (JNK) is based on activated IRE1" recruiting the adaptor 
molecule tumor necrosis factor type 2 receptor associated protein (TRAF2) to 
form a heterodimeric complex  with ASK1 on the outer membrane of the ER 
(Nishitoh et al., 2002; Nishitoh et al., 1998; Urano et al., 2000). JNK initiates 
apoptosis through activating or inhibitory phosphorylation of serine (Ser) or 
threonine (Thr) residues of a proline (Pro)-rich consensus sequence (Pro-X-
Ser/Thr-Pro) in the polypeptide sequence of effector subjects. The proto-
oncogenes c-Jun and c-Myc, tumor suppressor p53 as well as mitochondrial-
derived transcription factors of Bcl2 related proteins (Bcl2, Bcl-xL, Bad, BimEL, 
Bax, Bmf) are activated in consequence of ER-related proapoptotic stimuli 
(Besnard et al., 2011; Bogoyevitch and Kobe, 2006; Davis, 2000; Germain et al., 
2006; Kaufman, 2002; Lei et al., 2002; Leppa and Bohmann, 1999; Noguchi et 
al., 1999; Rogatsky et al., 1998; Schreiber et al., 1999; Scorrano et al., 2003; 
Yamamoto et al., 1999; Yang et al., 2007). Furthermore recruitment of TRAF2 by 
IRE1" leads to the separation of procaspase-12 (pCASP12), which is sequestered 
in the inactive state in a stable complex with TRAF2 on the cytosolic surface of 
the endoplasmic reticulum until its activation solely through ER affecting insults 
(Kaufman, 2002; Nakagawa et al., 2000; Yoneda et al., 2001). Activating 
cleavage and dimerization of pCASP12 enables transmission of apoptotic signals 
from the ER to the cytoplasm and initiation of a cytosolic caspase-9-dependent 
signal cascade, which ultimately triggers ER stress-induced apoptosis through 
caspase 3 activation (Morishima et al., 2002; Rao et al., 2001; Yoneda et al., 
2001). Beyond caspase-8 activated by death receptor-mediated signaling, JNK 
was identified to facilitate mitochondrial cytochrome c (Cyt-c) release upon ER 
stress tightly linked to the apoptotic peptidase activating factor 1 (APAF1)-
dependent activation of caspase-9, which in turn mediates apoptosis initiation by 
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caspase-3 activation (Davis, 1999; Gross et al., 1999; Jimbo et al., 2003; Tournier 
et al., 2000; Zou et al., 1999). Furthermore overexpression of the proapoptotic 
transcription factor CHOP is tightly linked to the initiation of apoptosis in 
response to chronic ER stress (Oyadomari and Mori, 2004; Zinszner et al., 1998). 
As a member of the CCAAT/enhancer binding protein family (C/EBP), CHOP, 
also designated as growth arrest- and DNA damage-inducible gene 153 (GADD 
153), features a C-terminal basic leucine zipper (bZIP) domain mediating binding 
to consensus sequences of target genes (Maytin et al., 2001; Oyadomari and Mori, 
2004; Ramji and Foka, 2002; Ron and Habener, 1992). CHOP transcription is 
mainly regulated through ATF6 and ATF4 pathway converging in the 
transcriptional activation of the CHOP promoter by binding to a functional ERSE 
element in the promoter sequence of the CHOP gene (Ma et al., 2002; Shen et al., 
2002; Yoshida et al., 2000; Zinszner et al., 1998). ER stress-associated CHOP 
activation leads to the initialization of several proapoptotic strategies including 
downregulation of the anti-apoptotic factor B-cell CLL/lymphoma 2 (Bcl-2), 
interactions with mitochondria-derived apoptotic signaling and alteration of the 
cellular redox-state by gluthatione depletion, the main buffer system of the 
endoplasmic reticulum and imperative for antioxidative defense as well as 
undisturbed ER function (McCullough et al., 2001; Oyadomari and Mori, 2004). 
For instances, high-level expression of mutant insulin mRNA as a result of 
heterozygous mutations in the insulin gene (INS) and the consequent interminable 
accumulation of misfolded proinsulin polypeptides in the endoplasmic reticulum 
ultimately triggers apoptosis of perturbed !-cells following exhausting of 
compensatory abilities of the UPR by chronic ER stress. Progressive !-cell demise 
gradually culminates in insulin deficiency and full-blown clinical diabetes 
mellitus (Eizirik et al., 2008; Harding and Ron, 2002; Hodish et al., 2010; van der 
Kallen et al., 2009). 
3. Animal models for translational diabetes research 
Translational medicine means by definition the interface between basic research 
and clinical application (Wehling, 2008). Animal models, which are reasonably 
predictive of humans in terms of safety and efficacy of new therapeutic strategies 
are of particular relevance in this field (Kirk, 2003). Animal models are useful for 
investigations on the etiology and pathogenesis of various human diseases and on 
the feasibility of new effective therapeutic concepts (Kirk, 2003). The increasing 
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supply of a diverse spectrum of new technologies for the genetic engineering of 
animal models provides the opportunity to create a diversity of tailored animal 
models for specific questions of translational research and thus complies the 
requirements on the refinement of animal experiments (Aigner et al., 2010; Kues 
and Niemann, 2004; Melo et al., 2007; Prather et al., 2003; Rees and Alcolado, 
2005). In particular, diabetes research necessitates suitable animal models for 
investigations on the genetics and pathogenesis of this complex disease as well as 
on the accruement of its associated complications to directly draw benefits for 
human counterparts (Rees and Alcolado, 2005). 
3.1. Mutations in the insulin gene and diabetes mellitus in rodent 
models  
Diabetic rodent models have traditionally been used for molecular genetic 
analyzes of accountable genes, description of related phenotypic characteristics as 
well as for studying the underlying disease mechanisms and the 
pathomorphologial consequences of hyperglycemia (Aigner et al., 2008). 
Hyperglycemic mouse lines expressing mutant Ins2 gene are derived either from 
spontaneous mutations or from chemical mutagenesis within the N-ethyl-N-
nitrosourea (ENU) mouse mutagenesis project paving the way for the 
establishment of mutant mouse lines through selective phenotype-driven breeding, 
which in turn facilitates genotypic analyzes through the identification of the 
chromosomal regions by linkage analyzes followed by analyzes of candidate 
genes (forward genetics) (Aigner et al., 2008; Herbach et al., 2007; Yoshioka et 
al., 1997). Mutagenic effect of the alkylating ENU is deployed at high frequency 
on premeiotic spermatogonial stem cells of male mice after intraperitoneal 
application, inflicting random point mutations on their genome (Aigner et al., 
2008; Justice et al., 1999; Russell et al., 1979). 
3.1.1. The Munich Ins2C95S mutant mouse – diabetic mouse line derived 
from the Munich ENU mouse mutagenesis project 
The diabetic Munich Ins2C95S mutant mouse is derived from the Munich ENU 
mouse mutagenesis project based on the genetic background of the inbred strain 
C3HeB/FeJ (C3H) (Aigner et al., 2008; Herbach et al., 2007). Genome-wide 
linkage analyzes and candidate sequencing identified a T!A transversion at 
nucleotide position 1903 in exon 3 of the Ins2 gene to underlie the diabetic 
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phenotype in these mice. The distinct mutation was inherited in an autosomal 
dominant manner and results in an amino acid exchange from cysteine to serine at 
position 95 (C95S) of the preproinsulin polypeptide and the disruption of the 
C95(A6)-C100(A11) intrachain disulfide bond, disturbing preproinsulin 
biosynthesis and assembly (Herbach et al., 2007; Stoy et al., 2007; Weiss, 2009). 
Heterozygous Munich Ins2C95S mutant mice remained normoglycemic until the 
age of almost four weeks and showed unaltered fasted and postprandial serum 
insulin levels compared to corresponding age- and sex-matched wild-type mice. 
However serum insulin levels 10 minutes after oral glucose challenge were 
already significantly reduced in comparison to controls, indicating disturbed 
glucose-stimulated insulin secretion of "-cells in heterozygous Ins2C95S mutant 
mice. This is underlined by significantly reduced homeostasis model assessment 
of baseline insulin secretion (HOMA-B) indices in heterozygous Ins2C95S mutants 
compared to sex-matched wild-type mice, suggesting disturbed steady-state "-cell 
function (Herbach et al., 2007; Matthews et al., 1985). Fasting blood glucose 
levels of male heterozygous Munich Ins2C95S mutant mice increased further over 
time and reached almost 400 mg/dl, whereas female mutants preserved a mild 
hyperglycemia and marginally disturbed glucose tolerance. Furthermore 
heterozygous male Ins2C95S mutants exhibited growth retardation compared to 
corresponding females at the age of 3 months (Herbach et al., 2007). Studies 
conducted on ovariecomized heterozygous Munich Ins2C95S mutant mice have 
shown that the gender dimorphism observed in these mice is mainly based upon 
protective effects of estrogen in females (Schuster, 2011). Furthermore 
significantly increased HOMA of insulin resistance (HOMA-IR) indices and 
delayed response to exogenous insulin injection in male heterozygous Ins2C95S 
mutant mice compared to wild-type controls were suggestive of a certain degree 
of insulin resistance (Herbach et al., 2007). Qualitative-histological and 
quantitative-stereological analyzes on immunohistochemically stained sections of 
pancreatic tissue detected a largely altered composition of the pancreatic islets 
with a progressive reduction of the total "-cell volume in male hetereozygous 
InsC95S mutant mice accountable for the seriously disturbed glycemic control in 
these mice (Herbach et al., 2007). On the electron microscopic level, pancreatic "-
cells of heterozygous Munich Ins2C95S mutant mice were correspondingly almost 
devoid of insulin secretory granules and the ER appeared enlarged, whereas 
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alterations in female mutants were present but less pronounced (Herbach et al., 
2007; Kautz, 2011). Kidney weights of heterozygous male Ins2C95S mutant mice 
were significantly increased, displaying an early sign for diabetic kidney disease 
(Kautz, 2011; Mahimainathan et al., 2006). Diabetes-associated pathological 
alterations of the kidney have not been investigated in the Munich Ins2C95S mouse 
model so far (Kautz, 2011).  
Homozygous Ins2C95S mutant mice revealed a fulminant early-onset 
hyperglycaemic phenotype with significantly elevated blood glucose levels of 
almost 400 mg/dl and significantly reduced body weights compared to wild-type 
mice irrespective of the gender. Life expectancy of both genders was lower 
compared to sex-matched heterozygous Ins2C95S mutant mice and wild-type 
control mice (Herbach et al., 2007).  
3.1.2. The Akita mouse model expressing Ins2C96Y mutant gene 
The Akita mouse model is a stable diabetic mouse line based on the genetic 
background C57BL/6 (B6) and originally derived from a spontaneous mutation in 
the Ins2 gene (Yoshioka et al., 1997). A G!A transition at nucleotide position 
1907 in exon 3 of the Ins2 gene on chromosome 7 was identified as diabetogenic 
locus in these mice. This missense mutation is inherited in an autosomal-dominant 
manner and precludes formation of the C96(A7)-C31(B7) intermolecular disulfide 
bond by substitution of the cysteine residue at position 96 to tyrosine (C96Y) 
(Wang et al., 1999). The Akita Ins2C96Y mutation entails conformational 
rearrangement of the nascent preproinsulin 2 polypeptide with detrimental 
influence on the insulin secretory pathway as previously described (Stoy et al., 
2007; Wang et al., 1999; Weiss, 2009).  
As observed in heterozygous Munich Ins2C95S mutant mice, severe diabetic 
symptoms in heterozygous Akita Ins2C96Y mutant mice were recognised from the 
age of four weeks and showed likewise a distinct gender dimorphism (Herbach et 
al., 2007; Yoshioka et al., 1997). Male heterozygous Akita Ins2C96Y mutant mice 
revealed significantly increased randomly fed blood glucose levels of 280 mg/dl 
at four weeks of age progressing steadily up to over 500 mg/dl at the age of nine 
weeks, demonstrating the highly diabetogenic impact of one mutated Ins2 allele in 
spite of the presence of one wild-type Ins2 and two wild-type Ins1 alleles in 
rodents (Wang et al., 1999; Yoshioka et al., 1997). Attendant randomly fed 
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immunoreactive plasma insulin levels of male heterozygous Akita Ins2C96Y mutant 
mice were reduced by 60% compared to age- and sex-matched wild-type controls 
and by 22% compared to age-matched female mutants. In addition 
hyperglycaemic male heterozygous Akita Ins2C96Y mutant mice developed a 
peripheral insulin resistance (Hong et al., 2007). Furthermore impaired growth 
was observed in male heterozygous Akita Ins2C96Y mutant mice in comparison to 
female mutants and non-affected wild-type mice. The diabetic phenotype in male 
mutants was ultimately severe enough to halve their life expectancy compared to 
female mutants and sex-matched wild-type mice (Yoshioka et al., 1997). Insulin 
staining on pancreatic sections of male and female heterozygous Akita Ins2C96Y 
mutant mice and sex-matched non-affected control mice of four to 30 weeks of 
age revealed a time-dependent progressive loss of functional "-cells. The volume 
fraction of insulin-positive cells in the islets was diminished by approximately 
90% in proportion to an unaltered relative area of islets in the endocrine pancreas 
of male heterozygous Akita Ins2C96Y mutant mice compared to age- and sex-
related control mice at the age of 30 weeks (Yoshioka et al., 1997). Moreover 
autoimmune components, diagnostic for type 1 diabetes mellitus were not 
detected in the pancreas of sex-matched heterozygous mutant mice at any time 
point investigated (Yoshioka et al., 1997). Electron microscopy of pancreatic "-
cells of sex-matched heterozygous Akita Ins2C96Y mutant mice revealed 
remarkable enlargement of the rough endoplasmic reticulum characterized by 
vacuole-like appearance and progressive degranulation from the earliest time 
point investigated. Swollen mitochondria were regularly observed (Izumi et al., 
2003; Kayo and Koizumi, 1998; Wang et al., 1999; Zuber et al., 2004). In fact, 
accumulated proinsulin 2 was identified in the lumen of the ER by immunogold-
labeling of pancreatic "-cells and electron microscopic morphometry revealed a 
significantly reduced average volume and volume density of secretory granules in 
pancreatic "-cells of Akita mutant mice compared to wild-type mice (Wang et al., 
1999; Zuber et al., 2004).  
As described for homozygous Munich Ins2C95S mutant mice, the hyperglycaemic 
phenotype was much more pronounced in homozygous Akita Ins2C96Y indicating 
dose-dependent impact of Ins2C96Y expression in the homozygous state (Kayo and 
Koizumi, 1998).  
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The Akita Ins2C96Y mouse model reflects clinical features of humans with PNDM 
due to a mutation in the INS gene and contributed substantially to the 
understanding of molecular mechanisms underlying "-cell failure in PNDM 
(Kayo and Koizumi, 1998).  
3.2. Large animal models and diabetes mellitus 
Although a large number of mouse models for diabetes research has been already 
established and rodents still represent the predominant species in biomedical 
research (Animal Welfare Report of the German Government, 2012), large animal 
models have been proven to bridge the gap between mouse models and human 
patients (Larsen and Rolin, 2004; Srinivasan and Ramarao, 2007; Swindle, 2008). 
Although rodent models seem to better suit biomedical research due to their well-
defined genetic background bearing vast analogy to humans, their high 
availability, the possibility of experimental standardization and not least because 
of the lower cost expenditure, investigations based on non-rodent models are 
urgently required with regard to enhanced comparability to human conditions 
(Bogue, 2003; Clee and Attie, 2007; Lunney, 2007; Mouse Genome Sequencing 
et al., 2002; Srinivasan and Ramarao, 2007). In particular the pig turned out to be 
an attractive model organism for human physiology and pathophysiology in many 
respects (Douglas, 1972; Lunney, 2007). Furthermore early sexual maturity, 
favorable short generation time, and the possibility of multiple offspring are 
conditions precedent to rapid establishment of a representative cohort of pigs to 
address specific questions of translational research (Aigner et al., 2010; Vajta et 
al., 2007). 
3.2.1. Importance of porcine animal models for translational diabetes 
research 
In general important similarities between humans and pigs in terms of anatomy 
and physiology of the gastrointestinal tract, morphology of the pancreas as well as 
structure and pharmacokinetics of insulin underline the importance of the pig as 
excellent biomedical model for translational diabetes research (Larsen and Rolin, 
2004; Larsen et al., 2003b). Moreover body weight and size of the pig, 
considerably mimicking the human conditions, enable application of standard 
diagnostic and surgical techniques of human medicine for research purposes on 
the pig. Vice versa new diagnostic methods, already experimentally validated in 
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pigs, can be directly implemented in humans (Lunney, 2007; Matsunari and 
Nagashima, 2009; Roberts et al., 2009). Despite some anatomical differences of 
the efferent pancreatic duct system, the porcine pancreas is akin to the human 
pancreas in size, shape, in situ position and blood supply of the endocrine and 
exocrine parts of the organ (Murakami et al., 1997). In both species, endocrine 
cells are predominantly clustered in the islets of Langerhans or as single scattered 
isolated cells including small cell clusters in the exocrine part of the pancreas, 
emphasizing a less defined islet architecture than rodents (Cabrera et al., 2006; 
Jay et al., 1999; Kim et al., 2009; Steiner et al., 2010; Wieczorek et al., 1998). !-
cells represent the most abundant endocrine cell type of the porcine pancreas by 
80% volume fraction at last and thus resembling the !-cell content of humans 
(Cabrera et al., 2006; Jay et al., 1999; Larsen et al., 2003b; Veriter et al., 2012). 
The distribution of the different endocrine cell types is almost comparable in both 
species (Cabrera et al., 2006; Jay et al., 1999; Steiner et al., 2010; Wieczorek et 
al., 1998). The structure and size of pancreatic islets of adult individuals is 
comparable throughout all species, ranging between 90 and 200 %m in diameter 
(Murakami et al., 1997) but is very similar in humans and pigs (Kim et al., 2009). 
However, adult pigs are preferred for experimental islet isolation and as feasible 
donor species for experimental islet xenotransplantation due to a more distinct 
reticular capsule separating endocrine and exocrine parts of the pancreas and thus 
resembling those of humans (Brandhorst et al., 1995; Jay et al., 1999; van Deijnen 
et al., 1992; Wieczorek et al., 1998). The human insulin amino acid sequence 
differs from that of the porcine insulin by only one amino acid at position 30 of 
the B-chain and has been effectively used for treating humans suffering from 
diabetes for decades (Bromberg and LeRoith, 2006; Sonnenberg and Berger, 
1983). The human and porcine amino acid sequence of the incretin hormone 
glucose-dependent insulinotropic polypeptide (GIP) agree except for two amino 
acid substitutions at positions 18 (His ! Arg) and 34 (Asn ! Ser), and the 
sequence of the incretin hormone glucagon-like peptide-1 (GLP-1) is even 
completely conserved in both species (Moody et al., 1984; Orskov, 1992). 
Throughout almost all mammalian species, the islet amyloid polypeptide (IAPP) 
is predominantly synthesized in pancreatic !-cells and stored in the halo region of 
their secretory granules, co-localised and co-secreted with hexameric insulin 
(Johnson et al., 1988; Lukinius et al., 1996; O'Brien et al., 1993; Westermark et 
al., 2011). The process of islet amyloid polypeptide expression is observed early 
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during ontogeny in immature, pluripotent endocrine stem cells of the fetal 
pancreas and thus IAPP immunoreactivity is detectable from gestational week 13 
in humans for instance (In 't Veld et al., 1992; Lukinius et al., 1996). By the way 
of an exception in humans and in the pig likewise, IAPP storage is not only 
confined to !-cell granules but also found in the immediate vicinity of "-cell 
granules and randomly throughout &-cells, even if less pronounced (Lukinius et 
al., 1996). In contrast to humans, the porcine IAPP is unsusceptible to amyloid 
fibrillogenesis (Betsholtz et al., 1989). Cytotoxic amyloid deposits derived from 
human IAPP are found in pancreatic islets of 90% of diabetic subjects and 
therefore contribute to !-cell failure and consequently to the progression of 
diabetic symptoms in humans (Butler et al., 2003; Clark et al., 1996; Turner et al., 
1988; Westermark et al., 2011). The propensity to form amyloid deposits due to !-
pleated sheet confirmation of human IAPP is related to the amyloidogenic 
sequence in the portion of molecule spanning amino acid residues at position 20 
to 29 of IAPP, bearing less homology to the corresponding region of porcine 
IAPP molecules (Betsholtz et al., 1989; Clark et al., 1996; Potter et al., 2010; 
Westermark et al., 2011). Not exclusively human IAPP is highly fibrillogenic, but 
also domestic cats and cynomolgus macaques (M. fascicularis) feature an almost 
identical amyloidogenic region of IAPP related to the ability of amyloid plaque 
formation and therefore contributing to spontaneous diabetes mellitus similar to 
human age-associated type 2 diabetes mellitus (Hoenig et al., 2000; O'Brien et al., 
1996). In pigs just as much as in humans, "-cell mass clearly correlates with "-
cell function and therefore with undisturbed metabolic control respectively. A 
decrease in "-cell mass by 50% was found to be sufficient for deficient insulin 
secretion accompanied by disturbed glucose tolerance and tentative 
hyperglycemia in pigs as well as in humans (Butler et al., 2003; Kendall et al., 
1990; Kjems et al., 2001; Kloppel et al., 1985; Renner et al., 2010). In contrast, 
rodents compensate for a reduction of functional "-cell mass by 80% through 
substantial capability of "-cell proliferation. The regulation of "-cell mass is 
therefore much more dynamic in comparison to humans and pigs, where "-cell 
replication does not seem to be an important strategy to prevent hyperglycemia 
(Bonner-Weir, 2000; Bonner-Weir et al., 1983; Butler et al., 2003; Finegood et 
al., 1995; Renner et al., 2010; Tyrberg et al., 2001). The instant, extensive 
postmortal autolysis of pancreatic tissue restricts the availability of human tissue 
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for pathological examinations and thus the ascertainment of representative studies 
about islet morphology and dynamics of "-cell mass with diabetes (Butler et al., 
2003). In the pig, a decline of blood glucose levels related to abrosia is 
concomitant with diverse adaptation mechanisms, including an increase of free 
fatty acids (FFA) and glycerol by force of enhanced oxidation of body fat, 
adaptive hepatic gluconeogenesis and formation of ketone bodies, almost identical 
to human metabolism (Larsen and Rolin, 2004). The plasma glucose and insulin 
levels rise steadily with increasing age, assumedly due to incremental peripheral 
insulin resistance and reduced beta-cell function, whereas glucose tolerance 
declines with age individually influenced by the general health status and the body 
mass index (BMI) (Broughton and Taylor, 1991; Larsen et al., 2001; Matthews et 
al., 1985; Rosenthal et al., 1982). Generally, physiological blood glucose levels of 
both species range between 70 and 115 mg/dl and are therefore comparable in 
domestic pigs and humans, whereas the Göttingen minipig displays significantly 
lower plasma glucose levels questioning the conformance to human criteria 
(Canavan et al., 1997; Eriksson et al., 1989; Fritsche et al., 2000; Kraft W., 2005; 
Larsen et al., 2001; Weyer et al., 1999). Hence, the domestic pig represents an 
excellent model for human glucose metabolism and constitutes an available 
source of pancreatic tissue suitably conserved at euthanasia (Lunney, 2007). The 
accomplishment of physiological tests, including glucose tolerance tests followed 
by quantitative stereological evaluation of the  "-cell mass post mortem in a 
representative porcine disease model thus impart knowledge of islet morphology, 
the relation between "-cell function and "-cell mass and enable new possibilities 
for the development of new diagnostic approaches for humans (Larsen et al., 
2003a). Despite anatomical differences in the gastrointestinal tract, there are a 
variety of functional compatibilities between pigs and humans regarding the 
physiology of digestion. For instance, the time required for intestinal transit and 
the efficiency of digestion correspond most closely to that of humans (Miller and 
Ullrey, 1987). As humans, the pig is truly omnivorous and balanced nutrition is 
particularly combined with dietary quality in contrast to ruminants, where 
fermentation of nutrients through symbiotic microorganisms is crucial (Huge et 
al., 1995). By reason of connatural constitution of the skin and the subcutaneous 
tissue, including scarce body hair, thickness of dermis and epidermis, transdermal 
permeability as well as dimension, distribution and accessibility of peripheral 
veins, the pig was found to be closely comparable to humans in this regard. 
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Evaluation of pharmacokinetics and pharmacodynamics after subcutaneous 
injection of drugs in the pig model is advisable (Benech-Kieffer et al., 2000; 
Meyer, 1996; Qvist et al., 2000). Moreover, there are decisive equivalents in the 
biotransformation of drugs through a similar cytochrome p450 oxidase 
concentration in the liver. Even though there are some differences compared to 
humans, the pig represents a considerable model for preclinical pharmacology 
(Monshouwer and Witkamp, 2000). 
3.2.2. Induction of insulin-deficient diabetes mellitus in the pig model 
3.2.2.1. Chemical and surgical induction of insulin deficiency in the pig 
model 
Clinically apparent diabetes mellitus caused by an absolute insulin deficiency in 
the pig model has been experimentally induced as yet by either total 
pancreatectomy or by !-cell destruction through cytotoxic action of chemical 
agents such as streptozotocin and alloxan (Dufrane et al., 2006; Renner et al., 
2012; Stump et al., 1988; Wilson et al., 1986). Satisfactory results including 
constant severe hyperglycemia and impaired intravenous glucose tolerance were 
achieved first at resection of the pancreas by 80% involving both, other endocrine 
cell types and exocrine parts of the pancreas (Chaib et al., 2011; Lohr et al., 1989; 
Stump et al., 1988). Thus, total pancreatectomy is an disputable invasive method 
exerting intended detrimental influence on pancreatic !-cells but also attended 
with unrequested serious dyspepsia requiring irrepealable replacement of 
pancreas-derived digestive enzymes and dysfunction of endocrine pancreas-
related signaling pathways at large, barely imitating human diabetics (Stump et 
al., 1988; Wilson et al., 1986). The diabetogenic agent streptozotocin (STZ) (2-
deoxy-2(3-(methyl-3-nitrosoureido)-D-glucopyranose) constitutes a cytotoxic 
glucosamine analogue forcing the way in pancreatic !-cells through selective 
glucose transporter 2 (GLUT2) affinity (Herr et al., 1967; Schnedl et al., 1994; 
Tjalve et al., 1976). In succession, STZ specifically alkylates DNA and provokes 
strand breaks, which in turn induce tivation of the poly (ADP-ribose) polymerase 
(PARP) to restore DNA integrity. The thereby immense ATP demand leads to a 
negative cellular energy balance and ultimately provokes !-cell necrosis 
promoting consecutive insulin deficiency (Bennett and Pegg, 1981; Lenzen, 2008; 
Uchigata et al., 1982; Yamamoto et al., 1981a, b). The glucomimetic agent 
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alloxan (2, 4, 5, 6-tetraoxypyrimidine) displays likewise a substrate of the GLUT2 
transporter of pancreatic !-cells (Gorus et al., 1982; Lenzen, 2008). The bipartite 
diabetogenic effect of alloxan impinges pancreatic !-cell function upon 
disturbance of the glucose-mediated insulin release by inhibiting glucokinase 
activity and inflicts damage on pancreatic DNA by generation of reactive oxygen 
species through redox cycling reactions and thereby inducing same fatal cellular 
responses as stated previously for STZ (Lenzen, 2008; Lenzen et al., 1988; 
Lenzen et al., 1987; Malaisse, 1982; Tiedge et al., 2000; Yamamoto et al., 1981b). 
However, the effects of STZ and alloxan on the pig model are unsatisfactory 
variable due to low physiological expression levels of the GLUT2 transporter 
(Dufrane et al., 2006). Therefore the establishment and characterization of 
clinically relevant genetically engineered pig models constitute a major 
improvement (Aigner et al., 2010).     
3.2.2.2. Permanent neonatal diabetes mellitus in transgenic pigs expressing 
a dominant-negative hepatocyte nuclear factor 1 alpha (HNF-1") – 
diabetes induction by genetic modification of the porcine genome   
Nine autosomal dominant mutations in the hepatocyte nuclear factor 1" (HNF1A) 
gene located on chromosome 12q, referred to as MODY3 locus, have recently 
been reported to be responsible for genetic defects in insulin secretion and thus for 
derailed glucose homeostasis and onset of clinically manifest type 2 diabetes 
mellitus before 25 years of age (Byrne et al., 1996; Fajans et al., 1994; Vaxillaire 
et al., 1995; Vaxillaire et al., 1997; Yamagata et al., 1996b). Although there are 
diverse promising approaches, the pathomechanism of this progressive disease is 
still poorly understood since the identification of transcription factor HNF 1" by 
Yamamata et al. (Yamagata et al., 1996b). To clarify the underlying reason for 
human HNF1A mutant gene implicating "-cell dysfunction and disturbed insulin 
secretion in humans, Umeyama et al. generated a transgenic porcine model 
expressing a dominant-negative transcription factor HNF 1-" (Umeyama et al., 
2009). An expression vector consisting of the 2.3 kb cDNA sequence with the 
insertion of a cytosine into a poly C tract in exon 4, identified as most common 
frameshift mutation HNF1"P291fsinsC (Kaisaki et al., 1997), under the 
transcriptional control of the porcine insulin promoter flanked by chicken !-globin 
insulators (Watanabe et al., 2007) was introduced into porcine in-vitro matured 
oocytes using a combined method of intracytoplasmic sperm injection (ICSI) with 
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somatic cell nuclear transfer (SCNT) (Kurome et al., 2006). Fibroblasts, recovered 
from a transgenic male cell clone carrying ten copies of the transgene, served as 
nuclear donor cells for another SCNT. A total of 22 live piglets were born, 
however only five of them survived the postnatal period and only 2 piglets grew 
older than two months, respectively. Piglets exhibited a persistent diabetic 
phenotype with non-fasting blood glucose levels over 200 mg/dl and a disturbed 
oral glucose tolerance due to immunohistochemically detectable pathological 
alterations of the pancreatic islet structure and insufficient insulin content of the 
pancreatic !-cells. Despite efforts to limit expression of mutant HNF-1" to the 
pancreas by utilization of the porcine insulin promoter, ectopic expression was 
observed. On this account, altered biochemical parameters were suggestive of 
hepatic dysfunction and could be histologically confirmed, whereas histologically 
stained kidney tissue showed abnormal morphogenesis without any clinical 
effects. In conclusion, a longer survival time is essential to properly characterize 
an animal model and make it practically useful as a model of human diseases for 
translational research. Therefore further studies are required to improve the 
survival rate of dominant-negative mutant HNF-1" transgenic pigs and on 
exclusive pancreas expression of the transgene (Umeyama et al., 2009). 
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III. ANIMALS, MATERIALS AND METHODS 
1. Animals 
All animals investigated in this study were hemizygous male and female 
transgenic pigs expressing a mutant porcine INS gene (INSC94Y) as well as non-
transgenic littermates. Animals were housed under controlled conditions in single 
pens or in age-matched groups. Stables were planar-fixed and interspersed with 
straw. Animals were fed a standard commercial diet (Table 1) once daily and had 
free access to water. Pigs were trained carefully prior to all experiments as well as 
for insulin therapy. All animal experiments were approved by the responsible 
animal welfare authority (Regierung von Oberbayern, Munich, AZ 55.2-1-54-
2531-26-06 and AZ 55.2-1-54-2532-68-11). 
 
Table 1: Diet composition 
                                             Deuka primo care                              Deuka porfina U 
                                                      (piglets 6.5 kg up to 40 kg)                 (growing and adult pigs) 
MJ ME/kg 14.0 12.6 
Crude protein% 17.0 16.5 
Lysine% 1.4 0.9 
Methionine% 0.42 0.27 
Crude fat% 4.3 3.0 
Crude ash% 4,6 5.5 
Crude fiber  4.0 6.0 
Calcium% 0.65 0.85 
Phosphorus% 0.55 0.55 
Sodium% 0.25 0.2 
ME: metabolizable energy 
2. Materials 
2.1. Apparatuses 
Accu-jet® pro pipette controller Brand, Wertheim                   
Agarose gel electrophoresis chamber                    WG-Biotech, Ebersberg 
Agarose gel electrophoresis chamber                    OWL Inc., USA 
AU 400 autoanalyzer Olympus, Hamburg 
AxioCam scanning camera Carl Zeiss AG, Oberkochen 
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Beckmann DU-640 spectrophotome Beckman Coulter GmbH, Krefeld 
Benchtop 96 tube working rack                            Stratagene, La Jolla, USA 
Branson sonifier cell disrupter B15  Branson Ultrasonic Corporation, USA  
DryEase® Mini-Gel drying base and 
frame 
Life TechnologiesTM GmbH, Darmstadt                                                                     
Electrophoresis Power Supply EPS 
500/400 
GE Healthcare GmbH, Munich 
EM 10 transmission electron 
microscope 
Carl Zeiss AG, Oberkochen  
Gel documentation system                                     Bio Rad, Munich 
Gel documentation system                                     Intas, Göttingen 
Glass cuvette with glass rack insert VWR International GmbH, Darmstadt 
Guardian® REAL-Time System Medtronic GmbH, Meerbusch 
Hellma®cuvette suprasil                                         Hellma GmbH, Müllheim 
HM 315 microtome                                                Microm, Walldorf 
Homogeniser ART-Micra D-8    ART, Müllheim 
Hybridisation oven                                                 H.Saur, Reutlingen 
Illumina Genome Analyzer IIx Illumina Inc., San Diego, USA 
Incubator  Memmert, Schwabach 
LB 2111 '-counter Berthold, Bad Wildbach 
Mettler PM 6000                                                    Mettler-Toledo, Gießen 
Microprocessor pH meter WTW, Weilheim 
Microwave                                                              Siemens, Munich 
Mini Proteom® 3 Cell Assembly                            Bio Rad, Munich 
MS1 minishaker                                                      IKA, Staufen 
Multipipette® plus Eppendorf, Hamburg 
Object micrometer Carl Zeiss AG, Oberkochen 
Optimax X-Ray Film Processor  
1170-1-0000 
 
PROTEC, Oberstenfeld 
NanoDrop ND-1000 
spectrophotometer                 
NanoDrop Technologies, Wilmington, 
USA                                                                                
Pipettes                                           
(1000 %l, 200 %l, 20 %l, 10 %l, 2 %l)               
Gilson Inc, USA 
Power Pac 300 gel electrophoresis 
unit 
BioRad, Munich 
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Precision® XceedTM Glucometer                                               Abbott, Wiesbaden
Reichert-Jung TM60 milling 
maschine 
Leica Microsystems GmbH, Wetzlar 
Reichert-Jung Ultracut E microtome Leica Microsystems GmbH, Wetzlar  
RH Basic heating plate with magnetic 
stirrer         
IKA, Staufen 
Shandon Citadel tissue processor 1000 Thermo Fisher Scientific, GmbH, 
Schwerte 
Stemi SV11 stereomicroscope Carl Zeiss AG, Oberkochen  
Severin 900 microwave                                           Severin, Sundern 
Staining box according to 
Schifferdecker        
Carl Roth GmbH & Co. KG,  
Karlsruhe 
Sterilising oven                                                        Heraeus, Munich 
SunriseTM microplate reader for 
ELISA            
Tecan, Austria 
Thermomixer 5436                                          Eppendorf, Hamburg 
Trans Blot® SD Semi-Dry Transfer 
cell         
BioRad, Munich 
Varioklav 400 autoclave                                  H+P Labortechnik, Oberschleißheim                                                                          
WB 6 water bath                                                   Firmengruppe Preiss-Daimler, 
X-ray cassette Siemens Titan           
(18 x 24 cm)       
Rego, Augsburg 
 
Centrifuges: 
Biofuge pico                                                          Heraeus, Munich 
Megafuge 1.0 R                                                Heraeus, Munich 
Rotanta 96 Hettich, Tuttlingen 
Eppendorf centrifuge 5810R Eppendorf, Hamburg 
Eppendorf centrifuge 5430R Eppendorf, Hamburg 
 
Thermocycler: 
Biometra Uno Thermoblock                            Biometra,Göttingen 
Biometra T Professional                                  Biometra, Göttingen 
Mastercycler® gradient                                    Eppendorf, Hamburg 
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Scales: 
Analytical balance                                            Sartorius, Göttingen 
Chyo Petit Balance MK-2000B                       YMC Co, Japan 
Chyo IL-200                                                     YMC Co, Japan 
Chyo MJ-3000                                                  YMC Co, Japan 
Kern EOB 15K5   Kern und Sohn GmbH, Barlingen-
Frommern 
2.2. Consumables 
AmershamTM HyperfilmTM ECL 
High Performance 
chemiluminescense film              
GE Healthcare limited, Munich 
BD Micro-Fine UltraTM pen needles 
(0.33 x 12.7 mm 29 G)                       
Becton Dickinson GmbH, Heidelberg 
Blood lancets                         Henry Schein® Vet GmbH, Hamburg 
Cavafix® Certo® central venous 
catheter       
B. Braun, Melsungen 
Cellstar® cell culture plates (12 well)             Greiner Bio-One GmbH, Solingen 
Cover slips for histology Greiner Bio-One GmbH, Solingen 
Cover slips for histology VWR International GmbH, Darmstadt 
Cover slips Carl Menzel GmbH, Braunschweig 
Culture tubes with caps   
(12 ml, 6ml) 
Carl Roth GmbH & Co. KG, Karlsru 
Culture tubes with caps 
(12 ml, 6 ml) 
Carl Roth GmbH & Co. KG, Karlsruhe 
Disposable plastic pipettes                              Falcon®, Becton Dickinson, Heidelberg 
Disposal polypropylene bags Sarstedt AG+Co Nürnbrecht 
DryEase® Mini cellophane                              Life TechnologiesTM GmbH, Darmstadt 
1000 eco Lab pipette tips                   
(200 %l, 1000 %l)    
neoLAB Migge Laborbedarf-Vertriebs, 
GmbH, Heidelberg  
Extra Thick Blot Paper, Protean®II 
xi size, pre-cut                                                    
Bio Rad, Munich 
Freestyle Precision XtraTM Plus 
blood glucose stripes 
Abbott, Wiesbaden  
Gelatine epon embedding capsules Plano, Germany 
Gel blotting paper (Whatman paper)             Schleicher&Schüll, Dassel 
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Hybond-N+ nylon membrane                          GE Healthcare, Munich 
Hypodermic needles (18 G/ 20 G)                  Henry Schein®Vet GmbH, Hamburg 
Immobilon®-P nitrocellulose transfer 
membranes 
MilliporeTM, Billerica, USA 
Latex Powder-Free sempercare 
premiumgloves 
Satra Technology Center, Nordhamshire, 
UK 
Microscope slides Star Frost® Engelbrecht, Edermünde 
Monovette® blood collection system 
(Serum, EDTA)  
Sarstedt, Nümbrecht 
Multi Guiard Barrier Tips                  
(10 %l, 20 %l, 200 %l, 1000 %l)                          
SorensonTM Bioscience Inc., Utah, USA 
OP-Cover (60 x 90 cm)  A. Albrecht, Aulendorf 
Pipette tips (20 %l)  Treff Lab, Degersheim, Switzerland  
Parafilm®M American Can Company, Greenwich,USA 
PCR reaction tubes (0.2 ml)                        Braun, Wertheim 
Perfusor® cable (50 cm)                                B. Braun, Melsungen 
Quali-PCR tubes (0.2 ml) and cap-
strips   
G. Kisker Biotech GbR, Steinfurt 
 
Rotilabo® weighing bowls                    
(20 ml, 330 ml) 
Carl Roth GmbH & Co. KG, Karlsruhe 
Safe-Lock 1.5 ml Eppendorf Tubes®            Eppendorf, Hamburg 
Saran Barrier Food wrap Dow, USA 
Sempercare® nitrile gloves  Satra Technology Center, Nordh 
Sephadex G-50 columns GE Healthcare limited, Munich 
Single-use syringes                              
(2,5 ml, 10 ml, 20 ml) 
Henry Schein®Vet GmbH, Hamburg 
Skin adhesive spray                                       A. Albrecht, Aulendorf 
Sterican® cannulas (18 G, 20 G)                    B. Braun, Melsungen 
Super RX Fuji medical x-ray film FujiFilm Corp., Japan 
Tissue culture dishes (60 x 15 mm)              Sarstedt, Nümbrecht 
Uni-Link embedding cassettes                       Engelbrecht, Edermünde 
Vasco® OP Protect gloves                              B. Braun, Melsungen 
Vascocan® indwelling venous 
catheters and stylets                                                        
B. Braun, Melsungen 
Vicryl (2-0) suture material                            Ethicon, Norderstedt 
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3-way-Stopcock                                              Fresenius Kabi, Bad Homburg 
2.3. Chemicals 
All chemicals were used in p.a. quality unless noted otherwise. 
 
Acrylamide (30%)/ Bis solution                     Bio Rad, Munich 
Agarose UltraPureTM Electrophoresis 
grade    
InvitrogenTM, Karlsruhe 
Ammonium persulfate (APS)                       Bio Rad, Munich 
Acetic acid (glacial acetic acid)                     Rotipuran®, Carl Roth GmbH & Co 
 KG, Karlsruhe 
Benzoylperoxide Merck KGaA, Darmstadt  
Boric acid (H3BO3)                                              Carl Roth GmbH & Co KG, 
 Karlsruhe 
Bromophenolblue      Merck KGaA, Darmstadt 
Complete Protease inhibitor cocktail 
tablets 
Roche Diagnostics Deutschland,  
GmbH, Mannheim 
Coomassie® Brilliant Blue R250 
(0.05%) 
Sigma-Aldrich Chemie GmbH, Steinheim 
Coomassie® Brilliant Blue G250 Sigma-Aldrich Chemie GmbH, Steinheim 
3,3´Diaminobenzidine 
tetrahydrochloride (DAB)   
KemEnTec, Copenhagen, Denmark 
5,5´Diethylbarbituric acid sodium 
salt 
Merck KGaA, Darmstadt 
Diethylpyrocarbonate (DEPC)                       Sigma-Aldrich Chemie GmbH, Steinheim 
1,4-Dithiothreitol (DTT)                                Biomol Feinchemikalien GmbH, Hamburg 
1.4-Dithiothreitol (DTT, 0.1 M)                     InvitrogenTM, Karlsruhe 
2-Dodecenyl succinic acid anhydride SERVA Electrophoresis, Heidelberg 
Ethanol         Merck KGaA, Darmstadt 
Ethidiumbromide (1mg/ml)                           Merck KGaA, Darmstadt 
Ethylenediaminetetraacetic acid  
(EDTA, Titriplex®III)                                    
Merck KGaA, Darmstadt 
Ethyleneglycol-bis-(2-aminoethyl-) Carl Roth GmbH & Co. KG, 
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tetra-acetic acid (EGTA)                  Karlsruhe 
Ethylene glycol monobutyl ether Merck KGaA, Darmstadt 
Ethylmercury thiosalicylic acid 
sodium salt 
SERVA Electrophoresis, Heidelberg 
Formaldehyde solution (37%)      Sigma-Aldrich Chemie GmbH, Steinheim 
Glucose solution (50% )                                    B. Braun, Melsungen 
Glutaraldehyde Merck KGaA, Darmstadt 
Glycerol Rotipuran®                                Carl Roth GmbH & Co. KG, Karlsruhe 
Glycidyl ether 100 Serva Electrophoresis, Heidelberg 
Glycine Carl Roth GmbH & Co. KG,  
Karlsruhe 
Hydrochloric acid (2 M)                                 neoLAB Migge Laborbedarf- 
Vertriebs GmbH, Heidelberg 
Hydrochloric acid (25%) (Prolabo®)             VWR International GmbH, Darmstadt 
Hydrogen peroxide (35%) neoLAB Migge Laborbedarf- 
Vertriebs GmbH, Heidelberg 
2-Hydroxyethyl methacrylate 
(HEMA) 
Sigma-Aldrich Chemie GmbH, Steinheim 
Lead nitrate solution (1 M) 
(Pb(NO3)2 
Merck KGaA, Darmstadt 
Magnesium chloride                                       Sigma-Aldrich Chemie GmbH, Steinheim 
Magnesium chloride (25 mM)                         Qiagen GmbH, Hilden 
Mayer`s Hemalum solution Applichem GmbH, Darmstadt 
2-Mercaptoethanol                                          Sigma-Aldrich Chemie GmbH, Steinheim 
Methanol (Ensure® )                                               Merck KGaA, Darmstadt 
Methyl methacrylate (MMA) Sigma-Aldrich Chemie GmbH,  
Steinheim 
Methyl nadic anhydride SERVA Electrophoresis GmbH,  
Heidelberg 
Nonylphenyl polyethylene glycol  
(Nonidet® P-40)                                            
Fluka Chemie, Buchs, Schweiz 
Osmium tetroxide (OsO4) chemPUR®, Karlsruhe 
Paraformaldehyde Merck KGaA, Darmstadt                                                   
Phenylmethylsulfanylfluoride Sigma-Aldrich Chemie GmbH, Steinheim   
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(PMSF)      
Polyethylene glycol 400 Merck KGaA, Darmstadt 
Phosphoric acid (H3PO4) 
(Emprove®) 
Merck KGaA, Darmstadt 
Ponceau S Sigma-Aldrich Chemie GmbH, Steinheim   
Potassium chloride                                        Merck KGaA, Darmstadt  
Potassium dihydrogen phosphate 
(KH2PO4) 
neoLAB Migge Laborbedarf- 
Vertriebs GmbH, Heidelberg 
Potassiumhydrogenphosphate Merck KGaA, Darmstadt 
Potassium hydroxide pellets                          Merck KGaA, Darmstadt 
2-Propanol Merck KGaA, Darmstadt 
RPMI 1640 cell culture medium Biochrom AG, Berlin 
D(+) saccharose neoLAB Migge Laborbedarf- 
Vertriebs GmbH, Heidelberg 
Saccharose Merck KGaA, Darmstadt 
Safranin O Chroma Technology GmbH, Olching 
Silver nitrate (AgNO3)                                                   Applichem GmbH, Darmstadt 
Sodium acetate (C2H3NaO2) Merck KGaA, Darmstadt 
Sodium carbonate (Suprapur® ) Merck KGaA, Darmstadt 
Sodium chloride (Ensure® )                                     Merck KGaA, Darmstadt 
Sodium citrate  solution (1 M) Merck KGaA, Darmstadt 
Sodiumdodecylsulfate (SDS)                     Serva Electrophoresis, Heidelberg 
Sodium hydroxide (NaOH)                  VWR International GmbH, Darmstadt 
Sodium hydroxide solution (2 M)                                 VWR International GmbH, Darmstadt 
Sodium-orthovanadate (Na3VO4)                    Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium phosphate dibasic dehydrate  
(Na2HPO4 x 2 H2O)    
neoLAB Migge Laborbedarf- 
Vertriebs GmbH, Heidelberg 
2-Sodium tetraborate (Borax) Merck KGaA, Darmstadt 
Sodium thiosulfate-pentahydrate 
(Na2S2O3 x 5 H2O)                      
Merck KGaA, Darmstadt    
 
Tetraethylethylenediamine (Temed)            Carl Roth GmbH & Co. KG, Karlsruhe 
2, 4, 6-tris-(dimethylaminomethyl) 
phenol 
Serva Electrophoresis GmbH, Heidelberg 
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Tris-(hydroxymethyl)-
aminomethane (Tris)          
Carl Roth GmbH & Co. KG, Karlsruhe 
Tween®20                                                     Sigma-Aldrich Chemie GmbH, Steinheim 
Uranyl acetate Merck KGaA, Darmstadt 
w/v nonfat dry milk (blotting grade)            Carl Roth GmbH & Co. KG, Karlsruhe 
Xylene Applichem GmbH, Darmstadt 
2.4. Antibodies, drugs, enzymes, oligonucleotides, standards 
2.4.1. Antibodies 
2.4.1.1. Primary antibodies 
Monoclonal mouse anti-human actin, 
clone C4          
MilliporeTM, Billerica, USA 
Monoclonal rabbit anti-human 
phospho-eIF2" XPTM  
Cell Signaling Technology®, New 
England Biolabs GmbH, Frankfurt am 
Main 
 
Polyclonal rabbit anti-human BiP   Cell Signaling Technology®, New 
England Biolabs GmbH, Frankfurt am 
Main 
Polyclonal rabbit anti-mouse 
GADD153 
Santa Cruz Biotechnology®, Heidelberg 
Polyclonal guinea pig anti-porcine 
insulin      
Dako cytomation, Hamburg 
Polyclonal rabbit anti-human 
glucagon           
Dako cytomation, Hamburg 
Polyclonal rabbit anti-bovine 
pancreatic  
polypeptide                                              
Dunn Labortechnik GmbH, Asbach 
Polyclonal rabbit anti-human 
somatostatin     
Dako cytomation, Hamburg 
2.4.1.2. Secondary antibodies 
AP-conjugated goat anti-guinea pig 
IgG         
Southern Biotech, Birmingham, USA 
HRP-conjugated goat anti-rabbit IgG                   Cell Signaling Technology®, New 
England Biolabs GmbH, Frankfurt am 
Main 
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HRP-conjugated goat anti-rabbit IgG Dako cytomation, Hamburg 
HRP-conjugated goat anti-mouse IgG                     Dianova GmbH, Hamburg 
2.4.2. Drugs 
Altrenogest (Regumate®)                                 Serumwerke Bernburg, Bernburg 
Azaperon (Stresnil®)                                        Janssen Pharmaceutica, Beerse, Belgium 
Cefquinom (Cobactan®)                                    Intervet, Unterschleißheim 
Choriongonadotropine (hCG) 
(Ovogest®)        
Intervet, Unterschleißheim 
Embutramid, Mebezonium, Tetracain 
(T61®) 
Intervet, Unterschleißheim 
Heparin-Sodium (25.000 IE/5ml)                     B. Braun, Melsungen 
Insulin aspart                    
(NovoRapid® Penfill®, 100 units/ml)                 
Novo Nordisk Pharmaceuticals, 
Bagsvaerd, Denmark  
Insulin glargine                        
(Lantus® Solostar® Pen, 100 units/ml)  
Sanofi-Aventis Deutschland GmbH, 
Frankfurt 
PMSG (Intergonan®)                                          Intervet, Unterschleißheim 
Sodium chloride solution (0.9%) ad 
us. vet. 
B. Braun, Melsungen 
Ketamine hydrochloride (Ursotamin®) Serumwerke Bernburg, Bernburg 
Metamizol-Sodium (Vetalgin®) Intervet, Unterschleißheim 
Meloxicam (Metacam®) Boehringer Ingelheim, Ingelheim 
Xylazine (Xylazin 2%) WDT, Garbsen 
2.4.3. Enzymes  
BamH1 and recommended buffer                   MBI Fermentas, St. Leon Roth 
DNA Polymerase I (E.coli) (DNaseI) InvitrogenTM, Karlsruhe 
Herculase#II and buffer (10 x) Agilent, Böblingen 
Klenow fragment exo- (5 U/%l) and 
buffer (10 x)  
MBI Fermentas, St. Leon Roth 
Proteinase K (20 mg/ml) Roche Diagnostics Deutschland GmbH, 
Mannheim 
RNaseOUTTM (Recombinant 
Ribonuclease Inhibitor) (40 U/%l) 
InvitrogenTM, Karlsruhe 
SuperScriptTM II Reverse 
Transcriptase (200 U/%l) 
InvitrogenTM, Karlsruhe 
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Taq DNA Polymerase (5 U/ml)  Agrobiogen, Hilgertshausen  
2.4.4. Oligonucleotides 
All oligonucleotides were designed manually and manufactured by Thermo Fisher 
Scientific, USA. 
ACTB (sense)                       5´ TGGACTTCGAGCAGAGATGG 3´ 
ACTB (antisense)          5´ CACCGTGTTGGCGTAGAGG 3´  
Insulin (sense)    5‘ CGGGAGGCGGAGAACCCTCA 3‘  
Insulin (antisense) 5‘ CCCTCAGGGGCGGCCTAGTT 3‘ 
neoPf (sense)               5´ CAGCTGTGCTCGACGTTGTC 3´ 
neoSr (antisense)            5´ GAGTCAACTAGTCCTCAGAAGAACTCGTCAAG 3` 
2.4.5. Protein standards 
Bovine serum albumin (BSA) Fraction V            Carl Roth GmbH & Co. KG, 
Karlsruhe 
2.5. Buffers, media and solutions 
Unless indicated otherwise, water, deionized in a Millipore device (EASYpure® 
II, pure Aqua, Schnaitsee) and termed as aqua bidest., was used as solvent. 
Buffers, media and solutions were stored at room temperature (RT) unless 
indicated otherwise. 
2.5.1. Buffers and solutions for electron microscopy 
2.5.1.1. Soerensen´s phosphate buffer 
192 ml Solution A 
808 ml Solution B 
2.5.1.1.1. Solution A 
4.5 g KH2PO4 
ad 500 ml Aqua bidest. 
2.5.1.1.2. Solution B 
11.9 g Na2HPO4 x 2 H2O 
ad 1000 ml Aqua bidest. 
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2.5.1.2. Soerensen´s washing solution 
6.8 g D(+) Saccharose 
100 ml Soerensen´s phosphate buffer 
1% Merthiolate solution  
2.5.1.2.1. Merthiolate solution 
1% Ethylmercury thiosalicylic acid sodium salt 
2.5.1.3. Fixation solution for Epon embedding 
0.5 g D(+) Saccharose 
0.1 M HCl 
2 ml Veronal-acetate buffer 
5 ml 2% Osmium tetroxide 
2.5.1.3.1. Veronal-acetate buffer 
1.5 g 5,5´Diethylbarbituric acid sodium salt 
1 g Sodium acetate 
ad 50 ml Aqua bidest. 
adjusted to pH 10.3 
2.5.1.4. Glycidyl ether embedding mixture 
70 ml Solution A 
130 ml Solution B 
3 ml 2,4,6- Tris-(dimethylaminomethyl) phenol 
2.5.1.4.1. Solution A 
62 ml Glycidyl ether100 
100 ml 2-Dodecenyl succinic acid anhydride 
2.5.1.4.2. Solution B 
100 ml Glycidyl ether100 
89 ml   Methyl nadic anhydride  
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2.5.1.5. Azur II-methyleneblue/Toluidine blue staining solution 
1 g 2-Sodiumtetraborate (Borax) 
1 g Toluidine blue/Azur II-methyleneblue 
ad 100 ml Aqua bidest. 
 
Borax was dissolved in aqua bidest. Azur II-methyleneblue/Toluidine blue was 
added to the solution and subsequently the solution was stirred on a magnetic 
stirrer for two hours. Solution needs to be filtered prior to use. 
2.5.1.6. Safranin O staining solution 
1 g 2-Sodiumtetraborate (Borax) 
1 g Safranin O 
40 g Saccharose 
ad 100 ml  Aqua bidest. 
 
First borax was dissolved in aqua bidest. After addition of Safranin O and 
saccharose, the solution was stirred for approximately two hours. The next day, 
solution was completed by adding some drops of formaldehyde (37%) followed 
by filtration. 
2.5.1.7. Uranyl acetate contrasting solution 
1 g Uranyl acetate 
ad 50 ml Aqua bidest. 
 
Solution was carefully pivoted and filtered prior to use. 
2.5.1.8. Lead acetate contrasting solution 
6 ml Sodium citrate 
4 ml Lead nitrate solution (1 M) 
8 ml NaOH (1 M) 
ad 50 ml Aqua bidest. 
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Sodium citrate was gently stirred in aqua bidest. Lead nitrate solution was added 
dropwise causing precipitation. Application of NaOH cleared the solution 
immediately. Filtration was required prior to use. 
2.5.1.9. Solution A for plastic embedding 
338 mg Benzoylperoxide 
20 ml Methyl methacrylate 
60 ml 2-Hydroxyethyl methacrylate 
16 ml Ethylene glycol monobutyl ether 
2 ml Polyethylene glycol 400 
2.5.2. Buffers and solutions for molecular biological procedures 
2.5.2.1. DEPC water (0.1% (v/v)) 
1 ml DEPC was dissolved in 1000 ml aqua bidest. overnight at room temperature 
while stirring. Afterwards the solution was autoclaved three times to inactivate 
DEPC and stored at -20°C. 
2.5.2.2. DNase I buffer 
10 mM Tris 
10 mM MgCl2 
adjusted to pH 7.4 and stored at -20°C. 
2.5.2.3. dNTPs 
dATP, dCTP, dGTP and dTTP were mixed with aqua bidest. in a final 
concentration 2 mM or 10 mM respectively, aliquoted and stored at -20°C. 
2.5.2.4. Proteinase-K-solution 
20 mg Proteinase K 
1 ml Aqua bidest. 
aliquoted and stored at -20°C. 
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2.5.2.5. Buffers for agarose gel electrophoresis 
2.5.2.5.1. TAE buffer (50x) 
542 g Tris 
57.1 ml Glacial acetic acid 
100 ml EDTA 0.5 M (pH 8.0) 
ad 1000 ml Aqua bidest.  
 
Buffer was diluted to single concentration with aqua bidest. prior to use. 
2.5.2.5.2. TBE buffer (10x) 
108 g Tris 
55 g Boric acid  
40 ml EDTA 0.5 M (pH 8.0) 
ad 1000 ml Aqua bidest. 
 
Concentrated stock buffer was autoclaved and diluted to single concentration prior 
to use. 
2.5.3. Buffers and solutions for protein extraction and polyacrylamide gel 
electrophoresis 
2.5.3.1. Bradford reagent 
0.01% Coomassie G-250 
5% Ethanol 
10% H3PO4 
ad 500 ml Aqua bidest. 
 
Solution was well mixed, filtered and stored protected from light. 
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2.5.3.2. 5 x Laemmli 
65.5 ml 1 M Tris pH 6.8 
100 ml Glycerol (100%) 
2 ml 0.5 M EDTA pH 8 
20 g SDS 
0.1% Bromophenol blue 
ad 200 ml Aqua bidest 
2.5.3.3. PBS buffer (10x) 
136 mM NaCl 
8.1 mM Na2HPO4 
2.7 mM KCl 
1.5 mM KH2PO4  
adjusted to pH 7.4 
 
After filtration, buffer was autoclaved and diluted to single concentration with 
aqua bidest. for use. 
2.5.3.4. Ponceau S solution 
0.2 g Ponceau 
3 ml Glacial acetic acid 
ad 100 ml Aqua bidest. 
2.5.3.5. SDS running buffer (10x) 
30.3 g Tris 
144 g Glycine 
10 g SDS 
ad 1000 ml Aqua bidest. 
 
Buffer was stored at 4°C and diluted with aqua bidest. to single concentration 
right before use. 
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2.5.3.6. Stock solutions for protein extraction buffer 
2.5.3.6.1. Complete Protease inhibitor solution (25x) 
One tablet was dissolved in 2 ml aqua bidest. to prepare a 25x stock solution, 
aliquoted, stored at -20°C and used within 12 weeks according to manufacturer´s 
instructions. 
2.5.3.6.2. 1 M DTT 
1 M DTT 
dissolved in aqua bidest., aliquoted and stored at -20°C. 
2.5.3.6.3. 300 mM EDTA 
300 mM EDTA 
adjusted to pH 8.0, autoclaved and stored at room temperature. 
2.5.3.6.4. 300 mM EGTA 
300 mM EGTA 
adjusted to pH 8.0, autoclaved and stored at room temperature. 
2.5.3.6.5. 2,5 M NaCl/ 261 mM Tris/ HCl pH 7.6 
2.5 M NaCl 
261 mM Tris 
adjusted to pH 7.6, autoclaved and stored at room temperature. 
2.5.3.6.6. 200 mM Na3VO4 
200 mM Na3VO4 
 
dissolved in aqua bidest. on a magnetic stirrer and adjusted to pH 10 until solution 
turns yellow. Solution was boiled for approximately 10 minutes until it cleared 
again and cooled down on ice. Solution was repeatedly adjusted to pH 10, boiled, 
and cooled down on ice until it remained clear and of stable pH 10. Aliquots of 
1 ml were stored at -20°C. Prior to use, solution was thawed by boiling for 
10 minutes on a heating block to dissolve crystals. 
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2.5.3.6.7. 100 mM PMSF 
100 mM PMSF 
dissolved in isopropanol, aliquoted and stored at -20°C. 
2.5.3.6.8. Protein extraction buffer working solution 
100 %l 2,5 M NaCl/261 mM Tris HCl pH 7.6 
5 %l Nonidet® P-40 
10 %l 300 mM EDTA 
10 %l 300 mM EGTA  
10 %l 100 mM PMSF 
10 %l 200 mM Na3VO4 
1 %l 1 M DTT 
40 %l Complete 25x 
814 %l Aqua bidest. 
  
2.5.4. Buffers and solutions for Southern blot analysis 
2.5.4.1. Southern blot church buffer 
1% BSA 
1 mM EDTA pH 8.0 
500 mM Sodium phosphate buffer pH 7.2 
7% SDS 
2.5.4.2. 1 M Sodium-phosphate buffer pH 7.2 
4 ml H3PO4 (85%) 
89 g Na2HPO4 x 2 H2O 
ad 1000 ml Aqua bidest. 
2.5.4.3. Southern blot high-stringency buffer 
1 mM EDTA pH 8.0 
40 mM Sodium phosphate buffer pH 7.2 
1% SDS 
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2.5.4.4. Southern blot low-stringency buffer 
0.5% BSA 
1 mM EDTA pH 8.0 
40 mM Sodium phosphate buffer pH 7.2 
5% SDS  
2.5.4.5. Southern blot neutralisation buffer 
0.5 M Tris 
1.5 M NaCl 
adjusted to pH 7.5 
2.5.4.6. Southern blot SSC (20x) 
0.3 M Sodium citrate 
3 M NaCl 
2.5.4.7. Southern blot strand break solution 
0.5 M NaOH 
1.5 M NaCl 
2.5.5. Buffers and solutions for tissue preparation and 
immunhistochemical procedures 
2.5.5.1. DAB solution 
One tablet DAB was dissolved in 10 ml aqua bidest, filtered, aliquoted and stored 
at -20°C protected from light. Prior to use 1 %l H2O2 per 1 ml DAB solution was 
added. 
2.5.5.2. Paraformaldehyde solution (4%) 
4% paraformaldehyde 
ad 1000 ml PBS buffer (1x) 
 
Solution was heated to 55°C in a water bath, repeatedly interrupted by vigorous 
stirring on a magnetic stirrer. A few drops of 2 M NaOH were added to clear the 
solution. After cooling down to room temperature the solution was adjusted to 
pH 7.4, filtered and stored at 4°C. 
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2.5.5.3. TBS buffer for immunohistochemistry (10x) 
90 g NaCl 
60.5 g Tris 
ad 1000 ml Aqua bidest. 
adjusted to pH 7.6.  
Concentrated stock buffer was autoclaved and diluted to single concentration with 
aqua bidest. right before use. 
2.5.5.4. 100 mM Tris/HCl pH 8.5 
100 mM Tris 
adjusted to pH 8.5. Exact adjustment to pH 8.5 is crucial for desirable staining 
intensity. 
2.5.6. Buffers and solutions for Western blot analyzes  
2.5.6.1. Elution buffer 
62.5 mM Tris/HCl pH 6.7 
2% SDS 
100 mM 2-Mercaptoethanol 
2.5.6.2. TBS-T-BSA 
0.1% TBS-T 
5% BSA 
2.5.6.3. TBS –T (0.1%) 
100 ml 10 x TBS buffer for Western blot 
1 ml Tween® 20     
ad 1000 ml Aqua bidest. 
2.5.6.4. TBS-T-w/v nonfat dry milk  
0.1% TBS-T  
5% w/v nonfat dry milk 
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2.5.6.5. Transfer buffer (10x) 
58 g Tris 
29 g Glycine 
3.7 g SDS 
ad 1000 ml Aqua bidest. 
 
Buffer was stored at 4°C. Prior to further processing concentrated buffer was 
diluted to single concentration with aqua bidest. and 20% methanol was added.   
2.5.6.6. Tris-buffered saline (TBS) buffer for Western blot (10x) 
80 g NaCl 
30 g Tris 
ad 1000 ml Aqua bidest. 
adjusted to pH 7.4  
 
Buffer was autoclaved, stored at room temperature and diluted to single 
concentration with aqua bidest. prior to use. 
2.5.7. Solutions for non-colloidal Coomassie staining of polyacrylamide 
gels 
2.5.7.1. Coomassie solution (Non-colloidal) 
0.5 g Coomassie® Brilliant Blue R250 (0.05%) 
50% Methanol 
10% Glacial acetic acid 
ad 1000 ml Aqua bidest. 
2.5.7.2. Destaining solution 
7% Glacial acetic acid 
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2.5.8. Solutions for silver staining of polyacrylamide gels 
2.5.8.1. Fixation solution 
500 ml Ethanol 
120 ml Glacial acetic acid 
500 %l Formaldehyde (37%) 
ad 1000 ml Aqua bidest. 
2.5.8.2. Pretreating solution 
50 mg Na2S2O3 x 5 H2O 
50 ml Aqua bidest. 
 
2.5.8.3. Impregnation solution 
50 mg AgNO3 
35 %l Formaldehyde (37%) 
50 ml Aqua bidest. 
2.5.8.4. Development solution 
1.5 g Na2CO3  
0.1 mg Na2S2O3 x 5 H2O 
50 %l Formaldehyde (37%) 
50 ml Aqua bidest. 
2.5.8.5. Stop solution  
0.1 M EDTA pH 8.0 
2.5.8.6. Drying solution 
30% Methanol 
10% Glycerol 
diluted in aqua bidest.      
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2.6. Kits 
Glucagon Radioimmunoassay (RIA) 
Kit        
MilliporeTM, Billerica , USA 
NexttecTM Genomic DNA Isolation Kit                  Nexttec GmbH, Leverkusen 
Porcine Insulin Radioimmunoassay 
(RIA) Kit    
MilliporeTM, Billerica, USA 
QiaexIITM Gel Extraction Kit Qiagen GmbH, Hilden  
RNeasy® Mini total RNA isolation Kit         Qiagen GmbH, Hilden  
Vector Red® Alkaline Phosphatase 
Substrate Kit 
Vector Laboratories, Inc., Burlingame, USA 
Taq DNA Polymerase Kit                     Qiagen GmbH, Hilden 
Wizard genomic DNA purification Kit®  Promega, Wisconsin, USA 
 
2.7. Other reagents 
"-[32P]-dCTP Perkin-Elmer, Netherlands 
AmershamTM ECLTM Western Blotting 
Detection Reagent  
GE Healthcare , Munich  
Developing and fixing solution Agfa-Gevaert N.V., Mortsel, Belgium 
Bode Sterilium®  hand sanitizer                     Bode Chemie, Hamburg      
6 x DNA loading dye                                     MBI Fermentas, St. Leon Roth 
dNTPs ( dATP, dCTP, dGTP, dTTP) 
(100 mM)     
MBI Fermentas, St. Leon Roth 
Exendine-4 Sigma Aldrich Chemie GmbH,  
Steinheim 
5 x First-Strand Buffer for cDNA 
synthesis      
InvitrogenTM, Karlsruhe 
Goat serum MP Biomedicals, Illkirch, France 
Histokitt  Glaswarenfabrik Karl Hecht GmbH, 
Sondheim/Rhön 
Porcine serum MP Biomedicals, Illkirch, France 
Lifosan® soft wash lotion                                     B. Braun, Melsungen 
Q-solution Qiagen GmbH, Hilden  
Random Primer Hexamers (600 %g/ml)                InvitrogenTM, Karlsruhe 
Random Primers (3 %g/%l) InvitrogenTM, Karlsruhe 
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RNase-free water                                                 Affymetrix Inc., USA 
Vet-Sept® solution (10%)                                    A. Albrecht, Aulendorf  
2.8. DNA molecular weight markers and protein molecular weight 
markers 
Gene RulerTM (1kb DNA Ladder)                       MBI Fermentas, St. Leon Roth 
Lambda DNA/EcoRI + HindIII-Marker              MBI Fermentas, St. Leon Roth 
PageRulerTM Prestained Protein Ladder  Thermo Fisher Scientific, Schwerte 
pUC Mix Marker 8                                               MBI Fermentas, St. Leon Roth 
Unstained Protein Molecular Weight 
Marker      
Thermo Fisher Scientific, Schwerte  
2.9. Software 
GraphPad Prism® version 5.02 GraphPad Software Inc., La Jolla, USA 
IMAGEQUANT® image processing 
software (version 5.2)  
MolecularDynamics Inc., Sunnyvale,  
California, USA 
MagellanTM data analysis software                       Tecan, Austria 
Medtronic CareLink Pro software, 
version 3.2A 
Medtronic GmbH Diabetes, Meerbusch 
Olympus VisiomorphTMimage analysis   Visiopharm, Hoersholm, Denmark 
SAS (version 8.2) SAS Institut Inc., USA 
SPSS (version 21.0) IBM, New York, USA 
Videoplan® image analysis system Carl Zeiss AG, Oberkochen 
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3. Methods 
3.1. Generation of INSC94Y transgenic pigs 
INSC94Y transgenic pigs were generated by additive gene transfer and somatic cell 
nuclear transfer (SCNT). The expression construct consisting of a 2.1 kb fragment 
of the porcine insulin promoter for !-cell-specific expression, a 1.0 kb coding 
region of the porcine insulin gene sequence including the G!A transition at 
nucleotide position 340 leading to an amino acid exchange from Cysteine to 
Tyrosine at amino acid position 94 and a neomycine resistance cassette flanked by 
two loxP sites was kindly provided by Dr. Heinrich Flaswinkel, LMU Munich. 
Primary porcine fetal fibroblasts were cultered, nucleofected with the INSC94Y 
expression construct and selected in principle as previously described (Klymiuk et 
al., 2012). Stable transfected cell clones were used for SCNT using in vitro 
matured oocytes according to the method of Kurome et al. (2006). Reconstructed 
embryos were laparoscopically transferred into estrus synchronized recipient gilts 
in accordance to Besenfelder et al. (1997). Operational procedure is in principle 
illustrated in Figure 2. Cell culture experiments have been performed by Dr. 
Annegret Wünsch, Institute of Molecular Animal Breeding and Biotechnology, 
LMU Munich. SCNT and embryo transfer (ET) have been carried out by 
Dr. Mayuko Kurome and Dr. Barbara Kessler, Institute of Molecular Animal 
Breeding and Biotechnology, LMU Munich.  
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Figure 2: Schematic illustration of effective INSC94Y transgenesis in the pig by 
somatic cell nuclear transfer  
The graphic illustrates the generation of INSC94Y transgenic pigs by additive gene 
transfer followed by SCNT. The INSC94Y expression vector was nucleofected into 
porcine fetal fibroblasts and transgenic clones were selected according to the 
neomycine resistance cassette. Pools of stable transfected cell clones were used 
for SCNT and ET procuring INSC94Y founder animals for potential re-cloning or 
establishment of transgenic lines (Aigner et al., 2010); with kind permission from 
Springer Science and Business Media. 
 
3.2. Identification of INSC94Y transgenic pigs 
Genotyping of founder animals and offspring was achieved by specific PCR on 
tissue samples of newborn piglets. Furthermore Southern blot analysis was carried 
out on genomic DNA of founder boars and transgenic offspring to visualize 
transgene integration pattern and to determinate numbers of integration sites. 
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3.2.1. Polymerase chain reaction (PCR) 
3.2.1.1. DNA isolation from ear punches 
Ear punches were obtained from newborn piglets and stored at -20°C until further 
processing. For isolation of genomic DNA the NexttecTM Genomic DNA Isolation 
Kit (Nexttec GmbH, Leverkusen) was used according to manufacturer´s 
instructions. All steps were carried out at room temperature unless indicated 
otherwise. For tissue digestion, samples were transferred into 1.5 ml reaction 
tubes and incubated in lysis buffer at 60°C overnight. For proper lysis and high 
DNA yield 3 %l DTT were additionally added to each sample. For DNA 
purification, 120 %l of the lysate were transferred to NexttecTM clean columns the 
next day, incubated for three minutes and centrifugated at 700 x g for one minute. 
The eluate containing the purified DNA was immediately used for genotyping 
PCR or stored at 4°C until further processing. 
3.2.1.2. PCR conditions 
Genotyping was performed using primers specific for the neomycin resistance 
cassette as follows: 
neoPf (sense):          5´- CAGCTGTGCTCGACGTTGTC-3´ 
neoSr (antisense):    5´- GAGTCAACTAGTCCTCAGAAGAACTCGTCAAG-3` 
 
The ubiquitously expressed house-keeping gene ACTB was additionally amplified 
to control genomic DNA integrity.  
The following ACTB specific primers were used: 
ACTB (sense):        5´-TGGACTTCGAGCAGAGATGG-3´ 
ACTB (antisense): 5´-CACCGTGTTGGCGTAGAGG-3´ 
 
 
PCR components were mixed on ice to a total volume of 20 %l or 25 %l 
respectively in 0.2 ml reaction tubes as follows: 
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Table 2: Reaction batch for neoPf/neoSr PCR 
 
 
Table 3: Reaction batch for the amplification of ACTB  
 
 
PCR conditions are listed below: 
 
Table 4: Protocol neoPf/neoSr PCR 
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Table 5: Protocol ACTB PCR 
 
 
For termination of the reaction, thermocycler cooled down to 4°C. PCR samples 
were stored at 4°C for contemporary processing or frozen at -20°C. Genomic 
DNA from a previously genotyped transgenic pig served as positive control and 
aqua bidest. was used as non-template control. 
3.2.1.3. Agarose gel electrophoresis 
After completion of PCR amplification, DNA fragments were separated according 
to their length via agarose gel electrophoresis. 1( TAE buffer was heated with 
2% agarose in a microwave until agarose was completely melted. Ethidium 
bromide (0.5 µg/ml) was added and the gel was poured to set in a gel 
electrophoresis chamber attached with a comb. After gel polymerization the 
electrophoresis chamber was filled with 1x TAE running buffer and the comb was 
immediately removed. 6 x DNA loading dye was added to the DNA samples and 
samples as well as a Gene RulerTM 1 kb DNA molecular weight standard were 
loaded into the gel slots. DNA fragments were visualized when irradiated in UV-
light and fragment size was analyzed in relation to the molecular weight standard. 
A digital picture was taken to document the results. 
3.2.2. Southern Blot 
3.2.2.1. Isolation and restiction digest of genomic DNA  
For Southern blot analysis genomic DNA was isolated from ear punches of 
respective transgenic founder boars and transgenic offspring in accordance with 
the protocol indicated in chapter 3.3.1. 
Digestion of genomic DNA was accomplished by an overnight incubation at 37°C 
with the restriction enzyme BamH1 in 1.5 ml reaction tubes in a total volume of 
60 µl as follows: 
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15 µg genomic DNA 
4 µl BamH1 restriction enzyme 
ad 60 µl Aqua bidest. 
 
The next day, after application of a 6 x DNA loading dye to each sample, DNA 
fragments were separated by electrophoresis on a polymerized 1% TAE agarose 
gel matrix according to their size. Agarose gel preparation and electrophoresis 
was performed as described in chapter 3.2.1.3. A Gene RulerTM 1 kb DNA Ladder 
served as DNA molecular weight standard. 
3.2.2.2. Transfer of restriction enzyme digested DNA 
Following electrophoresis, the gel, containing restriction enzyme digested DNA 
was pivoted in 0.3M hydrochloric acid for approximately 45 minutes until color 
changeover of the bromophenol blue bands to yellow. After washing twice with 
aqua bidest., the gel was incubated in strand break solution for around 45 minutes 
until color of the bands turned back to blue. Pretreatment for transfer was 
achieved by immersion of the gel in neutralisation buffer for 20 minutes, followed 
by another washing step and incubation in 5x SSC for 20 minutes. Subsequently 
assayed DNA was transferred to a positive loaded Hybond-N+ Nylon membrane 
in a semi-dry manner by capillary transfer. The standard assembly of a Southern 
blot containing the gel upside-down on cling film, Hybond-N+ Nylon membrane, 
two layers of Whatman paper and multiple layers of absorbent papers was 
arranged. Finally weight was applied and transfer was carried out for 24 hours. 
Cross-linking of transferred DNA to the membrane was accomplished by UV-
light irradiation at a dose of 120 J/cm2 and membrane was stored at room 
temperature. 
3.2.2.3. Establishment and radioactive labeling of the probe 
For the detection of the integrated transgene, a probe specific for the neomycin 
resistance cassette of the INSC94Y expression vector was created. Probes were 
amplified by PCR using transgene-specific primers as mentioned below: 
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neoPf (sense):          5´- CAGCTGTGCTCGACGTTGTC-3´ 
neoSr (antisense):    5´- GAGTCAACTAGTCCTCAGAAGAACTCGTCAAG-3` 
 
Plasmid DNA containing the INSC94Y construct served as template. PCR was 
carried out considering details given in chapter 3.2.1.2. The PCR product was 
loaded onto a 1% TAE agarose gel and separated as described in chapter 3.2.1.3. 
Band was excised with a scalpel blade and DNA was eluated from the gel using 
QiaexII Gel Extraction kit (Qiagen) according to manufacturer’s instructions. 
Concentration of extracted DNA was estimated by comparison with a Lambda 
DNA/EcoRI + HindIII- molecular weight marker. The probes were radioactively 
labeled with "-[32P]-dCTP (Perkin-Emer, Netherlands), integrated using Klenow 
fragment of Polymerase I (Klenow exo-) as polymerase, and reagents as follows: 
 
50-100 ng    extracted DNA probe 
7 µl 10 x Klenow buffer 
10 µl Random Primer (3 µg/µl) 
ad 50 µl      Aqua bidest. 
 
Probe DNA was subsequently denatured at 97°C for 10 minutes. Diluents were 
chilled on ice for 2 minutes and 20 µl hybridisation mix were added to each 
sample and incubated for one hour at 37°C. 
Hybridisation master mix: 
 
3 µl C-Mix (0.33 M of each dATP, dCTP, dGTP, dTTP) 
5 µl "-[32P]-dCTP (3000 Ci/mmol) 
1 µl Klenow exo- 
ad 20 µl  Aqua bidest. 
 
Centrifugation through Sephadex G-50 columns separated unincorporated 
nucleotides. Adequate amount of purified probes were denatured at 97°C for five 
minutes a second time and stored on ice.  
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3.2.2.4. Hybridisation and signal detection 
Previously, blotted Hybond-N+ Nylon membranes were moistened with 5 x SSC 
and prehybridized in 30 ml Southern blot church buffer for one hour at 58°C in a 
hybridisation oven. Subsequently labeled probes were diluted in Southern blot 
church buffer and probes were allowed to hybridize to the nylon membranes 
overnight at 58°C under permanent rotation in the hybridisation oven. The next 
day, membranes were washed twice with low-stringency buffer at room 
temperature and twice with high-stringency buffer at 58°C.  
For signal detection, blots were exposed to X-ray films in an X-ray cassette for at 
least 24 hours at -80°C. X-ray films were developed in developing and fixing 
solutions in accordance with manufacturer’s protocol and subsequently analyzed. 
3.3. Expression analysis of the INSC94Y transgene by reverse 
transcription PCR (RT-PCR) and next generation sequencing 
technology 
Expression of the INSC94Y transgene on RNA level was analyzed in porcine 
pancreatic tissue of all seven INSC94Y transgenic founder boars and representatives 
of the INSC94Y transgenic F1-offspring of diabetic founder boar 9747. 
Genomic DNA of an INSC94Y transgenic pig was additionally used as template for 
the PCR reaction to differentiate between genomic DNA and cDNA by 
amplification with intron-spanning primers.  
To verify complete DNaseI digest, minus RT reactions of all samples were 
performed additionally by replacing SuperScriptTM II Reverse Transcriptase with 
RNase-free water and processed accordingly.  
3.3.1. Isolation of genomic DNA from ear punches 
For DNA isolation, tissue was obtained from ear punches. Tissue was stored at -
80°C until further processing. Isolation of genomic DNA was carried out using 
the Wizard genomic DNA purification Kit® (Promega) according to the 
manufacturer’s instructions. For tissue digestion, ear punches (3-5 mm) were 
transferred into separate 1.5 ml reaction tubes and incubated on a thermomixer at 
55°C overnight, gently shaking in lysis buffer as follows: 
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Mastermix:  
120 %l 0.5 M EDTA pH8.0 
500 %l Nuclei lysis solution 
17.5 %l         Proteinase K 
 
The next day, undigestible components were separated by centrifugation 
(14.000 x g, 20°C) and supernatant was decanted into new 1.5 ml reaction tubes. 
For RNA clean-up, RNase-A was added, mixed accurately and incubated for 
15 to 30 minutes at 37°C. After cooling down to room temperature, protein 
precipitation was achieved by addition of 200 %l protein precipitaton solution 
followed by a centrifugation step (13.000-16.000 x g, 4 minutes). Supernatant was 
transferred into 1.5 ml reaction tubes, containing 600 %l isopropanol and mixed 
carefully by inverting the tubes. Two minutes of centrifugation at 13.000 x g 
yielded a DNA pellet and the supernatant was discarded. The DNA pellet was 
washed twice in 70% ethanol, vortexed briefly and then centrifuged for two 
minutes at 13000 x g. Resulting supernatant was discarded reiterately. The DNA 
pellet was subsequently air-dried and resuspended in 50–100 %l DNA rehydration 
solution, gently shaking on a thermomixer at 65°C for 60 minutes. Until further 
usage the samples were stored at 4°C.  
The genomic DNA concentration was determined by measuring optic density at 
wavelengths of 260 nm and 280 nm using NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies) and finally adjusted to 100 ng/µl for PCR use.  
3.3.2. Isolation of total RNA from porcine pancreatic tissue 
Total RNA was extracted from pancreatic tissue using RNeasy® Mini total RNA 
isolation Kit (Qiagen) according to manufacturer´s instructions. In brief, 30-50 mg 
of frozen pancreatic tissue were transferred into sterile 6 ml culture tubes and 
homogenized for one minute with 600 %l of the recommended buffer using an 
ART-Micra D-8 tissue-homogenizer (23.500 rpm). Immediately afterwards, lysate 
was pipetted into a new 1.5 ml reaction tube followed by a centrifugation step 
(3 minutes, 14.000 rpm, 4°C). Supernatant was decanted into another sterile 
1.5 ml reaction tube, diluted 1:1 with ethanol (70%) and dilution was gently 
mixed by pipetting. After certain purification and centrifugation steps through 
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clean-up columns in corresponding buffers according to the manufacturer’s 
protocol, total RNA was eluted in 50 µl RNase-free water.  
3.3.3. Quantification of total RNA and evaluation of RNA quality 
Quantification of total RNA was implemented using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies) at a wavelength of 260 and 280 nm 
respectively. Total RNA quality was evaluated by visualization of 18 S and 28 S 
ribosomal bands using agarose gel electrophoresis. Therefore, a 1% TBE-agarose 
gel was prepared as described in chapter 3.2.1.3. Additionally ethidium bromide 
was both added to the 1% TBE-agarose solution (1 %l/50 ml) and the 1 x TBE 
running buffer (9 %l/l). A total of 500 ng RNA per sample was diluted to at least 
equal volumes with DEPC water, 6 x DNA loading dye was applied and samples 
were transferred into the gel slots.  
3.3.4. DNaseI digest and reverse transcription 
To prevent DNA contamination, eluted RNA samples were digested with DNaseI. 
Therefore 800 ng of total RNA were incubated with 20 U of DNaseI for 
30 minutes at 37°C on a thermomixer, diluted to an equal volume of 20 %l.  
 
800 ng Total RNA 
2 %l DNaseI reaction buffer 
2 %l DNaseI (10 U/%l) 
ad 20 µl RNase-free water 
 
Inactivation of the enzyme was achieved by incubation at 75°C for ten minutes 
followed by cooling down on ice for several minutes and centrifugation. 
10 %l DNaseI digested RNA were used for reverse transcription with the 
SuperScriptTM II Reverse Transcriptase (Invitrogen) using random hexamer 
primers in a total volume of 20 %l as follows: 
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10 %l DNaseI digested RNA 
1%l Random Hexamers Primers (600 %g/ml) 
1 %l dNTPs ( 10 mM) 
 
Reagents were incubated at 65°C on a thermomixer for 5 minutes, chilled on ice 
for two minutes and spun down briefly.  
 
4 %l 5 x first-strand buffer 
2 %l DTT (100 mM) 
1 %l RNaseOUT 
 
Previously mentioned components were added followed by gentle mixing and an 
incubation step for 2 minutes at 25°C. 
Next, 1 %l of SuperScriptTM II Reverse Transcriptase was added to each sample 
followed by an incubation step for 10 minutes at 25°C. Then, the temperature was 
raised to 50°C for enzyme activation and samples were incubated for another 
50 minutes. To inactivate the enzyme, samples were incubated at 70°C for 
15 minutes thereafter. Obtained cDNA was chilled on ice, spun down and stored 
at -20°C until further processing.  
3.3.5. PCR 
cDNA was amplified by applying insulin-specific primers: 
 
Insulin (sense):    5´-CGGGAGGCGGAGAACCCTCA-3‘ 
Insulin (antisense): 5‘-CCCTCAGGGGCGGCCTAGTT-3‘ 
 
1 %l of the cDNA served as template for PCR using the following protocol: 
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Table 6: Reaction batch for amplification of INS cDNAs 
 
 
Table 7: PCR protocol  
 
 
Additionally cDNA integrity was verified by amplification of ACTB using the 
same cDNA templates. PCR reaction batch and conditions are described in Table 
3 and Table 5. Agarose gel electrophoresis was performed as described in 
chapter 3.2.1.3. 
3.3.6. Next generation sequencing 
The ratio of mutant INSC94Y and wild-type INS transcripts was determined by next 
generation sequencing of RT-PCR amplicons (Genome Analyzer IIx, Illumina; 
>10,000 reads per sample). Previously prepared RT-PCR products were A-tailed 
and ligated to barcoded adapters using the NEBnext DNA Library Prep Master 
Mix Set (New England Biolabs, Ipswich, USA). Sequencing-ready amplicons 
were purified with Agencourt Ampure XP magnetic beads and quantified on a 
Bioanalyzer DNA1000 chip (Agilent, Santa Clara, USA). Amplicons were 
sequenced in an 80 bp single read run on an Illumina Genome Analyzer GAIIx. 
Reads containing either the wild-type or the mutant codon 94 were counted for 
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each sample. Next generation sequencing analysis was performed by Dr. Stefan 
Krebs, Laboratory of Functional Genome Analysis, Gene Center, LMU Munich. 
3.4. Physiological characterization of INSC94Y transgenic pigs 
3.4.1. Blood glucose levels and body weight gain 
To evaluate the impact of INSC94Y transgene expression on glucose homeostasis, 
random blood glucose levels were determined at short intervals, starting prior to 
first colostrum ingestion up to the age of weaning. After weaning fasting blood 
glucose levels (18-hour fasting period) were analyzed regularly in at last 4-week 
intervals. Therefore a drop of blood was taken from a superficial ear vein with a 
small lancet and instantly examined using a FreeStyle Precision® XceedTM 
Glucometer with Precision XtraTM Plus blood glucose test stripes (Abbott).  
In addition body weight gain was recorded on a regular basis using a mobile 
animal scale. 
In both cases, non-transgenic female and male littermates served as wild-type 
controls.  
3.4.2. Determination of insulin levels by radioimmunoassay (RIA) 
Fasting plasma insulin levels of two different age groups were investigated, 8-
day-old and 4.5-month-old male and female INSC94Y transgenic pigs and littermate 
controls. Blood samples were collected in EDTA monovettes and immediately 
stored on ice. After centrifugation (15 minutes, 1500 x g, 4°C), plasma was 
carefully separated and stored at -80°C until assayed. Fasting plasma insulin 
levels were determined in duplicates using a porcine insulin RIA kit (MilliporeTM) 
according to manufacturer´s instructions. A fixed concentration of 125I-labeled 
insulin was used as labeled tracer antigen. Unlabeled insulin of the plasma 
samples and 125I-labeled insulin compete for a constant number of binding sites on 
the anti-porcine insulin antibody (use of a constant dilution). Consequently, the 
amount of tracer antigen decreases, if the concentration of unlabeled antigen 
increases. Following separation of antibody-bound from free tracer, the antibody-
bound fraction was counted in a '-counter. Samples of unknown concentration 
were analyzed by comparison with a previously determined standard curve. 
Merely duplicates with a coefficient of variance (CV) less than 10% were taken 
into account. 
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3.4.3. Determination of glucagon levels by radioimmunoassay (RIA) 
Basal plasma glucagon levels were measured in INSC94Y transgenic pigs and non-
transgenic littermates at the age of 8 days and at the age of 4.5 months. Blood 
samples were collected and processed as described in 3.4.2. Glucagon levels were 
determined using a commercially available glucagon radioimmunoassay (RIA) kit 
according to the manufacturer’s protocol (in principle procedure described in 
3.4.2.). 125I-labeled glucagon was utilized as a tracer antigen. 
3.4.4. Homeostasis model assessment of !-cell function (HOMA - B) and 
insulin resistance (HOMA - IR) 
The parameters homeostasis model assessment of !-cell function (HOMA - B) 
and insulin resistance (HOMA - IR) were calculated in 4.5-month-old INSC94Y 
transgenic pigs and non-transgenic littermates according to Matthews et al. 
(1985). 
HOMA - IR= FSI (#U/ml) * FBG (mmol/l) / 22.5 
HOMA - B (%) = 20*FSI / (FBG - 3.5) 
 
FSI: Fasting serum insulin (%U/ml) 
FBG: Fasting blood glucose (mmol/l) 
 
3.4.5. Insulin therapy of INSC94Y transgenic pigs  
To guarantee a healthy adolescence and to preserve fertility, INSC94Y transgenic 
pigs were started on insulin therapy at the age of approximately 4.5 months. A 
combination of long-acting Lantus® insulin (Sanofi) and short-acting NovoRapid® 
insulin (NovoNordisk) was administered subcutaneously once daily using a 
commercial insulin pen with appropriate BD Micro-Fine UltraTM pen needles 
(Becton Dickinson GmbH). In total, a dosage of 0.5 -1 I.U. per kg body weight 
was applied. Blood glucose concentration was determined once to twice daily 
using a Precision® XceedTM Glucometer with appropriate Precision XtraTM Plus 
blood glucose test stripes (Abbott) as described in chapter 3.4.1. 
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3.4.6. Continuous blood glucose monitoring  
In order to evaluate glucose control under insulin treatment continuous glucose 
monitoring was performed using the Guardian® REAL-Time System (Medtronic). 
The Guardian® REAL-Time System measures glucose levels within the 
intracellular fluid. An insulin-treated INSC94Y transgenic pig and an untreated 
control animal were profiled over a period of 42 hours. For this purpose, a sensor 
was placed subcutaneously behind the ear under general anesthesia (detailed 
description of general anesthesia regimen in chapter 3.4.7.1) measuring interstitial 
glucose levels every 10 seconds (Figure 3). A transmitter connected to the glucose 
sensor transferred all data electronically to an external computer. The mean 
glucose concentration was calculated by the computer every five minutes and 
displayed on the monitor. Capillary blood glucose levels were determined up to 
five times per day using the Precision® XceedTM glucometer to calibrate the 
device. Data analysis was carried out using the Medtronic CareLink Pro software 
(version 3.2A). 
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Figure 3: Placement of a continuous glucose monitoring system in a pig 
For achieving a continuous glucose monitoring profile of an insulin-treated 
INSC94Y transgenic pig and an untreated control animal a sensor was inserted 
subcutaneously near the ear (A/B) and connected to a transmitter (C/D) for 
electronical data transmission. 
 
3.4.7. Analyzes of glucose metabolism by glucose tolerance tests 
Intravenous glucose tolerance tests were performed in normoglycemic transgenic 
founder boars at the age of seven months to investigate potential early 
abnormalities in glucose tolerance and insulin secretion indicating prediabetic 
status. 
3.4.7.1. Surgical insertion of central venous catheters 
To allow reiterated blood sampling for acccomplishment of glucose tolerance 
tests, pigs received two central venous catheters, which were both surgically 
inserted into the external jugular vein. In general, the surgery was performed 
aseptically under general anaesthesia and pigs were treated peri-and postsurgically 
with analgesics. In addition antibiotics were administered postsurgically to 
prevent infections. Pigs were anaesthetised by intramuscular injection of ketamine 
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hydrochloride (2 ml/10 kg BW) and azaperone (0.5 ml/10 kg BW). To maintain 
anaesthesia, ketamine hydrochloride (2 ml/10 kg BW) and xylazine (0.5 ml/ 10 
kg BW) was injected intravenously through a catheter in the ear vein as needed. 
Peri- and post-surgical analgesia was achieved by intravenous injection of 
metamizol (1 ml/10kg BW) and an intramuscular application of meloxicam 
(2 ml/100 kg BW). Pigs were positioned in dorsal recumbency. After cleansing 
and disinfection of the jugular grove, an incision of approximately five 
centimetres length was made to allow vein exposure. Holding sutures were 
placed, adjacent tissue was carefully removed from the vein and a venotomy was 
made followed by insertion of the catheters. A proximal and a distal ligature 
prevented blood reflux and fixed the catheter in the required position. The incision 
was immediately sutured in two layers. Catheters were externally fixated with a 
suture to the skin, covered by sterile gauze and adhesive tape was placed like a 
neck brace. On withers height catheters were coiled in a pouch to allow easy 
access. To avoid obstruction by coagulation, catheters were flushed once daily 
with 250 I.U. heparin/ml 0.9% isotonic NaCl solution. Previously to the glucose 
tolerance test, undisturbed general condition of the pigs was ensured. 
3.4.7.2. Intravenous glucose tolerance test (IVGTT) 
IVGTT was performed in pigs placed in single pens, freely moving and fasted 18-
hours overnight. The pigs were injected a concentrated 50% glucose solution 
(0.5 g/kg BW) followed by 20 ml 0.9% isotonic NaCl solution. 
 Blood samples were taken at -10, 0, 1, 3, 5, 7, 10, 15, 20, 30, 40, 50, 60 and 90 
minutes relative to intravenous glucose load and the catheter was flushed with 
3 ml of a 0.9% isotonic NaCl solution after each blood sampling. Blood samples 
were processed as described in 3.4.2. Plasma glucose levels were determined 
using an AU 400 autoanalyzer (Olympus) while insulin levels were measured in 
duplicates using a porcine insulin RIA kit (Millipore) as described in 
chapter 3.4.2. The area under the glucose/insulin curve was determined using 
GraphPad Prism software (version 5.02). 
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3.5. Morphological characterization of INSC94Y transgenic pigs 
3.5.1. Necropsy 
INSC94Y transgenic and non-transgenic pigs of defined age were subjected to 
routine necropsy. Therefore pigs were anaesthetised with ketamine hydrochloride 
(2 ml/10 kg BW) and azaperon (0.5 ml/10 kg BW) in their accustomed 
surroundings followed by vein catheter insertion and euthanization by an 
intravenous injection of T61 (1 ml/10 kg BW). Then, organs were subjected to 
macroscopic evaluation and desired tissue samples were harvested.  
3.5.2. Pancreas preparation for quantitative-stereological analyzes 
To avoid autolysis, the pancreas was immediately processed. Following 
explantation of the whole organ, surrounding tissue was carefully removed and 
the pancreas was weighed. In 4.5-month-old animals the pancreas was cut at the 
intersection between splenic and connective lobe and placed lengthwise on the 
table (Figure 4). The pancreas was cut into 0.5 cm thick slices. Slices were tilted 
to their left side and fixed in 4% neutral buffered formalin overnight. The next 
day, slices to be analyzed, were selected by systematic random sampling. 
Therefore slices were covered by a 1 cm2 point-counting grid and the total number 
of points hitting pancreatic tissue was counted and divided by the number 20 as 
total sample number. For simplification, the above-mentioned quotient is called Y 
in the following. Starting at a random number (X) between one and Y, pieces with 
a volume of 0.5 cm3 were collected at the sites X, X+Y, X+2*Y, X+3*Y,…, 
X+20*Y. Selected samples were placed in an embedding cassette right cut surface 
downwards and routinely processed for paraffin histology. Following paraffin 
embedding, half of the pancreatic samples were cut into approximately 4 %m thick 
sections with a HM 315 microtome (Microm), mounted on 3-
aminopropyltriethoxysilane-treated glass slides for immunohistochemistry and 
dried at 37°C in an incubator overnight. 
Due to their smaller size, pancreata of 8-day-old piglets were not subjected to 
systematic random sampling, but rather fixed in total in 4% neutral buffered 
formalin overnight, cut longitudinally into 0.3 cm3 thick slices the next day and 
routinely processed for paraffin embedding. 
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Figure 4: Preparation of the pancreas for quantitative-stereological analyzes 
The pancreas of 4.5-month-old INSC94Y transgenic pigs and non-transgenic 
littermates was separated between splenic and connective lobe. White bar 
indicates the separation site; (picture kindly provided by Dr. Simone Renner). 
 
3.5.3. Immunhistochemical stainings of pancreatic tissue 
For quantitative stereological analyzes, different immunohistochemical stainings 
were performed. In 4.5-month-old INSC94Y transgenic pigs (3 male, 4 females) and 
non-transgenic controls (1 male, 6 female) a double immunohistochemical 
staining to visualize !-cells and non-!-cells as well as a single staining to detect "-
cells was carried out. Pancreatic tissue sections of transgenic and non-transgenic 
8-day-old piglets (n=4 per group) were used for a single staining detecting insulin 
containing !-cells. 
For detection of insulin containing cells, the indirect alkaline phophatase method 
(AP) was implemented, whereas glucagon, somatostatin and pancreatic 
polypeptide containing cells were immunostained utilizing the indirect 
immunoperoxidase technique. Sections were deparaffinized for 20 minutes in 
xylene, rehydrated in a descending alcohol series and washed in distilled water. 
Endogenous peroxidase activity was blocked by incubation in 1% hydrogen 
peroxide solution for 15 minutes. Following a washing step in TBS buffer 
(pH 7.4) for 10 minutes, sections were subjected to incubation with non-immune 
goat serum for 30 minutes to reduce non-specific binding. Subsequently, slides 
were incubated for one hour at room temperature with the respective primary 
antibody diluted to the desired concentration in TBS buffer (pH 7.4), washed 
again in TBS buffer (pH 7.4) for 10 minutes and incubated with the corresponding 
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secondary antibody containing 5% porcine serum, likewise diluted in TBS buffer 
(pH 7.4). After a further washing step in TBS buffer (pH 7.4), immunoreactivity 
was visualized with a suitable chromogen protected from light. Last, slices were 
counterstained in Mayer´s hemalum solution, washed in distilled water and 
dehydrated in an ascending alcohol series, followed by clearing in xylene and 
mounting using histokitt. For staining of non-!-cells, all three primary antibodies 
were mixed and sections were simultaneously immunostained. 
For details on antibodies and chromogens see Table 8. 
 
 
 
  
Table 8: Immunhistochemical procedures 
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3.5.4. Quantitative stereological analyzes of the pancreas 
Stereometrical procedure was carried out using an Olympus VisiomorphTM image 
analysis system (Visiopharm, Hoersholm, Denmark) coupled to a light 
microscope (BX41, Olympus). That way, images were displayed via a colour 
video camera (DP72, Olympus) on a monitor in the desired magnifications. 
Planimetric evaluation of !-, "- and non-"-cell (!-, #-, pp-cells) areas as well as 
islet profiles and the cross-sectional area of pancreatic tissue was manually 
determined on immunhistochemically stained pancreatic sections by circling their 
cut surfaces with a cursor using the stereology software newCAST (Visiopharm, 
Hoersholm, Denmark). The area of "-cells in 8-day-old animals was determined 
in a semi-automated fashion using the software visiomorph 
(Visiopharm, Hoersholm, Denmark). All photographs were taken under equal 
conditions. To assess the relative proportions, scale bars were designed by 
photographing an object micrometer (Zeiss, Oberkochen) at the same 
magnification. As conventional histological tissue procession provokes shrinkage 
of the organ, the volume of the pancreas (V(Pan)) before embedding was calculated 
by the quotient of the pancreas weight and the specific weight of the porcine 
pancreas (1.07 g/cm3) determined by the submersion method (Scherle, 1970). 
Volume fractions of target cells in reference compartments were computed values. 
The volume density of the islets in the pancreas (Vv(Islet/Pan)) was calculated by 
dividing the total islet area (A(Islet)) by the total pancreas area (A(Pan)). The product 
of Vv(Islet/Pan) and V(Pan) yielded the total volume of islets in the pancreas 
(V(Islet,Pan)). The volume densities of !- and "-cells in the islet (Vv(!-cells/Islet); Vv("-
cells/Islet)) or in the pancreas (Vv(!-cells/Pan); Vv("-cells/Pan)) respectively as well as their 
total volumes in their reference compartments (V(!-cell,Islet); V(!-cell,Pan); V("-cell,Islet); 
V("-cell,Pan)) were calculated accordingly. The volume density and the total volume 
of "-cells in the pancreas refer to "-cells in the islet and isolated "-cells in the 
pancreas. Isolated "-cells were evaluated separately and their volume fractions 
were likewise calculated. 
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3.5.5. Transmission electron microscopy (TEM) 
In order to investigate ultrastructural morphology of pancreatic "-cells, pancreata 
of 8-day-old and 4.5-month-old transgenic and non-transgenic pigs 
(n=3 per group) were subjected to electron microscopy. Pancreas samples of 
approximately 1 mm3 were obtained by systematic random sampling during 
routine necropsy. Samples were fixed by immersion in 6.25% glutaraldehyde in 
Soerensen’s phosphate buffer (pH 7.4) for 24 hours. After fixation, samples were 
washed in Soerensen´s washing solution at least three times until complete 
removal of glutaraldehyde. Subsequently, tissue was fixed in 1% osmium 
tetroxide fixation solution for two hours at 4°C, followed by another washing step 
in Soerensen’s washing solution. Subsequently pancreas samples were routinely 
processed for epon embedding containing dehydration in an ascending acetone 
series, incubation in a solution with equal amounts of acetone (100%) and 
glycidylic ether 100 (Epon) for one hour at room temperature followed by 
incubation in undiluted glycidylic ether 100 twice for 30 minutes and final 
embedding in glycidylic ether-embedding mixture in gelatine capsules. 
Polymerization was achieved by incubation at 60°C for 48 hours. Epon blocks 
were trimmed using a TM60 milling machine (Leica) and semi-thin sections 
(0.5 µm) were prepared using a Reichert-Jung Ultracut E microtome (Leica). In 
order to visualize the distribution of the pancreatic islets within the semi-thin 
sections, sections were at first stained with toluidine blue staining solution for 
15 seconds at 55°C on a heating plate, rinsed with aqua bidest. and dried. 
Subsequently sections were incubated in Safranin O staining solution for another 
15 seconds, rinsed with aqua bidest., dried and finally covered with coverslips 
using histofluid mounting medium. Following identification of the islets under a 
microscope and marking their positions, ultra-thin sections (70-80 nm) were 
sliced just at these localizations, also using Reichert-Jung Ultracut E microtome. 
Finally, sections were mounted on copper rings and contrasted with uranyl acetate 
and lead citrate according to the method of Reynolds (1963). Electron microscopy 
was performed using an EM 10 transmission electron microscope (Zeiss).  
Electron microscopical evaluation of the endocrine pancreas was carried out in 
Cooperation with the Institute of Veterinary Pathology at the Center for Clinical 
Veterinary Medicine, LMU Munich, Prof. Dr. Walter Hermanns. 
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3.5.6. Physiological, morphological and quantitative-stereological 
evaluation of the kidneys 
Morphology of the kidneys as well as the kidney function of INSC94Y trangenic 
pigs (3 males and 4 females) and their corresponding non-transgenic littermate 
controls (1 male and 6 females) were investigated at 4.5 months of age. 
Additionally kidney samples of 1-year-old cloned diabetic INSC94Y transgenic 
pigs, kindly provided by Minitube of America, Inc., were examined histologically. 
Furthermore urine samples of these animals were assayed for evidence of 
albuminuria as an initial diabetes-induced functional disorder of the kidney. The 
oldest stage investigated for diabetic kidney disease likewise was the diabetic 
INSC94Y transgenic founder boar at the age of approximately three years. One age-
matched, non-transgenic boar served as wild-type control for urine analyzes. 
Histopathological evaluation of diabetic secondary lesions in the kidneys of 
INSC94Y transgenic pigs was performed in cooperation with Dr. Andreas Blutke, 
Institute of Veterinary Pathology at the Center for Clinical Veterinary Medicine, 
LMU Munich, Research Group of Prof. Dr. Rüdiger Wanke.  
3.5.6.1. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) analysis of urine samples 
Urine samples of respective pigs were either collected after spontaneous emiction 
or obtained by cystocentesis under general anesthesia as described in chapter 
3.4.7.1. Urine samples were mixed well by vortexing, aliquoted and immediately 
frozen at -80°C until assayed. In advance urine samples were profiled by an AU 
400 autoanalyzer (Olympus) and especially creatinine levels were determined. 
Urine samples were standarized by dilution to a constant creatinine concentration 
of 1500 µmol/l with aqua bidest. and stored on ice for contemporary processing. 
Urine protein fractions were separated by electrophoresis on a polymerized gel 
matrix according to their molecular weight. 12% SDS polyacrylamide separating 
gel was prepared as indicated in Table 9, poured into the intercept of two glass 
plates clamped in a Mini Protean® 3 Cell Assembly chamber (BioRad), 
immediately overlayed with aqua bidest. and allowed to polymerize for one hour 
at room temperature.  
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Table 9: Composition of SDS polyacrylamide separating gel (12%, for 4 gels) 
 
 
Following complete polymerization, aqua bidest. was carefully drained and a 5% 
stacking SDS polyacrylamide gel (Table 10) was casted instead. Subsequently a 
10-well or 15-well comp respectively was inserted into the fluid stacking gel. 
 
Table 10: Composition of SDS polyacrylamide stacking gel (5%, for 4 gels) 
 
 
While the stacking gel was polymerizing for at least 45 minutes, previously 
diluted samples were prepared. One-fifth volume fraction of 5 x Laemmli buffer 
and 5% 2-mercaptoethanol was added to 1 µl of the urine sample resulting in a 
final concentration of 25 µl. Before sample application, the urine samples were 
denatured at 95°C for five minutes on a heating block, chilled on ice for two 
minutes and finally the lid condensate was briefly centrifuged. A bovine serum 
albumin standard was prepared with a concentration of 100 µg/ml and 
0.6 µg/25 µl were assayed accordingly. The comb was removed carefully and the 
gel was placed into an electrophoresis cell of the Mini Protean® 3 Cell Assembly. 
1 x SDS running buffer was filled to the top of the inner cell and up to one third of 
the outer cell. Urine samples, the bovine albumin standard and additionally a 
PageRulerTM Prestained Protein Ladder as well as an unstained protein molecular 
weight marker (Thermo Fisher Scientific) were loaded into the slots. 
Electrophoresis was run at 100 V for approximately 15 minutes until chromogen 
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reached the SDS polyacrylamide separating gel and prestained protein ladder 
begun to separate. Subsequently electric voltage was raised to 160 V and 
electrophoresis ran for another 60 minutes until leakage of the chromogen. Finally 
the gel was removed from the glass frame and subjected to non-colloidal 
Coomassie staining and silver staining as described in chapter 3.5.6.2. and in 
chapter 3.5.6.3. For detection of albuminuria, gel bands of approximately 66 kDa 
corresponding to the molecular weight of bovine serum albumine standard 
(66.5 kDa) were compared with age-matched non-transgenic control pigs. 
3.5.6.2. Non-colloidal Coomassie staining of SDS polyacrylamide gels 
For Coomassie staining the gel was at first pivoted in aqua bidest. for two 
minutes. Then, aqua bidest. was carefully drained and gels were incubated in 
Coomassie staining solution at 4°C overnight pitching on a tumbling shaker. To 
prevent evaporation, staining bowl was wrapped in cellophane. The next day, gels 
were destained, while pivoting in destaining solution for as long as required but at 
last until gel background has cleared. Destaining solution was replaced whenever 
necessary. Gels were scanned for documentation and dried for long-term storage. 
Initially gels were incubated in drying solution for one hour. The DryEase® Mini-
Gel drying base and frame (Life TechnologiesTM GmbH) was used for drying 
polyacrylmide gels. Previously two cellophane sheets were moistened in drying 
solution and the stained gel was placed between these two sheets without blisters. 
Finally the DryEase® Mini-Gel drying base and frame were aligned and closed 
with plastic clamps. Gels were dried standing upright on a benchtop for 
approximately 2 days.   
3.5.6.3. Silver staining of SDS polyacrylamide gels 
In general all steps were performed at room temperature. The SDS 
polyacrylamide gel was incubated in fixation solution followed by thrice 
20 minutes in 50% ethanol on a tumbling shaker. Pretreatment was achieved by 
incubation in sodium thiosulfate solution for one minute before being rinsed with 
aqua bidest. for 3 x 20 seconds. Afterwards gel was impregnated for 20 minutes 
and washed in aqua bidest. twice for 20 seconds. Development in developmental 
solution under visual control until bands appear was arbitrative. The gel was 
rinsed again in aqua bidest. for 20 minutes and the reaction was stopped with 
0.1 M EDTA pH 8.0. After being washed for further three times two minutes in 
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aqua bidest., gel was dried and analyzed as described before (3.5.6.2). 
3.5.6.4. Tissue preparation for histology and transmission electron 
microscopy of the kidneys 
For histopathological investigation, the left kidney was explanted immediately 
after euthanasia (3.5.1) and instantly fixed by orthograde vascular perfusion using 
4% phosphate buffered formaldehyde solution of 37°C for 15 minutes (Figure 5). 
After perfusion, the kidney was decapsulated and fixed by immersion in 4% 
phosphate buffered formaldehyde solution for 24 hours. After dabbing the fixed 
kidney with a paper towel the organ weight was determined. The perfused kidney 
was then cut perpendicular to the longitudinal axis. In a systematic random 
sampling according to Nyengaard (1999), six samples from the renal cortex were 
selected, carefully resected with a scalpel blade and subjected to either plastic or 
epon embedding (LIT). Relative kidney weights were calculated from the 
cumulative weight of both kidneys as percent of body weight. 
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Figure 5: Schematic illustration of orthograde vascular kidney perfusion in 
the pig 
For orthograde vascular kidney perfusion the pig was positioned in dorsal 
recumbency and the abdomen was opened through a median transection as 
indicated by the dashed line (A); renal artery and vein were ligated and kidney 
was immediately removed (B); isolated kidney was perfused using 4% phosphate 
buffered formaldehyde solution of 37°C for 15 minutes via an arterial access (C), 
while outflow of the perfusate was ensured through the equilateral vein (D); the 
change in color of the organ surface to pale yellow was an indicator for sufficient 
perfusion (E); (illustration kindly provided by Dr. Andreas Blutke). 
 
3.5.6.4.1. Plastic histology of kidney samples 
For plastic embedding, renal tissue was left immersed in 4% paraformaldehyde 
overnight  and routinely processed using a Shandon Citadel tissue processor 1000 
(Thermo Fisher Scientific). Tissue embedding in glycolmethacrylate and methyl-
methacrylate (GMA/MMA) was performed as previously described (Hermanns et 
al., 1981). Initially paraformaldehyde fixed slices were transferred into embedding 
capsules and fixed by rubber-sponge kit. Incubation in 2-
hydroxymethylmethacrylate-methyl methacrylate solution at 4°C on a tumbling 
shaker for 18 hours was followed by incubation in plastic embedding solution for 
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four hours at 4°C. Finally kidney slices were embedded in plastic cups using 60 µl 
dimethylanilin as initiator of polymerization. Complete polymerization was 
accomplished by water quenching at 4°C. Sections of approximately 1.5 $m 
thickness were prepared utilizing a HM 360 rotary microtome (Microm), dried on 
a heating plate and stored at 64°C overnight prior to further staining procedure. 
Afterwards a hematoxylin and eosin staining (HE), a periodic acid Schiff staining 
(PAS) and a periodic acid silver methenamine staining (PASM) was performed on 
tissue samples as indicated per particular in Table 11 and in Table 12. 
 
Table 11: Protocol for HE staining 
 
 
Table 12: Protocol for PAS staining 
 
Finally sections were covered with coverslips using Histofluid! mounting 
medium. 
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3.5.6.4.2. Determination of the mean glomerular volume 
The mean glomerular volume was quantitatively stereologically determined in 
plastic embedded renal tissue from seven 4.5-month-old INSC94Y transgenic pigs (3 
male, 4 female) and seven age matched non-transgenic controls (3 male, 
4 female), using an Olympus VisiomorphTM image analysis system (Visiopharm, 
Hoersholm, Denmark). Technical details are per particulars given in 3.5.4. The 
mean glomerular volume was estimated from planimetric measurements of the 
mean glomerular profile areas as described previously (El-Aouni et al., 2006; 
Herbach et al., 2009; Weibel and Gomez, 1962). 144 ± 8 glomerular profiles 
per animal (range: 135–155) were systematically sampled and their contours were 
circled using the cursor of the analysis system as described in chapter 3.5.4. The 
mean glomerular volume was calculated as follows: 
 
Equation 1 (Hirose et al., 1982; Wanke, 1996):   
V(glom)(s) = ß/k*a(glom)1.5  
 
V(glom)(s) : stereologically estimated mean glomerular volume  
ß: shape coefficient 
k: size coefficient  
a (glom): arithmetic mean of areas of glomerular profiles 
 
The shape- and the size coefficients were taken from Wanke (1996). The results 
were corrected for embedding shrinkage by considering a shrinkage correction 
factor for plastic embedded porcine renal tissue in accordance with Wanke (1996) 
using the following equation: 
 
Equation 2 (Wanke, 1996): 
V(glom) = V(glom)(s)/fs3  
 
V(glom):  stereologically estimated mean glomerular volume 
fs:  linear tissue shrinkage correction factor for porcine kidney tissue 
embedded in GMA/MMA 
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Additionally the mean glomerular volume to body weight (BW) ratio 
(V(glom)/BW (mm3/kg)x 10-3) was calculated. 
3.5.6.4.3. Transmission electron microscopy of renal samples and 
determination of the true harmonic mean thickness (Th) of the 
glomerular basement membrane (GBM) 
For the determination of the true harmonic mean thickness of the glomerular 
basement membrane (ThGBM), cubes of approximately 1 mm3 of cortical kidney 
tissue obtained from three female INSC94Y transgenic pigs and three female non-
transgenic control pigs of 4.5 months of age were fixed by immersion in 6.25% 
glutaraldehyde in Soerensen´s phosphate buffer (pH 7.4) for 24 hours and 
routinely assayed for epon embedding (chapter 3.5.5). To localize patent 
glomerula within Epon embedded cortical kidney tissue, Toluidine blue/Safranin 
blue-stained semi-thin sections (0.5 µm) were evaluated. Ultra-thin sections 
(70 nm) were prepared and contrasted with uranyl-acetate and lead citrate 
considering the standard protocol as described in chapter 3.5.5. Transmission 
electronical micrographs of peripheral glomerular capillary loops were taken in a 
systematic pattern (five to six glomerular cross section profiles) at a final 
magnification of 8.000 fold according to Herbach et al. (2009). Photographs of 
standard cross-grating replicas at same magnifications served for calibration. The 
glomerular basement membrane (GBM) thickness was determined by the 
orthogonal intercept method (Dische, 1992; Hirose et al., 1982; Jensen et al., 
1979; Ramage et al., 2002). Micrographs in the respective magnification were 
covered by a transparent 2.5 x 2.5 cm counting grid. A transparent logarithmic 
ruler according to the description of Ramage et al. (2002) was surveyed for 
measuring latitude of the glomerular basement membrane (GBM) by 
determination of the shortest distance from the endothelial cytoplasmic membrane 
to the outer lining of the lamina rara externa underneath the cytoplasmic 
membrane of the epithelial foot processes. An average number of 
348 ± 67 intercepts per animal were measured (number of observations). The 
apparent harmonic mean thickness of the GBM and the true harmonic mean 
thickness of the GBM are calculated values: 
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Apparent mean thickness [mm] (Ih): 
Ih =  ! N° / ! (Midpoints * N°)  
 
N°:  Number of observations 
 
Harmonic mean thickness [nm] (Th): 
Th=  8/3" * 106 / M * Ih  
 
8/3%:  correction factor for potential oblique sectioning 
M:  Final print magnification 
 
3.5.7. Preparation of the eye lenses for the documentation of diabetic 
cataract 
Entire lenses were immediately removed from remaining ocular tissue of 
dissected whole eye globes. Isolated lenses were stored in 0.2 M PBS buffer 
pH 7.4 and evaluated with a Stemi SV11 stereomicroscope (Zeiss, Oberkochen) at 
0.6 x zoom. Images were acquired by means of an AxioCam scanning camera 
(Zeiss, Oberkochen). Preparation of the eye lenses was performed in cooperation 
with Dr. Oliver Puk, Helmholtz Center Munich-German Research Center for 
Environmental Health, Institute of Developmental Genetics, Neuherberg, 
Research group of Prof. Dr. Jochen Graw. 
3.5.8. Preparation of the nerves, histological procedure and single fiber 
teasing 
Histopathological evaluation of nervous tissue of INSC94Y transgenic pigs was 
performed in cooperation with Dr. Daniela Emrich, Institute of Veterinary 
Pathology at the Center for Clinical Veterinary Medicine, LMU Munich, Research 
group of Prof. Dr. Kaspar Matiasek. Morphology of nervous tissue of 
INSC94Y transgenic pigs and age-matched non-transgenic littermates was 
investigated at 4.5 months of age. The oldest stage investigated for diabetes-
associated nerve injury was the diabetic INSC94Y transgenic founder boar at the age 
of approximately three years. One age-matched, non-transgenic boar served as 
wild-type control. A biopsy of the tibial nerve fascicle was obtained from its 
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origin at the fibular nerve during routine necropsy and immediately immersed in 
2.5% glutaraldehyde in Soerensen´s phosphate buffer (pH 7.4) for 1 hours and 
routinely assayed for epon embedding (chapter 3.5.5.). Epon blocks were trimmed 
using a TM60 milling machine (Leica) and semi-thin sections (0.5 µm) were 
prepared using a Reichert-Jung Ultracut E microtome (Leica). Semi-thin sections 
were stained with azur II-methyleneblue-safranin. Sections were at first stained 
with azur II-methyleneblue staining solutions for 25 seconds at 55°C on a heating 
plate, rinsed with aqua bidest. and dried. Subsequently sections were incubated in 
Safranin O staining solution for another 15 seconds, rinsed with aqua bidest., 
dried and finally covered with coverslips using histofluid mounting medium.  
In addition, single tibial nerve fascicles of about 1 cm length were subjected to 
single fiber teasing as previously described (Wieczorek, 2002). Nerve biopsies 
were likewise immersed in 2.5% glutaraldehyde in Soerensen´s phosphate buffer 
(pH 7.4) for 1 hours and subsequently fixed in 2% osmium tetroxide fixation 
solution for two hours at 4°C. Following a washing step in Soerensen’s phosphate 
buffer stowed with saccharose (0.2 mol/l), fascicles were incubated in glycerol-
anhydrous over night and single fiber teasing was performed. Teased fibers were 
placed on microscope slides, finally covered with coverslips and microscopically 
evaluated. 
3.6. Western blot analysis of isolated pancreatic islets 
In order to confirm quantitative-stereological analyzes and electron microscopy of 
pancreatic "-cells of INSC94Y transgenic and non-transgenic pigs of particular age 
groups, pancreatic islets of one transgenic and one non-transgenic neonatal piglet 
at 8 days of age were isolated and subjected to Western blot analysis with regard 
to the abundance of the endoplasmic reticulum stress markers GADD 153/CHOP-
10 (Growth arrest and DNA damage 153/ C/EBP-homologous protein 10), 
PeIF2# (phosphorylated eukaryotic translation initiation factor 2#) and 
BiP/Grp78 (Binding Ig protein / Glucose regulated protein 78).  
3.6.1. Isolation of neonatal porcine islets of Langerhans 
Isolation of porcine neonatal pancreatic islets was carried out by Dr. Lelia Wolf-
van Bürck, Diabetes Zentrum, Medizinische Klinik Campus Innenstadt, LMU 
Munich, Research Group of Prof. Dr. Jochen Seißler.  
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After explantation of pancreata derived from 8-day-old INSC94Y transgenic piglets 
and age-matched non-transgenic littermates (n=3 per group), neonatal islet-like 
cell clusters were isolated according to Korbutt et al. (1996). Following the 
isolation process, isolated islet cell clusters (ICC) were cultured in RPMI stowed 
with 2% human serum albumin, 1% antibiotic-antimycotic, 10 mmol/l 
nicotinamide as well as 20 nmol/l exendine-4 for 6 days at 37°C. Afterwards, 
islet-like cell clusters were hand-picked under a stereomicroscope, transferred into 
a 1.5 ml reaction tube (500 ICCs per sample) and stored at -80°C. Prior to further 
use, islet cell clusters were suspended in 50 $l protein extraction buffer working 
solution followed by sonication (7 strokes/1 second) using a Branson sonifier cell 
disrupter B15 (Branson Ultrasonic Corporation, USA). In order to destroy cell 
membrane integrity islet sonicates were frozen at -80°C for at least overnight. The 
next day, sonicated islet samples were carefully thawed on ice followed by a 
centrifugation step (5 minutes, 5.000 rpm, 4°C). Supernatant was carefully 
separated, immediately assayed or stored at -20°C.  
3.6.2. Determination of islet protein content 
To determine the protein content of sonicated islet samples the Bradford method 
was applied. Previously, a protein standard was prepared referring to the current 
Bradford reagent by dissolving bovine serum albumin (BSA) in aqua bidest. to a 
concentration of 5 mg/ml and a spectrophotometrically determined extinction of 
0.33 at a wavelength of 595 nm. From the initial solution, standard concentrations 
of 100, 87.5, 75, 62.2, 50, 37.5, 25, 12.5, 0 (blank) $g/ml were produced in a final 
volume of 100 $l each, and 1000 $l Bradford reagent were added respectively. 
Extinction was measured at a wavelength of 595 nm using a Beckmann DU-640 
spectrophotometer (Beckman Coulter GmbH). The standard curve was created 
from extinction values as x-axis and protein concentrations in $g/ml as y-values. 
Then, islet samples to be analyzed were diluted 1:100 and 1:50 in aqua bidest., 
absorbance was measured spectrophotometrically at a wavelength of 595 nm and 
protein concentration of islet lysates was determined using previously established 
standard curve. 
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3.6.3. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blot analysis of isolated islets 
Islet sonicates were at first separated by electrophoresis on a 12% SDS 
polyacrylamide gel as described in 3.5.6.1. Previously, islet samples were diluted 
with protein extraction buffer working solution, 5 x Laemmli buffer and 5% 2-
mercaptoethanol to a final protein concentration of 15 µg/25 µl total sample 
volume. Denaturation was achieved at 95° C for five minutes on a heating block, 
chilling on ice for two minutes and final centrifugation of the lid condensate. A 
PageRulerTM Prestained Protein Ladder and an unstained protein molecular weight 
marker (Thermo Fisher Scientific) served as protein molecular weight markers.   
3.6.4. Western blot analysis  
After completion of electrophoresis, the proteins were transferred from SDS-
polyacrylamide gel to a protein-binding Immobilon®-P nitrocellulose transfer 
membrane by means of electrophoresis using a Trans Blot® SD Semi-Dry 
Transfer cell (BioRad). Previously nitrocellulose transfer membranes were 
activated by pivoting in 100% methanol for ten minutes followed by immersion in 
1 x transfer buffer for 30 minutes on a tumbling shaker. SDS-gel was placed on 
the moistened nitrocellulose transfer membrane between two layers of extra thick 
absorbent paper, soaked with 1 x transfer buffer. Proteins were transferred to the 
membrane with 1 mA/cm2 (15 V) for one hour. To confirm blotting success, 
membranes were reversibly stained with Ponceau S solution and washed twice in 
aqua bidest. until background has cleared. Subsequently membranes were left 
drying for approximately 30 minutes and were refrigerated at 4°C.  
3.6.5. Western immunoblot analyzes 
Detection of specific proteins was achieved by immunoblot analyzes via antigen-
antibody coupling. Washing and incubation procedures were accomplished under 
consequent agitation of the membranes in a hybridisation oven at room 
temperature unless indicated otherwise. The membrane was activated by pivoting 
in 5 ml 100% methanol and washed afterwards three times for five minutes in an 
adjustable volume of TBS-T (0.1%). To avoid non-specific binding of respective 
antibodies, membrane was blocked in 5% TBS-T-w/v nonfat dry milk for one 
hour. Following another washing step in TBS-T (0.1%) 
(1 x 15minutes, 2 x 5 minutes), primary antibody was diluted to appropriate 
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concentration in appropriate buffer and incubated at 4°C overnight. The next day, 
membrane was washed repeatedly (1 x 15 minutes, 2 x 5 minutes) and 
subsequently incubated with the corresponding horseradish peroxidase-conjugated 
secondary antibody in suitable concentration for one hour. After washing thrice in 
TBS-T (0.1%) as described above, immunoreactivity was detected using 
HyperfilmTM ECL chemiluminescense film and ECLTM detection reagent 
(AmershamTM, GE Healthcare Limited) according to manufacturer´s instructions 
in a darkroom. After suitable exposition time, immunereactivity was visualized 
using an Optimax X-ray Film processor 1170-1-0000 (PROTEC, Oberstenfeld). 
After signal detection, ECLTM detection reagent was removed completely by 
washing in TBS-T (0.1%) and either stripped for further processing or meanwhile 
stored at 4°C. "-actin was used as loading control. Primary and secondary 
antibodies with appropriate concentrations and dilution buffers are listed in Table 
13. Optical density was determined using the ImageJ 1.410 image processing 
software and was divided by the optical density of "-actin.  
3.6.6. Stripping of the membrane 
To reuse the membrane for additional immunoblots, linked antibodies were 
eluted. Therefore, membranes were incubated in 25 ml elution buffer for 
30 minutes at 70°C, while agitating in a hybridisation oven. Subsequently 
membranes were washed twice in aqua bidest. at room temperature and 
additionally twice in TBS-T (0.1%). Finally membranes were transferred into a 
new 50 ml tube and subjected to further antibody incubation. 
3.7. Statistics 
All data are presented as means ± standard error of means (SEM) or means ± 
standard deviations (SD) as indicated. Longitudinal data of blood glucose levels 
and body weight gain were statistically evaluated by analysis of variance (PROC 
MIXED; SAS 8.2), taking the fixed effects of group (transgenic vs. control) and 
age as well as random effects of the individual animal into account. For other 
parameters the two-tailed, unpaired Mann-Whitney-U test in combination with an 
exact test procedure (SPSS 21.0) or two-tailed, unpaired Student’s t-test was used 
unless indicated otherwise. P values less than 0.05 were considered significant. 
 
  
Table 13: Reagents for Western immunoblot analyzes  
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IV. RESULTS 
1. Generation of INSC94Y transgenic pigs 
Transgenic founder pigs displaying INSC94Y transgene expression were established 
using somatic cell nuclear transfer according to Kurome et al. (2006). The INSC94Y 
construct was constituted of the 2.1 kb sequence of the porcine insulin gene 
promoter for !-cell-specific expression and the 1.0 kb coding region of the 
porcine insulin gene (INS) including a G!A tranversion at nucleotide position 
340. A loxP-flanked neomycin resistance cassette (neoR) was linked for positive 
selection of transgenic clones (Figure 6 A). This targeted mutation results in an 
exchange from cysteine to tyrosine (Cys ! Tyr) at position 94 of the porcine 
proinsulin polypeptide (Figure 6 B) and therefore interferes with the insulin 
secretory pathway (Stoy et al., 2007).  
 
 
Figure 6: INSC94Y construct and alignment of porcine insulin polypeptide 
Schematic illustration of the INSC94Y genetic construct carrying a fragment of the 
porcine insulin gene (pInsulinC94Y) under the control of the porcine insulin gene 
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promoter and a neomycin resistance cassette (neoR) for positive selection 
(published in Renner et al. 2012) (A). Amino acid sequence of the human 
proinsulin molecule with targeted INSC96Y mutation and consequent amino acid 
shift (Cys!Tyr) indicated in blue. The corresponding porcine INS mutation is 
located at position 94 of the proinsulin polypeptide due to the gap of two amino 
acid residues in the C-peptide sequence (indicated in red) (B); comparative INS 
alignment was gathered and modified from (http://www.ncbi.nlm.nih.gov/protein 
(AAA59179.1, AAL69550.1, AAI45869, AAI45555.1). 
 
A total of 562 embryos derived from INSC94Y nucleofected cell clones were 
transferred laparoscopically to five cycle synchronized recipient gilts. Two 
pregnancies went to term and provided seven male piglets. Genotyping PCR on 
genomic DNA isolated from ear punches determined seven transgenic founder 
animals. Detailed outcomes of cloning are summarized in Table 14. 
 
Table 14: Results of nuclear transfer experiments using INSC94Y transfected 
nuclear donor cells 
 
 
Founder boar 9747 exhibited growth retardation as well as elevated fasting blood 
glucose levels at the age of 85 days, further increasing over time and was 
therefore chosen as suitable founder animal for INSC94Y breeding (Figure 7). The 
other six founders remained normoglycemic within the observation period of 
seven months (Figure 7). Non-diabetic INSC94Y transgenic founder boars 9727, 
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9728, 9745 and 9746 exhibited undisturbed intravenous glucose tolerance (IVGT) 
at the age of seven months, indicated by adequate insulin release compared to 
intravenous glucose application and commensurate decline of blood glucose 
levels (Figure 8 A/B). Founder boars 9725 and 9726 showed a delayed and 
reduced glucose-stimulated insulin secretion and lowering of blood glucose levels 
was consequently decelerated in comparison with two age-matched non-
transgenic control pigs (Figure 8 A/B). 
 
 
Figure 7: Fasting blood glucose concentrations of INSC94Y transgenic founder 
boars 
Transgenic founder boar 9747 exhibited hyperglycemia at the age of 85 days, 
whereas blood glucose levels of the other six founder boars remained within the 
reference range (70-115 mg/dl depending on the lab); Start of the insulin therapy 
is indicated with the black arrow; published by Renner et al. (2012);      
“Copyright 2012 American Diabetes Association From Diabetes®, Vol. 61, 2012 
Reprinted with permission from the American Diabetes Association.” 
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Figure 8: Intravenous glucose tolerance of INSC94Y transgenic founder boars 
IVGT of non-diabetic INSC94Y transgenic founders (tg) 9727, 9728, 9745 and 9746 
was unaltered in an intravenous glucose tolerance test at 7 months of age. Non-
diabetic INSC94Y transgenic founders (tg) 9725 and 9726 showed moderately 
impaired IVGT compared to age-matched wild-type control pigs (wt); (A) plasma 
insulin levels; (B) plasma glucose levels.  
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To test germ-line transmission of the INSC94Y construct, the diabetic founder boar 
9747 was mated to non-transgenic German Landrace-Swabian-Hall crossbred 
sows. He transmitted the INSC94Y transgene to half of the offspring adhering to 
mendelian rules of inheritance. A transgenic line was established by conventional 
breeding. The efforts of INSC94Y transgenic pig breeding are in detail listed below: 
 
Table 15: Inheritance of the INSC94Y transgene 
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2. Genotyping of INSC94Y transgenic pigs by PCR and 
Southern blot analyzes 
The INSC94Y transgenic offspring were identified by transgene-specific PCR on 
genomic DNA isolated from ear punches of neonatal piglets. A band of 500 bp 
could be detected, if the INSC94Y transgene has been integrated into the genome, 
while non-transgenic littermate control pigs did not show any signal (Figure 9 A). 
Additionally a 330 bp fragment was amplified using ACTB specific primers and 
served as control for DNA integrity (Figure 9 B). 
 
 
Figure 9: Identification of INSC94Y transgenic pigs and non-transgenic 
littermates by PCR analysis 
(A) Transgene-specific PCR to detect the neomycin resistance cassette (neoR) 
linked to the INSC94Y expression vector; (B) ACTB specific PCR to control 
genomic DNA integrity; (A/B) wt: non-transgenic littermates; tg: INSC94Y 
transgenic pigs; Marker: Gene RulerTM 1kb DNA ladder with visible marker-
bands indicating the size of double-stranded DNA of 10.000 to 250 bp from top to 
bottom; +: genomic DNA of a previously genotyped INSC94Y transgenic pig as 
positive control; -: aqua bidest. as non-template control.  
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To visualize transgene integration pattern and to determine numbers of integration 
sites in the genome, Southern blot analysis was conducted on BamH1 digested 
genomic DNA using a transgene-specific "-[32P]-dCTP labeled probe specific for 
the neomycin resistance cassette. All seven INSC94Y transgenic founder boars 
revealed a single integration site of the INSC94Y transgene with different pattern of 
transgene integration. INSC94Y transgenic offspring of the diabetic founder 9747 
showed an identical trangene integration pattern without segregation, confirming 
germ line transmission of the transgene and constituting a single integration site in 
the genome (Figure 10). 
 
 
Figure 10: Southern blot analysis of INSC94Y transgenic founder boars and 
INSC94Y transgenic offspring (F2-generation) 
Southern blot analysis of BamH1 digested genomic DNA derived from INSC94Y 
transgenic founder boars (9725, 9726, 9727, 9728, 9745, 9746, 9747) and INSC94Y 
transgenic offspring of the diabetic founder 9747 (1334, 1336, 1340, 1341) argues 
for a single integration site for each founder. Transgenic offspring of founder 
9747 do not show segregation of transgene copies confirming a single integration 
site; WT: non-transgenic control pig; Marker: Gene RulerTM 1kb DNA ladder 
with visible marker-bands indicating the size of double-stranded DNA of 10.000 
to 250 bp from top to bottom; Data provided by Dr. Andrea Bähr, Institute of 
Molecular Animal Breeding and Biotechnology, LMU Munich; published by 
Renner et al. (2012); “Copyright 2012 American Diabetes Association From 
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Diabetes®, Vol. 61, 2012 Reprinted with permission from the American Diabetes 
Association.” 
 
3. Expression analysis of the INSC94Y transgene in the 
pancreas 
To demonstrate expression of the INSC94Y transgene, total RNA was extracted 
from pancreatic tissue of INSC94Y transgenic founder boars as well as of three 
INSC94Y transgenic F1-offspring of founder boar 9747 and separated by agarose 
gel electrophoresis. Discrete 28S and 18S ribosomal bands in the absence of 
considerable RNA degradation argued for adequate RNA quality (Figure 11 A). 
RNA samples were reverse transcribed and cDNA was assayed by PCR using 
insulin-specific primers. Additionally ACTB specific PCR was achieved using the 
same templates to verify cDNA integrity. Separation by agarose gel 
electrophoresis revealed sharp bands of 192 bp (Insulin) or 231 bp (ACTB) 
respectively with identical intensity. Minus RT reactions obtained no signals 
demonstrating complete DNaseI digest of total RNA (Figure 11 B). The ratio of 
mutant INSC94Y and endogenous INS cDNA amplicons was determined by next 
generation sequencing. The ratio of INSC94Y to endogenous INS  transcripts in 
pancreas samples of the diabetic INSC94Y transgenic founder boar 9747 was 0.75 
and at least five-fold higher than in the six normoglycemic transgenic founder 
boars (0.06 ± 0.02; n=6). INSC94Y transgenic F1-offspring exhibited a similar 
INSC94Y: INS ratio compared with their diabetic sire (0.78 ± 0.05; n=3) indicating 
dose-dependent diabetogenic impact of INSC94Y expression. 
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Figure 11: Expression analysis on RNA level from pancreatic tissue of 
INSC94Y transgenic founder boars and transgenic F1-offspring 
(A) Total RNA of pancreatic tissue of INSC94Y transgenic founder boar (9747) and 
transgenic F1-offspring (n=3; 9904, 9906, 9919), separated by agarose gel 
electrophoresis, revealed adaequate RNA quality indicated by defined 28S and 
discrete 18S ribosomal RNA bands being half as bright as the 28S ribosomal 
band; tg: INSC94Y transgenic pigs; wt: non-transgenic littermate control pigs. (B) 
Insulin and ACTB specific PCR of pancreatic tissue of INSC94Y transgenic founder 
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boars (left panel) and diabetic founder 9747 and his offspring (right panel); M: 
pUC Mix molecular weight marker with visible marker-bands indicating the size 
of double-stranded DNA of 1118 to 110 bp from top to bottom; gDNA: genomic 
DNA; H2O: aqua bidest. as non-template control; -RT: minus RT; +RT: plus RT; 
(published in Renner et al. 2012; “Copyright 2012 American Diabetes Association 
From Diabetes®, Vol. 61, 2012 Reprinted with permission from the American 
Diabetes Association.”). (C) The ratio of mutant INSC94Y to endogenous INS 
transcripts was determined by next generation sequencing of cDNA amplicons 
derived from RT-PCR. INSC94Y transgenic founder 9747 and his diabetic offspring 
(F1) exhibited similar INSC94Y expression levels but at least five-fold higher 
expression compared to normoglycemic founder boars (9725, 9726, 9727, 9728, 
9745 and 9746). Data indicated as means ± SEM; published in parts by Renner et 
al. (2012); “Copyright 2012 American Diabetes Association From Diabetes®, Vol. 
61, 2012 Reprinted with permission from the American Diabetes Association.” 
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4. Physiological characteristics of INSC94Y transgenic pigs 
4.1. Body weight gain  
Body weight of INSC94Y transgenic pigs and non-transgenic littermate control pigs 
was determined on a regular basis starting at birth to evaluate the impact of 
INSC94Y expression on weight gain. INSC94Y transgenic pigs grew comparably to 
non-transgenic littermates up to 8 weeks of age but then exhibited decelerated 
growth rates (Figure 12 A) resulting in a 41% reduced body weight at the age of 
4.5 months (Figure 12 B). 
 
Figure 12: Growth retardation in INSC94Y transgenic pigs 
(A) Body weight gain of INSC94Y transgenic pigs (tg) was significantly reduced 
compared to littermate controls (wt) within the observation period of 142 days. 
(B) Body weight was unaltered at the age of 8 days (left panel) but was 
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significantly reduced by 41% in 4.5-month-old INSC94Y transgenic pigs compared 
to non-transgenic littermates (right panel). Data indicated as means ± SEM; 
*: p<0.05; **: p<0.01; ***: p<0.001 vs. controls; n: number of animals 
investigated; published in parts by Renner et al. (2012); “Copyright 2012 
American Diabetes Association From Diabetes®, Vol. 61, 2012 Reprinted with 
permission from the American Diabetes Association.” 
 
4.2. Blood glucose control and insulin secretion  
4.2.1. Blood glucose concentration  
In order to clarify effects of INSC94Y transgene expression on glucose homeostasis, 
random blood glucose levels were determined at short intervals. After weaning 
fasting blood glucose levels were measured regularly up to the age of 142 days. 
Transgenic F1- and F2-offspring exhibited significantly elevated random blood 
glucose levels within 24 hours after birth compared to wild-type littermates 
(193.8 ± 11.9 vs. 146 ± 9 mg/dl; p<0.05). Fasting blood glucose levels were 
increasingly higher in INSC94Y transgenic pigs compared to non-transgenic 
littermates, reaching 415 ± 28 versus 84 ± 9 mg/dl (p<0.001) at 115 days of age 
(Figure 13). 
 
 
Figure 13: Blood glucose control in INSC94Y transgenic and wild-type pigs 
INSC94Y transgenic pigs (tg) developed significantly elevated random blood 
glucose levels within 24 hours after birth in comparison to non-transgenic 
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littermate controls (wt) (left graph). Fasting blood glucose concentrations were 
significantly elevated compared to wild-type control pigs throughout the 
observation period. Data indicated as means ± SEM; *: p<0.05; **: p<0.01; 
***: p<0.001 vs. controls; n: number of animals investigated; published by 
Renner et al. (2012); “Copyright 2012 American Diabetes Association From 
Diabetes®, Vol. 61, 2012 Reprinted with permission from the American Diabetes 
Association.” 
 
4.2.2. Continuous blood glucose monitoring  
To preserve an undisturbed general state of health for long-time survival of 
INSC94Y transgenic pigs, an insulin treatment regimen was established starting at 
the age of 4.5 months. A combination of long-acting insulin (Lantus®) and short-
acting insulin (NovoRapid®) was administered subcutaneously once daily in a 
dosage of 0.5 – 1 unit per kg body weight appropriate to respective blood glucose 
concentrations. Diabetic INSC94Y transgenic pigs were rescued from growth 
retardation and matured almost normally. Diabetes-associated fertility disorder 
was prevented over a considerable period. For the ease of verifying successful 
insulin regimen, glucose control of an insulin-treated INSC94Y transgenic pig was 
evaluated continuously using the Guardian® REAL-Time continuous glucose 
monitoring device and was compared to an untreated age-matched control pig. 
Interstitial glucose concentrations were profiled over a period of 42 hours and an 
average blood glucose concentration of 123.2 ± 41.9 mg/dl (SD) was determined 
in the insulin-treated pig versus 92 ± 11.9 mg/dl (SD) in the control pig. The 
amplitude spectrum of interstitial glucose levels of the insulin-treated INSC94Y 
transgenic pig ranged between 40 and 198 mg/dl (Figure 14 A) and was thus more 
heterogenous than in the control pig (98 to 114 mg/dl) (Figure 14 B), but 
nevertheless within a fairly controlled range. 
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Figure 14: Continuous 42-hour glucose monitoring profile of an INSC94Y 
transgenic pig under insulin treatment and an untreated wild-type littermate 
Interstitial glucose levels of an insulin-treated INSC94Y transgenic pig (tg) (A) and 
a non-transgenic age-matched control pig (wt) (B) were evaluated over 42 hours 
to control the insulin treatment protocol. The INSC94Y transgenic pig was treated 
with a combination of long-acting (Lantus®) and short-acting (NovoRapid®) 
insulin injected subcutaneously at a dose of 0.5 to 1 unit/kg BW; ICG: interstitial 
glucose concentration; modified according to Renner et al. (2012); “Copyright 
2012 American Diabetes Association From Diabetes®, Vol. 61, 2012 Reprinted 
with permission from the American Diabetes Association.” 
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4.2.3. Insulin levels 
Additionally, plasma insulin levels were determined in 8-day-old as well as in 4.5-
month-old INSC94Y transgenic pigs (tg) and their non-transgenic littermates (wt) by 
a commercial radioimmunoassay. Despite early significant hyperglycemia (Figure 
13) basal plasma insulin levels of randomly fed 8-day-old INSC94Y transgenic pigs 
(n=6) were only slightly reduced (7 ± 1 vs. 10 ± 4 #U/ml; n=4; p=0.76) compared 
to non-transgenic littermates (n=4) (Figure 15). In contrast, 4.5-month-old 
INSC94Y transgenic pigs (n=6) revealed significantly reduced fasting plasma insulin 
levels (2 ± 0.42 vs. 5.1 ± 0.77 #U/ml; p<0.01) compared to non-transgenic 
littermate control pigs (n=6) (Figure 15). 
 
Figure 15: Basal and fasting insulin levels of 8-day-old and 4.5-month-old 
INSC94Y transgenic and age-matched wild-type littermates 
Basal plasma insulin levels of 8-day-old INSC94Y transgenic pigs (tg) were nearly 
unaltered in comparison to wild-type littermates (wt) (left panel), while 4.5-
month-old INSC94Y transgenic pigs (tg) revealed significantly reduced fasting 
plasma insulin levels compared to non-transgenic littermates (wt) (right panel). 
Data indicated as means ± SEM; **: p<0.01 vs. control; n: number of animals 
investigated; published by Renner et al. (2012); “Copyright 2012 American 
Diabetes Association From Diabetes®, Vol. 61, 2012 Reprinted with permission 
from the American Diabetes Association.” 
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4.2.4. Homeostasis model assessment of !-cell function (HOMA - B) and 
insulin resistance (HOMA - IR) 
The homeostasis model assessment of !-cell function (HOMA - B) and of insulin 
resistance (HOMA - IR) were calculated according to Matthews et al. (1985) by 
means of fasting blood glucose and plasma insulin levels determined in 4.5-
month-old INSC94Y transgenic pigs (n=6) in comparison with their wild-type 
littermates (n=6). HOMA - B indices were significantly reduced in 4.5-month-old 
INSC94Y transgenic pigs indicating disturbed glucose-stimulated baseline insulin 
secretion (1.8 ± 0.39 vs. 47.2 ± 10.45; p< 0.01) (Figure 16). HOMA - IR indices 
were significantly elevated in INSC94Y transgenic pigs at 4.5 months of age (2.4 ± 
0.48 vs. 1.2 ± 0.24; p<0.05) suggestive of insulin resistance (Figure 16). 
 
Figure 16: Homeostasis model assessment of baseline insulin secretion 
(HOMA-B) and of insulin resistance (HOMA-IR) of INSC94Y transgenic pigs 
4.5-month-old INSC94Y transgenic pigs revealed significantly reduced baseline 
insulin secretion (left panel) and significantly increased insulin resistance indices 
(tg) compared to littermate controls (right panel). Data indicated as means ± SEM; 
*: p<0.05; **: p<0.01 vs. control; n: number of animals investigated; published by 
Renner et al. (2012); “Copyright 2012 American Diabetes Association From 
Diabetes®, Vol. 61, 2012 Reprinted with permission from the American Diabetes 
Association.” 
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4.2.5. Plasma glucagon levels  
In randomly fed 8-day-old INSC94Y transgenic pigs, basal plasma glucagon levels 
were determined by a commercial glucagon radioimmunoassay and revealed a 
marked but not yet significant increase compared to non-transgenic littermates 
(192.98 ± 41.91 vs. 154.99 ± 6.64 pg/ml; n=4 per group; p=0.687) (Figure 17; left 
panel). Fasting plasma glucagon levels of INSC94Y transgenic pigs at the age of 4.5 
months were likewise noticeably but not significantly higher than in age-matched 
wild-type controls (101.25 ± 6.8 vs. 82.3 ± 10.35 pg/ml; n=7 per group; p=0.262) 
(Figure 17; right panel). 
 
Figure 17: Basal and fasting glucagon levels of 8-day-old and 4.5-month-old 
INSC94Y transgenic pigs and wild-type littermates 
Basal plasma glucagon levels of 8-day-old (left panel) and fasting plasma 
glucagon levels of 4.5-months-old INSC94Y transgenic pigs (tg) (right panel) were 
slightly but not significantly increased in comparison to wild-type littermates (wt) 
(p=0.687 and p=0.262 respectively); Data indicated as means ± SEM; n: number 
of animals investigated. 
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5. Morphological evaluation of the endocrine pancreas 
Pancreata of 8-day-old and 4.5-month-old INSC94Y transgenic pigs and related non-
transgenic littermates were investigated by immunohistochemistry, quantitative 
stereological analyzes and transmission electron microscopy to determine, if 
INSC94Y transgene expression affects cellular islet composition and ultrastructural 
architecture of pancreatic !-cells. 
5.1. Absolute pancreas weight  
Following explantation, pancreas was weighed to the nearest gram. Absolute 
pancreas weights were unaltered in INSC94Y transgenic pigs compared to non-
transgenic controls (n=4 per group) at the age of 8 days (4.4 ± 0.6 vs. 4.9 ± 0.4 g; 
p=0.49) (Figure 18, left panel). Absolute pancreas weights of 4.5-month-old 
INSC94Y transgenic pigs were significantly decreased compared to wild-type 
controls (79 ± 6 vs. 134 ± 5 g; p<0.001) (Figure 18, right panel). The reduction of 
the absolute pancreas weights in 4.5-month-old INSC94Y transgenic pigs was in 
proportion to the lower body weight at 4.5 months of age (Figure 12 B).  
 
Figure 18: Absolute pancreas weights of INSC94Y transgenic and wild-type 
littermates 
8-day-old INSC94Y transgenic pigs (tg) and non-transgenic controls (wt) revealed 
similar absolute pancreas weights (left panel). 4.5-month-old INSC94Y transgenic 
pigs revealed a significant reduction of the absolute pancreas weight compared to 
their non-transgenic littermates (right panel). Data indicated as means ± SEM;  
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***: p<0.001 vs. control; n: number of animals investigated; published by Renner 
et al. (2012); “Copyright 2012 American Diabetes Association From Diabetes®, 
Vol. 61, 2012 Reprinted with permission from the American Diabetes 
Association.” 
 
5.2. Qualitative histological and quantitative stereological analyzes of 
the endocrine pancreas 
Pancreatic sections of 8-day-old INSC94Y transgenic pigs and non-transgenic 
controls (n=4 per group) underwent single immunostaining detecting insulin. 
Sections of pancreatic tissue of seven 4.5-month-old INSC94Y transgenic pigs and 
seven littermate controls obtained by systematic random sampling were 
immunhistochemically stained for insulin containing cells and glucagon, 
somatostatin and pancreatic polypeptide positive cells, referred to as non-!-cells. 
Furthermore a single immunostaining for glucagon containing cells was 
performed on pancreatic sections of respective 4.5-month-old INSC94Y transgenic 
pigs and non-transgenic littermate controls.   
5.2.1. Histological evaluation of the endocrine pancreas  
Qualitative histology on pancreatic tissue of 8-day-old INSC94Y transgenic pigs 
indicated predominantly a great quantity of scattered, single !-cells and age-
appropriate small clusters of !-cells with equal staining intensity. Histological 
evaluation of 8-day-old non-transgenic controls presented likewise regarding 
equal amounts and distribution of insulin-positive cells (Figure 19 A). At the age 
of 4.5 months, non-transgenic littermates revealed typical porcine islet 
composition and distribution of the endocrine cells. Porcine islets were irregularly 
shaped and insulin positive !-cells were located as major fraction in the central 
area of the islets surrounded by non-!-cells. Some non-!-cells were also dispersed 
as single cells in the adjacent exocrine pancreatic tissue (Figure 19 B). Compared 
to littermate controls, pancreas sections of 4.5-month-old INSC94Y transgenic pigs 
demonstrated a notably reduced number of insulin positive !-cells, mostly 
presented as single, scattered !-cells or small !-cell clusters up to medium-sized 
islets. Islet-like structures with few !-cell nuclear profiles surrounded by a 
proportionately larger number of non-!-cells were also interpreted as islets. 
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Staining intensity of !-cells was less pronounced in 4.5-month-old INSC94Y 
transgenic pigs indicating decreased insulin content compared to controls (Figure 
19B). 
 
Figure 19: Representative histological sections of pancreatic tissue of an 8-
day-old and a 4.5-month-old INSC94Y transgenic pig and age-matched 
controls 
(A) Immunohistochemical staining for insulin on pancreatic tissue of an 8-day-old 
INSC94Y transgenic pig (tg) and a littermate control (wt) demonstrating age-
appropriate !-cell formation. (B) Double immunohistochemical staining for 
insulin (pink) and glucagon, somatostatin and pancreatic polypeptide (brown) of a 
4.5-month-old INSC94Y transgenic pig (tg) and a non-transgenic control pig (wt) 
showing markedly altered islet composition in the transgenic pig. Scale bar = 
50 µm; published by Renner et al. (2012); “Copyright 2012 American Diabetes 
Association From Diabetes®, Vol. 61, 2012 Reprinted with permission from the 
American Diabetes Association.” 
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5.2.2. Quantitative stereological evaluation of the volume density and the 
total volume of !-cells in the pancreas 
In addition quantitative stereological evaluation of the endocrine pancreas was 
accomplished in order to determine the volume density of !-cells in the pancreas 
(Vv (!-cell/Pan)) and the total !-cell volume (V(!-cell, Pan)) in 8-day-old and 4.5-month-
old INSC94Y transgenic pigs and non-transgenic littermates. In accordance with 
qualitative histological findings, neither Vv (!-cell/Pan) (3.18 ± 0.4 vs. 2.98 ± 0.1%; 
p=1.0) nor V(!-cell, Pan) (136.7 ± 36.5 vs. 137.2 ± 14.8 mm3; p=0.682) were altered 
in 8-day-old INSC94Y transgenic piglets (n=4) compared to wild-type control 
piglets (n=4) (Figure 20 A). At the age of 4.5 months, Vv(!-cell/Pan) was significantly 
reduced by 54% (0.54 ± 0.05 vs. 1.18 ± 0.17%; p<0.01) in INSC94Y transgenic pigs 
(n=7) in comparison to non-transgenic littermates (n=7). Moreover, V(!-cell, Pan) was 
significantly diminished by 72% (409.2 ± 54.7 vs. 1476.7 ± 228.03 mm3; 
p<0.001) (Figure 20 B). Due to the growth retardation in general and the 
proportional lower absolute pancreas weights in 4.5-month-old INSC94Y transgenic 
pigs, V(!-cell, Pan) was additionally calculated in relation to the body weight (V(!-
cell, Pan)/BW (mm3/kg)). V(!-cell, Pan)/BW was significantly reduced by 53% 
compared to control littermates (8.95 ± 0.96 vs. 18.84 ± 2.61 mm3/kg; p<0.01) 
(Figure 21). 
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Figure 20: Quantitative stereological analyzes of islet parameters of 8-day-
old and 4.5-month-old INSC94Y transgenic and wild-type littermates 
The volume density of !-cells in the pancreas (Vv (!-cell/Pan)) and the total !-cell 
volume (V(!-cell, Pan)) were determined in 8-day-old and 4.5-month-old INSC94Y 
transgenic pigs (tg) and control littermates (wt). (A) Volume density of !-cells in 
the pancreas and the total !-cell volume did not differ between 8-day-old INSC94Y 
transgenic pigs and controls (p=1.0 and p=0.68 respectively). (B) Significant 
reduction of the volume density of !-cells in the pancreas and the total !-cell 
volume in 4.5-month-old INSC94Y transgenic pigs compared to control littermates 
(**: p<0.01; ***: p<0.001). (A/B) Data indicated as means ± SEM; n: number of 
animals investigated; Parameter V(!-cell, Pan) of 8-day-old and 4.5-month-old INSC94Y 
transgenic pigs and controls were published by Renner at el. (2012); “Copyright 
2012 American Diabetes Association From Diabetes®, Vol. 61, 2012 Reprinted 
with permission from the American Diabetes Association.” 
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Figure 21: The total !-cell volume in relation to body in 4.5-month-old 
INSC94Y transgenic pigs and non-transgenic littermates 
The total !-cell volume in relation to body weight (V(!-cell, Pan)/BW) indicated a 
significant reduction by 53% in INSC94Y transgenic pigs (tg) compared to non-
transgenic control pigs (wt); Data indicated as means ± SEM; n: number of 
animals investigated; published by Renner et al. (2012); “Copyright 2012 
American Diabetes Association From Diabetes®, Vol. 61, 2012 Reprinted with 
permission from the American Diabetes Association.” 
 
5.2.3. Qualitative histological and quantitative stereological evaluation of 
the total "-cell volume 
For qualitative histological evaluation, pancreatic sections of 4.5-month-old 
INSC94Y transgenic pigs and non-transgenic littermate pigs were stained for 
glucagon containing cells. Non-transgenic pigs revealed physiological distribution 
of "-cells, which were mainly located in a narrow mantle in the periphery of the 
islet, but also dispersed as minor fraction in the adjacent exocrine tissue (Figure 
22; left panel). In INSC94Y transgenic pigs, glucagon-positive area appeared 
enlarged and completely disordered in "-cell conglomerates (Figure 22; right 
panel). 
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Figure 22: Immunohistochemical staining for glucagon containing cells in 
4.5-month-old INSC94Y transgenic pigs and non-transgenic littermates 
Representative histological sections of pancreatic tissue of a 4.5-month-old 
INSC94Y transgenic pig (tg) and a non-trangenic littermate (wt). 
Immunhistochemical staining for glucagon revealed an altered islet composition 
with formation of "-cell conglomerates in 4.5-month-old INSC94Y transgenic pigs. 
Scale bar = 100 µm. 
 
Furthermore the total "-cell volume in the pancreas (V("-cell, Pan)) and the total "-
cell volume in relation to body weight (V("-cell, Pan)/BW) was determined in 4.5-
month-old INSC94Y transgenic pigs and non-transgenic littermates by means of 
quantitative stereological analyzes. The total "-cell volume in the pancreas (V("-
cell, Pan)) was nearly unaltered in 4.5-month-old INSC94Y transgenic pigs compared 
to wild-type littermates (187.03 ± 78.47 vs. 213.38 ± 20.59 mm3; p=0.075; n=7 
per group) (Figure 23 A). However the total "-cell volume in relation to body 
weight (V("-cell, Pan)/BW) was markedly but not yet significantly increased in 4.5-
month-old INSC94Y transgenic pigs compared to wild-type littermates (4.26 ± 1.84 
vs. 2.74 ± 0.184 mm3/kg; p=0.538; n=7 per group) (Figure 23 B). 
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Figure 23: Quantitative stereological analyzes of the total "-cell volume in 
4.5-month-old INSC94Y transgenic pigs and non-transgenic littermates 
The total "-cell volume (V("-cell, Pan)) in the pancreas and the total "-cell volume in 
relation to body weight (V("-cell, Pan)/BW) were determined in 4.5-month-old 
INSC94Y transgenic pigs (tg) and non-transgenic littermates (wt). There was no 
difference in the total "-cell volume (V("-cell, Pan)) between INSC94Y transgenic pigs 
and non-transgenic littermates at the age of 4.5 months (A), whereas the total "-
cell volume in relation to body weight (V("-cell, Pan)/BW) was marginally increased 
(B); Data indicated as means ± SEM; n: number of animals investigated. 
 
5.3. Ultrastructural morphology of !-cells  
Ultrathin sections of pancreatic tissue of INSC94Y transgenic and non-transgenic 8-
day-old and 4.5-month-old pigs were subjected to electron microscopy concerning 
the ultrastructural architecture of pancreatic !-cells to evidence pathological 
mechanisms of diabetes mellitus present in INSC94Y transgenic pigs. In 8-day-old 
INSC94Y transgenic pigs, insulin secretory granules were still apparent in noticeable 
quantity in !-cells, which exhibited dilation of the endoplasmic reticulum (Figure 
24 A). Electron microscopy of representative 4.5-month-old wild-type pigs 
indicated high number of insulin secretory granules in the cytoplasm of pancreatic 
!-cells, while cytoplasm of the !-cells of INSC94Y transgenic pigs at the age of 
4.5 months were nearly devoid of insulin secretory granules. Insulin secretory 
granules were consistently characterized by an irregularly shaped, electron-dense 
core with surrounding wide lucent halo. However, the core of insulin secretory 
granules in 4.5-month-old INSC94Y transgenic pigs appeared less electron-dense as 
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compared to wild-type control. Furthermore endoplasmic reticulum (ER) was 
seriously enlarged in 4.5-month-old INSC94Y transgenic pigs indicated by 
numerous cross-sectional areas of the endoplasmic reticulum (Figure 24 B).  
 
Figure 24: Representative transmission electron micrographs of pancreatic 
!-cell profiles of 8-day-old and 4.5-month-old INSC94Y transgenic pigs and 
age-matched wild-type pigs 
(A) In 8-day-old INSC94Y transgenic pigs, !-cells exhibited nearly unaltered 
density of insulin secretory granules (arrow) but the endoplasmic reticulum was 
already dilated (asterisk). (B) !-cells represented in 4.5-month-old wild-type pigs 
(wt) revealed high density of insulin secretory granules and regular lamellae of the 
endoplasmic reticulum, in contrast to highly reduced number of insulin secretory 
granules (arrow) and severe dilation of the endoplasmic reticulum (asterisk) in the 
INSC94Y transgenic pig. Scale bar = 0.5 µm; published by Renner et al. (2012); 
“Copyright 2012 American Diabetes Association From Diabetes®, Vol. 61, 2012 
Reprinted with permission from the American Diabetes Association.” 
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6. Evaluation of diabetes-associated secondary alterations in 
INSC94Y transgenic pigs  
Diabetes-associated morphological and functional secondary alterations in the 
kidney and in peripheral nerves of INSC94Y transgenic pigs compared to non-
transgenic littermates were investigated by means of histology, quantitative 
stereological methods and functional analyzes at 4.5 months of age. To evaluate 
complications of longstanding diabetes mellitus, 1-year-old cloned diabetic 
INSC94Y transgenic pigs were scrutinised for evidence of diabetic kidney disease. 
To investigate time dependent progression of diabetic nephropathy and diabetic 
neuropathy likewise, diabetic INSC94Y transgenic founder boar 9747 at the age of 
three years and an age-matched non-transgenic boar were examined for 
peculiarities of diabetes-associated alterations in respective organs. 
6.1. Absolute organ weights 
Mean absolute and relative organ weights (% of body weight) in 8-day-old and 
4.5-month-old INSC94Y transgenic pigs and respective non-transgenic controls are 
summarized in Table 16 and Table 17. 
At the age of 8 days, INSC94Y transgenic piglets showed only a slight tendency 
towards reduced absolute weights of most organs compared with age-matched 
wild-type piglets. Indeed, the absolute weight of the hearts was already 
significantly reduced in INSC94Y transgenic piglets compared to wild-type 
littermates (31.3 ± 0.96 vs. 25.1 ± 2.1 g; p<0.05; n= 4 per group) (Table 16). As 
the mean body weight was significantly reduced in 4.5-month-old 
INSC94Y transgenic pigs (Figure 12), the absolute weights of most organs were 
proportionately decreased in comparison to non-transgenic littermate controls 
(Table 17). 
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Table 16: Absolute and relative organ weights of 8-day-old INSC94Y transgenic 
pigs and wild-type littermates 
 
Table 17: Absolute and relative organ weights of 4.5-month-old INSC94Y 
transgenic pigs and wild-type controls 
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6.2. Evaluation of diabetic nephropathy  
6.2.1. Absolute and relative kidney weights 
Aberrant from the significantly decreased absolute weights of the other organs by 
at least 30% (Table 17), the absolute weight of the kidneys, cumulatively 
calculated from the weights of both kidneys, were diminished by only 15% in 
INSC94Y transgenic pigs at 4.5 months of age in comparison to non-transgenic 
littermates (314.29 ± 21.93 vs. 371.71 ± 10.26 g; p=0.058) (Figure 25; left panel). 
Thus, relative kidney weights, indicated as the cumulative weight of both kidneys 
as percent of body weight, were significantly increased compared to non-
transgenic littermates (0.7 ± 0.07 vs. 0.5 ± 0.06%; p<0.01) (Figure 25; right 
panel). 
 
Figure 25: Absolute and relative kidney weights of 4.5-month-old INSC94Y 
transgenic and non-transgenic littermates 
Absolute kidney weight of 4.5-month-old INSC94Y transgenic pigs (tg) 
demonstrates a reduction by 15% compared to non-transgenic littermates (wt) 
(314.29 ± 21.93 vs. 371.71 ± 10.26 g; p=0.058) (left panel). The relative weight 
(% of body weight) of both kidneys was significantly increased in 4.5-month-old 
INSC94Y transgenic pigs in comparison with their corresponding non-transgenic 
controls (right panel); Data indicated as means ± SEM; ***: p<0.001 vs. control; 
n: number of animals investigated; published by Renner et al. (2012); “Copyright 
2012 American Diabetes Association From Diabetes®, Vol. 61, 2012 Reprinted 
with permission from the American Diabetes Association.” 
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6.2.2. Glomerular histology and quantitative stereological analyzes of the 
kidneys 
Histopathological analyzes on perfused renal tissue of INSC94Y transgenic and non-
transgenic control pigs were accomplished following plastic embedding 
(glycolmethacrylate and methyl-methacrylate (GMA/MMA), hematoxylin and 
eosin staining (HE) (Figure 26 A) as well as periodic acid silver methenamine 
staining (PASM) (Figure 26 B). Glomerula were investigated with regard to 
glomerular hypertrophy, expansion of the mesangial matrix and pathological 
alterations displaying glomerulosclerosis, which included hyalinosis and 
obliterations of capillaries. Investigated sections of diabetic INSC94Y transgenic 
pigs at 4.5 months of age and severely diabetic 1-year-old cloned 
INSC94Y transgenic pigs alike did not provide evidence for diabetes-associated 
kidney disease. Furthermore histological sections of INSC94Y transgenic pigs were 
examined comparatively with non-transgenic controls for the presence of atrophic 
tubuli, interstitial fibrosis or tubular protein sediments without detecting any 
noticeable alterations (Figure 26 A/B). 
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Figure 26: Representative histological sections of renal tissue of a 4.5-month-
old INSC94Y transgenic pig and a non-transgenic littermate 
Light microscopy on cross sections at the equator level of representative 
glomerula of an INSC94Y transgenic pig (tg) and a non-transgenic littermate (wt) at 
4.5 months of age without evidence of morphological alterations suggestive of 
diabetic kidney disease; (A/B) GMA/MMA embedded renal tissue; (A) HE-
staining; (B) PASM-staining; Scale bar = 50 #m; Data provided by Dr. Andreas 
Blutke, Intitute of Veterinary Pathology, Ludwig-Maximilians-University, 
Munich, Research Group Prof. Dr. Rüdiger Wanke. 
 
The mean glomerular volume (V(glom)) was determined by means of planimetric 
measurements of the mean glomerular profile areas on kidney tissue of 4.5 
months old INSC94Y transgenic pigs and non-transgenic littermates (144 ± 8 
glomerular profiles per animal) and the mean glomerular volume to body weight 
(BW) ratio (V(glom)/BW (mm3/kg)x10-3) was calculated. The mean glomerular 
volume to body weight (BW) ratio (V(glom)/BW (mm3/kg)x10-3) was significantly 
increased by 30% on the average in comparison to corresponding age-matched 
control pigs (41.68 ± 6.71 vs. 32.05 ± 5.56 (mm3/kg)x10-3; p<0.01 vs. control) 
(Figure 27). 
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Figure 27: Mean glomerular volume to body weight ratio (V(glom)/BW 
(mm3/kg)x10-3) in 4.5-month-old INSC94Y transgenic and littermate control 
pigs 
4.5-month-old INSC94Y transgenic pigs (tg) displayed a significant increase of their 
mean glomerular volume to body weight ratio (V(glom)/BW (mm3/kg)x10 -3 as 
compared to non-transgenic control pigs (wt). Data indicated as means ± SEM; *: 
p<0.05 vs. control; n: number of animals investigated; Data provided by 
Dr. Andreas Blutke, Intitute of Veterinary Pathology, Ludwig-Maximilians-
University, Munich, Research Group Prof. Dr. Rüdiger Wanke; published by 
Renner et al. (2012); “Copyright 2012 American Diabetes Association From 
Diabetes®, Vol. 61, 2012 Reprinted with permission from the American Diabetes 
Association.” 
 
6.2.3. Transmission electron microscopy of glomerular structures and 
thickness of the glomerular basement membrane (ThGBM)  
Transmission electron microscopy (TEM) was achieved on cortical kidney tissue 
derived from 4.5-month-old INSC94Y transgenic pigs and non-transgenic littermates 
(three females per group). The true harmonic mean thickness of the glomerular 
basement membrane (ThGBM) was determined using transmission electronical 
micrographs of peripheral glomerular capillary loops of the respective pigs. 
Investigated glomerular cross section profiles of INSC94Y transgenic pigs did not 
indicate any morphological alterations of glomerular capillary structures 
compared to non-transgenic controls, including podocytes, podocyte foot 
processes as well as the endothelium (Figure 28; left panel). INSC94Y transgenic 
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animals revealed a nearly identical true harmonic mean thickness (Th) of the 
glomerular basement membrane (GBM) of peripheral glomerular capillary loops 
as compared to respective non-transgenic controls (126.52 ± 2.37 vs. 126.66 ± 
2.42 nm; p=0.9 vs. control; n=3 per group) (Figure 28; right panel). 
 
Figure 28: Thickness of the glomerular basement membrane (GBM) in 4.5-
month-old INSC94Y transgenic pigs and littermate controls 
Representative transmission electron micrographs (TEM) of peripheral glomerular 
capillary loops of an INSC94Y transgenic pig (tg) at 4.5 months of age and a control 
pig (wt) representing unaltered thickness of the glomerular basement membrane 
(ThGBM) in the transgenic pig; US: urinary space; CL: glomerulary capillary 
lumen; p: podocyte foot process; scale bar: 500 nm;  (left panel). Identical true 
harmonic mean thickness (Th) of the glomerular basement membrane (GBM) of 
peripheral glomerular capillary loops of INSC94Y transgenic pigs (tg) and control 
littermates (wt); Data indicated as means ± SEM; p= 0.9 vs. control; n: number of 
animals investigated; Data provided by Dr. Andreas Blutke, Intitute of Veterinary 
Pathology, Ludwig-Maximilians-University, Munich, Research Group 
Prof. Dr. Rüdiger Wanke; published by Renner et al. (2012); “Copyright 2012 
American Diabetes Association From Diabetes®, Vol. 61, 2012 Reprinted with 
permission from the American Diabetes Association.” 
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6.2.4. Urine protein excretion patterns 
In order to investigate diabetes-associated functional kidney failure in 
INSC94Y transgenic pigs, urine samples of seven representative INSC94Y transgenic 
pigs (3 males and 4 females) and three non-transgenic littermates (2 females and 
1 male) at the age of 4.5 months were assayed for the onset of albuminuria in 
general. Urine samples of 1-year-old cloned diabetic INSC94Y transgenic pigs were 
additionally evaluated to acquire insights in the possible progression of 
albuminuria in the course of time, when hyperglycemia was left untreated. Urine 
samples of the insulin-treated diabetic INSC94Y transgenic founder boar 9747 and a 
F1-female (9901), collected at the day of necropsy at the age of three years both, 
were analyzed likewise for evidence of albuminuria due to prolonged disease 
duration. An age-matched non-transgenic boar and a female served as wild-type 
controls for urine analyzes. Gel bands of approximately 66 kDa corresponding to 
the molecular weight of bovine serum albumin (BSA) standard (66.5 kDa) were 
compared with related age-matched, non-transgenic controls. Noticeable 
albuminuria did not become evident in INSC94Y transgenic pigs at any time point 
investigated (Figure 29 A/B). However, one male INSC94Y transgenic pig at 4.5-
month of age (9900) revealed a slight tendency towards a broadening of the 
66 kDa band compared to age-matched, non-transgenic controls (Figure 29 A).  
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Figure 29: SDS-PAGE urine protein analyzes of INSC94Y transgenic pigs and 
age-matched wild-type pigs 
Urine protein fractions were separated by electrophoresis in a 12% SDS 
polyacrylamide gel followed by Coomassie staining (left panel) and silver staining 
(right panel) of SDS gels detecting bands of 66 kDa corresponding to the 
molecular weight of BSA standard (66.5 kDa); urine samples were diluted each to 
a creatinine level of 1500 #mol/l irrespective of the investigated age group. 
(A) Same urine protein excretion patterns in 4.5-month-old INSC94Y transgenic 
pigs (tg) and representative non-transgenic littermates (wt) without evidence of 
albuminuria; (B) Urine analyzes of diabetic INSC94Y transgenic pigs at the age of 
1 year (1317, 1319, 1320, 1349, 1352) (tg), one 3-year-old INSC94Y transgenic 
female as well as the 3-year-old INSC94Y transgenic founder boar (9747) (tg) were 
unsuggestive of albuminuria compared to their representative age-matched 
controls (Y108, 9852) (wt); (A/B) Marker: PageRulerTM Prestained Protein 
Ladder with visible marker-bands indicating the molecular weight of protein 
standards of 170 kDa  to 15 kDa from top to bottom; BSA: bovine serum 
albumine standard (600 ng/lane); spacing lane: H20. 
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6.3. Evaluation of diabetic neuropathy  
For histological examination of peripheral nervous tissue a segment of the tibial 
nerve of representative 4.5-month-old INSC94Y transgenic pigs and corresponding 
non-transgenic littermates was separated immediately after euthanasia and 
routinely processed for epon embedding. Comparative azur II-methylene blue-
safranin staining of tibial nerve fascicle profiles of diabetic INSC94Y transgenic 
pigs and corresponding controls at the age of 4.5 months revealed an unaltered 
fiber density with physiological homogenous myelination of the fiber caliber and 
inconspicuous vasculature. A pathognomonic loss of myelinated fibers was not 
detectable in 4.5-month-old INSC94Y transgenic pigs.  In addition, higher 
magnification levels did likewise not adduce light microscopic evidence of axonal 
degeneration as well as demyelination processes indicated by a high percentage of 
thin myelin sheaths. Therefore, nerve biopsies of 4.5-month-old 
INSC94Y transgenic pigs did not furnish proof of diabetes-induced injury of nervous 
tissue (Figure 30). Histological evaluation of nervous tissue of the insulin-treated 
INSC94Y transgenic founder boar at the age of three years also revealed unchanged 
morphology compared to an age-matched wild-type boar.         
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Figure 30: Representative histological sections of a tibial nerve fascicle of a 
4.5-month-old INSC94Y transgenic pig and a non-transgenic littermate 
Light microscopy of semithin sections of a tibial nerve fascicle of an INSC94Y 
transgenic pig (tg) and a non-transgenic control littermate (wt) at 4.5 months of 
age revealing physiological fiber density unsuggestive of diabetes-induced 
myelinopathy and axonal atrophy; Azur II-methylene blue-safranin staining on 
semithin sections illustrated at different magnification levels; Scale bar = 100 #m; 
Data provided by Dr. Daniela Emrich, Intitute of Veterinary Pathology, Ludwig-
Maximilians-University, Munich, Research Group Prof. Dr. Kaspar Matiasek; 
published by Renner et al. (2012); “Copyright 2012 American Diabetes 
Association From Diabetes®, Vol. 61, 2012 Reprinted with permission from the 
American Diabetes Association.” 
 
Furthermore single fiber teasing on tibial nerve biopsies of 4.5-month-old 
INSC94Y transgenic pigs was accomplished and evaluated for the presence of 
segmental or paranodal demyelination as well as signs of Wallerian degeneration 
without detecting any remarkable structural abnormalities compared to non-
transgenic littermates.  
IV. Results    136 
 
Teased fibers showed homogenous physiological myelinization of the internodes 
devoid of structural alterations of the nodes of Ranvier (Figure 31). 
 
Figure 31: Single fiber teasing of a tibial nerve fascicle of a 4.5-month-old 
INSC94Y transgenic pig and a non-transgenic littermate  
Teased fibers sampled from the tibial nerve fascicle evidenced homogenous 
physiological myelinization without structural alterations of nodular architecture; 
Scale bar = 100 #m; Data provided by Dr. Daniela Emrich, Intitute of Veterinary 
Pathology, Ludwig-Maximilians-University, Munich, Research Group Prof.  
Dr. Kaspar Matiasek; published by Renner et al. (2012); “Copyright 2012 
American Diabetes Association From Diabetes®, Vol. 61, 2012 Reprinted with 
permission from the American Diabetes Association.” 
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6.4. Progressive cataract in INSC94Y transgenic pigs 
A cataract of the eye lenses was already observed in 8-day-old INSC94Y transgenic 
pigs, progressing with increasing age. However, diabetic cataract in INSC94Y 
transgenic pigs turned out being reversible with exogenous insulin replacement 
and vision could be recovered (Figure 32). At the age of 8 days, lenses revealed 
incipient opacity at the edges, while in 4.5-month-old INSC94Y transgenic pigs the 
entire lenses were tarnished, which would have led to a deterioration of the visual 
acuity in all probability (Figure 33).  
  
 
Figure 32: Progressive cataract in INSC94Y transgenic pigs  
Representative photographs of a 3-month-old INSC94Y transgenic pig showing 
almost completely opaque lenses indicating an advanced state of diabetes-induced 
cataract.  
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Figure 33: Progressive diabetic cataract in INSC94Y transgenic pigs and wild-
type littermates 
Light microscopy on eye lenses of a representative 8-day-old and a 4.5-month-old 
INSC94Y transgenic pig (tg) and a non-transgenic littermate (wt). Microscopical 
pictures demonstrate incipient cataract in the transgenic pig at 8 days of age with 
progression until the whole lens was affected at 4.5 months of age; Data provided 
by Dr. Oliver Puk, Helmholtz Center Munich-German Research Center for 
Environmental Health, Institute of Developmental Genetics, Neuherberg, 
Research group of Prof. Dr. Jochen Graw; published by Renner et al. (2012); 
“Copyright 2012 American Diabetes Association From Diabetes®, Vol. 61, 2012 
Reprinted with permission from the American Diabetes Association.” 
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7. Evaluation of endoplasmic reticulum stress in 
INSC94Y transgenic pigs 
The presence of endoplasmic reticulum stress in 8-day-old INSC94Y transgenic pigs 
was evaluated by Western blot analysis of isolated pancreatic islets derived from a 
neonatal INSC94Y transgenic piglet in comparison with a non-transgenic littermate. 
Three independent islet lysates of an INSC94Y transgenic piglet and of a non-
transgenic littermate were used in each case. Endoplasmic reticulum stress 
markers were identified by specific antibodies and the fragment size was 
compared to the molecular weight standard. Quantification was accomplished by 
normalizing their optical densities with that of !-actin (43 kDa). 
7.1. C/EBP-homologous protein 10 (CHOP-10) 
The proapoptotic endoplasmic reticulum stress marker CHOP-10, also referred to 
as Growth arrest and DNA damage protein 153 (GADD 153) was characterized 
by a specific band of 20 kDa, which was detectable in the INSC94Y transgenic 
piglet as well as in the non-transgenic control. However, the 
INSC94Y transgenic piglet demonstrated a clearly higher optical density of 
CHOP/!-actin compared to the non-transgenic control (0.196 ± 0.05 vs. 0.076 ± 
0.02) indicating upregulation of CHOP-10 expression (Figure 34). 
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Figure 34: Optical density of CHOP/!-actin in isolated islets of a neonatal 
INSC94Y transgenic pig and a non-transgenic littermate 
Western blot analysis of a neonatal INSC94Y transgenic pig and non-transgenic 
control indicated a band of 20 kDa, which meets the molecular weight specific for 
CHOP-10. The mean optical density of CHOP/!-actin was clearly elevated in the 
INSC94Y transgenic piglet (tg) compared to the non-transgenic control (wt); 
n: number of investigated islet lysates of an INSC94Y transgenic pig and a non-
transgenic control; data indicated by means ± SEM. 
 
7.2. Phosphorylated eucaryotic translation initiation factor 2"  (PeIF2") 
Evidence of the phosphorylated eukaryotic translation initiation factor 2" 
(PeIF2") was visualized in isolated islets of an INSC94Y transgenic piglet and of a 
non-transgenic littermate by a specific band of 36 kDa. The optical density of 
PeIF2"/!-actin was slightly decreased in the INSC94Y transgenic piglet compared to 
the non-transgenic control (Figure 35). 
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Figure 35: Optical density of PeIF2"/!-actin in isolated islets of a neonatal 
INSC94Y transgenic pig and a non-transgenic littermate 
The presence of PeIF2" in isolated islets of a neonatal INSC94Y transgenic pig and 
a non-transgenic control was reflected by a distinct band of 36 kDa. The 
INSC94Y transgenic piglet (tg) revealed a diminished mean optical density of 
PeIF2"/!-actin compared to the non-transgenic control pig (wt); n: number of 
investigated islet lysates of an INSC94Y transgenic pig and a non-transgenic control; 
data indicated by means ± SEM. 
 
7.3. Glucose regulated protein 78 (Grp78) 
A specific and clearly visible band of 78 kDa, associated with the molecular 
weight of the glucose regulated protein 78 (Grp78), also synonymously known as 
binding Ig protein (BiP), could be detected in the INSC94Y transgenic pig and in the 
non-transgenic control likewise. The INSC94Y transgenic pig showed a similar 
optical density of GRP78/!-actin compared to the non-transgenic control 
indicating unaltered expression levels of Grp78 (Figure 36).  
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Figure 36: Optical density of GRP78/!-actin in isolated islets of a neonatal 
INSC94Y transgenic pig and a non-transgenic littermate  
Grp78, indicated by a band of 78 kDa, was present in isolated islets of a neonatal 
INSC94Y transgenic pig (tg) and a non-transgenic control (wt). The optical density 
of GRP78/!-actin was unaltered in the INSC94Y transgenic piglet compared to the 
non-transgenic control; n: number of investigated islet lysates of an 
INSC94Y transgenic pig and a non-transgenic control; data indicated by means ± 
SEM.  
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V. DISCUSSION 
The present study included the generation and characterization of the first 
genetically engineered porcine animal model of permanent neonatal diabetes 
mellitus. Severe diabetes mellitus in hemizygous INSC94Y transgenic pigs is 
triggered by expression of a mutated INS gene (INSC94Y), resembling the 
INSC96Y mutation identified in human and the Ins2C96Y mutation of the 
Akita mouse model (Colombo et al., 2008; Stoy et al., 2007; Yoshioka et al., 
1997).  
1. Generation of INSC94Y transgenic pigs using somatic cell 
nuclear transfer 
INSC94Y transgenic pigs were generated by somatic cell nuclear transfer (SCNT) 
using pools of donor cells stably nucleofected with the porcine 
INSC94Y expression vector. Using this strategy it is possible to obtain a high 
proportion of transgenic founder animals with different integration sites and 
expression levels (Aigner et al., 2010). SCNT and transfer of reconstructed 
embryos into estrus synchronized recipient gilts resulted in seven live offspring 
derived from 237 transferred embryos equivalent to a reasonable cloning 
efficiency of 3% within the expected range (Klymiuk et al., 2012; Kurome et al., 
2008; Polejaeva et al., 2000; Umeyama et al., 2009; Vajta et al., 2007). Southern 
blot analysis using a probe specific for the neomycin resistance cassette attached 
to the INSC94Y expression cassette identified all seven cloned piglets as transgenic 
and suggested that each founder had a single transgene integration site at a 
different chromosomal locus, as expected after using pools of stable nucleofected 
cell clones for SCNT. Therefore it is not surprising, that the INSC94Y transgenic 
founder boars revealed different expression levels of the INSC94Y transgene 
attributable to chromosomal position effects resulting from the chromatin status of 
neighboring DNA (Clark et al., 1994; Recillas-Targa, 2006; Wolf et al., 2000). 
Maintenance of INSC94Y transgene integrity as well as germ line transmission 
adhering to mendelian rules was proven by Southern blot analysis of the 
INSC94Y transgenic offspring of the diabetic founder boar 9747 showing the same 
transgene integration pattern and similar levels of transgene expression as their 
transgenic sire. Indeed, the diabetic phenotype was exceedingly stable in the 
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INSC94Y transgenic progeny, which is an important advantage for their future use 
as a large animal model. 
2. Progressive diabetic phenotype in INSC94Y transgenic pigs 
2.1. Disturbed glycemic control in INSC94Y transgenic pigs   
The INSC94Y transgenic founder boar 9747 as well as the 
INSC94Y transgenic offspring exhibited blood glucose levels significantly 
exceeding the reference range specified for pigs (70-115 mg/dl depending on the 
laboratory) indicative of disturbed glucose homeostasis. INSC94Y transgenic 
offspring became hyperglycemic within 24 hours after birth, reaching blood 
glucose levels over 400 mg/dl at the age of 115 days. Disturbance of !-cell 
function during the fetal period was unlikely as blood glucose concentrations were 
unaltered prior to the first colostrum ingestion but cannot be completely excluded. 
In neonatal humans suffering from PNDM blood glucose levels over 600 mg/dl 
were reported (Hutchison et al., 1962; Shield et al., 1997; Stoy et al., 2007). The 
clinical appearance of heterozygous Akita Ins2C96Y mutant mice is in line with 
diagnostic findings relevant for the corresponding INSC94Y transgenic pig model 
(Izumi et al., 2003; Wang et al., 1999). Male heterozygous Akita Ins2C96Y mutant 
mice revealed significantly increased randomly fed blood glucose levels of 280 
mg/dl at 4 weeks of age progressing steadily up to over 500 mg/dl, demonstrating 
the highly diabetogenic impact of one mutated Ins2 allele in spite of the presence 
of one wild-type Ins2 and two wild-type Ins1 alleles in rodents (Wang et al., 1999; 
Yoshioka et al., 1997). Moreover, male heterozygous Munich Ins2C95S mutant 
mice, which feature a point mutation in the Ins2 gene disrupting the C95(A6)-
C100(A11) intrachain disulfide bond, likewise developed significantly elevated 
blood glucose levels of more than 300 mg/dl, confirming the dominant-
negative/toxic effect of the mutated Ins2 allele on !-cell function (Herbach et al., 
2007). However, heterozygous Akita Ins2C96Y as well as heterozygous Munich 
Ins2C95S mutant mice remained normoglycemic until the age of almost 4 weeks 
compared to wild-type controls (Herbach et al., 2007; Yoshioka et al., 1997). On 
the contrary, significantly elevated random blood glucose levels in 
INSC94Y transgenic pigs were detectable within 24 hours postpartum. Both 
heterozygous Akita Ins2C96Y and Munich Ins2C95S mutant mice displayed a distinct 
gender dimorphism with a less pronounced diabetic phenotype in females, 
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explainable by the protective effect of estrogen on !-cells (Herbach et al., 2007; 
Louet et al., 2004; Schuster, 2011; Yoshioka et al., 1997). Untreated 
INSC94Y transgenic pigs did not show any sex-related differences in the severity of 
diabetes and associated symptoms within the observation period of 4.5 months, 
potentially due to their sexual immaturity.  
The fact that only one INSC94Y transgenic founder boar (9747) became clinically 
diabetic, while the other six exhibited normoglycemia suggested a dose-dependent 
effect of mutant insulin due to different transgene expression levels. To proof this 
hypothesis and correct for the variation in !-cell content of arbitrarily taken 
pancreas specimens, the ratio of mutant INSC94Y and endogenous INS cDNA 
amplicons was determined. Expression of INSC94Y transcripts at a level of 75% of 
endogenous INS transcripts in pancreatic tissue of the diabetic INSC94Y transgenic 
founder boar 9747 as well as in the transgenic offspring most likely contributed to 
the development of the distinct diabetic phenotype and was supposedly even 
sufficient to provoke hyperglycemia already in postnatal transgenic piglets, 
particularly as the total !-cell volume was initially unaltered. The positive 
correlation of INSC94Y mRNA levels with the respective clinical picture approved 
the dose-dependent effect of mutant INSC94Y gene expression.  
Furthermore untreated 4.5-month-old INSC94Y transgenic pigs exhibited 
significantly reduced fasting plasma insulin levels compared to non-transgenic 
littermates. Likewise, male heterozygous Akita Ins2C96Y mice revealed a 60% 
 reduction in immunoreactive plasma insulin levels compared to age- and sex-
matched control mice at the age of seven weeks (Yoshioka et al., 1997). The 
molecular mechanism underlying insulin secretory failure in heterozygous 
Akita Ins2C96Y mice has been intensively investigated and is based upon drastic 
steric rearrangement of the mutant proinsulin polypeptide abetted through 
disturbed integrity of the C96(A7)-C31(B7) intramolecular disulfide bond (Wang 
et al., 1999; Yoshinaga et al., 2005). Wild-type proinsulin molecules feature a 
hydrophobic core with non-polar amino acid residues kept inwardly (Baker et al., 
1988; Mayer et al., 2007). Therefore mutant proinsulin is inclined to aggregate 
promoted through its increased hydrophobicity and incorrect disulfide pairing 
(Wang et al., 1999; Yoshinaga et al., 2005). Furthermore hydrophobic interaction 
with the molecular chaperone binding Ig protein (BiP) through fractionally 
exposed hydrophobic regions and an unpaired cysteine residue mediating 
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entrapment in the ER was depicted in mutant Ins2C96Y transfected CHO cell lines 
(Wang et al., 1999). Effective secretion of synchronously expressed wild-type 
proinsulin molecules is also hampered due to the formation of covalent 
intermolecular protein complexes with highly reactive hydrophobic mutant 
proinsulin (Hodish et al., 2010; Liu et al., 2007; Park et al., 2010; Wang et al., 
1999; Yoshinaga et al., 2005). Therefore, mutant misfolded proinsulin 
additionally retains wild-type insulin in the ER, acuminating ER-stress (Hodish et 
al., 2010). Despite early significant hyperglycemia, basal plasma insulin levels of 
randomly fed 8-day-old INSC94Y transgenic pigs were almost unaltered compared 
to age-matched control piglets. Consonantly, untreated heterozygous 
Munich Ins2C95S mice, regardless of gender, showed similar fasted and 
postprandial serum insulin levels compared to corresponding controls at the age of 
one month. However, after oral glucose challenge, serum insulin levels of 
Munich Ins2C95S mice were significantly reduced in comparison to controls, 
demonstrating disturbed glucose-stimulated insulin secretion (Herbach et al., 
2007). For that reason, consequences of glucose challenge need to be evaluated in 
postnatal INSC94Y transgenic pigs to verify initial insulin secretory deficiency 
preceding absolute insulin deficiency through clinically relevant loss of functional 
!-cells.  
Another factor contributing to the early onset of diabetes in 
INSC94Y transgenic pigs may be an autocrine stimulatory influence of insulin on its 
own secretion through binding to the insulin receptor present on the surface of 
pancreatic !-cells. Besides glucose, autocrine insulin-stimulated exocytosis 
presumably assists the agitated first instance insulin release (Aspinwall et al., 
1999; Borelli et al., 2004; Verspohl and Ammon, 1980). Moreover, there is 
increasing evidence that insulin biosynthesis is likewise translationally regulated 
through autocrine action of endogenous insulin mediated by the cytoplasmic 
tyrosine-kinase domain of insulin receptors of pancreatic !-cells (Hubbard, 2013; 
Lemmon and Schlessinger, 2010; Xu et al., 1998). In vitro studies using !TC-F7 
cell lines and isolated pancreatic islets derived from male Sprague Dawley rats 
confirmed insulin-stimulated activating phosphorylation of PHAS-I 
(phosphorylated heat- and acid stable eIF-4E binding protein regulated by insulin 
I) bound to the eukaryotic translation initiation factor 4E in the unphosphorylated 
state in order to repress translation initiation (Xu et al., 1998). Thus a secondary 
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negative feedback on insulin secretion and biosynthesis emanated from absent 
autocrine stimulus may contribute to the inherently deficient insulin release in 
INSC94Y transgenic pigs. In order to exemplify the existing disturbed !-cell 
function, homeostasis model of baseline insulin secretion index (HOMA-B) was 
determined by means of fasting plasma insulin and glucose levels reflective of the 
relationship between hepatic gluconeogenesis and insulin secretion in the fasting 
subject (Matthews et al., 1985; Turner et al., 1979). HOMA-B indices in 4.5-
month-old INSC94Y transgenic pigs were tremendously decreased by 96% in 
comparison to age-matched non-transgenic controls, indicating virtually no 
residual steady-state !-cell function. 20% remaining !-cell function has been 
referred to as the critical threshold of sufficient glycemic control (Turner et al., 
1982). Significantly reduced HOMA-B indices were previously calculated for 
heterozygous Munich InsC95S mice from the earliest time point investigated 
(1 month), supporting our findings in INSC94Y transgenic pigs (Herbach et al., 
2007). Nevertheless, since HOMA-B index was developed for and validated only 
in humans, the data from animal models need to be considered with care (Wallace 
et al., 2004). 
The homeostasis model assessment of insulin resistance index (HOMA-IR) 
according to Matthews et al. (1985) is a surrogate index to quantify insulin 
resistance in vivo largely correlating with the hyperinsulinemic euglycemic clamp 
technique in humans (DeFronzo et al., 1979; Lee et al., 2008; Wallace et al., 
2004). Although defined for human metabolism, HOMA-IR indices have proven 
applicable to a certain degree in insulin resistant mice and revealed reasonable 
correlation to comparative glucose clamp studies (Lee et al., 2008). Thus, 
significantly elevated HOMA-IR indices in 4.5-month-old INSC94Y transgenic pigs 
compared to age-matched wild-type controls most likely reflect accompanying 
insulin resistance. Dysregulation of glycemic control in type 2 diabetes mellitus is 
mainly expedited by obesity-induced peripheral and hepatic insulin resistance 
gradually triggering !-cell exhaustion and eventually overt diabetic symptoms 
(Johnson and Olefsky, 2013). The existence of autocrine feedback loops between 
insulin production, subsequent insulin secretion and percentage of endogenous 
insulin molecules bound to eligible receptors on pancreatic !-cells are supposed to 
implicate insulin resistance in lean, insulin-dependent subjects (Aspinwall et al., 
1999). X-ray crystallography recently clarified the three-dimensional structure of 
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the insulin-insulin receptor complex and underlined importance of proper steric 
arrangement of the mature insulin molecule for receptor binding affinity (Menting 
et al., 2013). Absolute necessity of the three highly conserved disulfide bonds for 
stability of the secondary structure and in consequence for receptor binding 
affinity of the insulin molecule was emphasized by in vitro studies using mutants 
of human insulin, each lacking one of the three disulfide bonds (Chang et al., 
2003). In addition, receptor binding affinity was barely detectable following A7-
B7 disulfide deletion of the insulin polypeptide in yeast (Guo and Feng, 2001). 
Therefore altered binding affinity of mutant porcine C94Y insulin causing steric 
rearrangement due to the lack of the stabilizing C94(A7)-C31(B7) intramolecular 
disulfide linking would not be astonishing. In vitro studies using the !-cell line 
HIT-T15 concluded that chronic exposure to high glucose levels increases 
intracellular reactive oxygen species (ROS) and concurrently decreases 
INS promoter activity through downregulation of the pancreatic and duodenal 
homeodomain transcription factor 1 (PDX1) and pancreatic !-cell-specific 
transcriptional activator (MAFA), disturbing insulin expression on the 
transcriptional level (Houstis et al., 2006; Melloul et al., 1993; Robertson, 2004; 
Robertson et al., 1992; Sharma et al., 1995). As pancreatic islets are poorly 
featured with antioxidative defence mechanisms, oxidative stress is barely warded 
off (Robertson, 2004). Glucotoxicity has also been validated as underlying cause 
of insulin resistance in humans (Vuorinen-Markkola et al., 1992; Yki-Jarvinen et 
al., 1987). In accordance, hyperglycemic male heterozygous Ins2C96Y mutant mice 
exhibited peripheral insulin resistance, which could be rescued by phlorizin 
application lowering blood glucose levels. Glucose transporter 4 (Glut4) 
expression was found to be downregulated in these insulin-resistant mice and 
therefore presumably entangled in the pathogenesis of impaired peripheral insulin 
sensitivity in male heterozygous Akita Ins2C96Y mutant mice (Hong et al., 2007). 
Amelioration of insulin resistance in male heterozygous Munich Ins2C95S mutant 
mice through exogenous insulin supplementation places emphasis on 
glucotoxicity as determinant of insulin resistance (Kautz, 2011). On these 
grounds, impaired insulin sensitivity and glucose-stimulated insulin secretion 
involved in deficient glycemic control in untreated INSC94Y transgenic pigs are 
presumably driven by chronically elevated blood glucose levels exerting chronic 
oxidative stress on pancreatic !-cells.  
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However in vitro studies awoke reasonable doubts if mutant proinsulin lacking 
C96(A7)-C31(B7)  disulfide bond can be secreted by pancreatic !-cells at all or if 
a general failure of glucose-stimulated exocytosis impedes sufficient insulin 
secretion. For instance, transfected HEK293 cells expressing recombinant mutant 
C96Y proinsulin polypeptide, following site-directed mutagenesis of human 
proinsulin cDNA, revealed a drastically decreased secretion of mutant proinsulin 
compared to control HEK293 cells transfected with an expression vector for wild-
type proinsulin. Moreover mutant proinsulin was very likely subjected to 
intracellular proteolysis (Colombo et al., 2008). The same observations were 
stated for CHO cell lines exhibiting retarded secretion of mutant proinsulin into 
the cell culture media after mutant Ins2C96Y tranfection in comparison to wild-type 
Ins2 tranfected CHO cells. Intracellular degradation of mutant proinsulin 
molecules was likewise supposed (Wang et al., 1999). Experiments using 
transfected 293T cells even ascertained completely absent secretion of 35S-labeled 
mutant C96Y proinsulin (Liu et al., 2005). Transfected MIN6 mouse insulinoma 
cells expressing mutant C96Y proinsulin provided with a selectable green 
fluorescent protein (GFP) reporter in the C-peptide, showed undetectable GFP-C 
peptide levels indicating outright failure of endoproteolytic cleavage and 
exocytosis of the mutant variant (Rajan et al., 2010). So far, it remains to be 
clarified if the mutant porcine C94Y insulin is at all secreted from pancreatic !-
cells of INSC94Y transgenic pigs.  
Hyperglucagonemia was found to be a concomitant phenomenon in insulin-
deficient diabetic patients and is therefore likely to redound to the pathogenesis of 
diabetes mellitus through augmented hepatic glucose production (Quesada et al., 
2008). Glucagon secretion was accelerated in chronically hyperglycemic patients 
presumably triggered by defective glucose sensing of "-cells and absent insulin 
repression (Gromada et al., 2007; Jacobson et al., 2009; Unger et al., 1970). Thus, 
hyperglycemic male heterozygous Munich Ins2C95S mutant mice developed 
elevated randomly fed glucagon levels compared to mild hyperglycemic female 
heterozygous Ins2C95S mutant mice and sex-matched normoglycemic wild-type 
mice, presumably worsening hyperglycemia by accelerating hepatic glucose 
supply. Paradoxically stimulated glucose-decoupled glucagon secretion in male 
heterozygous Munich Ins2C95S mutant mice emphasizes potentially disturbed 
glucose sensing of "-cells in the context of chronically elevated blood glucose 
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levels as hyperglucagonemia was ameliorated by insulin treatment (Kautz, 2011; 
Salehi et al., 2006). Basal plasma glucagon levels in randomly fed 8-day-old 
INSC94Y transgenic piglets and fasting plasma glucagon levels in 4.5-month-old 
INSC94Y transgenic pigs were determined by radioimmunoassay and compared to 
the levels of age-matched non-transgenic control pigs. 8-day-old 
INSC94Y transgenic pigs revealed noticeable higher randomly fed plasma glucagon 
levels than age-matched control littermates. Similarly, 4.5-month-old 
INSC94Y transgenic pigs exhibited mild hyperglucagonemia in the fasting state 
compared to age-related controls. In both age groups effects were clearly visible 
but not significant, arguing against a dominant role of glucagon in the disturbed 
glucose homeostasis of INSC94Y transgenic pigs. Furthermore large-scale 
comparative oral glucose tolerance tests in human type 2 diabetics demonstrated 
exceedingly decreased suppression of glucose-stimulated glucagon release during 
glucose challenge, despite unaltered fasting glucagon levels in these probands 
(Abdul-Ghani and DeFronzo, 2007). Therefore the relative changes of plasma 
glucagon levels during glucose challenge may enlighten the actual contribution of 
glucagon signaling in maintaining hyperglycemia in INSC94Y transgenic pigs.  
In conclusion, the disturbed glycemic control in INSC94Y transgenic pigs is 
triggered by a complex interaction of pathogenetic factors finally acuminating in 
the progressive diabetic phenotype observed in these pigs. Chronic hyperglycemia 
in INSC94Y transgenic pigs seems to be based upon the dominant-negative/toxic 
effect of INSC94Y transgene expression impeding adequate glucose-stimulated 
insulin secretion. Furthermore accompanying peripheral insulin resistance 
presumably contributes to the pathogenesis of disturbed glycemic control in 
INSC94Y transgenic pigs. With increasing age, the progressive loss of functional !-
cells is a factor to be taken into account. The INSC94Y transgenic pig model reflects 
clinical features and underlying disease mechanisms previously demonstrated in 
diabetic Ins2 mutant mice. Beyond diabetic rodents, characteristics of human 
permanent neonatal diabetes have been observed and validated in 
INSC94Y transgenic pigs.   
2.2. Growth retardation in INSC94Y transgenic pigs  
Intrauterine growth retardation (IUGR) and reduced birth weights are 
characteristic clinical features of humans born with PNDM attributed to the 
absence of insulin in utero as fetal growth factor (Cave et al., 2000; Polak and 
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Cave, 2007). In contrast, INSC94Y transgenic pigs did not exhibit reduced growth 
compared to non-transgenic littermates until weaning. This discrepancy possibly 
resulted from different fetal growth kinetics throughout gestation between pigs 
and humans. In the pig, the highest fetal growth rates are observed around birth, 
whereas the main fetal growth phase in humans is almost completed within 30 to 
36 weeks and potentially declines thereafter. (Litten-Brown et al., 2010). The 
onset of endogenous mutant INS expression in humans might differ from onset of 
INSC94Y transgene expression in the fetal pig and eventually falls in this sensitive 
phase during late gestation. After weaning, untreated INSC94Y transgenic pigs 
exhibited reduced growth rates resulting in a significantly decreased body weight 
at the age of 4.5 months as compared to wild-type littermates. Impaired growth 
was also observed in male heterozygous Akita Ins2C96Y mutant mice indicating a 
detrimental influence of Ins2C96Y expression on weight gain (Yoshioka et al., 
1997). Furthermore, these findings are concordant with decelerated growth of 
prepuberal children diagnosed with diabetes mellitus and receiving insufficient 
glycemic control (Edelsten et al., 1981; Jackson, 1984; Salardi et al., 1987; 
Tattersall and Pyke, 1973). An important aspect of growth disturbance in 
hypoinsulinemic subjects is the incompetence of sufficient glucose uptake 
implicating consecutive cellular glucose deprivation and limiting anabolic 
processes including linear bone growth (Bereket et al., 1995; reviewed in Martin 
et al., 1984). Furthermore an absolute insulin deficiency impinges growth upon 
regulation of the growth hormone (GH)-insulin-like growth factor (IGF) system as 
already clarified in diabetic mice. Therefore decreased hepatic growth hormone 
(GH) receptor density and decreased levels of insulin-like growth factor I (IGF-I) 
were found in poorly controlled diabetic patients (Bereket et al., 1995; Bereket et 
al., 1999; Clayton et al., 1994; Maes et al., 1986; Strasser-Vogel et al., 1995). 
However, the remarkable 41% reduction of the body weight in 4.5-months-old 
INSC94Y transgenic pigs compared to non-transgenic controls suggests that the 
effect of reduced insulin secretion on weight gain and linear growth is 
exceptionally remarkable in a thriving species like the pig, reflecting conditions 
during the pubertal growth spurt in humans. Accordant with the reversal of 
growth delay by adequate insulin therapy in adolescent humans, 
INSC94Y transgenic pigs could be likewise rescued from growth retardation by 
exogenous insulin supplementation, emphasizing the role of insulin as anabolic 
promoter of juvenile growth (Bereket et al., 1999; Rudolf et al., 1982). As insulin 
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is directly involved in osteoblastogenesis and bone mineralization, alterations of 
skeletal architecture related to insulin-deficiency are frequently diagnosed even in 
young diabetic patients (Engelhart and G., 2010; Gunczler et al., 1998; reviewed 
in Thrailkill et al., 2005; Santiago et al., 1977; Wiske et al., 1982). Therefore 
impact of INSC94Y transgene expression on bone growth and composition in 
adolescent pigs needs to be clarified.  
2.3. Evidence for endoplasmic reticulum stress in 
INSC94Y transgenic pigs 
To elucidate the involvement of endoplasmic reticulum stress in the pathogenesis 
of mutant INSC94Y gene-induced diabetes mellitus in INSC94Y transgenic pigs, the 
abundance of endoplasmic reticulum stress markers CCAAT/enhancer-binding 
protein (C/EBP) homologous protein 10 (CHOP-10), phosphorylated eukaryotic 
translation initiation factor 2" (PeIF") and binding Ig protein (BiP) was evaluated 
in isolated pancreatic islets derived from a neonatal INSC94Y transgenic piglet and 
a corresponding non-transgenic control piglet. Three independently sonicated islet 
lysates of an INSC94Y transgenic piglet and a non-transgenic control were used in 
each case in default of further viable islet samples after isolation process. Due to 
the limited number of animals being investigated, the data were not statistically 
evaluated. Islet isolation yielded physiological age-appropriate islet-like cell 
clusters from the neonatal INSC94Y transgenic piglet as well as from the age-
matched wild-type control piglet respectively. Western blot analyzes regarding the 
abundance of ER stress markers in neonatal INSC94Y transgenic pigs may serve as 
first appraisement, but need to be interpreted carefully. Hence, the protocol for 
Western immunoblot analyzes has been proven applicable for porcine tissue. The 
proapoptotic ER stress marker CHOP-10 was found to be twofold increased in 
islet lysates of the INSC94Y transgenic piglet compared to those of the age-matched 
wild-type control piglet, whereas PeIF2" and BiP were roughly unaltered 
compared to corresponding control islet sonicates. Accumulation of irreversibly 
misfolded mutant proinsulin polypeptides in the luminal space of the endoplasmic 
reticulum initiates a complex adaptive signaling pathway to overcome advancing 
accumulation of client polypeptides on the translational and transcriptional level 
anticipating chronic stress on the ER (Araki et al., 2003; Eizirik et al., 2008). The 
unfolded protein response pathway (UPR) is a balancing act between cell survival 
and cell demise mainly regulated by the stress-regulated transcription factors 
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IRE1", PERK and ATF6, kept in the inactive state through complexing with the 
molecular chaperone BiP (Bertolotti et al., 2000; Harding et al., 1999; Haze et al., 
2001; Scheuner and Kaufman, 2008; Shi et al., 1998; Tirasophon et al., 1998; Wu 
et al., 2007). Beyond functioning as ER sensing determinant, BiP binds folding 
intermediates and facilitates retention of unfolded substrates in the secretory 
pathway exerting for complete folding (Araki et al., 2003; Flynn et al., 1989). 
Therefore, BiP was found to be upregulated upon ER stress in pancreatic islets of 
human type 2 diabetic subjects in comparison to non-diabetic controls indicated 
by specifically increased immunostaining intensity (Laybutt et al., 2007). 
Furthermore mutant proinsulin 2 revealed increased propensities to constitute 
intermolecular protein complexes within the enlarged ER lumen of islets isolated 
from heterozygous Akita Ins2C96Y mutant mice implying BiP, which was therefore 
markedly upregulated (Allen et al., 2004; Wang et al., 1999). In contrast, 
induction of BiP expression was unexpectedly not observed in pancreatic islet 
protein lysates of untreated heterozygous Munich Ins2C95S mutant mice (Kautz, 
2011). Convincing conclusions concerning abundance of BiP in pancreatic islets 
of INSC94Y transgenic pigs might be drawn through analyzes of a statistically 
relevant number of respective pigs. Activated PERK mediates ER stress-induced 
mRNA translation attenuation in order to adjust new protein synthesis to the 
instantaneous functional capacity of the ER by phosphorylation of the eukaryotic 
initiation factor 2 " (Harding et al., 1999; Samuel, 1993; Shi et al., 1998; Vachon 
et al., 1990). Phosphorylated eIF2" lacks the ability to interconnect with the 
translation initiator methionyl tRNA (Met-RNA) and to bind to the 40S ribosomal 
subunit preventing translation initiation of client mRNAs (de Haro et al., 1996; 
Harding et al., 2000; Pain, 1996; Samuel, 1993). Upregulated PeIF2" associated 
with curtailed new protein synthesis was not detected in heterozygous Munich 
Ins2C95S mutant mice compared to control mice (Kautz, 2011). In vitro studies 
using a transfected CHO cell lineage expressing Ins2C96Y mutant gene revealed 
likewise unchanged protein biosynthesis activity compared to control CHO cells 
expressing wild-type Ins2. Thus, expression of Ins2C96Y mutant gene might 
presumably not interfere with protein biosynthesis in vivo (Izumi et al., 2003). On 
these grounds unaltered ratio of PeIF2" in neonatal INSC94Y transgenic pigs 
compared to age-related wild-type control pigs could be possible but needs to be 
further elucidated. Sustained and insuperable endoplasmic reticulum stress 
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induces programmed cell death successively acuminating in disturbed tissue 
function (Kaufman, 2002; Kim et al., 2008; Szegezdi et al., 2006; van der Kallen 
et al., 2009). Overexpression of CHOP-10 is tightly linked to the initiation of 
apoptosis in response to chronic ER stress (Marciniak et al., 2004; Oyadomari and 
Mori, 2004; Zinszner et al., 1998). Heterozygous Akita Ins2C96Y mutant mice 
revealed markedly increased Chop mRNA levels compared to corresponding 
wild-type mice indicating initiation of ER stress-induced apoptosis in pancreatic 
!-cells and corroborating the dominant-negative/toxic effect of 
Ins2C96Y expression in these mice (Oyadomari et al., 2002). In contrast, in double-
mutant heterozygous Akita Ins2C96Y mutant mice, additionally bearing a 
heterozygous or homozygous disrupted Chop gene, progression of diabetic 
symptoms was specifically decelerated or even prevented (Oyadomari et al., 
2002). In general, Chop-null mutation was shown to ameliorate severe !-cell 
dysfunction in a variety of rodent models of diabetes (Song et al., 2008). The 
optical density of CHOP-10/!-actin was significantly increased in islet sonicates 
of untreated male heterozygous Munich Ins2C95S mutant mice compared to 
corresponding controls, indicating ER stress mediated CHOP-10-induced 
apoptosis of !-cells (Kautz, 2011). Therefore, the high-level expression of mutant 
INSC94Y gene in the INSC94Y transgenic pig model and the supposedly interminable 
accumulation of misfolded mutant proinsulin polypeptides in the ER is likely to 
gradually culminate in !-cell apoptosis following exhaustion of the compensatory 
abilities of the UPR by chronic ER stress. This presumption is underlined by a 
considerable increase in the optical density of CHOP-10/!-actin in isolated islets 
of the INSC94Y transgenic piglet compared to those of the age-related control piglet. 
Preliminary findings achieved by Western blot analysis of ER stress markers in 
isolated pancreatic islet of INSC94Y transgenic pigs and respective control pigs are 
in line with the results of immunohistochemistry as well as electron microscopy of 
!-cells revealing insulin deficiency and drastic ER stress-induced !-cell demise. 
Therefore ER stress in pancreatic !-cells, likely triggering apoptosis of respective 
perturbed cells, might be a conceivable corollary of INSC94Y transgene expression 
and in most instances responsible for the restrained insulin supply and full-blown 
clinical diabetes mellitus in these pigs. A larger cohort of INSC94Y transgenic pigs 
and corresponding controls imperatively needs to be investigated to achieve 
reliable results in this case. 
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3. Morphological consequences of INSC94Y transgene 
expression 
3.1. Altered cellular composition of the endocrine pancreas in 4.5-
month-old INSC94Y transgenic pigs 
Pancreata of 8-day-old INSC94Y transgenic pigs and 4.5-month-old 
INSC94Y transgenic pigs were investigated by means of immunohistochemistry and 
quantitative stereological analyzes using state-of-the-art unbiased model-
independent stereological methods (Gundersen et al., 1988; Gundersen and 
Jensen, 1987; Wanke, 1994).  
Pancreatic sections of 8-day-old INSC94Y transgenic pigs and age-matched non-
transgenic controls were stained for insulin containing !-cells and revealed 
homogeneously evenly distributed single !-cells and small islet-like cell clusters 
of constant staining intensity. The qualitative histological findings were confirmed 
by an almost identical volume density of !-cells (Vv(!-cell/Pan)) and an unaltered 
total !-cell volume (V(!-cell, Pan)) of the endocrine pancreas of 8-day-old 
INSC94Y transgenic pigs in comparison to age-matched wild-type pigs. This is in 
line with insights achieved in sex-matched postnatal heterozygous Akita 
Ins2C96Y mutant mice exhibiting unaltered insulin-positive areas suggesting 
postnatal disturbance of !-cells (Kayo and Koizumi, 1998; Liu et al., 2010). 
However, alterations of the ultrastructural architecture of !-cells were already 
noticeable in heterozygous Akita Ins2C96Y mutant mice (Kayo and Koizumi, 1998; 
Liu et al., 2010) as well as in INSC94Y transgenic pigs at this early postnatal stage. 
However, INSC94Y transgenic pigs already exhibited severe hyperglycemia in 
contrast to still normoglycemic heterozygous Akita Ins2C96Y mutant mice (Kayo 
and Koizumi, 1998).  
Double immunohistochemical staining of pancreatic tissue of 4.5-month-old 
INSC94Y transgenic pigs and age-matched non-transgenic littermate controls 
visualizing insulin-positive !-cells on the one hand and glucagon, somatostatin as 
well as pancreatic polypeptide containing cells, referred to as non-!-cells, on the 
other hand revealed markedly altered islet composition in the transgenic pigs. 
Compared to age-matched non-transgenic control pigs, pancreas sections of 4.5-
month-old INSC94Y transgenic pigs comprise visibly less insulin-positive cells with 
notably weaker staining intensity suggesting decreased insulin content within the 
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!-cells. This is in line with a highly reduced number of insulin secretory granules 
in the cytoplasm of pancreatic !-cells of 4.5-month-old INSC94Y transgenic pigs 
compared to non-transgenic control pigs ascertained by means of electron 
microscopy. Mainly scattered single !-cells, small !-cell clusters and at most 
medium-sized islets were observed in the endocrine pancreas of 4.5-month-old 
INSC94Y transgenic pigs, whereas wild-type pigs revealed typical large, irregularly 
shaped pancreatic islets with a core of insulin-positive cells surrounded by a 
narrow mantle of non-!-cells. Quantitative stereological examination of the 
endocrine compartment of the pancreas of 4.5-month-old INSC94Y transgenic pigs 
and corresponding non-transgenic littermates revealed a significant 54% reduction 
of the volume density of !-cells in the pancreas (Vv(!-cell/Pan)) in the transgenic 
pigs, therefore representing less than 0.5% volume fraction of the pancreas. The 
visual perception of successive !-cell abatement received in 
INSC94Y transgenic pigs at the age of 4.5 months was quantitatively accredited by a 
72% reduction of the total !-cell volume (V(!-cell, Pan)) in comparison to non-
transgenic controls. Due to the significantly lowered absolute pancreas weights 
correlative with the remarkable overall growth deceleration, the total !-cell 
volume related to body weight (V(!-cell, Pan)/BW (mm3/kg)) was reduced by only 
53% and therefore proportionately lower compared to V(!-cell, Pan). As insulin 
staining was used to identify !-cells and a large number of !-cells of 
INSC94Y transgenic pigs were extensively degranulated, underestimation of the 
proportion of !-cells in the endocrine pancreas of 4.5-months-old 
INSC94Y transgenic pigs needs to be considered. In accordance, the volume fraction 
of insulin-positive cells in the islets was diminished by approximately 90% in 
proportion to an unaltered relative area of islets in the endocrine pancreas of male 
heterozygous Akita Ins2C96Y mutant mice compared to age- and sex-related control 
mice at the age of 30 weeks (Yoshioka et al., 1997). The total !-cell volume (V(!-
cell, Islet)) in the pancreatic islets and the volume density of !-cells in the islets (Vv(!-
cell/Islet)) of hyperglycemic, male heterozygous Munich Ins2C95S mutant mice were 
significantly decreased by around 80% compared to corresponding control mice 
(Herbach et al., 2007). Rodents feature the capability of extensive !-cell 
regeneration. In comparison to humans and pigs, where !-cell replication plays a 
minor role, !-cell content in the rodent pancreas is much more dynamically 
regulated and on demand through proliferation, neogenesis and apoptosis 
V. Discussion    157 
 
(Bonner-Weir, 2000; Bonner-Weir et al., 1983; Butler et al., 2003; Chick and 
Like, 1970; Finegood et al., 1995; Menge et al., 2008; Tyrberg et al., 2001). 
Nevertheless a decrease in !-cell mass by 50% was stated to effectually decrease 
insulin supply accompanied by impaired glucose tolerance and even overt 
hyperglycemia in pigs and in humans (Butler et al., 2003; Kendall et al., 1990; 
Kjems et al., 2001; Kloppel et al., 1985; Renner et al., 2010). Several in vivo and 
in vitro studies certificated a pro-apoptotic effect of long-standing hyperglycemia 
on pancreatic !-cells devoid of compensatory !-cell proliferation and neogenesis. 
Vice versa successive diminishment of residual !-cell exert detrimental impact on 
glycemic control (Donath and Halban, 2004; Kaiser et al., 2003). Although 
feasible stereological data of the human pancreas are rare due to restricted 
availability of adequate human pancreatic tissue from postmortem examinations, 
there is a clear agreement, that overt hyperglycemia in humans suffering from 
type 2 diabetes mellitus is attended or rather initiated by a reduced percentage of 
functional !-cells compared to non-diabetic controls aggravating with increasing 
body mass index (Butler et al., 2003; Cnop et al., 2005; Kloppel et al., 1985; 
Yoon et al., 2003). Furthermore viability of isolated islets from human donors 
impinged upon high glucose dosage, mimicking diabetic conditions and a 
considerable higher fraction of apoptotic cells was detected compared to culture 
conditions at a normal glucose concentration (Federici et al., 2001; Maedler et al., 
2008). In addition high glucose-induced oxidative stress was found to be 
deleteriously effective on !-cell survival and could therefore account for !-cell 
apoptosis in severe diabetic INSC94Y transgenic pigs (Ihara et al., 1999; Kaiser et 
al., 2003; Laybutt et al., 2002). Perpetual ER stress is very likely to represent 
another determinant of significantly reduced total !-cell volume in the pancreas of 
INSC94Y transgenic pigs. As described above, hydrophobic mutant proinsulin is 
presumably prone to accumulate within the ER of INSC94Y transgenic pigs and 
may provoke chronic ER-stress through activation of the unfolded protein 
response ultimately triggering progressive !-cell demise via programmed cell 
death.  
Furthermore 4.5-month-old INSC94Y transgenic pigs and corresponding age-related 
non-transgenic control pigs underwent a single immunohistochemical staining 
detecting glucagon-positive "-cells. Histological pancreas sections were evaluated 
for presence of a compensatory increase in the percentage of glucagon-producing 
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"-cells. As underlined by the qualitative histological appearance, the total "-cell 
volume in relation to body weight (V("-cell, Pan)/BW) revealed a twofold but not yet 
significant increase in INSC94Y transgenic pigs compared to age-matched non-
transgenic controls, indicating a visible trend of compensatory enlargement of 
functional "-cell volume fraction in the transgenic pigs. The total "-cell volume 
(V("-cell, Pan)) in the pancreas of 4.5-month-old INSC94Y transgenic pigs was almost 
unaltered compared to corresponding wild-type controls explainable by the 
significantly reduced body weight and the correspondingly decreased absolute 
pancreas weights in the transgenic pigs. Pancreata of human donors diagnosed 
with type 2 diabetes mellitus in their lifetime, correspondingly revealed a twofold 
increase in the relative "-cell volume (Yoon et al., 2003). An almost threefold 
increased proportion of glucagon-positive area was found in the islets of 
heterozygous Akita Ins2C96Y mutant mice compared to sex-matched wild-type 
controls in fact one day postpartum onwards (Kayo and Koizumi, 1998). In islets 
of untreated male heterozygous Munich Ins2C95S mutant mice the total volume of 
non-!-cells was notably increased compared to related wild-type mice (Kautz, 
2011). On equal term with the extensive !-cell replication in response to 
hyperglycemia, the higher percentage increase of the functional "-cell fraction in 
diabetic rodents is likewise ascribed to the generally higher regeneration potency 
in rodents (Butler et al., 2003; Menge et al., 2008). Indeed, the increase in the 
total volume of non-!-cells in untreated male heterozygous Munich 
Ins2C95S mutant mice was chiefly represented through expansion of the total "-cell 
volume (Herbach et al., 2007). Therefore stereological investigations on "-cell 
turnover in response to progressive !-cell demise in humans and in diabetic 
Ins2 mutant mice accredited that "-cell expansion is a regularly observed 
phenomenon following dramatic !-cell loss in humans and in mice, presumably 
contributing to paradoxically glucose-decoupled hyperglucagonemia in diabetic 
subjects (Herbach et al., 2007; Kautz, 2011; Kayo and Koizumi, 1998; Rahier et 
al., 1983; Yoon et al., 2003). As already mentioned, chronic exposure to high 
glucose concentrations is implicated in the transcriptional downregulation and 
disturbed biological activity of pancreatic and duodenal homeodomain 
transcription factor 1 (PDX-1) (Harmon et al., 1999; Sharma et al., 1995). 
Reduced Pdx-1 mRNA levels were shown to increase the volume density of 
glucagon-positive cells in transgenic mice (Harmon et al., 1999; Lottmann et al., 
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2001; Sharma et al., 1995). Furthermore, in vitro studies using eagerly 
differentiating rat insulinoma INSr! cells affirmed the assumption that 
suppression of Pdx-1 expression leads to the development of an "-cell-specific 
phenotype in a previously insulin producing !-cell lineage, indicated by increased 
glucagon mRNA levels and attenuation of Ins gene transcription. Opposed results 
were achieved by Pdx-1 overexpression in these cells facilitating insulin 
biosynthesis and maturation of insulin granules (Wang et al., 2001). On these 
grounds, slightly increased total "-cell volume in relation to body weight (V("-cell, 
Pan)/BW) and the trend of increased fasting plasma glucagon levels in 4.5-month-
old INSC94Y transgenic pigs compared to age-matched non-transgenic controls 
might be based on a moderate, incremental shift of progenitor cells towards "-cell 
differentiation triggered by chronic hyperglycemia present in these pigs. Further 
investigations are needed on this complex issue. 
3.2. Altered ultrastructural architecture of pancreatic !-cells in 
INSC94Y transgenic pigs 
To evidence pathological impact of INSC94Y transgene expression on the 
ultrastructural architecture of pancreatic !-cells, pancreatic tissue of 8-day-old and 
4.5-month-old INSC94Y transgenic pigs was subjected to transmission electron 
microscopy. Despite quantitative stereological evaluation on 
immunohistochemically stained pancreatic sections of pancreatic tissue of 8-day-
old INSC94Y transgenic pigs revealed an unaltered volume density of insulin-
positive cells (Vv(!-cell/Pan)), an unaltered total volume of insulin-positive cells (V(!-
cell, Pan)) and a similar staining intensity of insulin-positive cells in comparison to 
age-related wild-type pigs, ultrastructural correlates of !-cell disturbance were 
already evident. At the age of 8 days, the number of insulin secretory granules 
appeared to be moderately decreased compared to age-matched controls but 
granules were still present in a considerable quantity suggesting still satisfactory 
but successively abating trafficking of proinsulin molecules and maturation of 
insulin secretory granules. This is also in line with the unaltered randomly fed 
basal plasma insulin levels compared to related non-transgenic controls at this 
age. Hyperglycemia in 8-day-old INSC94Y transgenic pigs might therefore arise 
from disturbed glucose-induced insulin secretion. However, dilation of the 
endoplasmic reticulum was already present in 8-day-old INSC94Y transgenic pigs 
indicating early disturbance of endoplasmic reticulum integrity and already 
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initiated impairment of the secretory pathway of pancreatic !-cells at this early 
stage. In accordance, sex-matched heterozygous Akita Ins2C96Y mutant mice 
showed relevant structural alterations of pancreatic !-cells on the electron 
microscopic level including remarkable enlargement of the endoplasmic reticulum 
and partial degranulation, whereas stereologically determined insulin-positive and 
relative islet area were initially unaltered compared to corresponding control mice 
(Kayo and Koizumi, 1998; Liu et al., 2010). In 4.5-month-old INSC94Y transgenic 
pigs ultrastructural changes of the !-cell architecture were more pronounced. The 
highly reduced number of insulin secretory granules in the cytoplasm of 
pancreatic !-cells in 4.5-month-old INSC94Y transgenic pigs is likely responsible 
for the weaker staining intensity of insulin-positive cells on 
immunhistochemically stained pancreas sections of respective pigs. Pancreatic !-
cells of heterozygous Munich Ins2C95S mutant mice were correspondingly almost 
devoid of insulin secretory granules or contained few remaining secretory 
granules of altered size and organization (Herbach et al., 2007; Kautz, 2011). 
Diminished density of insulin secretory granules was also stated for heterozygous 
Akita Ins2C96Y mutant mice (Wang et al., 1999; Zuber et al., 2004). Additionally, 
the transcripts of E3 ubiquitin-protein ligase 3-hydroxy-3-methylglutaryl-
coenzyme (HMG-coA) reductase degradation 1 (Hrd1), an orthologue of yeast 
Hrd1p imperatively involved in ER-stress associated degradation (ERAD) of 
misfolded proteins, was found to be upregulated in pancreatic islets of 
heterozygous Akita Ins2C96Y mutant mice likely contributing to protective 
degradation of misfolded mutant proinsulin 2 of Akita mice in an endeavour to 
decrease the load on the ER (Allen et al., 2004; Kaneko et al., 2002; Kikkert et al., 
2004; Nadav et al., 2003). For that reason mutant proinsulin could likewise be 
partially degraded in pancreatic !-cells of INSC94Y transgenic pigs and not be 
efficiently delivered to secretory granules. This might also account for reduced 
density of secretory granules in !-cells of INSC94Y transgenic pigs. Indeed, the 
previously quoted hypothesis of decreased insulin content within the !-cells of 
4.5-month-old INSC94Y transgenic pigs based upon disturbed insulin biosynthesis 
is supported by relevant morphological alteration. Conspicuous distension of the 
rough endoplasmic reticulum, characterized by vacuole-like appearance, was 
incessantly observed in !-cells of heterozygous Akita Ins2C96Y mutant mice as 
well as in heterozygous Munich Ins2C95S mutant mice, progressing with increasing 
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age and was associated with drastic impairment of the secretory pathway in these 
Ins2 mutant mice (Herbach et al., 2007; Izumi et al., 2003; Kautz, 2011; Wang et 
al., 1999; Zuber et al., 2004). Further, accumulated proinsulin 2 was de facto 
identified in the lumen of the ER by immunogold-labeling of pancreatic !-cells of 
Akita mice (Wang et al., 1999; Zuber et al., 2004). Endoplasmic reticulum of 4.5-
month-old INSC94Ytransgenic pigs appeared to be seriously enlarged. Numerous 
cross-sectional profiles of the ER appeared to completely fill the cytoplasm of 
pancreatic !-cells of 4.5-month-old INSC94Ytransgenic pigs superseding insulin 
secretory granules in representative age-related wild-type control pigs. The 
suspicion of severe ER dysfunction based upon ER stress triggered by mutant 
C94Y proinsulin entrapped in the early secretory compartment of pancreatic !-
cells in INSC94Y transgenic pigs seems to be substantiated.  
3.3. Diabetes-associated secondary alterations in INSC94Y transgenic pigs 
Histology, quantitative stereological methods and functional analyzes were 
applied in order to evaluate longstanding complications of mutant INSC94Y gene-
induced diabetes mellitus on diverse organs of INSC94Y transgenic pigs. As a result 
of stagnant growth indicating detrimental influence of INSC94Y transgene 
expression on weight gain, absolute weights of most organs were proportionately 
decreased in untreated INSC94Y transgenic pigs at the age of 4.5 months in 
comparison to age-matched non-transgenic control pigs. Thus, relative organ 
weights (% of body weight) with a few exceptions were almost unaltered 
compared to corresponding controls. By way of an exception, the relative liver 
weights of untreated 4.5-month-old INSC94Y transgenic pigs were significantly 
higher than those of age-related non-transgenic pigs. Hepatomegaly is a well-
known complication in poorly controlled juvenile-onset human diabetics (Chatila 
and West, 1996; Sayuk et al., 2007; Torres and Lopez, 2001). Chronically 
elevated blood glucose levels gradually cause hepatocellular glycogen deposition 
as a result of insulin-independent hepatocellular entry of glucose, whereby hepatic 
glycogen production and storage is stimulated despite insulin-deficiency 
(Carcione et al., 2003; Evans et al., 1955; Torbenson et al., 2006; Torres and 
Lopez, 2001). Further complicating matters, glycogenolysis is decelerated by high 
blood glucose levels further raising hepatocellular glycogen levels and distending 
hepatocytes (Chatila and West, 1996; Sayuk et al., 2007; Stone and Van Thiel, 
1985). Hepatic steatosis as a cause of hepatomegaly in humans with diabetes 
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mellitus is mainly ascribed to obese patients diagnosed with type 2 diabetes 
mellitus accompanied by peripheral insulin resistance and hypertriglyceridaemia 
(Clark and Diehl, 2002; Toledo et al., 2006). As hepatic steatosis is rare with type 
1 diabetics of normal weight, hepatic glycogenosis is more likely to contribute to 
the modest hepatomegaly observed in non-obese 4.5-month-old 
INSC94Y transgenic pigs (Torbenson et al., 2006). Accomplishment of glycogen 
staining detecting glycogen deposits in liver tissue might offer valuable clues 
about the origin of elevated liver weights in INSC94Y transgenic pigs in comparison 
to related controls.  
Whereas absolute weights of most organs revealed an at least 30% reduction 
compared to age-matched non-transgenic controls, cumulative absolute kidney 
weights in 4.5-month-old INSC94Y transgenic pigs were diminished by only 15% as 
a notable exception. In consequence, cumulative kidney weights as percent of 
body weight were significantly increased in 4.5-month-old INSC94Y transgenic pigs 
compared to non-transgenic littermate controls. Moreover, planimetric 
measurements of the mean glomerular profile areas on kidney tissue of 4.5-
month-old INSC94Y transgenic pigs and age-matched non-transgenic controls 
evinced a significant increase of the mean glomerular volume to body weight ratio 
(V(glom)/BW) by 30% on the average. Renal and glomerular hypertrophy was also 
found in humans diagnosed with diabetes mellitus as an early pathological 
indicator of diabetic kidney disease (Cortes et al., 1987; Mahimainathan et al., 
2006; Mogensen et al., 1983; Osterby and Gundersen, 1975; Seyer-Hansen et al., 
1980). In correspondence, heterozygous male Munich Ins2C95S mutant mice 
revealed elevated kidney weights in comparison to associated wild-type controls 
as well as insulin-treated mutants. Diabetes-associated pathological alterations of 
the kidney have not been investigated in the Munich Ins2C95S mouse model so far 
(Kautz, 2011). Transgenic mice expressing a dominant-negative glucose-
dependent insulintropic polypeptide receptor (GIPRdn) demonstrated significantly 
increased kidney weights progressing with increasing age in comparison to age- 
and sex-matched control mice. Diabetic GIPRdn transgenic females were 
diagnosed with renal hypertrophy at 8 weeks of age, followed by detection of 
pronounced glomerular alterations at 20 weeks of age. Therefore early phase of 
diabetic kidney disease is recapitulated in this model (Herbach et al., 2009). 
Whereas GIPRdn transgenic mice developed pronounced changes in the 
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tubulointerstitial and glomerular architecture accompanied by remarkable 
albuminuria through podocyte abnormalities directly linked to high glucose level-
induced damage of renal tissue (Herbach et al., 2009), histopathological 
examination of renal tissue from 4.5-month-old INSC94Y transgenic pigs did not 
provide evidence for diabetes-associated kidney disease. Furthermore glomerular 
cross section profiles of INSC94Y transgenic pigs did not indicate evidence for 
podocyte injury. Consequently it was not surprising that INSC94Y transgenic pigs 
did not show albuminuria at any time point investigated. Although renal and 
glomerular hypertrophy was regularly observed in heterozygous 
Akita Ins2C96Y mutant mice, pathological alterations were rarely detectable and 
mild (Gurley et al., 2006; Gurley et al., 2010). A thickening of the glomerular 
basement membrane reliably indicates early-stage diabetes-associated renal 
disease in mice (Herbach et al., 2009). However, transmission electron microsopy 
of peripheral glomerular capaillary loops detected an unaltered true harmonic 
mean thickness of the glomerular basement membrane in INSC94Y transgenic pigs 
compared to respective non-transgenic control pigs at the age of 4.5 months. In 
human diabetes patients, thickening of the glomerular basement membrane 
necessitates years of progression until morphological alterations become 
detectable and even more until diabetes-induced nephropathy becomes clinically 
relevant. Moreover, the course of the disease can be decelerated by adequate 
insulin treatment (Mason and Wahab, 2003; Mogensen et al., 1983; Pagtalunan et 
al., 1997; Wolf, 2004). Therefore, it is not surprising that INSC94Y transgenic pigs 
did not demonstrate morphological alterations diagnostic for diabetic nephropathy 
within the observation period. Studies on Munich-Wistar rats with streptozotocin-
induced diabetes mellitus and non-diabetic control rats have shown that chronic 
hyperglycemia was solely not enough to induce and advance glomerular kidney 
injury (Zatz et al., 1985). Therefore complicating factors including high-protein 
diet or elevated blood pressure might be able to initiate and expedite diabetic 
kidney lesions in INSC94Y transgenic pigs.  
Periperal sensorimotor and autonomic polyneuropathy, mainly affecting 
myelinated nerve fibers, are well-known complications of sustained uncontrolled 
diabetes mellitus in humans (Mizisin et al., 2007). However, histology on 
semithin section as well as single fiber teasing of tibial nerve fascicles of INSC94Y 
transgenic pigs and non-transgenic control pigs revealed homogenous, 
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physiological myelinization unsuggestive of axonal degeneration. Accordingly, 
histological examinations on transverse sections of sciatic nerve fascicles of 
diabetic male heterozygous Akita Ins2C96Y mutant mice and non-diabetic control 
mice likewise did not show any indications for diabetes-induced nerve pathology 
(Yaguchi et al., 2003). In humans, emergence of diabetes-induced peripheral 
polyneuropathy is directly linked to the duration of chronic hyperglycemia 
(Tesfaye et al., 2005). Thus, development of chronic diabetic sensorimotor 
polyneuropathy in INSC94Y transgenic pigs is presumably highly time-dependent 
and may occur with increasing age.  
Similar to human, progressive cataract of the eye lenses was regularly observed in 
INSC94Y transgenic pigs attended by vision impairment in all likelihood (Stefek and 
Karasu, 2011). Since incipient cataract was already present at 8 days of age, 
diabetic cataract formation seems to be rather a matter of the severity of 
hyperglycemia than a matter of the duration of the exposure to high blood glucose 
levels. This hypothesis was confirmed as lens opacification was reversible with 
insulin therapy and reconstitution of physiological glycemic conditions in 
INSC94Y transgenic pigs. Since excessive amounts of glucose are supplied to the 
aqueous humor in response to chronic hyperglycemia, a high percentage is 
subjected to the polyol pathway and converted to sorbitol through aldose 
reductase action. Sorbitol accumulation triggers detrimental rearrangement of 
collagen fibers by increased osmotic water consumption into the lens and 
ultimately lens opacity (Kinoshita et al., 1979; Petrash, 2004). This mechanism 
was clearly enlightened by the protective pharmaceutical impact of aldose 
reductase inhibitors on cataract formation in young rats with streptozotocin-
induced diabetes mellitus (Kador et al., 2000). In contrast, the phenomenon of 
diabetes-induced lens opacification has never been observed in diabetic mice, 
presumably related to lower aldose reductase activity in lenses of mice in 
comparison with humans and rats (Chand et al., 1982; Petrash, 2004; Varma and 
Kinoshita, 1974). However, the underlying pathogenic mechanism of diabetes-
associated cataract formation in INSC94Y transgenic pigs remains to be elucidated. 
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VI. CONCLUDING REMARKS AND PERSPECTIVES 
INSC94Y transgenic pigs exhibit a progressive diabetic phenotype characterized by 
chronically elevated randomly fed and fasting blood glucose levels as well as 
excessive growth retardation. The dominant-negative/toxic effect of 
INSC94Y transgene expression leads to early-onset hyperglycemia through a 
clinically relevant impairment of !-cells. Insufficient glucose-stimulated insulin 
secretion and impaired peripheral glucose sensing are probably the initial causes 
of disturbed glycemic control in INSC94Y transgenic pigs, preceding insulin 
deficiency gradually evolving from loss of functional !-cells. In addition, chronic 
ER stress, perpetuated by interminable entrapment of unfolded mutant proinsulin 
polypeptides, ultimately contributes to insulin deficiency in INSC94Y transgenic 
pigs at the age of 4.5 months by progressive reduction of the total volume of 
functional !-cells via programmed cell death. Accompanying peripheral insulin 
resistance, presumably mediated by long-term glucose toxicity and altered insulin 
receptor binding potency of mutant porcine C94Y insulin, seems to exert 
remarkable impact on the severity of diabetic symptoms present in 
INSC94Y transgenic pigs. Nevertheless clinical features and underlying disease 
mechanisms, intensively investigated in diabetic Ins2 mutant mice, were likewise 
demonstrated in the INSC94Y transgenic pig model and diagnostic findings of 
human permanent neonatal diabetes mellitus have been observed and validated in 
INSC94Y transgenic pigs. Interestingly, INSC94Y transgenic pigs responded highly 
satisfactorily to exogenous insulin supplementation and could be raised to sexual 
maturity allowing for conventional breeding. Considerably mimicking the human 
conditions, the INSC94Y transgenic pig model has proven eligible for interesting 
questions of translational diabetes research. The consistent diabetic phenotype and 
its rescue by insulin supplementation make the INSC94Y transgenic pig a promising 
animal model for reliable preclinical testing of novel therapeutic and regenerative 
approaches. The accurately quantified and reproducible reduction of the total 
volume of functional !-cells related to a well-defined pecularity of diabetic 
symptoms in INSC94Y transgenic pigs constitutes a standardized system for testing 
putatively preservative or proliferative effects of anti-diabetic pharmaceuticals. 
Furthermore, the INSC94Y pig is a useful animal model for the development of 
imaging techniques to monitor !-cells in vivo. Resembling human body weight 
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and size, the INSC94Y transgenic pig enables application of standard diagnostic and 
surgical techniques of human medicine. Therefore, the INSC94Y transgenic pig 
model complies with the requirements for islet transplantation studies. Thus, 
practicability of the respective surgical procedure as well as the functionality of 
inserted pancreatic islet allografts can be evaluated in a genetically engineered 
diabetic pig model exhibiting robust hyperglycemia. Consequences of maternal 
diabetes on the developing organism and long-term effects on offspring mediated 
by intrauterine programming are other interesting questions in this field. 
Important aspects of oocyte maturation, early embryonic development and 
developmental stage at birth are almost comparable between humans and pigs 
(Prather et al., 2009). Furthermore, female INSC94Y transgenic pigs are adapted to 
estrus synchronization and have already proven to be able to establish and 
maintain pregnancy. Thus, the INSC94Y transgenic pig offers the possibility to 
study developmental consequences of pre-conceptional diabetes mellitus on 
oocyte maturation, embryonic development, fetal programming as well as 
offspring metabolism and growth in an organism considerably reflecting human 
reproductive biology. 
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VII. SUMMARY 
 
Genotypic and phenotypic characterization of INSC94Y trangenic pigs –           
a novel large animal model for permanent neonatal diabetes mellitus 
 
Different mutations in the human insulin (INS) gene have been described as a 
cause of non-autoimmune permanent neonatal diabetes mellitus (PNDM). Studies 
on heterozygous Akita Ins2C96Y and Munich Ins2C95S mutant mice already clarified 
fundamental mechanisms of the disease but have limitations for translational 
research. To establish a preclinical animal model of PNDM, considerably 
mimicking the human conditions, we generated INSC94Y transgenic pigs that 
correspond to the human INSC96Y mutation and the Ins2 mutation of the Akita 
mouse model. Transgenic pigs expressing high levels of INSC94Y mRNA (70–86% 
of endogenous INS transcripts) showed significantly elevated blood glucose levels 
within 24 hours after birth and exhibited reduced growth. Furthermore fasting 
insulin levels were significantly reduced by 60% in 4.5-month-old 
INSC94Y transgenic pigs compared to littermate controls. Despite the early onset of 
hyperglycemia, total !-cell volume of 8-day-old INSC94Y transgenic pigs was 
unaltered compared to littermate controls. However quantitative-stereological 
analyzes of pancreatic tissue of 4.5-month-old INSC94Y transgenic pigs revealed a 
72% reduction of the total !-cell volume and a 53% reduction of the total !-cell 
volume related to body weight. A highly reduced number of insulin secretory 
granules and severe dilation of the endoplasmic reticulum was detected by 
electron microscopy of pancreatic !-cells. Diabetes-induced pathological 
alterations of kidney and peripheral nerves were not detected within one year but a 
remarkable cataract was regularly observed.  
In summary, we have generated the first genetically modified diabetic pig model, 
which can be propagated by conventional breeding. The consistent diabetic 
phenotype and its rescue by insulin supplementation make the INSC94Y 
 transgenic pig a promising animal model for reliable preclinical testing of novel 
therapeutic and regenerative approaches including islet transplantation. Moreover 
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the INSC94Y transgenic pig model is implementable for the characterization of 
developmental consequences of pre-conceptional maternal diabetes mellitus on 
embryos, fetuses and offspring. Therefore the INSC94Y transgenic pig is a clinically 
relevant large animal model and has proven to be useful for a plethora of research 
options for translational medicine. 
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VIII. ZUSAMMENFASSUNG 
 
Genotypische und phänotypische Charakterisierung von INSC94Y transgenen 
Schweinen – ein neues Großtiermodell für den permanent neonatalen 
Diabetes mellitus 
 
Verschiedene Mutationen des humanen Insulin-Gens (INS) wurden als Ursache 
eines nicht-autoimmun bedingten permanenten neonatalen Diabetes mellitus 
beschrieben. Durch Studien an heterozygoten Akita Ins2C96Y und Munich 
Ins2C95S Mausmutanten konnten bereits grundlegende Mechanismen der 
Erkrankung aufgeklärt werden. Diese Mausmodelle weisen allerdings gewisse 
Beschränkungen im Hinblick auf die translationale Forschung auf. Um ein 
Großtiermodell zu erstellen, das die Gegebenheiten beim Menschen sehr gut 
widerspiegelt, wurden INSC94Y transgene Schweine generiert. Das 
INSC94Y transgene Schweinemodell stellt das korrespondierende Großtiermodell 
der Ins2 Mutation der Akita Maus sowie der humanen INSC96Y Mutation dar. Bei 
INSC94Y transgenen Schweinen mit hoher INSC94Y mRNA Expression (70-86% der 
endogenen INS Transkripte) waren bereits einen Tag nach der Geburt, signifikant 
erhöhte Blutglukosewerte und nach dem Absetzen ein massiv verzögertes 
Wachstum zu beobachten. Darüber hinaus waren die gefasteten Insulinspiegel im 
Plasma 4,5 Monate alter INSC94Y transgener Schweine im Vergleich zu den 
nichttransgenen Wurfgeschwistern signifikant um 60% reduziert. Obwohl 
INSC94Y transgene Schweine im Alter von 8 Tagen bereits eine schwere 
Hyperglykämie zeigten, war das Gesamt-!-Zellvolumen im Vergleich zu 
nichttransgenen Wurfgeschwistern noch unverändert. Dahingegen zeigten 
quantitativ-stereologische Analysen des pankreatischen Gewebes 
INSC94Y transgener Schweine im Alter von 4,5 Monaten eine Reduktion des 
Gesamt-!-Zellvolumens um 72%. Die körpergewichtsbezogene Reduktion des 
Gesamt-!-Zellvolumens betrug 53%. Eine stark reduzierte Anzahl sekretorischer 
Insulingranula und eine massive Erweiterung des endoplasmatischen Retikulums 
konnte mittels Elektronenmikroskopie pankreatischer !-Zellen 4,5 Monate alter 
INSC94Y transgener Schweine gezeigt werden. Diabetes-bedingte pathologische 
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Nierenveränderungen sowie Schädigung peripherer Nerven waren im 
Untersuchungszeitraum von einem Jahr nicht feststellbar. Allerdings zeigten 
INSC94Y transgene Schweine eine regelmäßige Kataraktentwicklung. 
Zusammenfassend gesagt, haben wir das erste genetisch modifizierte diabetische 
Schweinemodell entwickelt, das unter Insulinbehandlung konventionell vermehrt 
werden kann. Der konstante diabetische Phänotyp des 
INSC94Y transgenen Schweins, der durch Insulinsupplementierung gemildert 
werden kann, zeichnet es als vielversprechendes Tiermodell für die translationale 
Diabetesforschung aus. Neue therapeutische und regenerative Ansätze, die auch 
die Transplantation pankreatischer Inseln beinhalten, können an diesem 
diabetischen Großtiermodell validiert werden. Darüber hinaus ist das 
INSC94Y transgene Schweinemodell geeignet, um entwicklungsbiologische 
Auswirkungen eines präkonzeptionellen maternalen Diabetes mellitus auf 
Embryonen, Feten und Nachkommen zu charakterisieren. Aus diesem Grund ist 
das INSC94Y transgene Schweinemodell ein klinisch relevantes Großtiermodell und 
eröffnet vielfältige Forschungsmöglichkeiten für die translationale Medizin. 
  
 
!
IX. Index of figures    171 
 
IX. INDEX OF FIGURES 
Figure 1:  The unfolded protein response (UPR) pathway ...................................21 
Figure 2:  Schematic illustration of effective INSC94Y transgenesis in the pig by 
somatic cell nuclear transfer ...............................................................63 
Figure 3:  Placement of a continuous glucose monitoring system in a pig ..........77 
Figure 4:  Preparation of the pancreas for quantitative-stereological analyzes ....80 
Figure 5:  Schematic illustration of orthograde vascular kidney perfusion in the 
pig .......................................................................................................89 
Figure 6:  INSC94Y construct and alignment of porcine insulin polypeptide..........99 
Figure 7:  Fasting blood glucose concentrations of INSC94Y transgenic founder  
boars ..................................................................................................101 
Figure 8:  Intravenous glucose tolerance of INSC94Y transgenic founder boars ..102 
Figure 9:  Identification of INSC94Y transgenic pigs and non-transgenic littermates 
by PCR analysis ................................................................................104 
Figure 10: Southern blot analysis of INSC94Y transgenic founder boars and INSC94Y 
transgenic offspring (F2-generation) ................................................105 
Figure 11: Expression analysis on RNA level from pancreatic tissue of INSC94Y 
transgenic founder boars and transgenic F1-offspring......................107 
Figure 12: Growth retardation in INSC94Y transgenic pigs ..................................109 
Figure 13: Blood glucose control in INSC94Y transgenic and wild-type pigs ......110 
Figure 14: Continuous 42-hour glucose monitoring profile of an INSC94Y 
transgenic pig under insulin treatment and an untreated wild-type 
littermate ...........................................................................................112 
Figure 15: Basal and fasting insulin levels of 8-day-old and 4.5-month-old 
INSC94Y transgenic and age-matched wild-type littermates ...............113 
Figure 16: Homeostasis model assessment of baseline insulin secretion (HOMA-
B) and of insulin resistance (HOMA-IR) of INSC94Y transgenic pigs114 
Figure 17: Basal and fasting glucagon levels of 8-day-old and 4.5-month-old 
INSC94Y transgenic pigs and wild-type littermates.............................115 
Figure 18: Absolute pancreas weights of INSC94Y transgenic and wild-type 
littermates..........................................................................................116 
 
 
IX. Index of figures    172 
 
Figure 19: Representative histological sections of pancreatic tissue of an 8-day-
old and a 4.5-month-old INSC94Y transgenic pig and age-matched 
controls..............................................................................................118 
Figure 20: Quantitative stereological analyzes of islet parameters of 8-day-old 
and 4.5-month-old INSC94Y transgenic and wild-type littermates .....120 
Figure 21: The total !-cell volume in relation to body in 4.5-month-old INSC94Y 
transgenic pigs and non-transgenic littermates .................................121 
Figure 22: Immunohistochemical staining for glucagon containing cells in 4.5-
month-old INSC94Y transgenic pigs and non-transgenic littermates ..122 
Figure 23: Quantitative stereological analyzes of the total "-cell volume in 4.5-
month-old INSC94Y transgenic pigs and non-transgenic littermates ..123 
Figure 24: Representative transmission electron micrographs of pancreatic !-cell 
profiles of 8-day-old and 4.5-month-old INSC94Y transgenic pigs and 
age-matched wild-type pigs ..............................................................124 
Figure 25: Absolute and relative kidney weights of 4.5-month-old INSC94Y 
transgenic and non-transgenic littermates.........................................127 
Figure 26: Representative histological sections of renal tissue of a 4.5-month-old 
INSC94Y transgenic pig and a non-transgenic littermate.....................129 
Figure 27: Mean glomerular volume to body weight ratio (V(glom)/BW 
(mm3/kg)x10-3) in 4.5-month-old INSC94Y transgenic and littermate 
control pigs........................................................................................130 
Figure 28: Thickness of the glomerular basement membrane (GBM) in 4.5-
month-old INSC94Y transgenic pigs and littermate controls ...............131 
Figure 29: SDS-PAGE urine protein analyzes of INSC94Y transgenic pigs and age-
matched wild-type pigs .....................................................................133 
Figure 30: Representative histological sections of a tibial nerve fascicle of a 4.5-
month-old INSC94Y transgenic pig and a non-transgenic littermate...135 
Figure 31: Single fiber teasing of a tibial nerve fascicle of a 4.5-month-old 
INSC94Y transgenic pig and a non-transgenic littermate ....................136 
Figure 32: Progressive cataract in INSC94Y transgenic pigs.................................137 
Figure 33: Progressive diabetic cataract in INSC94Y transgenic pigs and wild-type 
littermates..........................................................................................138 
Figure 34: Optical density of CHOP/!-actin in isolated islets of a neonatal 
INSC94Y transgenic pig and a non-transgenic littermate ....................140 
 
IX. Index of figures    173 
 
Figure 35: Optical density of PeIF2"/!-actin in isolated islets of a neonatal 
INSC94Y transgenic pig and a non-transgenic littermate.....................141 
Figure 36: Optical density of GRP78/!-actin in isolated islets of a neonatal 
INSC94Y transgenic pig and a non-transgenic littermate ....................142!
!
X. Index of tables    174 
 
X. INDEX OF TABLES  
Table 1:  Diet composition....................................................................................38 
Table 2:  Reaction batch for neoPf/neoSr PCR ....................................................65 
Table 3:  Reaction batch for the amplification of ACTB ......................................65 
Table 4:  Protocol neoPf/neoSr PCR ....................................................................65 
Table 5:  Protocol ACTB PCR ..............................................................................66 
Table 6:  Reaction batch for amplification of INS cDNAs ...................................73 
Table 7:  PCR protocol .........................................................................................73 
Table 8:  Immunhistochemical procedures ...........................................................82 
Table 9:  Composition of SDS polyacrylamide separating gel (12%, for 4 gels).86 
Table 10: Composition of SDS polyacrylamide stacking gel (5%, for 4 gels).....86 
Table 11: Protocol for HE staining .......................................................................90 
Table 12: Protocol for PAS staining .....................................................................90 
Table 13: Reagents for Western immunoblot analyzes ........................................98 
Table 14: Results of nuclear transfer experiments using INSC94Y transfected 
nuclear donor cells ..............................................................................100 
Table 15: Inheritance of the INSC94Y transgene ...................................................103 
Table 16: Absolute and relative organ weights of 8-day-old INSC94Y transgenic 
pigs and wild-type littermates......................................................................126 
Table 17: Absolute and relative organ weights of 4.5-month-old INSC94Y 
transgenic pigs and wild-type controls ........................................................126!
XI. Reference list    175 
 
XI. REFERENCE LIST 
Abdul-Ghani, M., and DeFronzo, R. A. (2007). Fasting hyperglycemia impairs 
glucose- but not insulin-mediated suppression of glucagon secretion. J 
Clin Endocrinol Metab 92, 1778-84. 
ADA (2008). Economic costs of diabetes in the U.S. in 2007 - American Diabetes 
Association. Diabetes Care 31, 596-615. 
ADA (2013). Diagnosis and classification of diabetes mellitus - American 
Diabetes Association (ADA). Diabetes Care 36 Suppl 1, S67-74. 
Adesnik, M., Lande, M., Martin, T., and Sabatini, D. D. (1976). Retention of 
mRNA on the endoplasmic reticulum membranes after in vivo 
disassembly of polysomes by an inhibitor of initiation. J Cell Biol 71, 307-
13. 
Aguilar-Bryan, L., and Bryan, J. (2008). Neonatal diabetes mellitus. Endocr Rev 
29, 265-91. 
Aigner, B., Rathkolb, B., Herbach, N., Hrabe de Angelis, M., Wanke, R., and 
Wolf, E. (2008). Diabetes models by screen for hyperglycemia in 
phenotype-driven ENU mouse mutagenesis projects. Am J Physiol 
Endocrinol Metab 294, E232-40. 
Aigner, B., Renner, S., Kessler, B., Klymiuk, N., Kurome, M., Wunsch, A., and 
Wolf, E. (2010). Transgenic pigs as models for translational biomedical 
research. J Mol Med 88, 653-64. 
Alberti, K. G., and Zimmet, P. Z. (1998). Definition, diagnosis and classification 
of diabetes mellitus and its complications. Part 1: diagnosis and 
classification of diabetes mellitus provisional report of a WHO 
consultation. Diabet Med 15, 539-53. 
Allen, J. R., Nguyen, L. X., Sargent, K. E., Lipson, K. L., Hackett, A., and Urano, 
F. (2004). High ER stress in beta-cells stimulates intracellular degradation 
of misfolded insulin. Biochem Biophys Res Commun 324, 166-70. 
Araki, E., Oyadomari, S., and Mori, M. (2003). Impact of endoplasmic reticulum 
stress pathway on pancreatic beta-cells and diabetes mellitus. Exp Biol 
Med (Maywood) 228, 1213-7. 
Arima, T., Drewell, R. A., Arney, K. L., Inoue, J., Makita, Y., Hata, A., 
Oshimura, M., Wake, N., and Surani, M. A. (2001). A conserved 
imprinting control region at the HYMAI/ZAC domain is implicated in 
transient neonatal diabetes mellitus. Hum Mol Genet 10, 1475-83. 
Arima, T., Drewell, R. A., Oshimura, M., Wake, N., and Surani, M. A. (2000). A 
novel imprinted gene, HYMAI, is located within an imprinted domain on 
human chromosome 6 containing ZAC. Genomics 67, 248-55. 
Aspinwall, C. A., Lakey, J. R., and Kennedy, R. T. (1999). Insulin-stimulated 
insulin secretion in single pancreatic beta cells. J Biol Chem 274, 6360-5. 
Babenko, A. P., Polak, M., Cave, H., Busiah, K., Czernichow, P., Scharfmann, R., 
Bryan, J., Aguilar-Bryan, L., Vaxillaire, M., and Froguel, P. (2006). 
Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N 
Engl J Med 355, 456-66. 
Bach, J. F. (1994). Insulin-dependent diabetes mellitus as an autoimmune disease. 
Endocr Rev 15, 516-42. 
Bahr, A., and Wolf, E. (2012). Domestic animal models for biomedical research. 
Reprod Domest Anim 47 Suppl 4, 59-71. 
 
XI. Reference list    176 
 
Baker, E. N., Blundell, T. L., Cutfield, J. F., Cutfield, S. M., Dodson, E. J., 
Dodson, G. G., Hodgkin, D. M., Hubbard, R. E., Isaacs, N. W., Reynolds, 
C. D., and et al. (1988). The structure of 2Zn pig insulin crystals at 1.5 A 
resolution. Philos Trans R Soc Lond B Biol Sci 319, 369-456. 
Benech-Kieffer, F., Wegrich, P., Schwarzenbach, R., Klecak, G., Weber, T., 
Leclaire, J., and Schaefer, H. (2000). Percutaneous absorption of 
sunscreens in vitro: interspecies comparison, skin models and 
reproducibility aspects. Skin Pharmacol Appl Skin Physiol 13, 324-35. 
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., 
Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F., and Ochs, H. 
D. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 
27, 20-1. 
Bennett, R. A., and Pegg, A. E. (1981). Alkylation of DNA in rat tissues 
following administration of streptozotocin. Cancer Res 41, 2786-90. 
Bereket, A., Lang, C. H., Blethen, S. L., Gelato, M. C., Fan, J., Frost, R. A., and 
Wilson, T. A. (1995). Effect of insulin on the insulin-like growth factor 
system in children with new-onset insulin-dependent diabetes mellitus. J 
Clin Endocrinol Metab 80, 1312-7. 
Bereket, A., Lang, C. H., and Wilson, T. A. (1999). Alterations in the growth 
hormone-insulin-like growth factor axis in insulin dependent diabetes 
mellitus. Horm Metab Res 31, 172-81. 
Bernales, S., Papa, F. R., and Walter, P. (2006). Intracellular signaling by the 
unfolded protein response. Annu Rev Cell Dev Biol 22, 487-508. 
Bertolotti, A., Zhang, Y., Hendershot, L. M., Harding, H. P., and Ron, D. (2000). 
Dynamic interaction of BiP and ER stress transducers in the unfolded-
protein response. Nat Cell Biol 2, 326-32. 
Besenfelder, U., Modl, J., Muller, M., and Brem, G. (1997). Endoscopic embryo 
collection and embryo transfer into the oviduct and the uterus of pigs. 
Theriogenology 47, 1051-60. 
Besnard, A., Galan-Rodriguez, B., Vanhoutte, P., and Caboche, J. (2011). Elk-1 a 
transcription factor with multiple facets in the brain. Front Neurosci 5, 35. 
Betsholtz, C., Svensson, V., Rorsman, F., Engstrom, U., Westermark, G. T., 
Wilander, E., Johnson, K., and Westermark, P. (1989). Islet amyloid 
polypeptide (IAPP):cDNA cloning and identification of an amyloidogenic 
region associated with the species-specific occurrence of age-related 
diabetes mellitus. Exp Cell Res 183, 484-93. 
Blundell, T. L., Cutfield, J. F., Cutfield, S. M., Dodson, E. J., Dodson, G. G., 
Hodgkin, D. C., and Mercola, D. A. (1972). Three-dimensional atomic 
structure of insulin and its relationship to activity. Diabetes 21, 492-505. 
Bogardus, C., Lillioja, S., Mott, D. M., Hollenbeck, C., and Reaven, G. (1985). 
Relationship between degree of obesity and in vivo insulin action in man. 
Am J Physiol 248, E286-91. 
Bogoyevitch, M. A., and Kobe, B. (2006). Uses for JNK: the many and varied 
substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 70, 
1061-95. 
Bogue, M. (2003). Mouse Phenome Project: understanding human biology 
through mouse genetics and genomics. J Appl Physiol 95, 1335-7. 
Bonfanti, R., Colombo, C., Nocerino, V., Massa, O., Lampasona, V., Iafusco, D., 
Viscardi, M., Chiumello, G., Meschi, F., and Barbetti, F. (2009). Insulin 
gene mutations as cause of diabetes in children negative for five type 1 
diabetes autoantibodies. Diabetes Care 32, 123-5. 
XI. Reference list    177 
 
Bonner-Weir, S. (2000). Islet growth and development in the adult. J Mol 
Endocrinol 24, 297-302. 
Bonner-Weir, S., Trent, D. F., and Weir, G. C. (1983). Partial pancreatectomy in 
the rat and subsequent defect in glucose-induced insulin release. J Clin 
Invest 71, 1544-53. 
Borelli, M. I., Francini, F., and Gagliardino, J. J. (2004). Autocrine regulation of 
glucose metabolism in pancreatic islets. Am J Physiol Endocrinol Metab 
286, E111-5. 
Brandhorst, D., Brandhorst, H., Hering, B. J., Federlin, K., and Bretzel, R. G. 
(1995). Islet isolation from the pancreas of large mammals and humans: 10 
years of experience. Exp Clin Endocrinol Diabetes 103 Suppl 2, 3-14. 
Bromberg, J. S., and LeRoith, D. (2006). Diabetes cure--is the glass half full? N 
Engl J Med 355, 1372-4. 
Broughton, D. L., and Taylor, R. (1991). Review: deterioration of glucose 
tolerance with age: the role of insulin resistance. Age Ageing 20, 221-5. 
Brown, M. S., Ye, J., Rawson, R. B., and Goldstein, J. L. (2000). Regulated 
intramembrane proteolysis: a control mechanism conserved from bacteria 
to humans. Cell 100, 391-8. 
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., and Butler, P. 
C. (2003). Beta-cell deficit and increased beta-cell apoptosis in humans 
with type 2 diabetes. Diabetes 52, 102-10. 
Byrne, M. M., Sturis, J., Menzel, S., Yamagata, K., Fajans, S. S., Dronsfield, M. 
J., Bain, S. C., Hattersley, A. T., Velho, G., Froguel, P., Bell, G. I., and 
Polonsky, K. S. (1996). Altered insulin secretory responses to glucose in 
diabetic and nondiabetic subjects with mutations in the diabetes 
susceptibility gene MODY3 on chromosome 12. Diabetes 45, 1503-10. 
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P. O., and 
Caicedo, A. (2006). The unique cytoarchitecture of human pancreatic 
islets has implications for islet cell function. Proc Natl Acad Sci U S A 
103, 2334-9. 
Calfon, M., Zeng, H., Urano, F., Till, J. H., Hubbard, S. R., Harding, H. P., Clark, 
S. G., and Ron, D. (2002). IRE1 couples endoplasmic reticulum load to 
secretory capacity by processing the XBP-1 mRNA. Nature 415, 92-6. 
Canavan, J. P., Flecknell, P. A., New, J. P., Alberti, K. G., and Home, P. D. 
(1997). The effect of portal and peripheral insulin delivery on 
carbohydrate and lipid metabolism in a miniature pig model of human 
IDDM. Diabetologia 40, 1125-34. 
Carcione, L., Lombardo, F., Messina, M. F., Rosano, M., and De Luca, F. (2003). 
Liver glycogenosis as early manifestation in type 1 diabetes mellitus. 
Diabetes Nutr Metab 16, 182-4. 
Carroll, R. J., Hammer, R. E., Chan, S. J., Swift, H. H., Rubenstein, A. H., and 
Steiner, D. F. (1988). A mutant human proinsulin is secreted from islets of 
Langerhans in increased amounts via an unregulated pathway. Proc Natl 
Acad Sci U S A 85, 8943-7. 
Cave, H., Polak, M., Drunat, S., Denamur, E., and Czernichow, P. (2000). 
Refinement of the 6q chromosomal region implicated in transient neonatal 
diabetes. Diabetes 49, 108-13. 
Chaib, E., Galvao, F. H., Rocha-Filho, J. A., Silveira, B. L., Chen, L., de, C. C. M. 
P., Pariz, C. E., de Almeida, F. S., Waisberg, D. R., de Souza, Y. E., 
Machado, M. C., and D'Albuquerque, L. A. (2011). Total pancreatectomy: 
porcine model for inducing diabetes - anatomical assessment and surgical 
aspects. Eur Surg Res 46, 52-5. 
XI. Reference list    178 
 
Chan, S. J., Seino, S., Gruppuso, P. A., Schwartz, R., and Steiner, D. F. (1987). A 
mutation in the B chain coding region is associated with impaired 
proinsulin conversion in a family with hyperproinsulinemia. Proc Natl 
Acad Sci U S A 84, 2194-7. 
Chand, D., El-Aguizy, H. K., Richards, R. D., and Varma, S. D. (1982). Sugar 
cataracts in vitro: implications of oxidative stress and aldose reductase I. 
Exp Eye Res 35, 491-7. 
Chang, S. G., Choi, K. D., Jang, S. H., and Shin, H. C. (2003). Role of disulfide 
bonds in the structure and activity of human insulin. Mol Cells 16, 323-30. 
Chatila, R., and West, A. B. (1996). Hepatomegaly and abnormal liver tests due to 
glycogenosis in adults with diabetes. Medicine (Baltimore) 75, 327-33. 
Chen, X., Shen, J., and Prywes, R. (2002). The luminal domain of ATF6 senses 
endoplasmic reticulum (ER) stress and causes translocation of ATF6 from 
the ER to the Golgi. J Biol Chem 277, 13045-52. 
Chick, W. L., and Like, A. A. (1970). Studies in the diabetic mutant mouse. 3. 
Physiological factors associated with alterations in beta cell proliferation. 
Diabetologia 6, 243-51. 
Clark, A., Charge, S. B., Badman, M. K., and de Koning, E. J. (1996). Islet 
amyloid in type 2 (non-insulin-dependent) diabetes. APMIS 104, 12-8. 
Clark, A. J., Bissinger, P., Bullock, D. W., Damak, S., Wallace, R., Whitelaw, C. 
B., and Yull, F. (1994). Chromosomal position effects and the modulation 
of transgene expression. Reprod Fertil Dev 6, 589-98. 
Clark, J. M., and Diehl, A. M. (2002). Hepatic steatosis and type 2 diabetes 
mellitus. Curr Diab Rep 2, 210-5. 
Clayton, K. L., Holly, J. M., Carlsson, L. M., Jones, J., Cheetham, T. D., Taylor, 
A. M., and Dunger, D. B. (1994). Loss of the normal relationships 
between growth hormone, growth hormone-binding protein and insulin-
like growth factor-I in adolescents with insulin-dependent diabetes 
mellitus. Clin Endocrinol (Oxf) 41, 517-24. 
Clee, S. M., and Attie, A. D. (2007). The genetic landscape of type 2 diabetes in 
mice. Endocr Rev 28, 48-83. 
Clemens, M. J. (1994). Regulation of eukaryotic protein synthesis by protein 
kinases that phosphorylate initiation factor eIF-2. Mol Biol Rep 19, 201-
10. 
Cnop, M., Welsh, N., Jonas, J. C., Jorns, A., Lenzen, S., and Eizirik, D. L. (2005). 
Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: 
many differences, few similarities. Diabetes 54 Suppl 2, S97-107. 
Collinet, M., Berthelon, M., Benit, P., Laborde, K., Desbuquois, B., Munnich, A., 
and Robert, J. J. (1998). Familial hyperproinsulinaemia due to a mutation 
substituting histidine for arginine at position 65 in proinsulin: 
identification of the mutation by restriction enzyme mapping. Eur J 
Pediatr 157, 456-60. 
Colombo, C., Porzio, O., Liu, M., Massa, O., Vasta, M., Salardi, S., Beccaria, L., 
Monciotti, C., Toni, S., Pedersen, O., Hansen, T., Federici, L., Pesavento, 
R., Cadario, F., Federici, G., Ghirri, P., Arvan, P., Iafusco, D., Barbetti, F., 
Early Onset Diabetes Study Group of the Italian Society of Pediatric, E., 
and Diabetes (2008). Seven mutations in the human insulin gene linked to 
permanent neonatal/infancy-onset diabetes mellitus. J Clin Invest 118, 
2148-56. 
Connolly, T., and Gilmore, R. (1989). The signal recognition particle receptor 
mediates the GTP-dependent displacement of SRP from the signal 
sequence of the nascent polypeptide. Cell 57, 599-610. 
XI. Reference list    179 
 
Cortes, P., Dumler, F., Goldman, J., and Levin, N. W. (1987). Relationship 
between renal function and metabolic alterations in early streptozocin-
induced diabetes in rats. Diabetes 36, 80-7. 
Cudworth, A. G., and Woodrow, J. C. (1975). HL-A system and diabetes mellitus. 
Diabetes 24, 345-9. 
Davis, R. J. (1999). Signal transduction by the c-Jun N-terminal kinase. Biochem 
Soc Symp 64, 1-12. 
Davis, R. J. (2000). Signal transduction by the JNK group of MAP kinases. Cell 
103, 239-52. 
de Haro, C., Mendez, R., and Santoyo, J. (1996). The eIF-2alpha kinases and the 
control of protein synthesis. FASEB J 10, 1378-87. 
DeFronzo, R. A. (2004). Pathogenesis of type 2 diabetes mellitus. Med Clin North 
Am 88, 787-835, ix. 
DeFronzo, R. A., Tobin, J. D., and Andres, R. (1979). Glucose clamp technique: a 
method for quantifying insulin secretion and resistance. Am J Physiol 237, 
E214-23. 
Delepine, M., Nicolino, M., Barrett, T., Golamaully, M., Lathrop, G. M., and 
Julier, C. (2000). EIF2AK3, encoding translation initiation factor 2-alpha 
kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat 
Genet 25, 406-9. 
Derewenda, U., Derewenda, Z., Dodson, G. G., Hubbard, R. E., and Korber, F. 
(1989). Molecular structure of insulin: the insulin monomer and its 
assembly. Br Med Bull 45, 4-18. 
Dische, F. E. (1992). Measurement of glomerular basement membrane thickness 
and its application to the diagnosis of thin-membrane nephropathy. Arch 
Pathol Lab Med 116, 43-9. 
Donath, M. Y., and Halban, P. A. (2004). Decreased beta-cell mass in diabetes: 
significance, mechanisms and therapeutic implications. Diabetologia 47, 
581-9. 
Douglas, W. R. (1972). Of pigs and men and research: a review of applications 
and analogies of the pig, sus scrofa, in human medical research. Space Life 
Sci 3, 226-34. 
Dufrane, D., van Steenberghe, M., Guiot, Y., Goebbels, R. M., Saliez, A., and 
Gianello, P. (2006). Streptozotocin-induced diabetes in large animals 
(pigs/primates): role of GLUT2 transporter and beta-cell plasticity. 
Transplantation 81, 36-45. 
Edelsten, A. D., Hughes, I. A., Oakes, S., Gordon, I. R., and Savage, D. C. (1981). 
Height and skeletal maturity in children with newly-diagnosed juvenile-
onset diabetes. Arch Dis Child 56, 40-4. 
Edghill, E. L., Dix, R. J., Flanagan, S. E., Bingley, P. J., Hattersley, A. T., Ellard, 
S., and Gillespie, K. M. (2006). HLA genotyping supports a 
nonautoimmune etiology in patients diagnosed with diabetes under the age 
of 6 months. Diabetes 55, 1895-8. 
Edghill, E. L., Flanagan, S. E., and Ellard, S. (2010). Permanent neonatal diabetes 
due to activating mutations in ABCC8 and KCNJ11. Rev Endocr Metab 
Disord 11, 193-8. 
 
 
 
 
 
 
XI. Reference list    180 
 
Edghill, E. L., Flanagan, S. E., Patch, A. M., Boustred, C., Parrish, A., Shields, B., 
Shepherd, M. H., Hussain, K., Kapoor, R. R., Malecki, M., MacDonald, 
M. J., Stoy, J., Steiner, D. F., Philipson, L. H., Bell, G. I., Neonatal 
Diabetes International Collaborative, G., Hattersley, A. T., and Ellard, S. 
(2008). Insulin mutation screening in 1,044 patients with diabetes: 
mutations in the INS gene are a common cause of neonatal diabetes but a 
rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 57, 
1034-42. 
Edghill, E. L., Gloyn, A. L., Gillespie, K. M., Lambert, A. P., Raymond, N. T., 
Swift, P. G., Ellard, S., Gale, E. A., and Hattersley, A. T. (2004). 
Activating mutations in the KCNJ11 gene encoding the ATP-sensitive K+ 
channel subunit Kir6.2 are rare in clinically defined type 1 diabetes 
diagnosed before 2 years. Diabetes 53, 2998-3001. 
Eizirik, D. L., Cardozo, A. K., and Cnop, M. (2008). The role for endoplasmic 
reticulum stress in diabetes mellitus. Endocr Rev 29, 42-61. 
El-Aouni, C., Herbach, N., Blattner, S. M., Henger, A., Rastaldi, M. P., Jarad, G., 
Miner, J. H., Moeller, M. J., St-Arnaud, R., Dedhar, S., Holzman, L. B., 
Wanke, R., and Kretzler, M. (2006). Podocyte-specific deletion of 
integrin-linked kinase results in severe glomerular basement membrane 
alterations and progressive glomerulosclerosis. J Am Soc Nephrol 17, 
1334-44. 
Ellgaard, L., and Helenius, A. (2003). Quality control in the endoplasmic 
reticulum. Nat Rev Mol Cell Biol 4, 181-91. 
Ellgaard, L., Molinari, M., and Helenius, A. (1999). Setting the standards: quality 
control in the secretory pathway. Science 286, 1882-8. 
Engelhart, W. v., and G., B., eds. (2010). "Physiologie der Haustiere," pp. 1-736. 
Verlag Enke Ferdinand  
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widen, E., 
Schalin, C., and Groop, L. (1989). Early metabolic defects in persons at 
increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 
321, 337-43. 
Evans, R. W., Littler, T. R., and Pemberton, H. S. (1955). Glycogen storage in the 
liver in diabetes mellitus. J Clin Pathol 8, 110-3. 
Expert Committee on the Diagnosis and Classification of Diabetes mellitus 
(2003). Report of the expert committee on the diagnosis and classification 
of diabetes mellitus. Diabetes Care 26 Suppl 1, S5-20. 
Fajans, S. S., Bell, G. I., Bowden, D. W., Halter, J. B., and Polonsky, K. S. 
(1994). Maturity-onset diabetes of the young. Life Sci 55, 413-22. 
Fajans, S. S., Bell, G. I., and Polonsky, K. S. (2001). Molecular mechanisms and 
clinical pathophysiology of maturity-onset diabetes of the young. N Engl J 
Med 345, 971-80. 
Federici, M., Hribal, M., Perego, L., Ranalli, M., Caradonna, Z., Perego, C., 
Usellini, L., Nano, R., Bonini, P., Bertuzzi, F., Marlier, L. N., Davalli, A. 
M., Carandente, O., Pontiroli, A. E., Melino, G., Marchetti, P., Lauro, R., 
Sesti, G., and Folli, F. (2001). High glucose causes apoptosis in cultured 
human pancreatic islets of Langerhans: a potential role for regulation of 
specific Bcl family genes toward an apoptotic cell death program. 
Diabetes 50, 1290-301. 
Finegood, D. T., Scaglia, L., and Bonner-Weir, S. (1995). Dynamics of beta-cell 
mass in the growing rat pancreas. Estimation with a simple mathematical 
model. Diabetes 44, 249-56. 
 
XI. Reference list    181 
 
Flanagan, S. E., Patch, A. M., Mackay, D. J., Edghill, E. L., Gloyn, A. L., 
Robinson, D., Shield, J. P., Temple, K., Ellard, S., and Hattersley, A. T. 
(2007). Mutations in ATP-sensitive K+ channel genes cause transient 
neonatal diabetes and permanent diabetes in childhood or adulthood. 
Diabetes 56, 1930-7. 
Flores-Le Roux, J. A., Comin, J., Pedro-Botet, J., Benaiges, D., Puig-de Dou, J., 
Chillaron, J. J., Goday, A., Bruguera, J., and Cano-Perez, J. F. (2011). 
Seven-year mortality in heart failure patients with undiagnosed diabetes: 
an observational study. Cardiovasc Diabetol 10, 39. 
Flynn, G. C., Chappell, T. G., and Rothman, J. E. (1989). Peptide binding and 
release by proteins implicated as catalysts of protein assembly. Science 
245, 385-90. 
Fornace, A. J., Jr., Alamo, I., Jr., and Hollander, M. C. (1988). DNA damage-
inducible transcripts in mammalian cells. Proc Natl Acad Sci U S A 85, 
8800-4. 
Fosel, S. (1995). Transient and permanent neonatal diabetes. Eur J Pediatr 154, 
944-8. 
Frayling, T. M., Lindgren, C. M., Chevre, J. C., Menzel, S., Wishart, M., 
Benmezroua, Y., Brown, A., Evans, J. C., Rao, P. S., Dina, C., Lecoeur, 
C., Kanninen, T., Almgren, P., Bulman, M. P., Wang, Y., Mills, J., 
Wright-Pascoe, R., Mahtani, M. M., Prisco, F., Costa, A., Cognet, I., 
Hansen, T., Pedersen, O., Ellard, S., Tuomi, T., Groop, L. C., Froguel, P., 
Hattersley, A. T., and Vaxillaire, M. (2003). A genome-wide scan in 
families with maturity-onset diabetes of the young: evidence for further 
genetic heterogeneity. Diabetes 52, 872-81. 
Freedman, R. B. (1989). Protein disulfide isomerase: multiple roles in the 
modification of nascent secretory proteins. Cell 57, 1069-72. 
Fritsche, A., Stefan, N., Hardt, E., Haring, H., and Stumvoll, M. (2000). 
Characterisation of beta-cell dysfunction of impaired glucose tolerance: 
evidence for impairment of incretin-induced insulin secretion. 
Diabetologia 43, 852-8. 
Froguel, P., Vaxillaire, M., Sun, F., Velho, G., Zouali, H., Butel, M. O., Lesage, 
S., Vionnet, N., Clement, K., Fougerousse, F., and et al. (1992). Close 
linkage of glucokinase locus on chromosome 7p to early-onset non-
insulin-dependent diabetes mellitus. Nature 356, 162-4. 
Froguel, P., and Velho, G. (1999). Molecular Genetics of Maturity-onset Diabetes 
of the Young. Trends Endocrinol Metab 10, 142-146. 
Gardner, R. J., Mackay, D. J., Mungall, A. J., Polychronakos, C., Siebert, R., 
Shield, J. P., Temple, I. K., and Robinson, D. O. (2000). An imprinted 
locus associated with transient neonatal diabetes mellitus. Hum Mol Genet 
9, 589-96. 
Garin, I., Edghill, E. L., Akerman, I., Rubio-Cabezas, O., Rica, I., Locke, J. M., 
Maestro, M. A., Alshaikh, A., Bundak, R., del Castillo, G., Deeb, A., 
Deiss, D., Fernandez, J. M., Godbole, K., Hussain, K., O'Connell, M., 
Klupa, T., Kolouskova, S., Mohsin, F., Perlman, K., Sumnik, Z., Rial, J. 
M., Ugarte, E., Vasanthi, T., Neonatal Diabetes International, G., 
Johnstone, K., Flanagan, S. E., Martinez, R., Castano, C., Patch, A. M., 
Fernandez-Rebollo, E., Raile, K., Morgan, N., Harries, L. W., Castano, L., 
Ellard, S., Ferrer, J., Perez de Nanclares, G., and Hattersley, A. T. (2010). 
Recessive mutations in the INS gene result in neonatal diabetes through 
reduced insulin biosynthesis. Proc Natl Acad Sci U S A 107, 3105-10. 
 
XI. Reference list    182 
 
Gavin, J. R., 3rd (1998). New classification and diagnostic criteria for diabetes 
mellitus. Clin Cornerstone 1, 1-12. 
Gentz, J. C., and Cornblath, M. (1969). Transient diabetes of the newborn. Adv 
Pediatr 16, 345-63. 
Germain, P., Chambon, P., Eichele, G., Evans, R. M., Lazar, M. A., Leid, M., De 
Lera, A. R., Lotan, R., Mangelsdorf, D. J., and Gronemeyer, H. (2006). 
International Union of Pharmacology. LX. Retinoic acid receptors. 
Pharmacol Rev 58, 712-25. 
Gething, M. J., and Sambrook, J. (1992). Protein folding in the cell. Nature 355, 
33-45. 
Ghaemmaghami, S., Huh, W. K., Bower, K., Howson, R. W., Belle, A., 
Dephoure, N., O'Shea, E. K., and Weissman, J. S. (2003). Global analysis 
of protein expression in yeast. Nature 425, 737-41. 
Gillespie, K. M. (2006). Type 1 diabetes: pathogenesis and prevention. CMAJ 
175, 165-70. 
Glaser, B., Kesavan, P., Heyman, M., Davis, E., Cuesta, A., Buchs, A., Stanley, 
C. A., Thornton, P. S., Permutt, M. A., Matschinsky, F. M., and Herold, K. 
C. (1998). Familial hyperinsulinism caused by an activating glucokinase 
mutation. N Engl J Med 338, 226-30. 
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, 
A. S., Howard, N., Srinivasan, S., Silva, J. M., Molnes, J., Edghill, E. L., 
Frayling, T. M., Temple, I. K., Mackay, D., Shield, J. P., Sumnik, Z., van 
Rhijn, A., Wales, J. K., Clark, P., Gorman, S., Aisenberg, J., Ellard, S., 
Njolstad, P. R., Ashcroft, F. M., and Hattersley, A. T. (2004). Activating 
mutations in the gene encoding the ATP-sensitive potassium-channel 
subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350, 1838-
49. 
Gloyn, A. L., Reimann, F., Girard, C., Edghill, E. L., Proks, P., Pearson, E. R., 
Temple, I. K., Mackay, D. J., Shield, J. P., Freedenberg, D., Noyes, K., 
Ellard, S., Ashcroft, F. M., Gribble, F. M., and Hattersley, A. T. (2005). 
Relapsing diabetes can result from moderately activating mutations in 
KCNJ11. Hum Mol Genet 14, 925-34. 
Gorelick, F. S., and Shugrue, C. (2001). Exiting the endoplasmic reticulum. Mol 
Cell Endocrinol 177, 13-8. 
Gorus, F. K., Malaisse, W. J., and Pipeleers, D. G. (1982). Selective uptake of 
alloxan by pancreatic B-cells. Biochem J 208, 513-5. 
Gottschalk, M. E., Schatz, D. A., Clare-Salzler, M., Kaufman, D. L., Ting, G. S., 
and Geffner, M. E. (1992). Permanent diabetes without serological 
evidence of autoimmunity after transient neonatal diabetes. Diabetes Care 
15, 1273-6. 
Gray, C. S., Scott, J. F., French, J. M., Alberti, K. G., and O'Connell, J. E. (2004). 
Prevalence and prediction of unrecognised diabetes mellitus and impaired 
glucose tolerance following acute stroke. Age Ageing 33, 71-7. 
Gromada, J., Franklin, I., and Wollheim, C. B. (2007). Alpha-cells of the 
endocrine pancreas: 35 years of research but the enigma remains. Endocr 
Rev 28, 84-116. 
Gross, A., McDonnell, J. M., and Korsmeyer, S. J. (1999). BCL-2 family 
members and the mitochondria in apoptosis. Genes Dev 13, 1899-911. 
Gunczler, P., Lanes, R., Paz-Martinez, V., Martins, R., Esaa, S., Colmenares, V., 
and Weisinger, J. R. (1998). Decreased lumbar spine bone mass and low 
bone turnover in children and adolescents with insulin dependent diabetes 
mellitus followed longitudinally. J Pediatr Endocrinol Metab 11, 413-9. 
XI. Reference list    183 
 
Gundersen, H. J., Bendtsen, T. F., Korbo, L., Marcussen, N., Moller, A., Nielsen, 
K., Nyengaard, J. R., Pakkenberg, B., Sorensen, F. B., Vesterby, A., and et 
al. (1988). Some new, simple and efficient stereological methods and their 
use in pathological research and diagnosis. APMIS 96, 379-94. 
Gundersen, H. J., and Jensen, E. B. (1987). The efficiency of systematic sampling 
in stereology and its prediction. J Microsc 147, 229-63. 
Guo, Z. Y., and Feng, Y. M. (2001). Effects of cysteine to serine substitutions in 
the two inter-chain disulfide bonds of insulin. Biol Chem 382, 443-8. 
Gurley, S. B., Clare, S. E., Snow, K. P., Hu, A., Meyer, T. W., and Coffman, T. 
M. (2006). Impact of genetic background on nephropathy in diabetic mice. 
Am J Physiol Renal Physiol 290, F214-22. 
Gurley, S. B., Mach, C. L., Stegbauer, J., Yang, J., Snow, K. P., Hu, A., Meyer, T. 
W., and Coffman, T. M. (2010). Influence of genetic background on 
albuminuria and kidney injury in Ins2(+/C96Y) (Akita) mice. Am J 
Physiol Renal Physiol 298, F788-95. 
Halban, P. A. (1994). Proinsulin processing in the regulated and the constitutive 
secretory pathway. Diabetologia 37 Suppl 2, S65-72. 
Hamilton-Shield, J. P. (2007). Overview of neonatal diabetes. Endocr Dev 12, 12-
23. 
Haneda, M., Chan, S. J., Kwok, S. C., Rubenstein, A. H., and Steiner, D. F. 
(1983). Studies on mutant human insulin genes: identification and 
sequence analysis of a gene encoding [SerB24]insulin. Proc Natl Acad Sci 
U S A 80, 6366-70. 
Hansen, T., Urhammer, S. A., and Pedersen, O. B. (2002). [Maturity-onset 
diabetes of the young--MODY. Molecular-genetic, pathophysiological and 
clinical characteristics]. Ugeskr Laeger 164, 2017-22. 
Harding, H. P., Novoa, I., Zhang, Y., Zeng, H., Wek, R., Schapira, M., and Ron, 
D. (2000). Regulated translation initiation controls stress-induced gene 
expression in mammalian cells. Mol Cell 6, 1099-108. 
Harding, H. P., and Ron, D. (2002). Endoplasmic reticulum stress and the 
development of diabetes: a review. Diabetes 51 Suppl 3, S455-61. 
Harding, H. P., Zhang, Y., and Ron, D. (1999). Protein translation and folding are 
coupled by an endoplasmic-reticulum-resident kinase. Nature 397, 271-4. 
Harmon, J. S., Gleason, C. E., Tanaka, Y., Oseid, E. A., Hunter-Berger, K. K., 
and Robertson, R. P. (1999). In vivo prevention of hyperglycemia also 
prevents glucotoxic effects on PDX-1 and insulin gene expression. 
Diabetes 48, 1995-2000. 
Harris, M. I. (1988). Classification and diagnostic criteria for diabetes mellitus 
and other categories of glucose intolerance. Prim Care 15, 205-25. 
Hattersley, A. T. (2005). Molecular genetics goes to the diabetes clinic. Clin Med 
5, 476-81. 
Hay, C. W., and Docherty, K. (2006). Comparative analysis of insulin gene 
promoters: implications for diabetes research. Diabetes 55, 3201-13. 
Haze, K., Okada, T., Yoshida, H., Yanagi, H., Yura, T., Negishi, M., and Mori, K. 
(2001). Identification of the G13 (cAMP-response-element-binding 
protein-related protein) gene product related to activating transcription 
factor 6 as a transcriptional activator of the mammalian unfolded protein 
response. Biochem J 355, 19-28. 
Haze, K., Yoshida, H., Yanagi, H., Yura, T., and Mori, K. (1999). Mammalian 
transcription factor ATF6 is synthesized as a transmembrane protein and 
activated by proteolysis in response to endoplasmic reticulum stress. Mol 
Biol Cell 10, 3787-99. 
XI. Reference list    184 
 
Herbach, N., Rathkolb, B., Kemter, E., Pichl, L., Klaften, M., de Angelis, M. H., 
Halban, P. A., Wolf, E., Aigner, B., and Wanke, R. (2007). Dominant-
negative effects of a novel mutated Ins2 allele causes early-onset diabetes 
and severe beta-cell loss in Munich Ins2C95S mutant mice. Diabetes 56, 
1268-76. 
Herbach, N., Schairer, I., Blutke, A., Kautz, S., Siebert, A., Goke, B., Wolf, E., 
and Wanke, R. (2009). Diabetic kidney lesions of GIPRdn transgenic 
mice: podocyte hypertrophy and thickening of the GBM precede 
glomerular hypertrophy and glomerulosclerosis. Am J Physiol Renal 
Physiol 296, F819-29. 
Hermanns, W., Liebig, K., and Schulz, L. C. (1981). Postembedding 
immunohistochemical demonstration of antigen in experimental 
polyarthritis using plastic embedded whole joints. Histochemistry 73, 439-
46. 
Herr, R. R., Jahnke, J. K., and Argoudelis, A. D. (1967). The structure of 
streptozotocin. J Am Chem Soc 89, 4808-9. 
Hinnebusch, A. G. (1997). Translational regulation of yeast GCN4. A window on 
factors that control initiator-trna binding to the ribosome. J Biol Chem 
272, 21661-4. 
Hirose, K., Osterby, R., Nozawa, M., and Gundersen, H. J. (1982). Development 
of glomerular lesions in experimental long-term diabetes in the rat. Kidney 
Int 21, 689-95. 
Hodish, I., Liu, M., Rajpal, G., Larkin, D., Holz, R. W., Adams, A., Liu, L., and 
Arvan, P. (2010). Misfolded proinsulin affects bystander proinsulin in 
neonatal diabetes. J Biol Chem 285, 685-94. 
Hoenig, M., Hall, G., Ferguson, D., Jordan, K., Henson, M., Johnson, K., and 
O'Brien, T. (2000). A feline model of experimentally induced islet 
amyloidosis. Am J Pathol 157, 2143-50. 
Hollien, J., Lin, J. H., Li, H., Stevens, N., Walter, P., and Weissman, J. S. (2009). 
Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. 
J Cell Biol 186, 323-31. 
Hollien, J., and Weissman, J. S. (2006). Decay of endoplasmic reticulum-
localized mRNAs during the unfolded protein response. Science 313, 104-
7. 
Hong, E. G., Jung, D. Y., Ko, H. J., Zhang, Z., Ma, Z., Jun, J. Y., Kim, J. H., 
Sumner, A. D., Vary, T. C., Gardner, T. W., Bronson, S. K., and Kim, J. 
K. (2007). Nonobese, insulin-deficient Ins2Akita mice develop type 2 
diabetes phenotypes including insulin resistance and cardiac remodeling. 
Am J Physiol Endocrinol Metab 293, E1687-96. 
Hong, M., Luo, S., Baumeister, P., Huang, J. M., Gogia, R. K., Li, M., and Lee, 
A. S. (2004). Underglycosylation of ATF6 as a novel sensing mechanism 
for activation of the unfolded protein response. J Biol Chem 279, 11354-
63. 
Horikawa, Y., Iwasaki, N., Hara, M., Furuta, H., Hinokio, Y., Cockburn, B. N., 
Lindner, T., Yamagata, K., Ogata, M., Tomonaga, O., Kuroki, H., 
Kasahara, T., Iwamoto, Y., and Bell, G. I. (1997). Mutation in hepatocyte 
nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 17, 
384-5. 
Houstis, N., Rosen, E. D., and Lander, E. S. (2006). Reactive oxygen species have 
a causal role in multiple forms of insulin resistance. Nature 440, 944-8. 
 
 
XI. Reference list    185 
 
Hu, P., Han, Z., Couvillon, A. D., Kaufman, R. J., and Exton, J. H. (2006). 
Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress 
to the membrane death receptor pathway through IRE1alpha-mediated NF-
kappaB activation and down-regulation of TRAF2 expression. Mol Cell 
Biol 26, 3071-84. 
Hu, S. Q., Burke, G. T., Schwartz, G. P., Ferderigos, N., Ross, J. B., and 
Katsoyannis, P. G. (1993). Steric requirements at position B12 for high 
biological activity in insulin. Biochemistry 32, 2631-5. 
Hua, Q. X., Chu, Y. C., Jia, W., Phillips, N. F., Wang, R. Y., Katsoyannis, P. G., 
and Weiss, M. A. (2002). Mechanism of insulin chain combination. 
Asymmetric roles of A-chain alpha-helices in disulfide pairing. J Biol 
Chem 277, 43443-53. 
Hua, Q. X., Liu, M., Hu, S. Q., Jia, W., Arvan, P., and Weiss, M. A. (2006a). A 
conserved histidine in insulin is required for the foldability of human 
proinsulin: structure and function of an ALAB5 analog. J Biol Chem 281, 
24889-99. 
Hua, Q. X., Mayer, J. P., Jia, W., Zhang, J., and Weiss, M. A. (2006b). The 
folding nucleus of the insulin superfamily: a flexible peptide model 
foreshadows the native state. J Biol Chem 281, 28131-42. 
Hua, Q. X., Nakagawa, S., Hu, S. Q., Jia, W., Wang, S., and Weiss, M. A. 
(2006c). Toward the active conformation of insulin: stereospecific 
modulation of a structural switch in the B chain. J Biol Chem 281, 24900-
9. 
Huang, E. S., Basu, A., O'Grady, M., and Capretta, J. C. (2009). Projecting the 
future diabetes population size and related costs for the U.S. Diabetes 
Care 32, 2225-9. 
Huang, X. F., and Arvan, P. (1994). Formation of the insulin-containing secretory 
granule core occurs within immature beta-granules. J Biol Chem 269, 
20838-44. 
Hubbard, S. R. (2013). Structural biology: Insulin meets its receptor. Nature 493, 
171-2. 
Huge, A., Weber, E., and Ehrlein, H. J. (1995). Effects of enteral feedback 
inhibition on motility, luminal flow, and absorption of nutrients in 
proximal gut of minipigs. Dig Dis Sci 40, 1024-34. 
Hutchison, J. H., Keay, A. J., and Kerr, M. M. (1962). Congenital temporary 
diabetes mellitus. Br Med J 2, 436-40. 
Hwang, C., Sinskey, A. J., and Lodish, H. F. (1992). Oxidized redox state of 
glutathione in the endoplasmic reticulum. Science 257, 1496-502. 
Ihara, Y., Toyokuni, S., Uchida, K., Odaka, H., Tanaka, T., Ikeda, H., Hiai, H., 
Seino, Y., and Yamada, Y. (1999). Hyperglycemia causes oxidative stress 
in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 
48, 927-32. 
Imagawa, A., Hanafusa, T., Miyagawa, J., and Matsuzawa, Y. (2000). A novel 
subtype of type 1 diabetes mellitus characterized by a rapid onset and an 
absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl 
J Med 342, 301-7. 
In 't Veld, P. A., Zhang, F., Madsen, O. D., and Kloppel, G. (1992). Islet amyloid 
polypeptide immunoreactivity in the human fetal pancreas. Diabetologia 
35, 272-6. 
 
 
 
XI. Reference list    186 
 
Ishihara, M., Inoue, I., Kawagoe, T., Shimatani, Y., Kurisu, S., Hata, T., Nakama, 
Y., Kijima, Y., and Kagawa, E. (2006). Is admission hyperglycaemia in 
non-diabetic patients with acute myocardial infarction a surrogate for 
previously undiagnosed abnormal glucose tolerance? Eur Heart J 27, 
2413-9. 
Izumi, T., Yokota-Hashimoto, H., Zhao, S., Wang, J., Halban, P. A., and 
Takeuchi, T. (2003). Dominant negative pathogenesis by mutant 
proinsulin in the Akita diabetic mouse. Diabetes 52, 409-16. 
Jackson, R. L. (1984). Growth and maturation of children with insulin-dependent 
diabetes mellitus. Pediatr Clin North Am 31, 545-67. 
Jacobson, D. A., Wicksteed, B. L., and Philipson, L. H. (2009). The alpha-cell 
conundrum: ATP-sensitive K+ channels and glucose sensing. Diabetes 58, 
304-6. 
Jay, T. R., Heald, K. A., Carless, N. J., Topham, D. E., and Downing, R. (1999). 
The distribution of porcine pancreatic beta-cells at ages 5, 12 and 24 
weeks. Xenotransplantation 6, 131-40. 
Jensen, E. B., Gundersen, H. J., and Osterby, R. (1979). Determination of 
membrane thickness distribution from orthogonal intercepts. J Microsc 
115, 19-33. 
Jimbo, A., Fujita, E., Kouroku, Y., Ohnishi, J., Inohara, N., Kuida, K., Sakamaki, 
K., Yonehara, S., and Momoi, T. (2003). ER stress induces caspase-8 
activation, stimulating cytochrome c release and caspase-9 activation. Exp 
Cell Res 283, 156-66. 
Johnson, A. M., and Olefsky, J. M. (2013). The origins and drivers of insulin 
resistance. Cell 152, 673-84. 
Johnson, K. H., O'Brien, T. D., Hayden, D. W., Jordan, K., Ghobrial, H. K., 
Mahoney, W. C., and Westermark, P. (1988). Immunolocalization of islet 
amyloid polypeptide (IAPP) in pancreatic beta cells by means of 
peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J 
Pathol 130, 1-8. 
Jonsson, J., Carlsson, L., Edlund, T., and Edlund, H. (1994). Insulin-promoter-
factor 1 is required for pancreas development in mice. Nature 371, 606-9. 
Justice, M. J., Noveroske, J. K., Weber, J. S., Zheng, B., and Bradley, A. (1999). 
Mouse ENU mutagenesis. Hum Mol Genet 8, 1955-63. 
Kador, P. F., Lee, J. W., Fujisawa, S., Blessing, K., and Lou, M. F. (2000). 
Relative importance of aldose reductase versus nonenzymatic 
glycosylation on sugar cataract formation in diabetic rats. J Ocul 
Pharmacol Ther 16, 149-60. 
Kahn, S. E. (2003). The relative contributions of insulin resistance and beta-cell 
dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46, 
3-19. 
Kaisaki, P. J., Menzel, S., Lindner, T., Oda, N., Rjasanowski, I., Sahm, J., 
Meincke, G., Schulze, J., Schmechel, H., Petzold, C., Ledermann, H. M., 
Sachse, G., Boriraj, V. V., Menzel, R., Kerner, W., Turner, R. C., 
Yamagata, K., and Bell, G. I. (1997). Mutations in the hepatocyte nuclear 
factor-1alpha gene in MODY and early-onset NIDDM: evidence for a 
mutational hotspot in exon 4. Diabetes 46, 528-35. 
Kaiser, N., Leibowitz, G., and Nesher, R. (2003). Glucotoxicity and beta-cell 
failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 16, 5-22. 
Kaneko, M., Ishiguro, M., Niinuma, Y., Uesugi, M., and Nomura, Y. (2002). 
Human HRD1 protects against ER stress-induced apoptosis through ER-
associated degradation. FEBS Lett 532, 147-52. 
XI. Reference list    187 
 
Karjalainen, J., Salmela, P., Ilonen, J., Surcel, H. M., and Knip, M. (1989). A 
comparison of childhood and adult type I diabetes mellitus. N Engl J Med 
320, 881-6. 
Kaufman, R. J. (2002). Orchestrating the unfolded protein response in health and 
disease. J Clin Invest 110, 1389-98. 
Kautz, S. M. (2011). Mechanisms of !-cell loss in male Munich Ins2C95S mutant 
mice. Inaugural-Dissertation, Ludwig-Maximilians-University, Munich. 
Kayo, T., and Koizumi, A. (1998). Mapping of murine diabetogenic gene mody 
on chromosome 7 at D7Mit258 and its involvement in pancreatic islet and 
beta cell development during the perinatal period. J Clin Invest 101, 2112-
8. 
Kemmink, J., Darby, N. J., Dijkstra, K., Nilges, M., and Creighton, T. E. (1997). 
The folding catalyst protein disulfide isomerase is constructed of active 
and inactive thioredoxin modules. Curr Biol 7, 239-45. 
Kendall, D. M., Sutherland, D. E., Najarian, J. S., Goetz, F. C., and Robertson, R. 
P. (1990). Effects of hemipancreatectomy on insulin secretion and glucose 
tolerance in healthy humans. N Engl J Med 322, 898-903. 
Kikkert, M., Doolman, R., Dai, M., Avner, R., Hassink, G., van Voorden, S., 
Thanedar, S., Roitelman, J., Chau, V., and Wiertz, E. (2004). Human 
HRD1 is an E3 ubiquitin ligase involved in degradation of proteins from 
the endoplasmic reticulum. J Biol Chem 279, 3525-34. 
Kim, A., Miller, K., Jo, J., Kilimnik, G., Wojcik, P., and Hara, M. (2009). Islet 
architecture: A comparative study. Islets 1, 129-36. 
Kim, I., Xu, W., and Reed, J. C. (2008). Cell death and endoplasmic reticulum 
stress: disease relevance and therapeutic opportunities. Nat Rev Drug 
Discov 7, 1013-30. 
Kinoshita, J. H., Fukushi, S., Kador, P., and Merola, L. O. (1979). Aldose 
reductase in diabetic complications of the eye. Metabolism 28, 462-9. 
Kirk, A. D. (2003). Crossing the bridge: large animal models in translational 
transplantation research. Immunol Rev 196, 176-96. 
Kjems, L. L., Kirby, B. M., Welsh, E. M., Veldhuis, J. D., Straume, M., McIntyre, 
S. S., Yang, D., Lefebvre, P., and Butler, P. C. (2001). Decrease in beta-
cell mass leads to impaired pulsatile insulin secretion, reduced 
postprandial hepatic insulin clearance, and relative hyperglucagonemia in 
the minipig. Diabetes 50, 2001-12. 
Kloppel, G., Lohr, M., Habich, K., Oberholzer, M., and Heitz, P. U. (1985). Islet 
pathology and the pathogenesis of type 1 and type 2 diabetes mellitus 
revisited. Surv Synth Pathol Res 4, 110-25. 
Klymiuk, N., Bocker, W., Schonitzer, V., Bahr, A., Radic, T., Frohlich, T., 
Wunsch, A., Kessler, B., Kurome, M., Schilling, E., Herbach, N., Wanke, 
R., Nagashima, H., Mutschler, W., Arnold, G. J., Schwinzer, R., Schieker, 
M., and Wolf, E. (2012). First inducible transgene expression in porcine 
large animal models. FASEB J 26, 1086-99. 
Kokame, K., Agarwala, K. L., Kato, H., and Miyata, T. (2000). Herp, a new 
ubiquitin-like membrane protein induced by endoplasmic reticulum stress. 
J Biol Chem 275, 32846-53. 
Kokame, K., Kato, H., and Miyata, T. (2001). Identification of ERSE-II, a new 
cis-acting element responsible for the ATF6-dependent mammalian 
unfolded protein response. J Biol Chem 276, 9199-205. 
Korbutt, G. S., Elliott, J. F., Ao, Z., Smith, D. K., Warnock, G. L., and Rajotte, R. 
V. (1996). Large scale isolation, growth, and function of porcine neonatal 
islet cells. J Clin Invest 97, 2119-29. 
XI. Reference list    188 
 
Kraft W., D. U. M. (2005). Klinische Labordiagnostik in der Tiermedizin. 
Schattauerverlag, Stuttgart, New York. 
Kues, W. A., and Niemann, H. (2004). The contribution of farm animals to human 
health. Trends Biotechnol 22, 286-94. 
Kukreja, A., and Maclaren, N. K. (1999). Autoimmunity and diabetes. J Clin 
Endocrinol Metab 84, 4371-8. 
Kurome, M., Ishikawa, T., Tomii, R., Ueno, S., Shimada, A., Yazawa, H., and 
Nagashima, H. (2008). Production of transgenic and non-transgenic clones 
in miniature pigs by somatic cell nuclear transfer. J Reprod Dev 54, 156-
63. 
Kurome, M., Ueda, H., Tomii, R., Naruse, K., and Nagashima, H. (2006). 
Production of transgenic-clone pigs by the combination of ICSI-mediated 
gene transfer with somatic cell nuclear transfer. Transgenic Res 15, 229-
40. 
Kuzuya, T., Nakagawa, S., Satoh, J., Kanazawa, Y., Iwamoto, Y., Kobayashi, M., 
Nanjo, K., Sasaki, A., Seino, Y., Ito, C., Shima, K., Nonaka, K., 
Kadowaki, T., and Committee of the Japan Diabetes Society on the 
diagnostic criteria of diabetes, m. (2002). Report of the Committee on the 
classification and diagnostic criteria of diabetes mellitus. Diabetes Res 
Clin Pract 55, 65-85. 
Kwok, S. C., Steiner, D. F., Rubenstein, A. H., and Tager, H. S. (1983). 
Identification of a point mutation in the human insulin gene giving rise to 
a structurally abnormal insulin (insulin Chicago). Diabetes 32, 872-5. 
Ladias, J. A., Hadzopoulou-Cladaras, M., Kardassis, D., Cardot, P., Cheng, J., 
Zannis, V., and Cladaras, C. (1992). Transcriptional regulation of human 
apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the 
steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. 
J Biol Chem 267, 15849-60. 
Lan, M. S., Wasserfall, C., Maclaren, N. K., and Notkins, A. L. (1996). IA-2, a 
transmembrane protein of the protein tyrosine phosphatase family, is a 
major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad 
Sci U S A 93, 6367-70. 
Larsen, M. O., Gotfredsen, C. F., Wilken, M., Carr, R. D., Porksen, N., and Rolin, 
B. (2003a). Loss of beta-cell mass leads to a reduction of pulse mass with 
normal periodicity, regularity and entrainment of pulsatile insulin 
secretion in Gottingen minipigs. Diabetologia 46, 195-202. 
Larsen, M. O., and Rolin, B. (2004). Use of the Gottingen minipig as a model of 
diabetes, with special focus on type 1 diabetes research. ILAR J 45, 303-
13. 
Larsen, M. O., Rolin, B., Wilken, M., Carr, R. D., and Gotfredsen, C. F. (2003b). 
Measurements of insulin secretory capacity and glucose tolerance to 
predict pancreatic beta-cell mass in vivo in the nicotinamide/streptozotocin 
Gottingen minipig, a model of moderate insulin deficiency and diabetes. 
Diabetes 52, 118-23. 
Larsen, M. O., Rolin, B., Wilken, M., Carr, R. D., Svendsen, O., and Bollen, P. 
(2001). Parameters of glucose and lipid metabolism in the male Gottingen 
minipig: influence of age, body weight, and breeding family. Comp Med 
51, 436-42. 
Larsson, K., Elding-Larsson, H., Cederwall, E., Kockum, K., Neiderud, J., 
Sjoblad, S., Lindberg, B., Lernmark, B., Cilio, C., Ivarsson, S. A., and 
Lernmark, A. (2004). Genetic and perinatal factors as risk for childhood 
type 1 diabetes. Diabetes Metab Res Rev 20, 429-37. 
XI. Reference list    189 
 
Laybutt, D. R., Kaneto, H., Hasenkamp, W., Grey, S., Jonas, J. C., Sgroi, D. C., 
Groff, A., Ferran, C., Bonner-Weir, S., Sharma, A., and Weir, G. C. 
(2002). Increased expression of antioxidant and antiapoptotic genes in 
islets that may contribute to beta-cell survival during chronic 
hyperglycemia. Diabetes 51, 413-23. 
Laybutt, D. R., Preston, A. M., Akerfeldt, M. C., Kench, J. G., Busch, A. K., 
Biankin, A. V., and Biden, T. J. (2007). Endoplasmic reticulum stress 
contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 50, 752-
63. 
Leahy, J. L. (2005). Pathogenesis of type 2 diabetes mellitus. Arch Med Res 36, 
197-209. 
Lee, A. H., Iwakoshi, N. N., and Glimcher, L. H. (2003). XBP-1 regulates a 
subset of endoplasmic reticulum resident chaperone genes in the unfolded 
protein response. Mol Cell Biol 23, 7448-59. 
Lee, M. C., Miller, E. A., Goldberg, J., Orci, L., and Schekman, R. (2004). Bi-
directional protein transport between the ER and Golgi. Annu Rev Cell 
Dev Biol 20, 87-123. 
Lee, S., Muniyappa, R., Yan, X., Chen, H., Yue, L. Q., Hong, E. G., Kim, J. K., 
and Quon, M. J. (2008). Comparison between surrogate indexes of insulin 
sensitivity and resistance and hyperinsulinemic euglycemic clamp 
estimates in mice. Am J Physiol Endocrinol Metab 294, E261-70. 
Lei, K., Nimnual, A., Zong, W. X., Kennedy, N. J., Flavell, R. A., Thompson, C. 
B., Bar-Sagi, D., and Davis, R. J. (2002). The Bax subfamily of Bcl2-
related proteins is essential for apoptotic signal transduction by c-Jun 
NH(2)-terminal kinase. Mol Cell Biol 22, 4929-42. 
Lemmon, M. A., and Schlessinger, J. (2010). Cell signaling by receptor tyrosine 
kinases. Cell 141, 1117-34. 
Lenzen, S. (2008). The mechanisms of alloxan- and streptozotocin-induced 
diabetes. Diabetologia 51, 216-26. 
Lenzen, S., Freytag, S., and Panten, U. (1988). Inhibition of glucokinase by 
alloxan through interaction with SH groups in the sugar-binding site of the 
enzyme. Mol Pharmacol 34, 395-400. 
Lenzen, S., Tiedge, M., and Panten, U. (1987). Glucokinase in pancreatic B-cells 
and its inhibition by alloxan. Acta Endocrinol (Copenh) 115, 21-9. 
Leppa, S., and Bohmann, D. (1999). Diverse functions of JNK signaling and c-Jun 
in stress response and apoptosis. Oncogene 18, 6158-62. 
Lipson, K. L., Ghosh, R., and Urano, F. (2008). The role of IRE1alpha in the 
degradation of insulin mRNA in pancreatic beta-cells. PLoS One 3, e1648. 
Litten-Brown, J. C., Corson, A. M., and Clarke, L. (2010). Porcine models for the 
metabolic syndrome, digestive and bone disorders: a general overview. 
Animal 4, 899-920. 
Liu, C. Y., and Kaufman, R. J. (2003). The unfolded protein response. J Cell Sci 
116, 1861-2. 
Liu, C. Y., Schroder, M., and Kaufman, R. J. (2000). Ligand-independent 
dimerization activates the stress response kinases IRE1 and PERK in the 
lumen of the endoplasmic reticulum. J Biol Chem 275, 24881-5. 
Liu, C. Y., Wong, H. N., Schauerte, J. A., and Kaufman, R. J. (2002). The protein 
kinase/endoribonuclease IRE1alpha that signals the unfolded protein 
response has a luminal N-terminal ligand-independent dimerization 
domain. J Biol Chem 277, 18346-56. 
 
 
XI. Reference list    190 
 
Liu, M., Hodish, I., Haataja, L., Lara-Lemus, R., Rajpal, G., Wright, J., and 
Arvan, P. (2010). Proinsulin misfolding and diabetes: mutant INS gene-
induced diabetes of youth. Trends Endocrinol Metab 21, 652-9. 
Liu, M., Hodish, I., Rhodes, C. J., and Arvan, P. (2007). Proinsulin maturation, 
misfolding, and proteotoxicity. Proc Natl Acad Sci U S A 104, 15841-6. 
Liu, M., Li, Y., Cavener, D., and Arvan, P. (2005). Proinsulin disulfide maturation 
and misfolding in the endoplasmic reticulum. J Biol Chem 280, 13209-12. 
Lohr, M., Lubbersmeyer, J., Otremba, B., Klapdor, R., Grossner, D., and Kloppel, 
G. (1989). Increase in B-cells in the pancreatic remnant after partial 
pancreatectomy in pigs. An immunocytochemical and functional study. 
Virchows Arch B Cell Pathol Incl Mol Pathol 56, 277-86. 
Lottmann, H., Vanselow, J., Hessabi, B., and Walther, R. (2001). The Tet-On 
system in transgenic mice: inhibition of the mouse pdx-1 gene activity by 
antisense RNA expression in pancreatic beta-cells. J Mol Med (Berl) 79, 
321-8. 
Louet, J. F., LeMay, C., and Mauvais-Jarvis, F. (2004). Antidiabetic actions of 
estrogen: insight from human and genetic mouse models. Curr Atheroscler 
Rep 6, 180-5. 
Lu, J., Li, Q., Xie, H., Chen, Z. J., Borovitskaya, A. E., Maclaren, N. K., Notkins, 
A. L., and Lan, M. S. (1996). Identification of a second transmembrane 
protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-
dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. 
Proc Natl Acad Sci U S A 93, 2307-11. 
Lu, P. D., Harding, H. P., and Ron, D. (2004). Translation reinitiation at 
alternative open reading frames regulates gene expression in an integrated 
stress response. J Cell Biol 167, 27-33. 
Ludvik, B., Nolan, J. J., Baloga, J., Sacks, D., and Olefsky, J. (1995). Effect of 
obesity on insulin resistance in normal subjects and patients with NIDDM. 
Diabetes 44, 1121-5. 
Lukinius, A., Korsgren, O., Grimelius, L., and Wilander, E. (1996). Expression of 
islet amyloid polypeptide in fetal and adult porcine and human pancreatic 
islet cells. Endocrinology 137, 5319-25. 
Lunney, J. K. (2007). Advances in swine biomedical model genomics. Int J Biol 
Sci 3, 179-84. 
Ma, Y., Brewer, J. W., Diehl, J. A., and Hendershot, L. M. (2002). Two distinct 
stress signaling pathways converge upon the CHOP promoter during the 
mammalian unfolded protein response. J Mol Biol 318, 1351-65. 
Ma, Y., and Hendershot, L. M. (2002). The mammalian endoplasmic reticulum as 
a sensor for cellular stress. Cell Stress Chaperones 7, 222-9. 
Maedler, K., Schulthess, F. T., Bielman, C., Berney, T., Bonny, C., Prentki, M., 
Donath, M. Y., and Roduit, R. (2008). Glucose and leptin induce apoptosis 
in human beta-cells and impair glucose-stimulated insulin secretion 
through activation of c-Jun N-terminal kinases. FASEB J 22, 1905-13. 
Maes, M., Underwood, L. E., and Ketelslegers, J. M. (1986). Low serum 
somatomedin-C in insulin-dependent diabetes: evidence for a postreceptor 
mechanism. Endocrinology 118, 377-82. 
Mahimainathan, L., Das, F., Venkatesan, B., and Choudhury, G. G. (2006). 
Mesangial cell hypertrophy by high glucose is mediated by 
downregulation of the tumor suppressor PTEN. Diabetes 55, 2115-25. 
Malaisse, W. J. (1982). Alloxan toxicity to the pancreatic B-cell. A new 
hypothesis. Biochem Pharmacol 31, 3527-34. 
 
XI. Reference list    191 
 
Malecki, M. T., Jhala, U. S., Antonellis, A., Fields, L., Doria, A., Orban, T., Saad, 
M., Warram, J. H., Montminy, M., and Krolewski, A. S. (1999). Mutations 
in NEUROD1 are associated with the development of type 2 diabetes 
mellitus. Nat Genet 23, 323-8. 
Malecki, M. T., and Mlynarski, W. (2008). Monogenic diabetes: implications for 
therapy of rare types of disease. Diabetes Obes Metab 10, 607-16. 
Marciniak, S. J., Yun, C. Y., Oyadomari, S., Novoa, I., Zhang, Y., Jungreis, R., 
Nagata, K., Harding, H. P., and Ron, D. (2004). CHOP induces death by 
promoting protein synthesis and oxidation in the stressed endoplasmic 
reticulum. Genes Dev 18, 3066-77. 
Marquardt, T., and Helenius, A. (1992). Misfolding and aggregation of newly 
synthesized proteins in the endoplasmic reticulum. J Cell Biol 117, 505-
13. 
Mason, R. M., and Wahab, N. A. (2003). Extracellular matrix metabolism in 
diabetic nephropathy. J Am Soc Nephrol 14, 1358-73. 
Matschinsky, F. M., Glaser, B., and Magnuson, M. A. (1998). Pancreatic beta-cell 
glucokinase: closing the gap between theoretical concepts and 
experimental realities. Diabetes 47, 307-15. 
Matsunari, H., and Nagashima, H. (2009). Application of genetically modified 
and cloned pigs in translational research. J Reprod Dev 55, 225-30. 
Matsuoka, T. A., Zhao, L., Artner, I., Jarrett, H. W., Friedman, D., Means, A., and 
Stein, R. (2003). Members of the large Maf transcription family regulate 
insulin gene transcription in islet beta cells. Mol Cell Biol 23, 6049-62. 
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., 
and Turner, R. C. (1985). Homeostasis model assessment: insulin 
resistance and beta-cell function from fasting plasma glucose and insulin 
concentrations in man. Diabetologia 28, 412-9. 
Mayer, J. P., Zhang, F., and DiMarchi, R. D. (2007). Insulin structure and 
function. Biopolymers 88, 687-713. 
Maytin, E. V., Ubeda, M., Lin, J. C., and Habener, J. F. (2001). Stress-inducible 
transcription factor CHOP/gadd153 induces apoptosis in mammalian cells 
via p38 kinase-dependent and -independent mechanisms. Exp Cell Res 
267, 193-204. 
McCullough, K. D., Martindale, J. L., Klotz, L. O., Aw, T. Y., and Holbrook, N. 
J. (2001). Gadd153 sensitizes cells to endoplasmic reticulum stress by 
down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell 
Biol 21, 1249-59. 
Melloul, D., Ben-Neriah, Y., and Cerasi, E. (1993). Glucose modulates the 
binding of an islet-specific factor to a conserved sequence within the rat I 
and the human insulin promoters. Proc Natl Acad Sci U S A 90, 3865-9. 
Melo, E. O., Canavessi, A. M., Franco, M. M., and Rumpf, R. (2007). Animal 
transgenesis: state of the art and applications. J Appl Genet 48, 47-61. 
Melville, M. W., Tan, S. L., Wambach, M., Song, J., Morimoto, R. I., and Katze, 
M. G. (1999). The cellular inhibitor of the PKR protein kinase, P58(IPK), 
is an influenza virus-activated co-chaperone that modulates heat shock 
protein 70 activity. J Biol Chem 274, 3797-803. 
Menge, B. A., Tannapfel, A., Belyaev, O., Drescher, R., Muller, C., Uhl, W., 
Schmidt, W. E., and Meier, J. J. (2008). Partial pancreatectomy in adult 
humans does not provoke beta-cell regeneration. Diabetes 57, 142-9. 
 
 
 
XI. Reference list    192 
 
Menting, J. G., Whittaker, J., Margetts, M. B., Whittaker, L. J., Kong, G. K., 
Smith, B. J., Watson, C. J., Zakova, L., Kletvikova, E., Jiracek, J., Chan, 
S. J., Steiner, D. F., Dodson, G. G., Brzozowski, A. M., Weiss, M. A., 
Ward, C. W., and Lawrence, M. C. (2013). How insulin engages its 
primary binding site on the insulin receptor. Nature 493, 241-5. 
Merger, S. R., Leslie, R. D., and Boehm, B. O. (2012). The broad clinical 
phenotype of Type 1 diabetes at presentation. Diabet Med. 
Metzger, B. E., Buchanan, T. A., Coustan, D. R., de Leiva, A., Dunger, D. B., 
Hadden, D. R., Hod, M., Kitzmiller, J. L., Kjos, S. L., Oats, J. N., Pettitt, 
D. J., Sacks, D. A., and Zoupas, C. (2007). Summary and 
recommendations of the Fifth International Workshop-Conference on 
Gestational Diabetes Mellitus. Diabetes Care 30 Suppl 2, S251-60. 
Meyer, W. (1996). [Comments on the suitability of swine skin as a biological 
model for human skin]. Hautarzt 47, 178-82. 
Miller, E. R., and Ullrey, D. E. (1987). The pig as a model for human nutrition. 
Annu Rev Nutr 7, 361-82. 
Mirmira, R. G., Nakagawa, S. H., and Tager, H. S. (1991). Importance of the 
character and configuration of residues B24, B25, and B26 in insulin-
receptor interactions. J Biol Chem 266, 1428-36. 
Mirmira, R. G., and Tager, H. S. (1989). Role of the phenylalanine B24 side chain 
in directing insulin interaction with its receptor. Importance of main chain 
conformation. J Biol Chem 264, 6349-54. 
Mizisin, A. P., Nelson, R. W., Sturges, B. K., Vernau, K. M., Lecouteur, R. A., 
Williams, D. C., Burgers, M. L., and Shelton, G. D. (2007). Comparable 
myelinated nerve pathology in feline and human diabetes mellitus. Acta 
Neuropathol 113, 431-42. 
Mogensen, C. E., Christensen, C. K., and Vittinghus, E. (1983). The stages in 
diabetic renal disease. With emphasis on the stage of incipient diabetic 
nephropathy. Diabetes 32 Suppl 2, 64-78. 
Molven, A., Ringdal, M., Nordbo, A. M., Raeder, H., Stoy, J., Lipkind, G. M., 
Steiner, D. F., Philipson, L. H., Bergmann, I., Aarskog, D., Undlien, D. E., 
Joner, G., Sovik, O., Norwegian Childhood Diabetes Study, G., Bell, G. I., 
and Njolstad, P. R. (2008). Mutations in the insulin gene can cause MODY 
and autoantibody-negative type 1 diabetes. Diabetes 57, 1131-5. 
Monshouwer, M., and Witkamp, R. F. (2000). Cytochromes and cytokines: 
changes in drug disposition in animals during an acute phase response: a 
mini-review. Vet Q 22, 17-20. 
Moody, A. J., Thim, L., and Valverde, I. (1984). The isolation and sequencing of 
human gastric inhibitory peptide (GIP). FEBS Lett 172, 142-8. 
Morishima, N., Nakanishi, K., Takenouchi, H., Shibata, T., and Yasuhiko, Y. 
(2002). An endoplasmic reticulum stress-specific caspase cascade in 
apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-
12. J Biol Chem 277, 34287-94. 
Mouse Genome Sequencing, C., Waterston, R. H., Lindblad-Toh, K., Birney, E., 
Rogers, J., Abril, J. F., Agarwal, P., Agarwala, R., Ainscough, R., 
Alexandersson, M., et al. (2002). Initial sequencing and comparative 
analysis of the mouse genome. Nature 420, 520-62. 
Murakami, T., Hitomi, S., Ohtsuka, A., Taguchi, T., and Fujita, T. (1997). 
Pancreatic insulo-acinar portal systems in humans, rats, and some other 
mammals: scanning electron microscopy of vascular casts. Microsc Res 
Tech 37, 478-88. 
 
XI. Reference list    193 
 
Nadanaka, S., Okada, T., Yoshida, H., and Mori, K. (2007). Role of disulfide 
bridges formed in the luminal domain of ATF6 in sensing endoplasmic 
reticulum stress. Mol Cell Biol 27, 1027-43. 
Nadanaka, S., Yoshida, H., Kano, F., Murata, M., and Mori, K. (2004). Activation 
of mammalian unfolded protein response is compatible with the quality 
control system operating in the endoplasmic reticulum. Mol Biol Cell 15, 
2537-48. 
Nadav, E., Shmueli, A., Barr, H., Gonen, H., Ciechanover, A., and Reiss, Y. 
(2003). A novel mammalian endoplasmic reticulum ubiquitin ligase 
homologous to the yeast Hrd1. Biochem Biophys Res Commun 303, 91-7. 
Nakagawa, S. H., Hua, Q. X., Hu, S. Q., Jia, W., Wang, S., Katsoyannis, P. G., 
and Weiss, M. A. (2006). Chiral mutagenesis of insulin. Contribution of 
the B20-B23 beta-turn to activity and stability. J Biol Chem 281, 22386-
96. 
Nakagawa, S. H., and Tager, H. S. (1991). Implications of invariant residue 
LeuB6 in insulin-receptor interactions. J Biol Chem 266, 11502-9. 
Nakagawa, S. H., Zhao, M., Hua, Q. X., Hu, S. Q., Wan, Z. L., Jia, W., and 
Weiss, M. A. (2005). Chiral mutagenesis of insulin. Foldability and 
function are inversely regulated by a stereospecific switch in the B chain. 
Biochemistry 44, 4984-99. 
Nakagawa, T., and Yuan, J. (2000). Cross-talk between two cysteine protease 
families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 150, 
887-94. 
Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B. A., and Yuan, 
J. (2000). Caspase-12 mediates endoplasmic-reticulum-specific apoptosis 
and cytotoxicity by amyloid-beta. Nature 403, 98-103. 
Nanjo, K., Sanke, T., Miyano, M., Okai, K., Sowa, R., Kondo, M., Nishimura, S., 
Iwo, K., Miyamura, K., Given, B. D., and et al. (1986). Diabetes due to 
secretion of a structurally abnormal insulin (insulin Wakayama). Clinical 
and functional characteristics of [LeuA3] insulin. J Clin Invest 77, 514-9. 
Naya, F. J., Stellrecht, C. M., and Tsai, M. J. (1995). Tissue-specific regulation of 
the insulin gene by a novel basic helix-loop-helix transcription factor. 
Genes Dev 9, 1009-19. 
Neuhof, A., Rolls, M. M., Jungnickel, B., Kalies, K. U., and Rapoport, T. A. 
(1998). Binding of signal recognition particle gives ribosome/nascent 
chain complexes a competitive advantage in endoplasmic reticulum 
membrane interaction. Mol Biol Cell 9, 103-15. 
Nicol, D. S., and Smith, L. F. (1960). Amino-acid sequence of human insulin. 
Nature 187, 483-5. 
Nishitoh, H., Matsuzawa, A., Tobiume, K., Saegusa, K., Takeda, K., Inoue, K., 
Hori, S., Kakizuka, A., and Ichijo, H. (2002). ASK1 is essential for 
endoplasmic reticulum stress-induced neuronal cell death triggered by 
expanded polyglutamine repeats. Genes Dev 16, 1345-55. 
Nishitoh, H., Saitoh, M., Mochida, Y., Takeda, K., Nakano, H., Rothe, M., 
Miyazono, K., and Ichijo, H. (1998). ASK1 is essential for JNK/SAPK 
activation by TRAF2. Mol Cell 2, 389-95. 
Njolstad, P. R., Sovik, O., Cuesta-Munoz, A., Bjorkhaug, L., Massa, O., Barbetti, 
F., Undlien, D. E., Shiota, C., Magnuson, M. A., Molven, A., 
Matschinsky, F. M., and Bell, G. I. (2001). Neonatal diabetes mellitus due 
to complete glucokinase deficiency. N Engl J Med 344, 1588-92. 
 
 
XI. Reference list    194 
 
Noguchi, K., Kitanaka, C., Yamana, H., Kokubu, A., Mochizuki, T., and Kuchino, 
Y. (1999). Regulation of c-Myc through phosphorylation at Ser-62 and 
Ser-71 by c-Jun N-terminal kinase. J Biol Chem 274, 32580-7. 
Noiva, R. (1999). Protein disulfide isomerase: the multifunctional redox 
chaperone of the endoplasmic reticulum. Semin Cell Dev Biol 10, 481-93. 
Notkins, A. L., Lu, J., Li, Q., VanderVegt, F. P., Wasserfall, C., Maclaren, N. K., 
and Lan, M. S. (1996). IA-2 and IA-2 beta are major autoantigens in 
IDDM and the precursors of the 40 kDa and 37 kDa tryptic fragments. J 
Autoimmun 9, 677-82. 
Nyengaard, J. R. (1999). Stereologic methods and their application in kidney 
research. J Am Soc Nephrol 10, 1100-23. 
O'Brien, T. D., Butler, P. C., Westermark, P., and Johnson, K. H. (1993). Islet 
amyloid polypeptide: a review of its biology and potential roles in the 
pathogenesis of diabetes mellitus. Vet Pathol 30, 317-32. 
O'Brien, T. D., Wagner, J. D., Litwak, K. N., Carlson, C. S., Cefalu, W. T., 
Jordan, K., Johnson, K. H., and Butler, P. C. (1996). Islet amyloid and islet 
amyloid polypeptide in cynomolgus macaques (Macaca fascicularis): an 
animal model of human non-insulin-dependent diabetes mellitus. Vet 
Pathol 33, 479-85. 
Okada, T., Yoshida, H., Akazawa, R., Negishi, M., and Mori, K. (2002). Distinct 
roles of activating transcription factor 6 (ATF6) and double-stranded 
RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) 
in transcription during the mammalian unfolded protein response. Biochem 
J 366, 585-94. 
Oohashi, H., Ohgawara, H., Nanjo, K., Tasaka, Y., Cao, Q. P., Chan, S. J., 
Rubenstein, A. H., Steiner, D. F., and Omori, Y. (1993). Familial 
hyperproinsulinemia associated with NIDDM. A case study. Diabetes 
Care 16, 1340-6. 
Orskov, C. (1992). Glucagon-like peptide-1, a new hormone of the entero-insular 
axis. Diabetologia 35, 701-11. 
Osterby, R., and Gundersen, H. J. (1975). Glomerular size and structure in 
diabetes mellitus. I. Early abnormalities. Diabetologia 11, 225-9. 
Oyadomari, S., Koizumi, A., Takeda, K., Gotoh, T., Akira, S., Araki, E., and 
Mori, M. (2002). Targeted disruption of the Chop gene delays 
endoplasmic reticulum stress-mediated diabetes. J Clin Invest 109, 525-32. 
Oyadomari, S., and Mori, M. (2004). Roles of CHOP/GADD153 in endoplasmic 
reticulum stress. Cell Death Differ 11, 381-9. 
Pagtalunan, M. E., Miller, P. L., Jumping-Eagle, S., Nelson, R. G., Myers, B. D., 
Rennke, H. G., Coplon, N. S., Sun, L., and Meyer, T. W. (1997). Podocyte 
loss and progressive glomerular injury in type II diabetes. J Clin Invest 99, 
342-8. 
Pain, V. M. (1996). Initiation of protein synthesis in eukaryotic cells. Eur J 
Biochem 236, 747-71. 
Park, S. Y., Ye, H., Steiner, D. F., and Bell, G. I. (2010). Mutant proinsulin 
proteins associated with neonatal diabetes are retained in the endoplasmic 
reticulum and not efficiently secreted. Biochem Biophys Res Commun 391, 
1449-54. 
Parodi, A. J. (2000). Protein glucosylation and its role in protein folding. Annu 
Rev Biochem 69, 69-93. 
Patil, C., and Walter, P. (2001). Intracellular signaling from the endoplasmic 
reticulum to the nucleus: the unfolded protein response in yeast and 
mammals. Curr Opin Cell Biol 13, 349-55. 
XI. Reference list    195 
 
Pearson, E. R., Starkey, B. J., Powell, R. J., Gribble, F. M., Clark, P. M., and 
Hattersley, A. T. (2003). Genetic cause of hyperglycaemia and response to 
treatment in diabetes. Lancet 362, 1275-81. 
Petrash, J. M. (2004). All in the family: aldose reductase and closely related aldo-
keto reductases. Cell Mol Life Sci 61, 737-49. 
Pociot, F., and McDermott, M. F. (2002). Genetics of type 1 diabetes mellitus. 
Genes Immun 3, 235-49. 
Polak, M., and Cave, H. (2007). Neonatal diabetes mellitus: a disease linked to 
multiple mechanisms. Orphanet J Rare Dis 2, 12. 
Polak, M., Dechaume, A., Cave, H., Nimri, R., Crosnier, H., Sulmont, V., de 
Kerdanet, M., Scharfmann, R., Lebenthal, Y., Froguel, P., Vaxillaire, M., 
and French, N. D. S. G. (2008). Heterozygous missense mutations in the 
insulin gene are linked to permanent diabetes appearing in the neonatal 
period or in early infancy: a report from the French ND (Neonatal 
Diabetes) Study Group. Diabetes 57, 1115-9. 
Polejaeva, I. A., Chen, S. H., Vaught, T. D., Page, R. L., Mullins, J., Ball, S., Dai, 
Y., Boone, J., Walker, S., Ayares, D. L., Colman, A., and Campbell, K. H. 
(2000). Cloned pigs produced by nuclear transfer from adult somatic cells. 
Nature 407, 86-90. 
Potter, K. J., Abedini, A., Marek, P., Klimek, A. M., Butterworth, S., Driscoll, M., 
Baker, R., Nilsson, M. R., Warnock, G. L., Oberholzer, J., Bertera, S., 
Trucco, M., Korbutt, G. S., Fraser, P. E., Raleigh, D. P., and Verchere, C. 
B. (2010). Islet amyloid deposition limits the viability of human islet 
grafts but not porcine islet grafts. Proc Natl Acad Sci U S A 107, 4305-10. 
Prather, R. S., Hawley, R. J., Carter, D. B., Lai, L., and Greenstein, J. L. (2003). 
Transgenic swine for biomedicine and agriculture. Theriogenology 59, 
115-23. 
Prather, R. S., Ross, J. W., Isom, S. C., and Green, J. A. (2009). Transcriptional, 
post-transcriptional and epigenetic control of porcine oocyte maturation 
and embryogenesis. Soc Reprod Fertil Suppl 66, 165-76. 
Quesada, I., Tuduri, E., Ripoll, C., and Nadal, A. (2008). Physiology of the 
pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis 
and diabetes. J Endocrinol 199, 5-19. 
Qvist, M. H., Hoeck, U., Kreilgaard, B., Madsen, F., and Frokjaer, S. (2000). 
Evaluation of Gottingen minipig skin for transdermal in vitro permeation 
studies. Eur J Pharm Sci 11, 59-68. 
Rahier, J., Goebbels, R. M., and Henquin, J. C. (1983). Cellular composition of 
the human diabetic pancreas. Diabetologia 24, 366-71. 
Rajan, S., Eames, S. C., Park, S. Y., Labno, C., Bell, G. I., Prince, V. E., and 
Philipson, L. H. (2010). In vitro processing and secretion of mutant insulin 
proteins that cause permanent neonatal diabetes. Am J Physiol Endocrinol 
Metab 298, E403-10. 
Ramachandran, A., Snehalatha, C., Latha, E., Manoharan, M., and Vijay, V. 
(1999). Impacts of urbanisation on the lifestyle and on the prevalence of 
diabetes in native Asian Indian population. Diabetes Res Clin Pract 44, 
207-13. 
Ramage, I. J., Howatson, A. G., McColl, J. H., Maxwell, H., Murphy, A. V., and 
Beattie, T. J. (2002). Glomerular basement membrane thickness in 
children: a stereologic assessment. Kidney Int 62, 895-900. 
Ramji, D. P., and Foka, P. (2002). CCAAT/enhancer-binding proteins: structure, 
function and regulation. Biochem J 365, 561-75. 
 
XI. Reference list    196 
 
Rao, R. V., Ellerby, H. M., and Bredesen, D. E. (2004). Coupling endoplasmic 
reticulum stress to the cell death program. Cell Death Differ 11, 372-80. 
Rao, R. V., Hermel, E., Castro-Obregon, S., del Rio, G., Ellerby, L. M., Ellerby, 
H. M., and Bredesen, D. E. (2001). Coupling endoplasmic reticulum stress 
to the cell death program. Mechanism of caspase activation. J Biol Chem 
276, 33869-74. 
Recillas-Targa, F. (2006). Multiple strategies for gene transfer, expression, 
knockdown, and chromatin influence in mammalian cell lines and 
transgenic animals. Mol Biotechnol 34, 337-54. 
Rees, D. A., and Alcolado, J. C. (2005). Animal models of diabetes mellitus. 
Diabet Med 22, 359-70. 
Ren, B., Tibbelin, G., de Pascale, D., Rossi, M., Bartolucci, S., and Ladenstein, R. 
(1998). A protein disulfide oxidoreductase from the archaeon Pyrococcus 
furiosus contains two thioredoxin fold units. Nat Struct Biol 5, 602-11. 
Renner, S., Braun-Reichhart, C., Blutke, A., Herbach, N., Emrich, D., Streckel, 
E., Wunsch, A., Kessler, B., Kurome, M., Bahr, A., Klymiuk, N., Krebs, 
S., Puk, O., Nagashima, H., Graw, J., Blum, H., Wanke, R., and Wolf, E. 
(2012). Permanent Neonatal Diabetes in INSC94Y Transgenic Pigs. 
Diabetes. 
Renner, S., Fehlings, C., Herbach, N., Hofmann, A., von Waldthausen, D. C., 
Kessler, B., Ulrichs, K., Chodnevskaja, I., Moskalenko, V., Amselgruber, 
W., Goke, B., Pfeifer, A., Wanke, R., and Wolf, E. (2010). Glucose 
intolerance and reduced proliferation of pancreatic beta-cells in transgenic 
pigs with impaired glucose-dependent insulinotropic polypeptide function. 
Diabetes 59, 1228-38. 
reviewed in Martin, R. J., Ramsay, T. G., and Harris, R. B. S. (1984). Central role 
of insulin in growth and development. Domestic Animal Endocrinology 1, 
89-104. 
reviewed in Thrailkill, K. M., Lumpkin, C. K., Jr., Bunn, R. C., Kemp, S. F., and 
Fowlkes, J. L. (2005). Is insulin an anabolic agent in bone? Dissecting the 
diabetic bone for clues. Am J Physiol Endocrinol Metab 289, E735-45. 
Reynolds, E. S. (1963). The use of lead citrate at high pH as an electron-opaque 
stain in electron microscopy. J Cell Biol 17, 208-12. 
Roberts, R. M., Smith, G. W., Bazer, F. W., Cibelli, J., Seidel, G. E., Jr., Bauman, 
D. E., Reynolds, L. P., and Ireland, J. J. (2009). Research priorities. Farm 
animal research in crisis. Science 324, 468-9. 
Robertson, R. P. (2004). Chronic oxidative stress as a central mechanism for 
glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279, 
42351-4. 
Robertson, R. P., Zhang, H. J., Pyzdrowski, K. L., and Walseth, T. F. (1992). 
Preservation of insulin mRNA levels and insulin secretion in HIT cells by 
avoidance of chronic exposure to high glucose concentrations. J Clin 
Invest 90, 320-5. 
Rogatsky, I., Logan, S. K., and Garabedian, M. J. (1998). Antagonism of 
glucocorticoid receptor transcriptional activation by the c-Jun N-terminal 
kinase. Proc Natl Acad Sci U S A 95, 2050-5. 
Roglic, G., and Unwin, N. (2010). Mortality attributable to diabetes: estimates for 
the year 2010. Diabetes Res Clin Pract 87, 15-9. 
Ron, D. (2002). Translational control in the endoplasmic reticulum stress 
response. J Clin Invest 110, 1383-8. 
 
 
XI. Reference list    197 
 
Ron, D., and Habener, J. F. (1992). CHOP, a novel developmentally regulated 
nuclear protein that dimerizes with transcription factors C/EBP and LAP 
and functions as a dominant-negative inhibitor of gene transcription. 
Genes Dev 6, 439-53. 
Rosenthal, M., Doberne, L., Greenfield, M., Widstrom, A., and Reaven, G. M. 
(1982). Effect of age on glucose tolerance, insulin secretion, and in vivo 
insulin action. J Am Geriatr Soc 30, 562-7. 
Roy, B., and Lee, A. S. (1999). The mammalian endoplasmic reticulum stress 
response element consists of an evolutionarily conserved tripartite 
structure and interacts with a novel stress-inducible complex. Nucleic 
Acids Res 27, 1437-43. 
Rubio-Cabezas, O., Edghill, E. L., Argente, J., and Hattersley, A. T. (2009). 
Testing for monogenic diabetes among children and adolescents with 
antibody-negative clinically defined Type 1 diabetes. Diabet Med 26, 
1070-4. 
Rudolf, M. C., Sherwin, R. S., Markowitz, R., Bates, S. E., Genel, M., Hochstadt, 
J., and Tamborlane, W. V. (1982). Effect of intensive insulin treatment on 
linear growth in the young diabetic patient. J Pediatr 101, 333-9. 
Russell, W. L., Kelly, E. M., Hunsicker, P. R., Bangham, J. W., Maddux, S. C., 
and Phipps, E. L. (1979). Specific-locus test shows ethylnitrosourea to be 
the most potent mutagen in the mouse. Proc Natl Acad Sci U S A 76, 
5818-9. 
Rutkowski, D. T., and Kaufman, R. J. (2004). A trip to the ER: coping with stress. 
Trends Cell Biol 14, 20-8. 
Salardi, S., Tonioli, S., Tassoni, P., Tellarini, M., Mazzanti, L., and Cacciari, E. 
(1987). Growth and growth factors in diabetes mellitus. Arch Dis Child 62, 
57-62. 
Salehi, A., Vieira, E., and Gylfe, E. (2006). Paradoxical stimulation of glucagon 
secretion by high glucose concentrations. Diabetes 55, 2318-23. 
Samuel, C. E. (1993). The eIF-2 alpha protein kinases, regulators of translation in 
eukaryotes from yeasts to humans. J Biol Chem 268, 7603-6. 
Sanger, F. (1959). Chemistry of insulin; determination of the structure of insulin 
opens the way to greater understanding of life processes. Science 129, 
1340-4. 
Santiago, J. V., McAlister, W. H., Ratzan, S. K., Bussman, Y., Haymond, M. W., 
Shackelford, G., and Weldon, V. V. (1977). Decreased cortical thickness 
& osteopenia in children with diabetes mellitus. J Clin Endocrinol Metab 
45, 845-8. 
Sayeed, A., and Ng, D. T. (2005). Search and destroy: ER quality control and ER-
associated protein degradation. Crit Rev Biochem Mol Biol 40, 75-91. 
Sayuk, G. S., Elwing, J. E., and Lisker-Melman, M. (2007). Hepatic glycogenosis: 
an underrecognized source of abnormal liver function tests? Dig Dis Sci 
52, 936-8. 
Scherle, W. (1970). A simple method for volumetry of organs in quantitative 
stereology. Mikroskopie 26, 57-60. 
Scheuner, D., and Kaufman, R. J. (2008). The unfolded protein response: a 
pathway that links insulin demand with beta-cell failure and diabetes. 
Endocr Rev 29, 317-33. 
Schnedl, W. J., Ferber, S., Johnson, J. H., and Newgard, C. B. (1994). STZ 
transport and cytotoxicity. Specific enhancement in GLUT2-expressing 
cells. Diabetes 43, 1326-33. 
 
XI. Reference list    198 
 
Schreiber, M., Kolbus, A., Piu, F., Szabowski, A., Mohle-Steinlein, U., Tian, J., 
Karin, M., Angel, P., and Wagner, E. F. (1999). Control of cell cycle 
progression by c-Jun is p53 dependent. Genes Dev 13, 607-19. 
Schroder, M., and Kaufman, R. J. (2005). ER stress and the unfolded protein 
response. Mutat Res 569, 29-63. 
Schuster, M. S. (2011). Impact of 17!Estradiol on !-cell survival of female 
Munich Ins2C95S mutant mice. Inaugural Dissertation, Ludwig 
Maximilians Universität, Munich. 
Scorrano, L., Oakes, S. A., Opferman, J. T., Cheng, E. H., Sorcinelli, M. D., 
Pozzan, T., and Korsmeyer, S. J. (2003). BAX and BAK regulation of 
endoplasmic reticulum Ca2+: a control point for apoptosis. Science 300, 
135-9. 
Scully, T. (2012). Diabetes in numbers. Nature 485, S2-3. 
Sellick, G. S., Barker, K. T., Stolte-Dijkstra, I., Fleischmann, C., Coleman, R. J., 
Garrett, C., Gloyn, A. L., Edghill, E. L., Hattersley, A. T., Wellauer, P. K., 
Goodwin, G., and Houlston, R. S. (2004). Mutations in PTF1A cause 
pancreatic and cerebellar agenesis. Nat Genet 36, 1301-5. 
Senee, V., Chelala, C., Duchatelet, S., Feng, D., Blanc, H., Cossec, J. C., Charon, 
C., Nicolino, M., Boileau, P., Cavener, D. R., Bougneres, P., Taha, D., and 
Julier, C. (2006). Mutations in GLIS3 are responsible for a rare syndrome 
with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet 
38, 682-7. 
Seyer-Hansen, K., Hansen, J., and Gundersen, H. J. (1980). Renal hypertrophy in 
experimental diabetes. A morphometric study. Diabetologia 18, 501-5. 
Sharma, A., Olson, L. K., Robertson, R. P., and Stein, R. (1995). The reduction of 
insulin gene transcription in HIT-T15 beta cells chronically exposed to 
high glucose concentration is associated with the loss of RIPE3b1 and 
STF-1 transcription factor expression. Mol Endocrinol 9, 1127-34. 
Shaw, J. E., Sicree, R. A., and Zimmet, P. Z. (2010). Global estimates of the 
prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87, 4-
14. 
Shen, J., Chen, X., Hendershot, L., and Prywes, R. (2002). ER stress regulation of 
ATF6 localization by dissociation of BiP/GRP78 binding and unmasking 
of Golgi localization signals. Dev Cell 3, 99-111. 
Shen, J., Snapp, E. L., Lippincott-Schwartz, J., and Prywes, R. (2005). Stable 
binding of ATF6 to BiP in the endoplasmic reticulum stress response. Mol 
Cell Biol 25, 921-32. 
Shi, Y., Vattem, K. M., Sood, R., An, J., Liang, J., Stramm, L., and Wek, R. C. 
(1998). Identification and characterization of pancreatic eukaryotic 
initiation factor 2 alpha-subunit kinase, PEK, involved in translational 
control. Mol Cell Biol 18, 7499-509. 
Shield, J. P. (2000). Neonatal diabetes: new insights into aetiology and 
implications. Horm Res 53 Suppl 1, 7-11. 
Shield, J. P., Gardner, R. J., Wadsworth, E. J., Whiteford, M. L., James, R. S., 
Robinson, D. O., Baum, J. D., and Temple, I. K. (1997). Aetiopathology 
and genetic basis of neonatal diabetes. Arch Dis Child Fetal Neonatal Ed 
76, F39-42. 
Slingerland, A. S. (2006). Monogenic diabetes in children and young adults: 
Challenges for researcher, clinician and patient. Rev Endocr Metab Disord 
7, 171-85. 
 
 
XI. Reference list    199 
 
Song, B., Scheuner, D., Ron, D., Pennathur, S., and Kaufman, R. J. (2008). Chop 
deletion reduces oxidative stress, improves beta cell function, and 
promotes cell survival in multiple mouse models of diabetes. J Clin Invest 
118, 3378-89. 
Sonnenberg, G. E., and Berger, M. (1983). Human insulin: much ado about one 
amino acid? Diabetologia 25, 457-9. 
Sousa, M., and Parodi, A. J. (1995). The molecular basis for the recognition of 
misfolded glycoproteins by the UDP-Glc:glycoprotein glucosyltransferase. 
EMBO J 14, 4196-203. 
Sousa, M. C., Ferrero-Garcia, M. A., and Parodi, A. J. (1992). Recognition of the 
oligosaccharide and protein moieties of glycoproteins by the UDP-
Glc:glycoprotein glucosyltransferase. Biochemistry 31, 97-105. 
Spengler, D., Villalba, M., Hoffmann, A., Pantaloni, C., Houssami, S., Bockaert, 
J., and Journot, L. (1997). Regulation of apoptosis and cell cycle arrest by 
Zac1, a novel zinc finger protein expressed in the pituitary gland and the 
brain. EMBO J 16, 2814-25. 
Srinivasan, K., and Ramarao, P. (2007). Animal models in type 2 diabetes 
research: an overview. Indian J Med Res 125, 451-72. 
Stefek, M., and Karasu, C. (2011). Eye lens in aging and diabetes: effect of 
quercetin. Rejuvenation Res 14, 525-34. 
Steiner, D. F., Tager, H. S., Chan, S. J., Nanjo, K., Sanke, T., and Rubenstein, A. 
H. (1990). Lessons learned from molecular biology of insulin-gene 
mutations. Diabetes Care 13, 600-9. 
Steiner, D. J., Kim, A., Miller, K., and Hara, M. (2010). Pancreatic islet plasticity: 
interspecies comparison of islet architecture and composition. Islets 2, 
135-45. 
Stoffel, M., and Duncan, S. A. (1997). The maturity-onset diabetes of the young 
(MODY1) transcription factor HNF4alpha regulates expression of genes 
required for glucose transport and metabolism. Proc Natl Acad Sci U S A 
94, 13209-14. 
Stoffers, D. A., Ferrer, J., Clarke, W. L., and Habener, J. F. (1997a). Early-onset 
type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 17, 138-9. 
Stoffers, D. A., Zinkin, N. T., Stanojevic, V., Clarke, W. L., and Habener, J. F. 
(1997b). Pancreatic agenesis attributable to a single nucleotide deletion in 
the human IPF1 gene coding sequence. Nat Genet 15, 106-10. 
Stone, B. G., and Van Thiel, D. H. (1985). Diabetes mellitus and the liver. Semin 
Liver Dis 5, 8-28. 
Stoy, J., Edghill, E. L., Flanagan, S. E., Ye, H., Paz, V. P., Pluzhnikov, A., Below, 
J. E., Hayes, M. G., Cox, N. J., Lipkind, G. M., Lipton, R. B., Greeley, S. 
A., Patch, A. M., Ellard, S., Steiner, D. F., Hattersley, A. T., Philipson, L. 
H., and Bell, G. I. (2007). Insulin gene mutations as a cause of permanent 
neonatal diabetes. Proc Natl Acad Sci U S A 104, 15040-4. 
Stoy, J., Steiner, D. F., Park, S. Y., Ye, H., Philipson, L. H., and Bell, G. I. (2010). 
Clinical and molecular genetics of neonatal diabetes due to mutations in 
the insulin gene. Rev Endocr Metab Disord 11, 205-15. 
Strasser-Vogel, B., Blum, W. F., Past, R., Kessler, U., Hoeflich, A., Meiler, B., 
and Kiess, W. (1995). Insulin-like growth factor (IGF)-I and -II and IGF-
binding proteins-1, -2, and -3 in children and adolescents with diabetes 
mellitus: correlation with metabolic control and height attainment. J Clin 
Endocrinol Metab 80, 1207-13. 
 
 
XI. Reference list    200 
 
Stump, K. C., Swindle, M. M., Saudek, C. D., and Strandberg, J. D. (1988). 
Pancreatectomized swine as a model of diabetes mellitus. Lab Anim Sci 
38, 439-43. 
Sundar Rajan, S., Srinivasan, V., Balasubramanyam, M., and Tatu, U. (2007). 
Endoplasmic reticulum (ER) stress & diabetes. Indian J Med Res 125, 
411-24. 
Swindle, M. M. i. C., P.  M., ed. (2008). "Sourcebook of models for biomedical 
research." Humana Press Inc., Totowa, , NJ 233-239. 
Szegezdi, E., Logue, S. E., Gorman, A. M., and Samali, A. (2006). Mediators of 
endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7, 880-5. 
Tager, H., Given, B., Baldwin, D., Mako, M., Markese, J., Rubenstein, A., 
Olefsky, J., Kobayashi, M., Kolterman, O., and Poucher, R. (1979). A 
structurally abnormal insulin causing human diabetes. Nature 281, 122-5. 
Tao, B., Pietropaolo, M., Atkinson, M., Schatz, D., and Taylor, D. (2010). 
Estimating the cost of type 1 diabetes in the U.S.: a propensity score 
matching method. PLoS One 5, e11501. 
Tattersall, R. B., and Pyke, D. A. (1973). Growth in diabetic children. Studies in 
identical twins. Lancet 2, 1105-9. 
Taylor, D. R., Lee, S. B., Romano, P. R., Marshak, D. R., Hinnebusch, A. G., 
Esteban, M., and Mathews, M. B. (1996). Autophosphorylation sites 
participate in the activation of the double-stranded-RNA-activated protein 
kinase PKR. Mol Cell Biol 16, 6295-302. 
Temple, I. K., Gardner, R. J., Robinson, D. O., Kibirige, M. S., Ferguson, A. W., 
Baum, J. D., Barber, J. C., James, R. S., and Shield, J. P. (1996). Further 
evidence for an imprinted gene for neonatal diabetes localised to 
chromosome 6q22-q23. Hum Mol Genet 5, 1117-21. 
Tesfaye, S., Chaturvedi, N., Eaton, S. E., Ward, J. D., Manes, C., Ionescu-
Tirgoviste, C., Witte, D. R., Fuller, J. H., and Group, E. P. C. S. (2005). 
Vascular risk factors and diabetic neuropathy. N Engl J Med 352, 341-50. 
Tiedge, M., Richter, T., and Lenzen, S. (2000). Importance of cysteine residues 
for the stability and catalytic activity of human pancreatic beta cell 
glucokinase. Arch Biochem Biophys 375, 251-60. 
Tirasophon, W., Lee, K., Callaghan, B., Welihinda, A., and Kaufman, R. J. 
(2000). The endoribonuclease activity of mammalian IRE1 autoregulates 
its mRNA and is required for the unfolded protein response. Genes Dev 
14, 2725-36. 
Tirasophon, W., Welihinda, A. A., and Kaufman, R. J. (1998). A stress response 
pathway from the endoplasmic reticulum to the nucleus requires a novel 
bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. 
Genes Dev 12, 1812-24. 
Tjalve, H., Wilander, E., and Johansson, E. B. (1976). Distribution of labeled 
streptozotocin in mice: uptake and retention in pancreatic islets. J 
Endocrinol 69, 455-6. 
Toledo, F. G., Sniderman, A. D., and Kelley, D. E. (2006). Influence of hepatic 
steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 
diabetes. Diabetes Care 29, 1845-50. 
Torbenson, M., Chen, Y. Y., Brunt, E., Cummings, O. W., Gottfried, M., Jakate, 
S., Liu, Y. C., Yeh, M. M., and Ferrell, L. (2006). Glycogenic 
hepatopathy: an underrecognized hepatic complication of diabetes 
mellitus. Am J Surg Pathol 30, 508-13. 
Torres, M., and Lopez, D. (2001). Liver glycogen storage associated with 
uncontrolled type 1 diabetes mellitus. J Hepatol 35, 538. 
XI. Reference list    201 
 
Tournier, C., Hess, P., Yang, D. D., Xu, J., Turner, T. K., Nimnual, A., Bar-Sagi, 
D., Jones, S. N., Flavell, R. A., and Davis, R. J. (2000). Requirement of 
JNK for stress-induced activation of the cytochrome c-mediated death 
pathway. Science 288, 870-4. 
Turner, R. C., Holman, R. R., Matthews, D., Hockaday, T. D., and Peto, J. (1979). 
Insulin deficiency and insulin resistance interaction in diabetes: estimation 
of their relative contribution by feedback analysis from basal plasma 
insulin and glucose concentrations. Metabolism 28, 1086-96. 
Turner, R. C., Mathews, D. R., Holman, R. R., and Peto, J. (1982). Relative 
contributions of insulin deficiency and insulin resistance in maturity-onset 
diabetes. Lancet 1, 596-8. 
Turner, R. C., Matthews, D. R., Clark, A., O'Rahilly, S., Rudenski, A. S., and 
Levy, J. (1988). Pathogenesis of NIDDM--a disease of deficient insulin 
secretion. Baillieres Clin Endocrinol Metab 2, 327-42. 
Tyrberg, B., Ustinov, J., Otonkoski, T., and Andersson, A. (2001). Stimulated 
endocrine cell proliferation and differentiation in transplanted human 
pancreatic islets: effects of the ob gene and compensatory growth of the 
implantation organ. Diabetes 50, 301-7. 
Uchigata, Y., Yamamoto, H., Kawamura, A., and Okamoto, H. (1982). Protection 
by superoxide dismutase, catalase, and poly(ADP-ribose) synthetase 
inhibitors against alloxan- and streptozotocin-induced islet DNA strand 
breaks and against the inhibition of proinsulin synthesis. J Biol Chem 257, 
6084-8. 
Umeyama, K., Watanabe, M., Saito, H., Kurome, M., Tohi, S., Matsunari, H., 
Miki, K., and Nagashima, H. (2009). Dominant-negative mutant 
hepatocyte nuclear factor 1alpha induces diabetes in transgenic-cloned 
pigs. Transgenic Res 18, 697-706. 
Unger, R. H., Aguilar-Parada, E., Muller, W. A., and Eisentraut, A. M. (1970). 
Studies of pancreatic alpha cell function in normal and diabetic subjects. J 
Clin Invest 49, 837-48. 
Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., and 
Ron, D. (2000). Coupling of stress in the ER to activation of JNK protein 
kinases by transmembrane protein kinase IRE1. Science 287, 664-6. 
Vachon, G., Laalami, S., Grunberg-Manago, M., Julien, R., and Cenatiempo, Y. 
(1990). Purified internal G-domain of translational initiation factor IF-2 
displays guanine nucleotide binding properties. Biochemistry 29, 9728-33. 
Vajta, G., Zhang, Y., and Machaty, Z. (2007). Somatic cell nuclear transfer in 
pigs: recent achievements and future possibilities. Reprod Fertil Dev 19, 
403-23. 
van Deijnen, J. H., Hulstaert, C. E., Wolters, G. H., and van Schilfgaarde, R. 
(1992). Significance of the peri-insular extracellular matrix for islet 
isolation from the pancreas of rat, dog, pig, and man. Cell Tissue Res 267, 
139-46. 
van der Kallen, C. J., van Greevenbroek, M. M., Stehouwer, C. D., and 
Schalkwijk, C. G. (2009). Endoplasmic reticulum stress-induced apoptosis 
in the development of diabetes: is there a role for adipose tissue and liver? 
Apoptosis 14, 1424-34. 
Van Lommel, L., Janssens, K., Quintens, R., Tsukamoto, K., Vander Mierde, D., 
Lemaire, K., Denef, C., Jonas, J. C., Martens, G., Pipeleers, D., and 
Schuit, F. C. (2006). Probe-independent and direct quantification of 
insulin mRNA and growth hormone mRNA in enriched cell preparations. 
Diabetes 55, 3214-20. 
XI. Reference list    202 
 
Vanelli, M., De Fanti, A., Cantoni, S., and Chiari, G. (1994). Transient neonatal 
diabetes mellitus: a relapse after 10 years of complete remission. Acta 
Diabetol 31, 116-8. 
Varma, S. D., and Kinoshita, J. H. (1974). The absence of cataracts in mice with 
congenital hyperglycemia. Exp Eye Res 19, 577-82. 
Vattem, K. M., and Wek, R. C. (2004). Reinitiation involving upstream ORFs 
regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad 
Sci U S A 101, 11269-74. 
Vaxillaire, M., Boccio, V., Philippi, A., Vigouroux, C., Terwilliger, J., Passa, P., 
Beckmann, J. S., Velho, G., Lathrop, G. M., and Froguel, P. (1995). A 
gene for maturity onset diabetes of the young (MODY) maps to 
chromosome 12q. Nat Genet 9, 418-23. 
Vaxillaire, M., and Froguel, P. (2006). Genetic basis of maturity-onset diabetes of 
the young. Endocrinol Metab Clin North Am 35, 371-84, x. 
Vaxillaire, M., Rouard, M., Yamagata, K., Oda, N., Kaisaki, P. J., Boriraj, V. V., 
Chevre, J. C., Boccio, V., Cox, R. D., Lathrop, G. M., Dussoix, P., 
Philippe, J., Timsit, J., Charpentier, G., Velho, G., Bell, G. I., and Froguel, 
P. (1997). Identification of nine novel mutations in the hepatocyte nuclear 
factor 1 alpha gene associated with maturity-onset diabetes of the young 
(MODY3). Hum Mol Genet 6, 583-6. 
Velho, G., and Froguel, P. (1998). Genetic, metabolic and clinical characteristics 
of maturity onset diabetes of the young. Eur J Endocrinol 138, 233-9. 
Velho, G., Petersen, K. F., Perseghin, G., Hwang, J. H., Rothman, D. L., Pueyo, 
M. E., Cline, G. W., Froguel, P., and Shulman, G. I. (1996). Impaired 
hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. J 
Clin Invest 98, 1755-61. 
Veriter, S., Aouassar, N., Beaurin, G., Goebbels, R. M., Gianello, P., and Dufrane, 
D. (2012). Improvement of Pig Islet Function by In Vivo Pancreatic 
Tissue Remodeling: A "Human-Like" Pig Islet Structure With 
Streptozotocin Treatment. Cell Transplant. 
Verspohl, E. J., and Ammon, H. P. (1980). Evidence for presence of insulin 
receptors in rat islets of Langerhans. J Clin Invest 65, 1230-7. 
von Heijne, G. (1988). Transcending the impenetrable: how proteins come to 
terms with membranes. Biochim Biophys Acta 947, 307-33. 
von Muhlendahl, K. E., and Herkenhoff, H. (1995). Long-term course of neonatal 
diabetes. N Engl J Med 333, 704-8. 
Vuorinen-Markkola, H., Koivisto, V. A., and Yki-Jarvinen, H. (1992). 
Mechanisms of hyperglycemia-induced insulin resistance in whole body 
and skeletal muscle of type I diabetic patients. Diabetes 41, 571-80. 
Wallace, T. M., Levy, J. C., and Matthews, D. R. (2004). Use and abuse of 
HOMA modeling. Diabetes Care 27, 1487-95. 
Walsh, G., and Jefferis, R. (2006). Post-translational modifications in the context 
of therapeutic proteins. Nat Biotechnol 24, 1241-52. 
Walter, P., and Johnson, A. E. (1994). Signal sequence recognition and protein 
targeting to the endoplasmic reticulum membrane. Annu Rev Cell Biol 10, 
87-119. 
Wang, C. C. (1998). Isomerase and chaperone activities of protein disulfide 
isomerase are both required for its function as a foldase. Biochemistry 
(Mosc) 63, 407-12. 
 
 
 
XI. Reference list    203 
 
Wang, H., Maechler, P., Ritz-Laser, B., Hagenfeldt, K. A., Ishihara, H., Philippe, 
J., and Wollheim, C. B. (2001). Pdx1 level defines pancreatic gene 
expression pattern and cell lineage differentiation. J Biol Chem 276, 
25279-86. 
Wang, J., Takeuchi, T., Tanaka, S., Kubo, S. K., Kayo, T., Lu, D., Takata, K., 
Koizumi, A., and Izumi, T. (1999). A mutation in the insulin 2 gene 
induces diabetes with severe pancreatic beta-cell dysfunction in the Mody 
mouse. J Clin Invest 103, 27-37. 
Wang, Y., Shen, J., Arenzana, N., Tirasophon, W., Kaufman, R. J., and Prywes, 
R. (2000). Activation of ATF6 and an ATF6 DNA binding site by the 
endoplasmic reticulum stress response. J Biol Chem 275, 27013-20. 
Wanke, R. (1996). zur Morpho- und Pathogenese der progressiven 
Glomerulosklerose. pp. 1-257. Ludwig-Maximilians-Universität München. 
Wanke, R., Weis, S., Kluge, D., Kahnt, E., Schenck, E., Brem, G. and Hermanns, 
W. (1994). Morphometric evaluation of the pancreas of growth hormone-
transgenic mice. Acta Stereologica 13, 3-3. 
Warren-Perry, M. G., Manley, S. E., Ostrega, D., Polonsky, K., Mussett, S., 
Brown, P., and Turner, R. C. (1997). A novel point mutation in the insulin 
gene giving rise to hyperproinsulinemia. J Clin Endocrinol Metab 82, 
1629-31. 
Watanabe, M., Umeyama, K., Kawano, H. O., Izuno, N., Nagashima, H., and 
Miki, K. (2007). The production of a diabetic mouse using constructs 
encoding porcine insulin promoter-driven mutant human hepatocyte 
nuclear factor-1alpha. J Reprod Dev 53, 189-200. 
Wedemeyer, W. J., Welker, E., Narayan, M., and Scheraga, H. A. (2000). 
Disulfide bonds and protein folding. Biochemistry 39, 4207-16. 
Wehling, M. (2008). Translational medicine: science or wishful thinking? J 
Transl Med 6, 31. 
Weibel, E. R., and Gomez, D. M. (1962). A principle for counting tissue 
structures on random sections. J Appl Physiol 17, 343-8. 
Weiss, M. A. (2009). Proinsulin and the genetics of diabetes mellitus. J Biol Chem 
284, 19159-63. 
Welsh, M., Scherberg, N., Gilmore, R., and Steiner, D. F. (1986). Translational 
control of insulin biosynthesis. Evidence for regulation of elongation, 
initiation and signal-recognition-particle-mediated translational arrest by 
glucose. Biochem J 235, 459-67. 
Westermark, P., Andersson, A., and Westermark, G. T. (2011). Islet amyloid 
polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 91, 795-826. 
Weyer, C., Bogardus, C., and Pratley, R. E. (1999). Metabolic characteristics of 
individuals with impaired fasting glucose and/or impaired glucose 
tolerance. Diabetes 48, 2197-203. 
Wicksteed, B., Uchizono, Y., Alarcon, C., McCuaig, J. F., Shalev, A., and 
Rhodes, C. J. (2007). A cis-element in the 5' untranslated region of the 
preproinsulin mRNA (ppIGE) is required for glucose regulation of 
proinsulin translation. Cell Metab 5, 221-7. 
Wieczorek, G., Pospischil, A., and Perentes, E. (1998). A comparative 
immunohistochemical study of pancreatic islets in laboratory animals 
(rats, dogs, minipigs, nonhuman primates). Exp Toxicol Pathol 50, 151-72. 
Wieczorek, L. A. (2002). Nervenzupfpräparation (nerve fibre teasing) in der 
Diagnostik peripherer Neuropathien beim Tier: Methodik und 
Interpretation, Ludwig-Maximilians University, Munich. 
 
XI. Reference list    204 
 
Wild, S., Roglic, G., Green, A., Sicree, R., and King, H. (2004). Global 
prevalence of diabetes: estimates for the year 2000 and projections for 
2030. Diabetes Care 27, 1047-53. 
Wildin, R. S., Smyk-Pearson, S., and Filipovich, A. H. (2002). Clinical and 
molecular features of the immunodysregulation, polyendocrinopathy, 
enteropathy, X linked (IPEX) syndrome. J Med Genet 39, 537-45. 
Wilkinson, B. M., Regnacq, M., and Stirling, C. J. (1997). Protein translocation 
across the membrane of the endoplasmic reticulum. J Membr Biol 155, 
189-97. 
Wilson, J. D., Dhall, D. P., Simeonovic, C. J., and Lafferty, K. J. (1986). 
Induction and management of diabetes mellitus in the pig. Aust J Exp Biol 
Med Sci 64 ( Pt 6), 489-500. 
Wiske, P. S., Wentworth, S. M., Norton, J. A., Jr., Epstein, S., and Johnston, C. 
C., Jr. (1982). Evaluation of bone mass and growth in young diabetics. 
Metabolism 31, 848-54. 
Wolcott, C. D., and Rallison, M. L. (1972). Infancy-onset diabetes mellitus and 
multiple epiphyseal dysplasia. J Pediatr 80, 292-7. 
Wolf, E., Schernthaner, W., Zakhartchenko, V., Prelle, K., Stojkovic, M., and 
Brem, G. (2000). Transgenic technology in farm animals--progress and 
perspectives. Exp Physiol 85, 615-25. 
Wolf, G. (2004). New insights into the pathophysiology of diabetic nephropathy: 
from haemodynamics to molecular pathology. Eur J Clin Invest 34, 785-
96. 
Wu, J., Rutkowski, D. T., Dubois, M., Swathirajan, J., Saunders, T., Wang, J., 
Song, B., Yau, G. D., and Kaufman, R. J. (2007). ATF6alpha optimizes 
long-term endoplasmic reticulum function to protect cells from chronic 
stress. Dev Cell 13, 351-64. 
Xu, G., Marshall, C. A., Lin, T. A., Kwon, G., Munivenkatappa, R. B., Hill, J. R., 
Lawrence, J. C., Jr., and McDaniel, M. L. (1998). Insulin mediates 
glucose-stimulated phosphorylation of PHAS-I by pancreatic beta cells. 
An insulin-receptor mechanism for autoregulation of protein synthesis by 
translation. J Biol Chem 273, 4485-91. 
Yaguchi, M., Nagashima, K., Izumi, T., and Okamoto, K. (2003). 
Neuropathological study of C57BL/6Akita mouse, type 2 diabetic model: 
enhanced expression of alphaB-crystallin in oligodendrocytes. 
Neuropathology 23, 44-50. 
Yamagata, K., Furuta, H., Oda, N., Kaisaki, P. J., Menzel, S., Cox, N. J., Fajans, 
S. S., Signorini, S., Stoffel, M., and Bell, G. I. (1996a). Mutations in the 
hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the 
young (MODY1). Nature 384, 458-60. 
Yamagata, K., Oda, N., Kaisaki, P. J., Menzel, S., Furuta, H., Vaxillaire, M., 
Southam, L., Cox, R. D., Lathrop, G. M., Boriraj, V. V., Chen, X., Cox, N. 
J., Oda, Y., Yano, H., Le Beau, M. M., Yamada, S., Nishigori, H., Takeda, 
J., Fajans, S. S., Hattersley, A. T., Iwasaki, N., Hansen, T., Pedersen, O., 
Polonsky, K. S., Bell, G. I., and et al. (1996b). Mutations in the hepatocyte 
nuclear factor-1alpha gene in maturity-onset diabetes of the young 
(MODY3). Nature 384, 455-8. 
Yamamoto, H., Uchigata, Y., and Okamoto, H. (1981a). DNA strand breaks in 
pancreatic islets by in vivo administration of alloxan or streptozotocin. 
Biochem Biophys Res Commun 103, 1014-20. 
 
 
XI. Reference list    205 
 
Yamamoto, H., Uchigata, Y., and Okamoto, H. (1981b). Streptozotocin and 
alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in 
pancreatic islets. Nature 294, 284-6. 
Yamamoto, K., Ichijo, H., and Korsmeyer, S. J. (1999). BCL-2 is phosphorylated 
and inactivated by an ASK1/Jun N-terminal protein kinase pathway 
normally activated at G(2)/M. Mol Cell Biol 19, 8469-78. 
Yamamoto, K., Sato, T., Matsui, T., Sato, M., Okada, T., Yoshida, H., Harada, A., 
and Mori, K. (2007). Transcriptional induction of mammalian ER quality 
control proteins is mediated by single or combined action of ATF6alpha 
and XBP1. Dev Cell 13, 365-76. 
Yamamoto, K., Yoshida, H., Kokame, K., Kaufman, R. J., and Mori, K. (2004). 
Differential contributions of ATF6 and XBP1 to the activation of 
endoplasmic reticulum stress-responsive cis-acting elements ERSE, UPRE 
and ERSE-II. J Biochem 136, 343-50. 
Yang, X. O., Panopoulos, A. D., Nurieva, R., Chang, S. H., Wang, D., Watowich, 
S. S., and Dong, C. (2007). STAT3 regulates cytokine-mediated 
generation of inflammatory helper T cells. J Biol Chem 282, 9358-63. 
Yano, H., Kitano, N., Morimoto, M., Polonsky, K. S., Imura, H., and Seino, Y. 
(1992). A novel point mutation in the human insulin gene giving rise to 
hyperproinsulinemia (proinsulin Kyoto). J Clin Invest 89, 1902-7. 
Yared, Z., and Chiasson, J. L. (2003). Ketoacidosis and the hyperosmolar 
hyperglycemic state in adult diabetic patients. Diagnosis and treatment. 
Minerva Med 94, 409-18. 
Ye, J., Rawson, R. B., Komuro, R., Chen, X., Dave, U. P., Prywes, R., Brown, M. 
S., and Goldstein, J. L. (2000). ER stress induces cleavage of membrane-
bound ATF6 by the same proteases that process SREBPs. Mol Cell 6, 
1355-64. 
Yki-Jarvinen, H., Helve, E., and Koivisto, V. A. (1987). Hyperglycemia decreases 
glucose uptake in type I diabetes. Diabetes 36, 892-6. 
Yoneda, T., Imaizumi, K., Oono, K., Yui, D., Gomi, F., Katayama, T., and 
Tohyama, M. (2001). Activation of caspase-12, an endoplastic reticulum 
(ER) resident caspase, through tumor necrosis factor receptor-associated 
factor 2-dependent mechanism in response to the ER stress. J Biol Chem 
276, 13935-40. 
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., 
Kang, M. I., Cha, B. Y., Lee, K. W., Son, H. Y., Kang, S. K., Kim, H. S., 
Lee, I. K., and Bonner-Weir, S. (2003). Selective beta-cell loss and alpha-
cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin 
Endocrinol Metab 88, 2300-8. 
Yoshida, H., Haze, K., Yanagi, H., Yura, T., and Mori, K. (1998). Identification 
of the cis-acting endoplasmic reticulum stress response element 
responsible for transcriptional induction of mammalian glucose-regulated 
proteins. Involvement of basic leucine zipper transcription factors. J Biol 
Chem 273, 33741-9. 
Yoshida, H., Matsui, T., Hosokawa, N., Kaufman, R. J., Nagata, K., and Mori, K. 
(2003). A time-dependent phase shift in the mammalian unfolded protein 
response. Dev Cell 4, 265-71. 
Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., and Mori, K. (2001a). XBP1 
mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress 
to produce a highly active transcription factor. Cell 107, 881-91. 
 
 
XI. Reference list    206 
 
Yoshida, H., Okada, T., Haze, K., Yanagi, H., Yura, T., Negishi, M., and Mori, K. 
(2000). ATF6 activated by proteolysis binds in the presence of NF-Y 
(CBF) directly to the cis-acting element responsible for the mammalian 
unfolded protein response. Mol Cell Biol 20, 6755-67. 
Yoshida, H., Okada, T., Haze, K., Yanagi, H., Yura, T., Negishi, M., and Mori, K. 
(2001b). Endoplasmic reticulum stress-induced formation of transcription 
factor complex ERSF including NF-Y (CBF) and activating transcription 
factors 6alpha and 6beta that activates the mammalian unfolded protein 
response. Mol Cell Biol 21, 1239-48. 
Yoshinaga, T., Nakatome, K., Nozaki, J., Naitoh, M., Hoseki, J., Kubota, H., 
Nagata, K., and Koizumi, A. (2005). Proinsulin lacking the A7-B7 
disulfide bond, Ins2Akita, tends to aggregate due to the exposed 
hydrophobic surface. Biol Chem 386, 1077-85. 
Yoshioka, M., Kayo, T., Ikeda, T., and Koizumi, A. (1997). A novel locus, 
Mody4, distal to D7Mit189 on chromosome 7 determines early-onset 
NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 46, 887-94. 
Zatz, R., Meyer, T. W., Rennke, H. G., and Brenner, B. M. (1985). Predominance 
of hemodynamic rather than metabolic factors in the pathogenesis of 
diabetic glomerulopathy. Proc Natl Acad Sci U S A 82, 5963-7. 
Zhang, L., and Zhao, Y. (2007). The regulation of Foxp3 expression in regulatory 
CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol 
211, 590-7. 
Zimmet, P., Alberti, K. G., and Shaw, J. (2001). Global and societal implications 
of the diabetes epidemic. Nature 414, 782-7. 
Zinszner, H., Kuroda, M., Wang, X., Batchvarova, N., Lightfoot, R. T., Remotti, 
H., Stevens, J. L., and Ron, D. (1998). CHOP is implicated in programmed 
cell death in response to impaired function of the endoplasmic reticulum. 
Genes Dev 12, 982-95. 
Zoete, V., and Meuwly, M. (2006). Importance of individual side chains for the 
stability of a protein fold: computational alanine scanning of the insulin 
monomer. J Comput Chem 27, 1843-57. 
Zou, H., Li, Y., Liu, X., and Wang, X. (1999). An APAF-1.cytochrome c 
multimeric complex is a functional apoptosome that activates procaspase-
9. J Biol Chem 274, 11549-56. 
Zuber, C., Fan, J. Y., Guhl, B., and Roth, J. (2004). Misfolded proinsulin 
accumulates in expanded pre-Golgi intermediates and endoplasmic 
reticulum subdomains in pancreatic beta cells of Akita mice. FASEB J 18, 
917-9. 
XII. Acknowledgement    207 
 
XII. ACKNOWLEDGEMENT 
First of all I would like to express my gratitude to Prof. Dr. Eckhard Wolf for 
providing me the opportunity to work on this doctorate at the Chair for Molecular 
Animal Breeding and Biotechnology (LMU, Munich). I am particularly thankful 
for his constant support and encouragement as well as for critical discussions and 
for reviewing this manuscript. 
I am thankful to Dr. Simone Renner for mentoring and supporting this work as 
well as for reviewing this manuscript. 
I would like to thank Prof. Dr. Rüdiger Wanke for allowing me to work in his 
laboratory, for his scientific support and for the critical review of this manuscript 
Furthermore, I would like to thank Priv.-Doz. Dr. Nadja Herbach, Dr. Andreas 
Blutke and Dr. Daniela Emrich for great collaboration, for all the data they shared 
with me, for their helpful advice concerning all pathological questions as well as 
for reviewing parts of this manuscript. 
I would like to acknowledge Dr. Stefan Krebs for performing next generation 
sequencing, Dr. Oliver Puk for his collaboration concerning lens preparation and 
Dr. Lelia Wolf-van Bürck for isolating neonatal pancreatic islets. 
Many thanks to all my colleagues at the Moorversuchsgut for creating a 
memorable time. I am especially grateful to Dr. Andrea Bähr, Dr. Barbara Keßler 
and Michaela Dmochewitz for their expert assistance with the veterinary care for 
the diabetic pigs during all the weekends and their veterinary expertise. This 
applies likewise for Siegfried Elsner for his excellent animal care. Special thanks 
also to Angela Siebert, Miwako Kösters, Lisa Pichl and Elfi Holupirek for their 
great technical assistance. 
This doctorate was supported by a research scholarship from the Elite Network of 
Bavaria and the financial and scientific support is therefore deeply acknowledged. 
Furthermore I would like to thank Prof. Dr. Stefan Endres for providing me the 
opportunity to join in the research training group “Oligonucleotides in Cell 
Biology and Therapy” (DFG Graduiertenkolleg 1202) and all my fellow graduate 
students for their input and for sharing a nice time. 
 
XII. Acknowledgement    208 
 
Special thanks to Dr. Pauline Fezert, Dr. Stefanie Sklenak and Dr. Laura 
Klingseisen for their encouragement and friendship. 
My deepest gratitude goes to Lisa Streckel, for her priceless loyalty, 
encouragement as well as for her friendship. Thank you so much for everything.  
I am particularly thankful to my best friend Susanne Röll for sharing all the ups 
and downs, for her unlimited understanding and loyal friendship no matter what 
happened.  
To my daddy and my grandparents Centa and Albert Braun - in loving memory - 
their endless support and encouragement remain unforgotten. To my grandfather 
Erich Fischer, who certainly would have been very proud.   
The last and most important acknowledgement is dedicated to my parents, my 
sister, my grandmother, as well as Heidi and Pepp Hauner with their family for 
their love, unrestricted support and encouragement during all the years. Without 
you, all this would not have been possible. Thank you so much for everything. 
